<SEC-DOCUMENT>0001628280-19-010300.txt : 20190807
<SEC-HEADER>0001628280-19-010300.hdr.sgml : 20190807
<ACCEPTANCE-DATETIME>20190807164425
ACCESSION NUMBER:		0001628280-19-010300
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20190630
FILED AS OF DATE:		20190807
DATE AS OF CHANGE:		20190807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		191006113

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgmo-20190630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:8E3C7049FF875124899ED79CAC62FDEE,x:0d794287489942ac9fe1f4ad5ad80c23-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:sgmo="http://www.sangamo.com/20190630" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:AmendmentFlag" id="Fact-DE37197EC40E86C94CB2D79D0AB82707-wk-Fact-DE37197EC40E86C94CB2D79D0AB82707" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-FAA312CFA8DE28DC6AB4D79D0AC16214-wk-Fact-FAA312CFA8DE28DC6AB4D79D0AC16214">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-C04DBAA725D728C4639CD79D0AACB6AD-wk-Fact-C04DBAA725D728C4639CD79D0AACB6AD">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-11BCE90B3CB0F6E8CE9FD79D0AC2FC8F-wk-Fact-11BCE90B3CB0F6E8CE9FD79D0AC2FC8F">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-D43E9F458CDFC1EADFA6D79D0ADBB2DF-wk-Fact-D43E9F458CDFC1EADFA6D79D0ADBB2DF">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember" name="sgmo:ExpectedLeaseCommencementPeriod" id="Fact-C8D045CD64B733F56B58D79D0A936F3D-wk-Fact-C8D045CD64B733F56B58D79D0A936F3D">2019-06</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember" name="sgmo:LeaseCommencementPeriod" id="Fact-9958028BA8022E13C179D79D0A94D997-wk-Fact-9958028BA8022E13C179D79D0A94D997">2019-01</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="U_sgmoMilestone" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" id="Fact-B4661CDD43D96C4E54ADD79D0AA4271D-wk-Fact-B4661CDD43D96C4E54ADD79D0AA4271D">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="U_sgmoMilestone" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" id="Fact-6AEF45052DF8892D55E4D79D0AA26D4B-wk-Fact-6AEF45052DF8892D55E4D79D0AA26D4B">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" name="sgmo:ResearchAgreementTerm" id="Fact-183466E0F45D03BAC589D79D0AA3D1B1-wk-Fact-183466E0F45D03BAC589D79D0AA3D1B1">an option to extend the research term of the agreement for up to two additional one-year periods for a separate upfront fee of $10.0 million per year.</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2018Q2YTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" id="Fact-FDA4698EA3763BFD724ED79D0ACF41E2-wk-Fact-FDA4698EA3763BFD724ED79D0ACF41E2">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2018Q4YTD" name="us-gaap:GoodwillImpairmentLoss" id="Fact-9C8E9C9263B843DEA448D79D0A97C09C-wk-Fact-9C8E9C9263B843DEA448D79D0A97C09C">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember" name="us-gaap:LeaseExpirationDate1" id="Fact-08FFEC6CF2DB0B83C774D79D0AA0D3E9-wk-Fact-08FFEC6CF2DB0B83C774D79D0AA0D3E9">2019-08-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Fact-E0BF0B7788382EBD8B39D79D0ADA8A75-wk-Fact-E0BF0B7788382EBD8B39D79D0ADA8A75" format="ixt:booleantrue">true</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="Fact-28E745529FE5AE9E73F5D79D0A953DAD-wk-Fact-28E745529FE5AE9E73F5D79D0A953DAD">Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional five to ten years.</ix:nonNumeric><ix:nonNumeric contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact-C45928B185757F21FAB74ED1713376F8-wk-Fact-C45928B185757F21FAB74ED1713376F8">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="I2018Q2Apr5_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact-496882F3A1DA11876B2465B589C93AE3-wk-Fact-496882F3A1DA11876B2465B589C93AE3">P2Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2018Q4YTD" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" id="Fact-B8D9618F95719C0F1728D79D0AD0D82B-wk-Fact-B8D9618F95719C0F1728D79D0AD0D82B">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact-8EC921C02D025688B42FD79D0AC02FBC-wk-Fact-8EC921C02D025688B42FD79D0AC02FBC">1100000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact-72E691CCD4404ACC42F3D79D0AB5A471-wk-Fact-72E691CCD4404ACC42F3D79D0AB5A471">25600000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact-819A5F802B740687A297D79D0AAE8C4F-wk-Fact-819A5F802B740687A297D79D0AAE8C4F">3000000</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:SubsequentEventsTextBlock" id="Fact-10A6305C0043A65E531ED79D0A9D2D21-wk-Fact-10A6305C0043A65E531ED79D0A9D2D21" escape="true">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;[OPEN THROUGH FILING DATE]&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="sgmo-20190630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_sgmo_ChangeInCollaborationAgreementScopeMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BrammerBioMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember_us-gaap_OtherCommitmentsAxis_sgmo_ManufacturingCapabilityEstablishmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BrammerBioMAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingCapabilityEstablishmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_BalanceSheetLocationAxis_sgmo_IntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sgmo:IntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_sgmo_BuildToSuitLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_LeaseArrangementTypeAxis_sgmo_BuildToSuitLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputStockPriceCorrelationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputExchangeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputExchangeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputStockPriceCorrelationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_OtherProductsMember_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-05</xbrli:startDate>
			<xbrli:endDate>2018-04-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfFirstCommercialSaleMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3SD_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-02-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_sgmo_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-05</xbrli:startDate>
			<xbrli:endDate>2018-04-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2May01-May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr01-Apr30_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1Jan01-Jan31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3SD_srt_CounterpartyNameAxis_sgmo_BioverativIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-02-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2SD_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfCommercialMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-05</xbrli:startDate>
			<xbrli:endDate>2018-04-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-05</xbrli:startDate>
			<xbrli:endDate>2018-04-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr5_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeAndLaboratoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:ValbonneLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:ValbonneLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:ValbonneLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeSpaceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondAndValbonneLeasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeSpaceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeAndLaboratoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:ValbonneLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeSpaceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondAndValbonneLeasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeSpaceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondAndValbonneLeasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr01-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q1Dec07_us-gaap_SubsidiarySaleOfStockAxis_sgmo_AtTheMarketOfferingAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_sgmo_AtTheMarketOfferingAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Apr1-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep1-Sep30_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct01_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Nov23">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3July20_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="renewal_option">
		<xbrli:measure>sgmo:renewal_option</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="eurPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:EUR</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit><xbrli:unit id="U_sgmoMilestone">
		<xbrli:measure>sgmo:Milestone</xbrli:measure>
	</xbrli:unit><xbrli:unit id="U_sgmoProduct">
		<xbrli:measure>sgmo:Product</xbrli:measure>
	</xbrli:unit><xbrli:unit id="contract">
		<xbrli:measure>sgmo:contract</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="program">
		<xbrli:measure>sgmo:program</xbrli:measure>
	</xbrli:unit><xbrli:unit id="milestone">
		<xbrli:measure>sgmo:milestone</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s54E4B1E0AEA557999A3490E30B0C5934"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.29629629629629%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">________________________________________________</span></div><div style="line-height:100%;padding-top:13px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d94577764e500-wk-Fact-E542A454A9D03B1B232BD79D0AD4A4F6" name="dei:DocumentType" contextRef="FD2019Q2YTD"><span style="font-size:18pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">________________________________________________</span></div><div style="line-height:100%;padding-top:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</span></div><div style="line-height:100%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d94577764e523-wk-Fact-542F6A9F5FA375FC87F2E1E6E8A8BCEF" name="dei:DocumentQuarterlyReport" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9745;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d94577764e533-wk-Fact-6052432B98DF8A8F8F72677BB93B05D8" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q2YTD" format="ixt:datemonthdayyearen">June 30, 2019</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</span></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d94577764e552-wk-Fact-35CC7E53D7D9DF92E43FE1F14EA62A6A" name="dei:DocumentTransitionReport" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> to </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission file number </span><span><ix:nonNumeric id="d94577764e572-wk-Fact-5E0701716AB3AA086998E6D3DD5395A9" name="dei:EntityFileNumber" contextRef="FD2019Q2YTD"><span style="font-weight:bold;">000-30171</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">________________________________________________</span></div><div style="line-height:100%;padding-top:10px;text-align:center;font-size:24pt;"><span><ix:nonNumeric id="d94577764e581-wk-Fact-4FB1F0A0082DC7EC8490D79D0AD455A2" name="dei:EntityRegistrantName" contextRef="FD2019Q2YTD"><span style="font-size:24pt;font-weight:bold;">SANGAMO THERAPEUTICS, INC</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:24pt;font-weight:bold;">.</span></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:100%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">________________________________________________</span></div><div style="line-height:100%;padding-top:2px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:6%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d94577764e607-wk-Fact-E4A9971480AA718F6413E6D519B20B1F" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q2YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d94577764e627-wk-Fact-62B92FDF3569BED8F69BE6D5D32BCE8F" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q2YTD">68-0359556</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d94577764e691-wk-Fact-55E9CB996A10408D8C4124E96EB4DC92" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q2YTD">501 Canal Boulevard</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d94577764e696-wk-Fact-E518C21F3ED20E7DEE3C24E9DE1426F6" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q2YTD">Richmond</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d94577764e701-wk-Fact-9A844FD4F7DD684EEC9724E9FD8AC3C6" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q2YTD" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d94577764e711-wk-Fact-52C04A22D8498A954946E6D6A4E2C45B" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q2YTD">94804</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Zip Code)</span></div></td></tr></table></div></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d94577764e742-wk-Fact-F7003A45C8836DDF287FE6DC4A3807E2" name="dei:CityAreaCode" contextRef="FD2019Q2YTD"><span style="font-weight:bold;">510</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d94577764e747-wk-Fact-76DD2BCC30FD01B41141E6DCFEA11912" name="dei:LocalPhoneNumber" contextRef="FD2019Q2YTD"><span style="font-weight:bold;">970-6000</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:100%;padding-top:2px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">________________________________________________________________________________________________</span></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94577764e801-wk-Fact-96C07E8D62AD4C7D648BE6FFA2A826C1" name="dei:Security12bTitle" contextRef="FD2019Q2YTD">Common Stock, par value $0.01 per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94577764e811-wk-Fact-6FA112D4832C11F168A9E6FD6821BB8F" name="dei:TradingSymbol" contextRef="FD2019Q2YTD">SGMO</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94577764e821-wk-Fact-B09B177EF9D0EBBA9B9BE6FEE013D218" name="dei:SecurityExchangeName" contextRef="FD2019Q2YTD" format="ixt-sec:exchnameen">NASDAQ Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by section 13 or 15(d) of the Securities Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94577764e827-wk-Fact-468D686B52BC47CB22DEE6DE337D608C" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q2YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:12pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94577764e840-wk-Fact-4ECE9336E6D202D09ED0E6E06A87BDAD" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q2YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:12pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="line-height:100%;padding-top:2px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:23%;"></td><td style="width:16%;"></td><td style="width:6%;"></td><td style="width:27%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94577764e868-wk-Fact-56429D0DF3909F77078FE6E171932EB4" name="dei:EntityFilerCategory" contextRef="FD2019Q2YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9745;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d94577764e914-wk-Fact-EEB6E0D056165ECD482EE7B953814399" name="dei:EntitySmallBusiness" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:justify;padding-left:4px;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d94577764e940-wk-Fact-3039B3874E3F818289B9E7B99F483AB8" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:2px;text-indent:37px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94577764e950-wk-Fact-A21AED697297D2EA2315E7C5A30585AF" name="dei:EntityShellCompany" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:Wingdings;font-size:12pt;">x</span></div><div style="line-height:100%;padding-top:2px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">August&#160;2, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94577764e963-wk-Fact-A5A60F325F6D3408E60E62DAF131E7F5" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">115,675,077</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the issuer&#8217;s common stock, par value $0.01 per share, were outstanding.</span></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.29629629629629%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s5283C196704D58199ECD2CC1262E5DB6"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SANGAMO THERAPEUTICS, INC.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.08429118773945%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:15%;"></td><td style="width:80%;"></td><td style="width:5%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sE9C03CE438065F02B4F3104605C26B96"><span style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART I. FINANCIAL INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s95295548B68E5C68BA3B1623E796FCA7"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item&#160;1.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s95295548B68E5C68BA3B1623E796FCA7"><span style="font-family:inherit;font-size:10pt;">Financial Statements (Unaudited)</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s95295548B68E5C68BA3B1623E796FCA7">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6B90E9D96F3153AFA22B0E0380FFE3E1"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets at June 30, 2019 and December 31, 2018</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s6B90E9D96F3153AFA22B0E0380FFE3E1">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8D4CF1D7309B54BBB52BF65BF2C361B3"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2019 and 2018</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s8D4CF1D7309B54BBB52BF65BF2C361B3">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF4686E9AF04159BCB1E3249BB7D94DEC"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2019 and 2018</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sF4686E9AF04159BCB1E3249BB7D94DEC">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA226D2A9B4035A16AE70A49EC326A54F"><span style="font-family:inherit;font-size:10pt;">Condensed Statements of Stockholders&#8217; Equity for the Three and Six Months Ended June 30, 2019 and 2018</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s19288CBF0BE158F7A8E8F53F2C65C321">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA226D2A9B4035A16AE70A49EC326A54F"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2019 and 2018</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sA226D2A9B4035A16AE70A49EC326A54F">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9C760247323054F19C887676AFB9B2F7"><span style="font-family:inherit;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s9C760247323054F19C887676AFB9B2F7">10</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sDA0017B46BA05D38AE8971FB23ED7049"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item&#160;2.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDA0017B46BA05D38AE8971FB23ED7049"><span style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sDA0017B46BA05D38AE8971FB23ED7049">27</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3F7FD72C54EF518B963D3665389488A3"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item&#160;3.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3F7FD72C54EF518B963D3665389488A3"><span style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures about Market Risk</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3F7FD72C54EF518B963D3665389488A3">33</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s19BBE428BD095AE987B80F64DE2A2EBE"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item&#160;4.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s19BBE428BD095AE987B80F64DE2A2EBE"><span style="font-family:inherit;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s19BBE428BD095AE987B80F64DE2A2EBE">33</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s2F0B23FFAF9751579E38BB51335A4737"><span style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART II. OTHER INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s56357AA9935459389F163F2E9DC7AD0C"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item&#160;1.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s56357AA9935459389F163F2E9DC7AD0C"><span style="font-family:inherit;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s56357AA9935459389F163F2E9DC7AD0C">34</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s386BC9595F5D5649A8D5A09AF4D5C243"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item&#160;1A</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s386BC9595F5D5649A8D5A09AF4D5C243"><span style="font-family:inherit;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s386BC9595F5D5649A8D5A09AF4D5C243">34</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s85E7210EDBCC5A68BDB671BD504AA158"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 2.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s85E7210EDBCC5A68BDB671BD504AA158"><span style="font-family:inherit;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s85E7210EDBCC5A68BDB671BD504AA158">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s6AAC6AE0E7BC54FFB0E627DD19B09CDC"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 3.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6AAC6AE0E7BC54FFB0E627DD19B09CDC"><span style="font-family:inherit;font-size:10pt;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s6AAC6AE0E7BC54FFB0E627DD19B09CDC">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s5DEB01E3046A59B68224CC2F5FF1F417"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 4.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5DEB01E3046A59B68224CC2F5FF1F417"><span style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s5DEB01E3046A59B68224CC2F5FF1F417">70</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD9507AAAC7685687AC7FD0C62A3B0FBA"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item&#160;5.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD9507AAAC7685687AC7FD0C62A3B0FBA"><span style="font-family:inherit;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD9507AAAC7685687AC7FD0C62A3B0FBA">70</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sCE7763FE3EEB5584B01297D0D8846752"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item&#160;6.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCE7763FE3EEB5584B01297D0D8846752"><span style="font-family:inherit;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sCE7763FE3EEB5584B01297D0D8846752">71</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sCFCF9E91226E53CA8DB39F0B5FCE8CA2"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sCFCF9E91226E53CA8DB39F0B5FCE8CA2">72</a></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report, to &#8220;Sangamo,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Sangamo Therapeutics, Inc. and our subsidiaries, including Sangamo Therapeutics France S.A.S (formerly TxCell S.A.).</span></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ZFP Therapeutic</span><span style="font-family:inherit;font-size:9pt;">&#174;</span><span style="font-family:inherit;font-size:10pt;">, Engineering Genetic Cures</span><span style="font-family:inherit;font-size:9pt;">&#174;</span><span style="font-family:inherit;font-size:10pt;">, and Pioneering Genetic Cures</span><span style="font-family:inherit;font-size:9pt;">&#174;</span><span style="font-family:inherit;font-size:10pt;"> are registered trademarks of Sangamo Therapeutics, Inc. Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respective holders.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC8FB940D9EC05321A068B6ECFEFD2595"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some statements contained in this report are forward-looking with respect to our operations, research, development and commercialization activities, clinical trials, operating results and financial condition. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our strategy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">anticipated product candidate development and potential commercialization of any resulting products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the initiation, scope, rate of progress, enrollment, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the therapeutic and commercial potential of, and the ability of Sangamo and our collaborators or strategic partners to advance the development of, product candidates using our zinc finger protein, or ZFP, technology platform, including our ability to effectively deliver our zinc finger nucleases, or ZFNs, and ZFP transcription factors, or ZFP TFs, to produce a clinical benefit;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the benefits of the acquisition of TxCell S.A., now known as Sangamo Therapeutics France S.A.S.;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to establish and maintain collaborative, licensing and other similar arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">anticipated revenues from existing and new collaborations and the timing thereof;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our research and development and other expenses;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability of Sangamo and our collaborators or strategic partners to obtain and maintain regulatory approvals for product candidates using our ZFP technology platform;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain rights to the gene transfer technologies required to develop and commercialize our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to manage the growth of our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our projected operating and financial performance;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our operational and legal risks;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our plans, objectives, expectations and intentions and any other statements that are not historical facts.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In some cases, you can identify forward-looking statements by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should&#8221; and &#8220;will&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations&#8221; in this Quarterly Report. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE9C03CE438065F02B4F3104605C26B96"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</span></div><div><a id="s95295548B68E5C68BA3B1623E796FCA7"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL STATEMENTS</span></div></td></tr></table><div><a id="s6B90E9D96F3153AFA22B0E0380FFE3E1"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SANGAMO THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited; in thousands)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e610-wk-Fact-469CE8BB84B262C73103D79D0AC023A8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">169,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e629-wk-Fact-F26F58192F10765674D2D79D0AB3026E" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,418</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e644-wk-Fact-C8FF7A458F2325F6A97DE7D2B8F490E3" name="us-gaap:RestrictedCashCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e663-wk-Fact-9710C75C7B2F20140B6FE7D309FD3FDD" name="us-gaap:RestrictedCashCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e683-wk-Fact-DFBC3F61C2215E362C75D79D0ABEE556" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,877</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e702-wk-Fact-EA6990E80FF78DED8F8AD79D0AB3DD16" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e722-wk-Fact-0FF5B5FA23F4029AAACAD79D0AC80446" name="us-gaap:InterestReceivableCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">766</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e741-wk-Fact-12551A0C8D004E4C3F65D79D0ABD9EAA" name="us-gaap:InterestReceivableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e761-wk-Fact-D0AD10D95E07B3649524D79D0ABA2828" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e780-wk-Fact-1F7C0AA9A183C2393ADCD79D0AD06E3A" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e800-wk-Fact-2AE8514BCD1187F4F235D79D0ACC50D0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e819-wk-Fact-C92309ED9A8444BFC101D79D0AD0DDBC" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,340</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e839-wk-Fact-61AF287911C8A3090B0AD79D0ABE7F00" name="us-gaap:AssetsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">461,808</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e858-wk-Fact-7A267726DB6F5BF6E41CD79D0AC222D3" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">410,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e878-wk-Fact-803182B60E3827BF27F3E7D503D45988" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e897-wk-Fact-BEE14064AD6605239E9CE7D62590806A" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e918-wk-Fact-F2B6E69BBE24A0133386D79D0AD42C41" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,019</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e937-wk-Fact-72F3564834CE2CB30F0BD79D0ABE3437" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e957-wk-Fact-C5222250B38FFB640975D79D0ACCDE0B" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e976-wk-Fact-0AC24FA37B16936C2A5FD79D0AB78472" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e996-wk-Fact-0DAB4FD64ED43BFB22A5D79D0ACF834D" name="us-gaap:Goodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1015-wk-Fact-68C55902C4CD583B68B3D79D0ACFF628" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,044</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1035-wk-Fact-6F410EDDA81D8CBE76D2D79D0ACCE53E" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,435</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other non-current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1074-wk-Fact-AA07633196497B05E92ED79D0AC57158" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1093-wk-Fact-C258D560131929414DC3D79D0AC235A0" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1113-wk-Fact-2B69EB158C278134D3A0D79D0AAD634C" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1132-wk-Fact-F8D0E86062637492A54DD79D0AC99B81" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1157-wk-Fact-BC34558D4DA2573085E5D79D0AC964D0" name="us-gaap:Assets" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">673,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1176-wk-Fact-6AE923DCBB19027279BFD79D0AB0941A" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">590,395</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1278-wk-Fact-E7688D0BE907E6B8EA6ED79D0AC8CB4A" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1297-wk-Fact-5CEC5428DAFA0DDB177CD79D0AC498A3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation and employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1312-wk-Fact-0DA4997DA96961E29E8AD79D0ABA6BEA" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1331-wk-Fact-11EA634C7F0CDD29E3FED79D0AC37EBB" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1352-wk-Fact-A0344213EDDE36541BC9D79D0AD1412D" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1371-wk-Fact-AAA23BA81D6D602CCA50D79D0ABAE648" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1391-wk-Fact-40CF06639CDCF1840851D79D0AC9184D" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1410-wk-Fact-19CBF409F604A870A0ACD79D0ACF4816" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,511</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenues, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1430-wk-Fact-933527C99A9433EE90BFD79D0ABE8A8E" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">94,189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1449-wk-Fact-BD718900C7026E05594AD79D0AD11F5A" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1469-wk-Fact-5376ED04C4E343E95870D79D0AB9B12A" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1488-wk-Fact-9AD4C333EF37D9C4EAC3D79D0AB29B17" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,689</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1508-wk-Fact-09D3E0275C015DBE4308D79D0ABC94C2" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,661</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1527-wk-Fact-BE4422E3C3076F4B4C14D79D0AB9E8E7" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other non-current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1547-wk-Fact-0352D0FB09341A8106B8D79D0AB952B8" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1566-wk-Fact-48B9E843EDD439EB48D4D79D0AC87F08" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1586-wk-Fact-64F04C9ADD7EC731B5CAD79D0AC62E37" name="us-gaap:Liabilities" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">227,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1605-wk-Fact-5C4F7CC09DD083765CD1D79D0ABCAA35" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">223,138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commitments and contingencies</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1625-wk-Fact-B35A889FC5B402BE51FFD79D0AD305B5" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q2" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1644-wk-Fact-D83BB1B11F6834E7FA44D79D0AD1444C" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stockholders' equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1705-wk-Fact-F69554AF524365DC5056D79D0AB41F51" name="us-gaap:PreferredStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1724-wk-Fact-EE3409FA1BE57301D313D79D0ABA5B32" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1744-wk-Fact-8BD90D2D11B5CA16187FD79D0AB8C7AC" name="us-gaap:CommonStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1763-wk-Fact-344B3565BCD646374ED4D79D0AB8A7E8" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,022</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1784-wk-Fact-C18F9197C918D9B2FAB4D79D0AB8D0A0" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,078,976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1803-wk-Fact-7D5FA66BAC9785E31FA8D79D0AC1020D" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">929,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94603608e1823-wk-Fact-1D6979039EEDA2150B74D79D0ACCF21E" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">634,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94603608e1843-wk-Fact-8FCDFAB3D8A2196E10BED79D0ABEA42C" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">562,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94603608e1864-wk-Fact-F5DADB605C232397F561D79D0AC91231" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">765</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94603608e1884-wk-Fact-0520A7B6080F139363EDD79D0ABE1A78" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Sangamo Therapeutics, Inc. stockholders' equity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1905-wk-Fact-39245F6DF04D671371ABD79D0ABEE605" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">445,134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1924-wk-Fact-0936B750059FD353E827D79D0AC4634D" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">366,518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1944-wk-Fact-1930E75AE6EC2D9A44FDD79D0AC4175A" name="us-gaap:MinorityInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1963-wk-Fact-5BC2E4BF3B544D9C0A16D79D0ACC2989" name="us-gaap:MinorityInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders' equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e1983-wk-Fact-B5F04749C2EF2E4BE717D79D0AC7FA5D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">445,748</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e2002-wk-Fact-9498F1B95CD7A6294375D79D0AB77712" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">367,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders' equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e2027-wk-Fact-2F5FB8157C89F4827E9BD79D0ACC5E45" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">673,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94603608e2046-wk-Fact-C174C8F1B000D13A6965D79D0AB18303" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">590,395</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8D4CF1D7309B54BBB52BF65BF2C361B3"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SANGAMO THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited; in thousands, except per share amounts)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e658-wk-Fact-14AA779FB24F3D00B66DD79D0AA08A82" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e677-wk-Fact-C50E5033FADEF6CF6117D79D0AB7F074" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e696-wk-Fact-085F3FBCD3C0BBFF5C74E7D7F746D8E1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,619</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e716-wk-Fact-1FA1328069BE01046F68D79D0AA39396" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e813-wk-Fact-3DDDFD5EE461C788B9B8D79D0AA25424" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e832-wk-Fact-CC7E1BEFDC18D643D282D79D0AB9BA9F" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e851-wk-Fact-E26EB5136C9954BD6186E7D7F73B776C" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e871-wk-Fact-07846BCCB6D4DC3B4287D79D0AC1F81D" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,802</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e891-wk-Fact-C0F27562C8EF2DDD279ED79D0AA2E8D5" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e910-wk-Fact-6E7883E674AE7AB0BBBDD79D0AB31B3F" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e929-wk-Fact-CD5675688422578CFD6CE7D7F749EED3" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e949-wk-Fact-4445445BDA400C731865D79D0A97DD17" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e969-wk-Fact-4E651BECBE0C27DF2A40D79D0A99ED37" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,052</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e988-wk-Fact-5A618A48D23C719EB03BD79D0AA1F171" name="us-gaap:OperatingExpenses" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,556</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1007-wk-Fact-1001706181A51839FA6BD79D0AB6DB8A" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,020</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1027-wk-Fact-CB2DA7F269E236CF0C74D79D0AC1E955" name="us-gaap:OperatingExpenses" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1047-wk-Fact-A4755F752FFD506511ABD79D0A9C3184" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">33,504</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1067-wk-Fact-A36DEE2B4E4D29819B8CD79D0AB05049" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,140</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1087-wk-Fact-8061ABF127A296F024F9D79D0AAC1345" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">77,401</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1108-wk-Fact-D72A939BDE86808C12BDD79D0A95A665" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40,137</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest and other income, net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1129-wk-Fact-8C5E22E5FA6DE034AE2AD79D0AA720DF" name="us-gaap:InterestAndOtherIncome" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1148-wk-Fact-93EE227F4D4059028B53D79D0A9D73C2" name="us-gaap:InterestAndOtherIncome" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1167-wk-Fact-57F43E3FE824FDA112C9E7D7F7429080" name="us-gaap:InterestAndOtherIncome" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1187-wk-Fact-303AC8345A95042D0E17D79D0A99891C" name="us-gaap:InterestAndOtherIncome" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1207-wk-Fact-E6E469E7D668848601EDD79D0AA6963A" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,356</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1227-wk-Fact-ED7EC79FAB86196C138ED79D0AB6DB62" name="us-gaap:ProfitLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,640</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1247-wk-Fact-196061D9DAA4298342ABD79D0AC38062" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,559</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1268-wk-Fact-D9287DD0D5B87C14CB22D79D0ABA2F9C" name="us-gaap:ProfitLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,827</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to non-controlling interest</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1289-wk-Fact-1EEBBAFF58FB27E18596D79D0A9780E3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1309-wk-Fact-D259F091182A9D6EF6D0D79D0A9CBAA6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1328-wk-Fact-C398701DA594F86769A7E7D7F73F1EDD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1349-wk-Fact-72B4064E24C835452C1AD79D0A9E4B53" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss to Sangamo Therapeutics, Inc. stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1375-wk-Fact-524C04F00A6F600F373D64F2821068BF" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,284</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1395-wk-Fact-9E8B80E7D9C68B3BAEC9D79D0A96A909" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,640</ix:nonFraction></span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1415-wk-Fact-5F454D89C0AADD83986ED79D0AAA041F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,434</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1436-wk-Fact-A5E46909F15586123D16D79D0A9902AE" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,827</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share attributable to Sangamo</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160; Therapeutics, Inc. stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1460-wk-Fact-3DD3C47A023492ED6DD4D79D0AAE1DBE" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1480-wk-Fact-62D1BCF07F2F4796892DD79D0AA90914" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1500-wk-Fact-DC0F7D7B34F97E0942CEE7D7F7384E28" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582075e1521-wk-Fact-86EE9A1E001F25121A22D79D0A94A2C7" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares used in computing basic and diluted net loss per share attributable to</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160; Sangamo Therapeutics, Inc. stockholders</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1540-wk-Fact-125BA32C097D1DC3719AD79D0AB32604" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">114,382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1559-wk-Fact-42ADE23DA55EC674605FD79D0AA8ADB2" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">97,267</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1578-wk-Fact-DF42435B61B623594D6AE7D7F72D094D" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">108,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582075e1598-wk-Fact-AB51120060878CD44492D79D0AAB0479" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">91,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF4686E9AF04159BCB1E3249BB7D94DEC"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SANGAMO THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited; in thousands)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e659-wk-Fact-E6E469E7D668848601EDD79D0AA6963A" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,356</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e679-wk-Fact-ED7EC79FAB86196C138ED79D0AB6DB62" name="us-gaap:ProfitLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e699-wk-Fact-196061D9DAA4298342ABD79D0AC38062" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e720-wk-Fact-D9287DD0D5B87C14CB22D79D0ABA2F9C" name="us-gaap:ProfitLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94577302e736-wk-Fact-EE8977DB94F0070F369BD79D0AD61208" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,442</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94577302e755-wk-Fact-5EDC50C2D2F10CA4068ED79D0AD829E2" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e774-wk-Fact-96AD4EB7CBE7308400B9E7EA2C549F78" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94577302e795-wk-Fact-C67BC7681AE010F176BED79D0ADB3C72" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in unrealized gain on available-for-sale securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94577302e815-wk-Fact-5CC85C6B1D1FCB22EACFD79D0AD6D523" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94577302e834-wk-Fact-ADD23CF5EBAC892DB015D79D0AD45BDF" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94577302e853-wk-Fact-36DFA4688BB8D1F7FE7EE7EA2C50F42C" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">737</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94577302e873-wk-Fact-E645978D9CE423398C3FD79D0AD50260" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e893-wk-Fact-6DE645BBD2FE64B9FDC9D79D0ADAB0DC" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e913-wk-Fact-EDD8873C6710AA4F3165D79D0ADA47CC" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,410</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e933-wk-Fact-5098DCEAF1C921DD42ADD79D0AD35810" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">71,884</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e954-wk-Fact-CD42A610A1628FBB73A7D79D0AD21CA8" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss attributable to non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e975-wk-Fact-5A37E6433D24F91845F4D79D0ADB318D" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94577302e995-wk-Fact-43CCE8728075902ECFAAD79D0AD793F7" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e1014-wk-Fact-DE5DA36979CC03A66D92E7EA2C4DBF33" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94577302e1035-wk-Fact-A19357C55E72AB62B9E4D79D0AD51016" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e1060-wk-Fact-92E5FB47C4BB404FD1F4D79D0AD58EB8" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e1080-wk-Fact-DA82AB275826BB4FEE23D79D0ADBF6A3" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,410</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e1100-wk-Fact-08A0B59588F2AF7C39ACD79D0ACE0042" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">71,759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94577302e1121-wk-Fact-676981C617365AE7EAE0D79D0AD16C37" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="s19288CBF0BE158F7A8E8F53F2C65C321"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SANGAMO THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited; in thousands)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:28%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Income (Loss)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Controlling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders'</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e808-wk-Fact-28D8BC2E9BEA056C33BFD79D0AAEBF69" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">102,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e827-wk-Fact-BBD7D0B43BD54AD6865CD79D0AB9B9B4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,022</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e846-wk-Fact-C6A5B8BE9E4E109F766FD79D0AAA8737" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">929,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e866-wk-Fact-5E3AAC5FB352D640207CD79D0AA9B18F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">562,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e886-wk-Fact-16A4C01D7C388EA0B05CD79D0AA6FE58" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e906-wk-Fact-D8215CA7968732EF2F10D79D0ABDBA48" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e926-wk-Fact-9498F1B95CD7A6294375D79D0AB77712" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">367,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cumulative-effect adjustment of ASC&#160;Topic 842 on January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e994-wk-Fact-69358C537CB769F8A6B8D79D0ABCCAED" name="us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1" contextRef="FD2019Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1052-wk-Fact-8FFDE621A3A26B7C743DD79D0AACE34F" name="us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1" contextRef="FD2019Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1072-wk-Fact-538AF2FC41255E964D95D79D0ABD7BE1" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1086-wk-Fact-5F17FB2AB40724E3FC75D79D0AAE86EE" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1105-wk-Fact-6440E2357DE2C92ED569D79D0AB06DDB" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1183-wk-Fact-6FE7A581ED557CA9978CD79D0AAFBC2B" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance costs related to public offering</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e1236-wk-Fact-84B85B1501C05BF74671D79D0AB759EF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e1315-wk-Fact-86B8911A10FBE745B4A1D79D0ABD0C4D" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1369-wk-Fact-7A1995654C06691250C5D79D0AB5D209" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1447-wk-Fact-A4E5A61456F9E01B7F7DD79D0AA211C3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e1539-wk-Fact-CECFFE40AD0A7BCBFA59D79D0AB68999" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e1579-wk-Fact-5534DEFB859915846ED9D79D0ABA8FD2" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized gain on marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1672-wk-Fact-F5EA134A45339759236DD79D0AB8D666" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1711-wk-Fact-E5B885D623E4BCC735FDD79D0AACB2AC" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e1784-wk-Fact-C732B76143EC5C185F19D79D0AA54C05" name="us-gaap:ProfitLoss" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">42,150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e1823-wk-Fact-EBBC1B9BE5350981FD3CD79D0AAA3125" name="us-gaap:ProfitLoss" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e1844-wk-Fact-1637F39FEBBCE4DF9FBFD79D0AAAD261" name="us-gaap:ProfitLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">42,203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances at March&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1865-wk-Fact-1B08BCDBDC30A67CAAF7D79D0AAE81E2" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">102,329</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1879-wk-Fact-8EDB323E06C03B0B6CEBD79D0AB96A95" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1898-wk-Fact-0FD1E7C9D895AD7B7E69D79D0AA911F5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">934,112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e1918-wk-Fact-C4917C29FD221D324A44D79D0AA86CCC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">603,949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e1938-wk-Fact-B733EAAE2B899D42DC0FD79D0ABEE106" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1958-wk-Fact-0789D4D645317C9574A1D79D0AA97D40" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">686</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1978-wk-Fact-7BF2E015FA7D300655E4D79D0AC0FD85" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">329,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e1999-wk-Fact-860ED203DE331B3EC33AE7EBACE15F2E" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">492</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2013-wk-Fact-00383A463E57D71F34D9E7EBACEEA3AE" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2032-wk-Fact-A274AA10376B81C47C02E7EBACE5EBCE" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2110-wk-Fact-92982039B3F96293C851D79D0ABACF61" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,444</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock under employee stock purchase plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2130-wk-Fact-819B5BF81916255A2033E7EBACE916FB" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2144-wk-Fact-CA7A4D91D55AE7B56B3CE7EBACF6E1BA" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2163-wk-Fact-B566972FF1C3EDD711C3E7EBACDC0D42" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2241-wk-Fact-BAFA77E21AA8E74E26E0D79D0AAF4ECA" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock under public offering, net of issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2261-wk-Fact-EAD7D58978C56151D10ED79D0AA1B3D4" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2275-wk-Fact-8DB1248E64F8AC0C113CD79D0ABE2A75" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2294-wk-Fact-2DCF75B98671CC55958DE7ED9566BE66" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2372-wk-Fact-CD8007C53ADD16C7EF98D79D0AA12BC1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance costs related to TxCell Acquisition</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e2425-wk-Fact-964109E19A21F222D8E8FB7C653D18BA" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e2503-wk-Fact-1D050BBB50D7294A1B36FB7C6C0E4C30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2557-wk-Fact-C763E5ADAA28B2D9C72DE7EBACF21414" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2635-wk-Fact-32F678DAA9467C083DDAD79D0ABC5A6E" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2727-wk-Fact-84E797D463B35CCEBC24E7EBACD715A4" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,442</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2766-wk-Fact-030A11474AE9B7CB59EAD79D0AC3370E" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,442</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized gain on marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2858-wk-Fact-427F9B211313E75AA8B7E7EBACC71781" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e2897-wk-Fact-5CC85C6B1D1FCB22EACFD79D0AD6D523" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e2970-wk-Fact-D3E053A438A9F55320DB64F476C00845" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,284</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e3009-wk-Fact-DD66E5C402CEAAF05E86E7EBACFA7662" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e3030-wk-Fact-E6E469E7D668848601EDD79D0AA6963A" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,356</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3051-wk-Fact-9553FF6BA5D1154785DED79D0AA2B12E" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">115,603</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3070-wk-Fact-4452518C4A863A4614CDD79D0AC2F088" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3089-wk-Fact-7435E1A1DFCF1AAFB4B8D79D0AB2424E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,078,976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e3109-wk-Fact-DBD59724B9A989C1171DD79D0AA021C4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">634,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e3129-wk-Fact-6EBE5C6C90B7EF040716D79D0AAB804D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">765</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3149-wk-Fact-15C8F710AA71D2ACAEF4D79D0AAE3394" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3169-wk-Fact-B5F04749C2EF2E4BE717D79D0AC7FA5D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">445,748</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SANGAMO THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (CONTINUED)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited; in thousands)</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:31%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Income (Loss)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Controlling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interest</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders'</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3541-wk-Fact-7BC96A9C117CEBBDF92BD79D0AB2C743" name="us-gaap:CommonStockSharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">85,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3560-wk-Fact-F6325E466082BECAEEC9D79D0AAA68A8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">856</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3579-wk-Fact-48A370B290E4491715C7D79D0AAABDC9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">682,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e3599-wk-Fact-8B419733E3F627E09A53D79D0AA8445C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">495,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e3619-wk-Fact-2D651E762E729603989FD79D0AA86A4A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3659-wk-Fact-EC5C3E68C2CE1E8C9957D79D0AB4BF81" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">187,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cumulative-effect adjustment of ASC Topic 606 on January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3727-wk-Fact-116A4D8EB6FF3D3B61D7D79D0AA68C20" name="us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1" contextRef="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3785-wk-Fact-284508280E6BB3DCE7F7D79D0AA8CD4B" name="us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1" contextRef="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3805-wk-Fact-6C55E67DB594A2231499D79D0AABF06C" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,443</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3819-wk-Fact-D0CB5CBD22A401E536ABD79D0ABDC2DE" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3838-wk-Fact-1959570AC238E0AFD505D79D0AAAD666" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,570</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3916-wk-Fact-31A92C6B7263DF9AD60CD79D0AAFDB70" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e3969-wk-Fact-A8A3A113EA9699EC03A7D79D0AC5A3C2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,050</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4047-wk-Fact-E9129DB3D607EF751B1FD79D0AAEBF62" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,050</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized loss on marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e4139-wk-Fact-BFF86EE9B425A2A3C0A8D79D0ABAA877" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e4179-wk-Fact-136F6B78810DAEF7D6A4D79D0AAF9C77" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e4253-wk-Fact-D89227F8DE9DB1D565CAD79D0AACEFFB" name="us-gaap:ProfitLoss" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e4312-wk-Fact-1BF4D2AD14723FF5F48CD79D0AC6F3C1" name="us-gaap:ProfitLoss" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances at March&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4333-wk-Fact-5B0D7DC1ED7EF18A5243D79D0AB848B9" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">87,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4347-wk-Fact-C06440E78684D629FE92D79D0AB97BA9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4366-wk-Fact-C5A5368F36E69ED83564D79D0AB4172E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">696,429</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e4386-wk-Fact-1C7AFA84F26112792441D79D0ABA6B41" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">514,549</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e4406-wk-Fact-93CC7A0FE5BFFDA29288D79D0AB11BEA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">385</ix:nonFraction></span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4446-wk-Fact-34535606A1AA557EEEAAD79D0AAF2146" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4466-wk-Fact-DD3542C982CC48382C03D79D0AB1F168" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4480-wk-Fact-5725462223923956B3FAD79D0AB8CEE9" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4499-wk-Fact-80F4311D3642DED13E58D79D0AB4BEDB" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4577-wk-Fact-70907F010CBA3F4815EAD79D0AB034B6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock under employee stock purchase plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4597-wk-Fact-54DC91BD1A1EA45689BCD79D0ABA4CEA" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4611-wk-Fact-8D24CB51E2BEBA1CDA7ED79D0AC7DC98" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4630-wk-Fact-84BB0FFB01BBE182CA4CD79D0AC3BAC3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4708-wk-Fact-6CBF3CBBFD4BF6F0F700D79D0AB3CC06" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock under public offering, net of issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4729-wk-Fact-DFE7105114DDD3D9B1F6D79D0AB196BF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,157</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4743-wk-Fact-88E0574940CB05BB70DBD79D0AA7DFAC" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4762-wk-Fact-85BEBA6E1DD4282BC37BD79D0AB5463B" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">215,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4839-wk-Fact-3334D182EB5E0B30C86FD79D0AAA58DA" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">215,756</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4892-wk-Fact-7BF0B40AD630DC2E7938D79D0AA8F3AC" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e4970-wk-Fact-8287A838CA7BD2086510D79D0AA98DD5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e5062-wk-Fact-75F54DE24340477B05E6D79D0AACFA1D" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e5102-wk-Fact-AB1455AB7A5EF26FC874D79D0AAE3D1D" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized gain on marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e5195-wk-Fact-FF614FE720B607F3D9D2D79D0AB7AC18" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e5234-wk-Fact-ADD23CF5EBAC892DB015D79D0AD45BDF" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e5307-wk-Fact-494AA23CC3621D0CFCB9D79D0AC223E8" name="us-gaap:ProfitLoss" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e5366-wk-Fact-ED7EC79FAB86196C138ED79D0AB6DB62" name="us-gaap:ProfitLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances at June&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e5387-wk-Fact-DC1A8933C875AD3A269FD79D0AB7AA7A" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">101,624</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e5406-wk-Fact-8BC50779C5E50AB8BCFBD79D0ABE26B3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,016</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e5425-wk-Fact-C0215B6DEDCBA32B0D2ED79D0ABDE770" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">918,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e5445-wk-Fact-92A448CC55525C8E6041D79D0ABA147E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">531,189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94591244e5465-wk-Fact-1B78486915494C900AAFD79D0AAEF8C3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">157</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591244e5505-wk-Fact-F49426CF39A7B977B9E1D79D0AAB6515" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">387,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA226D2A9B4035A16AE70A49EC326A54F"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SANGAMO THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited; in thousands)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e609-wk-Fact-196061D9DAA4298342ABD79D0AC38062" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e629-wk-Fact-D9287DD0D5B87C14CB22D79D0ABA2F9C" name="us-gaap:ProfitLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e686-wk-Fact-9D67BF31B60FF965B8BAD79D0AB58BF1" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,583</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e705-wk-Fact-434E8D60B5BE124DDA64D79D0AB467FD" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of discount on marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e725-wk-Fact-730630A17E3F963D72EBD79D0AC60AC8" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e745-wk-Fact-77EB0F5EFD6841E6FE7AD79D0AC176B5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain on free shares</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e766-wk-Fact-0741745EAE772C8CC863D79D0ABA276A" name="sgmo:GainOnFreeShares" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e786-wk-Fact-22C6DFE5F1140D4F00DED79D0ABE8BF6" name="sgmo:GainOnFreeShares" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e806-wk-Fact-FA4AB85B4052116CD1AED79D0AC4027C" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e825-wk-Fact-2B2579233A728D46B16FD79D0AB6B46C" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss on lease termination</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e845-wk-Fact-2044221FAB16FEF54E10D79D0ACCAEEF" name="us-gaap:GainLossOnTerminationOfLease" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e864-wk-Fact-70F04990B02E57664B8AD79D0AB15AB2" name="us-gaap:GainLossOnTerminationOfLease" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e884-wk-Fact-ABF328D9AA13C462ED6DD79D0AB48AA7" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e903-wk-Fact-CA2A93A18B732FBA5F04D79D0AC0BD50" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e965-wk-Fact-7FC4E351CD0EC68B6A31D79D0ACCAEFA" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e985-wk-Fact-DB955E0175DAB7094981D79D0ABC79D0" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1006-wk-Fact-5DE2BAA6AA3AB36E514DD79D0ABDD228" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1026-wk-Fact-3D413B97475E2A145079D79D0AC9BDA2" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1047-wk-Fact-AD6A1535883945135B7ED79D0ABC8D5C" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1067-wk-Fact-BF0A13457002FF832A23D79D0AB52799" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1088-wk-Fact-D8707E9BA61D6326806AD79D0AB55D34" name="sgmo:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,923</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1107-wk-Fact-1B6EEBD76B05396F2CB9D79D0AC6C956" name="sgmo:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1127-wk-Fact-2E763E762900948F8465D79D0AB70F9D" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1146-wk-Fact-4F620AFE09501032A35CD79D0ABAC97F" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation and employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1166-wk-Fact-818E6D71DC3EEC7101E9D79D0AB2FCF4" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">764</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1186-wk-Fact-79F7145AADF3CB83AA96D79D0ACCA8E6" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1207-wk-Fact-31FE44694C362166C655D79D0AC1140E" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,821</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1227-wk-Fact-16B80DEE0FEB9430969DD79D0AB0BA56" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">138,474</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1247-wk-Fact-4DB8009C4F6AC8640C9AD79D0ACC6E16" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">563</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1267-wk-Fact-EA3076AC0B50F6581AD5D79D0AC9F418" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other non-current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1287-wk-Fact-3F02AF9FC26CAB9FAD6BD79D0ACCC82D" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1306-wk-Fact-0B0DDF087104253E33E4D79D0ACB017D" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1326-wk-Fact-1BB91A03B2D30F9EE6ACD79D0AC7FFCC" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,712</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1346-wk-Fact-AA8BDBA9D7325D1CD7B2D79D0AC8AE82" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">104,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing Activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1408-wk-Fact-2605385787671D0B22B1D79D0AB0DF1C" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">244,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1428-wk-Fact-4EC444EC863B21BA42D3D79D0AB56C27" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">451,240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1449-wk-Fact-9DE40F541C3395DDFD4ED79D0AB3AB91" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">226,884</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1468-wk-Fact-AE2B8019DBAC99497AE2D79D0AC8D77A" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">133,297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1488-wk-Fact-558AB24DA0C29F067445D79D0AC5AABE" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,760</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1508-wk-Fact-FEA05576E936AC1FEBA0D79D0ABE8B08" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1529-wk-Fact-2105E81ED4AC1364F0B2D79D0ABE38B8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1549-wk-Fact-48D9E8B9F9AC1DFF8EC0D79D0AB4DA17" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">323,711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing Activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from public offering of common stock, net of issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1611-wk-Fact-12337DAD009FC84A10B0F06E1D22F76B" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1630-wk-Fact-B287C64D6A186241C8E8D79D0AC47F8A" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">215,756</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taxes paid related to net share settlement of equity awards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1650-wk-Fact-6358FFC31F4CD108DA8EF06E1D61B23F" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94580089e1670-wk-Fact-CDB1E878478D1CF89E0ED79D0AB06CA3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1691-wk-Fact-362F2AB8191C3F7AB873F06E1D51C980" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1710-wk-Fact-3222AC8410A57913947DD79D0AC461B0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1730-wk-Fact-B2F0133BAEB11E142127F06E1D32E958" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1749-wk-Fact-D86F17918236C3D35849D79D0AB35703" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">228,984</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effects of changes in foreign exchange rates</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1769-wk-Fact-5104D35577C0DE09ED9AF06E1D134DF6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1788-wk-Fact-1867ED115FA69BB3A30ED79D0AC914FC" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase in cash, cash equivalents, and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1809-wk-Fact-C7269B6EB1E396E87CFDF06E1D70A3A0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1828-wk-Fact-A37A746B03BD7D11E0C6D79D0AC5DFED" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,580</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and restricted cash, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1848-wk-Fact-DAE7BEBFA9BAF982F94AF06E1D51D7A7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">143,918</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1867-wk-Fact-71D33DAE8A4A1514D091D79D0AB294EE" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, cash equivalents, and restricted cash, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1892-wk-Fact-88773D36DF82CA5AD75EF06E1D419FBE" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1911-wk-Fact-1A8FAD1695C801E7B622D79D0AB60F67" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62,906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosure of non-cash activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment included in accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1972-wk-Fact-12A3BAAD8E072E2EB895F06E1D418850" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e1991-wk-Fact-6FFFBAB17AAD697250AFD79D0AC1BE44" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e2011-wk-Fact-830FA104E50225467601F06ED1009FB1" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94580089e2030-wk-Fact-FD62260D919876954EF6D79D0AC6CEEB" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9C760247323054F19C887676AFB9B2F7"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SANGAMO THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div><a id="s95FE0B7C35885D75B8C0832242624F8E"></a></div><div style="line-height:120%;padding-top:16px;padding-left:60px;text-indent:-60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 1&#8212;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="TextSelection-4C702B131013D17116DCD79D0AE751A0-0-wk-Fact-A9DB694DD9765C67C89ED79D0AB59F53" continuedAt="TextSelection-4C702B131013D17116DCD79D0AE751A0-1" escape="true">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4C702B131013D17116DCD79D0AE751A0-1" continuedAt="TextSelection-4C702B131013D17116DCD79D0AE751A0-2"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or the &#8220;Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is focused on the research, development and commercialization of novel therapeutic strategies for unmet medical needs. Sangamo&#8217;s genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins (&#8220;ZFPs&#8221;). Potential applications of Sangamo&#8217;s technology include development of human therapeutics, plant agriculture and enhancement of pharmaceutical protein production.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next twelve months from the date the financial statements are issued. Sangamo will require additional financial resources to complete the development and commercialization of its products including ZFP Therapeutic products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and ZFP Therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-148DF0E835350A3306F2D79D0AE7919E-0-wk-Fact-4F90F0E8204CBA37AE0DD79D0A995226" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The condensed consolidated balance sheet data at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was derived from the audited consolidated financial statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (the &#8220;</span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report&#8221;) as filed with the SEC on March&#160;1, 2019. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and footnotes thereto for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, included in the </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:UseOfEstimates" id="TextSelection-D0843D8BA68FD8E8FA9FD79D0AE75A54-0-wk-Fact-C8C359F4CF6D0C30CE7AD79D0AB4FDB5" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In </span><span style="font-family:inherit;font-size:10pt;">March 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) as result of a decision made in a joint steering committee of Pfizer and Sangamo in </span><span style="font-family:inherit;font-size:10pt;">March 2019</span><span style="font-family:inherit;font-size:10pt;"> to increase the project scope and related project cost, which resulted in a decrease in the measure of the proportional performance. This adjustment decreased revenue by </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94582067e528-wk-Fact-331D9CE3AD9326851825D79D0AB934A1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_sgmo_ChangeInCollaborationAgreementScopeMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, increased net loss by </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94582067e532-wk-Fact-F9B1914B5F0B464EBC46D79D0AAEB0E9" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_sgmo_ChangeInCollaborationAgreementScopeMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and increased the Company&#8217;s basic net loss per share by </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94582067e536-wk-Fact-A4535B7A140596800744D79D0AB6CDDF" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_sgmo_ChangeInCollaborationAgreementScopeMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usdPerShare" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">0.03</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="TextSelection-ACD2ECAF9B6439127AA6D79D0AE6A487-0-wk-Fact-F78D984A3C488131BB1CD79D0AAD5599" continuedAt="TextSelection-ACD2ECAF9B6439127AA6D79D0AE6A487-1" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-4C702B131013D17116DCD79D0AE751A0-2" continuedAt="TextSelection-4C702B131013D17116DCD79D0AE751A0-3"><ix:continuation id="TextSelection-ACD2ECAF9B6439127AA6D79D0AE6A487-1"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adjustments are recorded as a component of Accumulated Other Comprehensive Income (Loss) (&#8220;AOCI&#8221;) within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="TextSelection-3964764824D48808E003D79D0AE77BAD-0-wk-Fact-F0133A85021A6F24E72BD79D0AB1B5D7" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain prior period amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94582067e573-wk-Fact-2EEAE80528ECE3B2EBEFD79D0AA1CB79" name="us-gaap:PriorPeriodReclassificationAdjustment" contextRef="FD2018Q4YTD_us-gaap_BalanceSheetLocationAxis_sgmo_IntangibleAssetsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> from Intangible assets to Other non-current assets on the Condensed Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="TextSelection-9FB097BAC53B5FB7037ED79D0AE65E9E-0-wk-Fact-84189C8D155F9F29190FD79D0AB34338" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo considers all highly-liquid investments purchased with original maturities of </span><span style="font-family:inherit;font-size:10pt;">three months or less</span><span style="font-family:inherit;font-size:10pt;"> at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:MarketableSecuritiesPolicy" id="TextSelection-E03A141FF7B95F85A885D79D0AE6A79F-0-wk-Fact-BF1EE5C705FAA49399D4D79D0AAF72E6" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in AOCI.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, net, which are determined using the specific identification method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ConcentrationRiskCreditRisk" id="TextSelection-429466946C3CCD79D674256A0E86BABD-0-wk-Fact-D50B276EA02CA31FCE6E2570FA7278EC" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the condensed consolidated balance sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019, the Company entered into an Option Agreement (the &#8220;Option&#8221;) with Brammer Bio MA (&#8220;Brammer&#8221;) whereby Brammer granted an option to secure dedicated capacity for Sangamo for manufacturing in Brammer&#8217;s facilities. The Company paid </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94582067e624-wk-Fact-281B596E578173D49273626F7C07844D" name="us-gaap:DepositAssets" contextRef="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Option, which expires on July&#160;31, 2020, and which is included in other non-current assets on the Condensed Consolidated Balance Sheets. If the Company exercises the option, the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94582067e628-wk-Fact-281B596E578173D49273626F7C07844D" name="us-gaap:DepositAssets" contextRef="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> will be applied towards future manufacturing services. If the Company does not exercise the option, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94582067e632-wk-Fact-AAB672EC8B0854F1E7BC6270CD92EA60" name="sgmo:DepositAssetsNonrefundable" contextRef="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> of the deposit is non-refundable. The remainder will be applied towards future services initiated within five years. In addition, the Company will pay Brammer </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94582067e636-wk-Fact-D2179F2EFD1F2B6B457C631BD62DF10F" name="us-gaap:OtherCommitment" contextRef="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember_us-gaap_OtherCommitmentsAxis_sgmo_ManufacturingCapabilityEstablishmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> to assist it in establishing its manufacturing capabilities in Brisbane, CA.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="TextSelection-7EFD3A14BA1BBECB84BCD79D0AE6EB97-0-wk-Fact-F6E367578CA22C96EE9AD79D0AB66444" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&#8217;s investment securities consist of the U.S. government-sponsored entities and various major corporations and financial institutions with high credit ratings. The free share asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-4C702B131013D17116DCD79D0AE751A0-3" continuedAt="TextSelection-4C702B131013D17116DCD79D0AE751A0-4"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeLeasesPolicyTextBlock" id="TextSelection-648FE0E52A8B54918764D79D0AE60D7F-0-wk-Fact-1E19345C7E334F6CA205D79D0AB1C41E" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-D24F68CEFD815B0FFAE4D79D0AE7DFA0-0-wk-Fact-245EBA40AF39872BB9BCD79D0AB1B8E4" continuedAt="TextSelection-D24F68CEFD815B0FFAE4D79D0AE7DFA0-1" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January&#160;1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 606&#8221;) using the modified retrospective method, resulting in a change to its accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s contract revenues consist of strategic partnering collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-4C702B131013D17116DCD79D0AE751A0-4" continuedAt="TextSelection-4C702B131013D17116DCD79D0AE751A0-5"><ix:continuation id="TextSelection-D24F68CEFD815B0FFAE4D79D0AE7DFA0-1"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, revenues related to Kite Pharma, Inc. (&#8220;Kite&#8221;), a wholly-owned subsidiary of Gilead Sciences, Inc., the hemoglobinopathies agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#8220;Sanofi&#8221;)), and the Company&#8217;s hemophilia A collaboration agreement with Pfizer represented </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e713-wk-Fact-85BED998E3CD5E85E286D79D0AB27020" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">61</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e717-wk-Fact-90E3A4AADE915B6584DDD79D0AB1DE04" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e721-wk-Fact-2277ECC0407C04A6AEB2EB8235422D50" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue, excluding the above change in estimate. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, revenues related to Kite, the Company&#8217;s hemophilia A collaboration agreement with Pfizer and the hemoglobinopathies agreement with Sanofi represented </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e734-wk-Fact-9B1D53637E45EA5FA873491A714D0474" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">52</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e738-wk-Fact-38D52B276DB79F94B688491AA9EC4396" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e742-wk-Fact-AD8E4C8F18D5B33B9FC9491ACD10FD3C" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue. During the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, revenues related to the Company&#8217;s hemophilia A collaboration agreement with Pfizer, the hemoglobinopathies agreement with Sanofi and the agreement with Kite represented </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e755-wk-Fact-A04BB5DA10CFFAA46009D79D0AB65ED1" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">47</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e759-wk-Fact-7F48C83BAAAF5FD49B8FD79D0AAF2391" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e763-wk-Fact-70B0CAB3E4AF8953FB6ED79D0AB2357A" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">22</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, revenues related to the Company&#8217;s hemophilia A collaboration agreement with Pfizer, Kite and the hemoglobinopathies agreement with Sanofi represented </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e776-wk-Fact-7ECA6C6E4867385B5BBC491CA738DACE" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">38</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e780-wk-Fact-4E6B653E5ADE3E41DB40491D1C6AE0E2" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e784-wk-Fact-26952926C853EC0006E5491D45C33B8C" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue. Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Funds received from third parties under contract or grant arrangements are recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#8217;s development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-849DD3E7599E2B1E0CECD79D0AE7614A-0-wk-Fact-AEAEE6A9228F607A43EFD79D0AB59E7A" continuedAt="TextSelection-849DD3E7599E2B1E0CECD79D0AE7614A-1" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Simplified Disclosure</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No.&#160;33-10532, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Update and Simplification</span><span style="font-family:inherit;font-size:10pt;">, as updated. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders&#8217; equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments are effective for all filings made on or after November&#160;5, 2018. As such, the Company adopted these SEC amendments on November&#160;5, 2018 and has presented the analysis of changes in stockholders&#8217; equity in these interim financial statements for </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> presented in this Quarterly Report on Form 10-Q. The Company&#8217;s adoption of these SEC amendments had no material effect on the Company&#8217;s reporting of financial position, results of operations, cash flows or stockholders&#8217; equity.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Accounting for Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016</span><span style="font-family:inherit;font-size:10pt;">-2</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 842&#8221;). ASC Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a ROU asset and corresponding liability, measured at the present value of the lease payments. On January&#160;1, 2019, the Company adopted ASC Topic 842 using the modified retrospective approach with a cumulative-effect adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94582067e833-wk-Fact-E3D7F9540A8AE62834F4D79D0AA7D1EC" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> reflected as a decrease to the opening balance of accumulated deficit as of the adoption date. Results for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are presented under ASC Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 &#8212; </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 840&#8221;).</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC Topic 842 provides a number of optional practical expedients in transition. The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-4C702B131013D17116DCD79D0AE751A0-5"><ix:continuation id="TextSelection-849DD3E7599E2B1E0CECD79D0AE7614A-1" continuedAt="TextSelection-8D24C70C9DEBA1F9AFCB660EA8993F5D-0"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effective date and did not elect the practical expedient pertaining to land easements as this is not applicable to the current contract portfolio.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="TextSelection-BBFE8CA8E501CA1E6361D79D0AE7D490-0-wk-Fact-4CD08C06BC43A9394B6ED79D0AAD31EB" continuedAt="TextSelection-BBFE8CA8E501CA1E6361D79D0AE7D490-1" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact of the adoption of ASC Topic 842 on the accompanying Condensed Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments Due to</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">the Adoption of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC Topic 842</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1029-wk-Fact-72F3564834CE2CB30F0BD79D0ABE3437" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582067e1048-wk-Fact-9085195DBE9B96121186D79D0A9DF89B" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62,500</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1068-wk-Fact-7F3771F37E4BD6C3F459D79D0A9A6896" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1103-wk-Fact-02FAD1B2901E49240DD1D79D0A9A703D" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1122-wk-Fact-F6F53C6E0F83E751408CD79D0A98C858" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid rent</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1162-wk-Fact-6EB419470AEE73895F58D79D0A992B05" name="us-gaap:PrepaidRent" contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1181-wk-Fact-43F510B2DBAA0F7D412DD79D0A9C47FE" name="us-gaap:PrepaidRent" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - current</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1347-wk-Fact-71EBEAD5C0138A2F6956D79D0A9D994A" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,408</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1366-wk-Fact-EFEF8D33FC3B396291C9D79D0A99B0F2" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,408</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred rent</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1389-wk-Fact-C77EEF3804C40866D6ADD79D0A9A8199" name="sgmo:DeferredRentNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582067e1408-wk-Fact-0EA8574F16263EF7FB5FD79D0A9BCE85" name="sgmo:DeferredRentNoncurrent" contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">271</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Build-to-suit lease obligation</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1451-wk-Fact-ACC03E9573B41CA1A5F1D79D0A98FBFA" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_sgmo_BuildToSuitLeaseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,689</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582067e1470-wk-Fact-B3FDB4993827F73D75D4D79D0A97561F" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_LeaseArrangementTypeAxis_sgmo_BuildToSuitLeaseMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27,689</ix:nonFraction></span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - long-term</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1532-wk-Fact-0F9E0FFDD15C3B6E5013D79D0A9D981F" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1551-wk-Fact-810A7B1D5C74074312BFD79D0A98EAF3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582067e1635-wk-Fact-8FCDFAB3D8A2196E10BED79D0ABEA42C" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">562,696</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94582067e1655-wk-Fact-B0C057104C8D891BEC96D79D0A9877CD" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94582067e1674-wk-Fact-E2BA0DCD58F9119D9DCAD79D0A9BE490" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">561,799</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">___________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Operating lease liabilities &#8211; current and deferred rent are included in accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheets.</span></div></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-BBFE8CA8E501CA1E6361D79D0AE7D490-1" continuedAt="TextSelection-BBFE8CA8E501CA1E6361D79D0AE7D490-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-BBFE8CA8E501CA1E6361D79D0AE7D490-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Build-to-suit lease obligation and operating lease liabilities &#8211; long-term are included in long-term portion of lease liabilities on the Condensed Consolidated Balance Sheets.</span></div></ix:continuation></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The adjustments due to the adoption of ASC Topic 842 primarily related to the recognition of operating lease ROU assets and operating lease liabilities for the Company&#8217;s leases. In addition, the adoption of ASC Topic 842 resulted in a change in accounting of the build-to-suit component of two leases under ASC Topic 840 to operating leases under ASC Topic 842 and as a result the Company derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, as the Company had been deemed to own these buildings under ASC Topic 840. For additional discussion of the build-to-suit properties, see &#8220;Note 7 &#8211; </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property and equipment, net</span><span style="font-family:inherit;font-size:10pt;">&#8221; to the Company&#8217;s consolidated financial statements included in its Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> filed with the SEC on March&#160;1, 2019. For a description of the leases, see &#8220;Note 8 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8211; Commitments and Contingencies &#8211; Leases</span><span style="font-family:inherit;font-size:10pt;">&#8221; in these condensed consolidated financial statements.</span></div><ix:continuation id="TextSelection-8D24C70C9DEBA1F9AFCB660EA8993F5D-0"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Not yet adopted</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 808&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January&#160;1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Goodwill Impairment Testing</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;">&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step </span><span style="font-family:inherit;font-size:10pt;">2</span><span style="font-family:inherit;font-size:10pt;"> from the goodwill impairment test. ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;"> requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;"> requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;"> will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF5506CC642CB54E4826A7E19748697EC"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 2&#8212;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-CA76499ABE164490D3BAD79D0AE80315-0-wk-Fact-E23056E65531E19527B1D79D0ACB4EDC" continuedAt="TextSelection-CA76499ABE164490D3BAD79D0AE80315-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-CA76499ABE164490D3BAD79D0AE80315-1" continuedAt="TextSelection-CA76499ABE164490D3BAD79D0AE80315-2"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale marketable securities and the free share asset/liability. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="line-height:120%;padding-top:8px;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="line-height:120%;padding-top:8px;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="line-height:120%;padding-top:8px;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="TextSelection-E3C30E72C8008F417CF4D79D0AE7172D-0-wk-Fact-ECA7BD8C4B04FE2CBD50D79D0ACCC5C2" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value measurements of the Company&#8217;s cash equivalents, available-for-sale marketable securities and the free share asset/liability are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2019<br/>Fair Value Measurements</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e837-wk-Fact-44BB882107E0F381E95ED79D0AD91E52" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e856-wk-Fact-13D237A45105768899C2D79D0AD49A9F" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e875-wk-Fact-0EA13261F28DE2FF021D165EBA9E94FA" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e895-wk-Fact-95DAC46929354ECE17E0165E6AABFA4C" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e910-wk-Fact-5D9F3A6CF34C6261093CD79D0AD6423F" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e929-wk-Fact-7F7E2AFD05C4FC2745B5165DE0830A7E" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e948-wk-Fact-3785F827E1673F8F6EEBD79D0AD9A511" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e968-wk-Fact-E79ABA0EAEDF26FD224E165E70110399" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e988-wk-Fact-EF43C30DE4F40235477CD79D0AD54B68" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">101,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1007-wk-Fact-6786CF8C804FEDD0A689D79D0AD93D08" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1026-wk-Fact-CF05E28C8DCAAA8EA47BD79D0AD3D759" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1046-wk-Fact-E2B80D095A8F360FDC79165E7554E87F" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1148-wk-Fact-0D5620D859E1BA8AE6F4D79D0AD40A88" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">170,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1167-wk-Fact-1920DC809005411C3B13165F8E39403D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1186-wk-Fact-6DE509C5CD0B64759D6DD79D0AD6B8EA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">170,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1206-wk-Fact-3CAC3327B080BF4D24A0166026CD8ED8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1226-wk-Fact-A76EEC92B78AB3966868D79D0AD492AC" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1245-wk-Fact-DB9234446FAA12F84C31165F92D1F1B6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1264-wk-Fact-AB2A36244AF2BEBFBF67D79D0AD958F5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1284-wk-Fact-4A57069CA41E280E0A2716602B59A893" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1304-wk-Fact-0EFA6101044078F5B374D79D0AD74129" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1323-wk-Fact-AE4C0E2861D601478A2F165F989BBBB7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1342-wk-Fact-993BBD2E88919FD7960CD79D0AD7965D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1362-wk-Fact-7D2F5885E3CCD2380B3916602FDC52D1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1383-wk-Fact-E4F7A3992DD514A6B821D79D0AD88F86" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">280,327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1402-wk-Fact-2E2B18A0B15C9F037541165F9E63F24C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1421-wk-Fact-656BB36B32BD37918668D79D0AD3EC01" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">280,327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1441-wk-Fact-0ECC28F00CFA1CAE3AD61660347E17DA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and marketable securities</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1466-wk-Fact-005D34D6311D380189AFD79D0AD49866" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">382,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1485-wk-Fact-DE69800E086FFBC8D398D79D0AD5C71F" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1504-wk-Fact-06E5296174A007CF76A6D79D0AD8BE5D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">310,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1524-wk-Fact-4B87E019D6373062E87D166038157A67" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Free shares asset</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1626-wk-Fact-2B6B134FE292C41292ADD79D0AD7905B" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1645-wk-Fact-A222215C9E92A7B0D4C91660C5008892" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1664-wk-Fact-1F724A32775AAAE3A3E61660CBFC2763" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e1684-wk-Fact-A7B66B03D3C4BC91CA8BD79D0AD7DADC" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018<br/>Fair Value Measurements</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2055-wk-Fact-E99D7D61A677C45268DED79D0ADB5E46" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2074-wk-Fact-26C0A527F26748FE2125D79D0ADC5A69" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2093-wk-Fact-FF91F2C4CD1ABD273F33165C758DE5D4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2113-wk-Fact-A864B28B099FED160C9F165C7F318601" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2128-wk-Fact-ADEFF80580F1C41039ADD79D0ADEBCB6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2147-wk-Fact-6691C7D18D91F7FB3A69D79D0AC6679C" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2166-wk-Fact-8CBF1531D0CB03122F6F165C83A62C19" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2186-wk-Fact-9316B23A5C78AF09D805165C8A07E28A" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2288-wk-Fact-565344D7198B5AF922AFD79D0ADB3026" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">177,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2307-wk-Fact-600E961310278992E9691662DDB90A66" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2326-wk-Fact-9951C1138669A094A8AFD79D0ADD51F3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">177,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2346-wk-Fact-4D66B70D55EB805927D616624DC914C9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2366-wk-Fact-CE0C96FFED9A5F5C32C2D79D0ADC158B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2385-wk-Fact-B6FFD2204135EF0254671662E1FE3CD8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2404-wk-Fact-FB1A22C10A794B98EE46D79D0AD98D2C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2424-wk-Fact-89EF59ACC111E7C09F301662530898EA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2444-wk-Fact-ABE74AB470FFC929355FD79D0ADE6DC8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2463-wk-Fact-2A1197A2E25B537561F81662E6C13AB1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2482-wk-Fact-146E276D5A1F94ECA19CD79D0ADD231D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2502-wk-Fact-A575576FB2C73ED6F8201662584097C4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2522-wk-Fact-BE4835F3A775F3833AE6D79D0ADC44F7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2541-wk-Fact-BDE74379EE7EF252AC271662EBDCDA66" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2560-wk-Fact-444C3294D7DAA1238900D79D0ADE390E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2580-wk-Fact-5C8B7B9B1C99B63E118A16625D9E3036" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and marketable securities</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2606-wk-Fact-F19F36E782D1D3977757D79D0ACFC5DC" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">363,006</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2625-wk-Fact-6D4460C47BFE5FAEB086D79D0AD6E1EC" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2644-wk-Fact-67CC27EB3C50B4776737D79D0ACEABA1" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2664-wk-Fact-74083BBBE7014941669D166261C6516E" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Free shares liability</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2766-wk-Fact-A498397E118C7AD7D9F1D79D0ADAD67C" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2785-wk-Fact-D21FB4756DF70D3261531661AACB8644" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2804-wk-Fact-8352DECA97B63957E33A1661B4A5A3CC" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2824-wk-Fact-02F48719FC8B8D01B219D79D0AD94941" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-CA76499ABE164490D3BAD79D0AE80315-2"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Free Share Asset/Liability</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;SPA&#8221;) with TxCell S.A., a French </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">soci&#233;t&#233; anonyme</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;TxCell&#8221;) (see Note 10 &#8212; </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisition of TxCell S.A.</span><span style="font-family:inherit;font-size:10pt;">), the Company entered into arrangements with the holders of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2857-wk-Fact-8BCA9FF2B4C38883C8E2D79D0ACB5793" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="shares" decimals="-3" scale="0" format="ixt:numdotdecimal">477,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> &#8220;free shares&#8221; of TxCell pursuant to which the Company has the right to purchase such shares from the holders thereof (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94585328e2861-wk-Fact-374D501EDA35AFE8D7B9D79D0ACCC8AF" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#8220;Monte Carlo simulation model&#8221;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Condensed Consolidated Statements of Operations. The number of free shares has not changed since the Acquisition Date. The free shares liability was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94585328e2865-wk-Fact-B56A88B2BE17B4ABC85353C77319C889" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and the Company recognized a gain due to an increase in the fair value of the free shares of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94585328e2874-wk-Fact-74636B55B1710CABF070D79D0ACB51B5" name="sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> bringing the balance to an asset of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94585328e2886-wk-Fact-EBC79AD34AB86E47CE4653C5FF4A775D" name="sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="TextSelection-DE0F72B781A5103CB19FD79D0AE86973-0-wk-Fact-1A4E789B6580F6809CA6D79D0ACDCE0F" escape="true"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Free Shares valuation assumptions:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo Stock Price (USD)</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2975-wk-Fact-9CC88978D1D87B613C10D79D0AC75215" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e2993-wk-Fact-D13A18728A4CAC9BAC05D79D0ACC5EEC" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TxCell Stock Price (EUR)</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3017-wk-Fact-38620D403835209AAACCD79D0AC9342A" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember" unitRef="eurPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3035-wk-Fact-B0EC7F69EB721A5DAAE0D79D0AC85D9E" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember" unitRef="eurPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR / USD Exchange Rate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3054-wk-Fact-F01E9E9F9C1F11DF6910D79D0ACDD444" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2019Q2_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputExchangeRateMember" unitRef="number" decimals="2" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3072-wk-Fact-71B68DCB2BE65C05D5BBD79D0ACD7168" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2018Q4_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputExchangeRateMember" unitRef="number" decimals="2" scale="0" format="ixt:numdotdecimal">0.87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated Correlation Sangamo and TxCell Stock Prices</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3096-wk-Fact-D83B2C5FE44394314982D79D0ACEDC07" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputStockPriceCorrelationMember" unitRef="number" decimals="1" scale="0" format="ixt:numdotdecimal">72.2</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3114-wk-Fact-15CAAFEA8302829A36551060E67C34A5" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputStockPriceCorrelationMember" unitRef="number" decimals="1" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo Stock Price (USD) Volatility Estimate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3138-wk-Fact-084E13A5CB09FF1097BED79D0AC531E3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" unitRef="number" decimals="1" scale="0" format="ixt:numdotdecimal">77.6</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3156-wk-Fact-CB8A8AB3BA949E0D9527D79D0ACE9B51" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" unitRef="number" decimals="1" scale="0" format="ixt:numdotdecimal">79.9</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TxCell Stock Price (EUR) Volatility Estimate</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3180-wk-Fact-F70D12146B726F8AC300D79D0AC99C02" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" unitRef="number" decimals="1" scale="0" format="ixt:numdotdecimal">76.2</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3198-wk-Fact-719855BB7519570B1766D79D0ACBBCDB" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" unitRef="number" decimals="1" scale="0" format="ixt:numdotdecimal">8.6</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR / USD Exchange Rate Volatility Estimate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3222-wk-Fact-A92AACB509A712CA7D5DD79D0AC99030" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember" unitRef="number" decimals="1" scale="0" format="ixt:numdotdecimal">7.0</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94585328e3240-wk-Fact-1085B38A22BC842E994DD79D0AC70C0A" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember" unitRef="number" decimals="1" scale="0" format="ixt:numdotdecimal">7.7</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk Free Rate and Cost of Debt by Expected Exercise Date</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varies</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varies</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="sFCE81F45CA60566F98685E5A84168720"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 3&#8212;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="TextSelection-A3F14F16AFC0AE5AB5E9D79D0AE868B6-0-wk-Fact-14B3B0D3A77EA7F47761D79D0AA38803" continuedAt="TextSelection-A3F14F16AFC0AE5AB5E9D79D0AE868B6-1" escape="true">CASH AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A3F14F16AFC0AE5AB5E9D79D0AE868B6-1" continuedAt="TextSelection-A3F14F16AFC0AE5AB5E9D79D0AE868B6-2"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="TextSelection-1705D338CC3A352EB19DEB90831EEB46-0-wk-Fact-B58E656F3E5D78AF6BB6EBC32B23B7B0" escape="true"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-58E05D56CB8A9BFFC4BCEBC3794D37D2-0-wk-Fact-4AA919D23C1EEFCDE112EBC3E9EA1B65" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e584-wk-Fact-469CE8BB84B262C73103D79D0AC023A8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">169,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e603-wk-Fact-F26F58192F10765674D2D79D0AB3026E" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,418</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e622-wk-Fact-C52421ED692E66C248FCEBD0C3C84ACE" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,406</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e642-wk-Fact-317B04E7E62722C03D89EBD0E395CD51" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in Restricted cash, current portion</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e657-wk-Fact-CFBDCDF444868A9DC9EAEBCC645D3A52" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e676-wk-Fact-C6C0BF06F7A7C28C5FC5EBD0A1A10EB7" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e695-wk-Fact-C331C34C6B209CAF8B86EBD0C47BC9D5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e715-wk-Fact-2E8059BFC37034CC5BC2EBD0E44AAFC1" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in Non-current restricted cash</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e735-wk-Fact-E647C4F45EEDCA08D26DEBCC840ADE77" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e754-wk-Fact-15363CC6223AA218C202EBD0A243562F" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e773-wk-Fact-93B1B77AE03DBE31E82DEBD0C51EDE46" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e793-wk-Fact-9451556B5A5B71EBB755EBD0E5165594" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e818-wk-Fact-88773D36DF82CA5AD75EF06E1D419FBE" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e837-wk-Fact-DAE7BEBFA9BAF982F94AF06E1D51D7A7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">143,918</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e856-wk-Fact-1A8FAD1695C801E7B622D79D0AB60F67" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62,906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e876-wk-Fact-71D33DAE8A4A1514D091D79D0AB294EE" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash consists of a letter of credit for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94595409e888-wk-Fact-3035D79704FA6D24934CEBD813F54B9F" name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> established as a deposit for the Brisbane lease.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-A3F14F16AFC0AE5AB5E9D79D0AE868B6-2"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Available-for-sale Securities</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:MarketableSecuritiesTextBlock" id="TextSelection-C9C5F0D29E37A3F203C1D79D0AE8FCAC-0-wk-Fact-79B1A443EF7ACC5F381FD79D0AAC7C1E" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the Company&#8217;s cash equivalents and available-for-sale securities (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1310-wk-Fact-90DB97609D8C03664D20D79D0AC38660" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1329-wk-Fact-D4621694D8589C6B8EAB1467D4DF0910" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1349-wk-Fact-D9B02DAE2A4C4105CA23146ED0B5FA54" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1368-wk-Fact-00AB876CF8FD29CCFCABD79D0AC8E897" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1388-wk-Fact-DAD3B38C1B8F8892D3D7D79D0ABE6DD6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1407-wk-Fact-5BA96F3F1853D7A8E73EEC08C6E82DDD" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1426-wk-Fact-478F3E298EA648F87BA2146F5EE88322" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1446-wk-Fact-A405EF678F5EAB45E1DCD79D0ACD8FD0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1471-wk-Fact-864352824D66DA0EF3CFD79D0AD0E491" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">101,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1490-wk-Fact-9B9BA8CA3A412F5D2AC7EC0D386A49CA" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1509-wk-Fact-E221F17080577C3D1D6A146FD52E68BF" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1529-wk-Fact-B33E43778DBC65F12131D79D0ABCF0CD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">101,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1641-wk-Fact-79FC21FCCB275107DCCED79D0AC332A0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">170,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1660-wk-Fact-C88048EB74FF600FBD69D79D0AC3E4DC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1679-wk-Fact-4B0ECD183874EDF5150E146AED56C42E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1699-wk-Fact-5F91A3807F7874552242D79D0AC857CC" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">170,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1724-wk-Fact-AB96E4095C0123F4D200D79D0AC2AAB5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1743-wk-Fact-845533BD1B1AB33EEC58D79D0AD31958" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94595409e1762-wk-Fact-235F7F1EFB3710DC1D9FD79D0AD2725A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1783-wk-Fact-67208BE55EA368272F8BD79D0AC10FBB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1808-wk-Fact-49EFCE4A266F1952802FD79D0AB9F96C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,973</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1827-wk-Fact-F5AAED09FDF2130BC4E2EBEE41D9A791" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1846-wk-Fact-5A6DDDB53AEFE70DB9DE146AEFDDE750" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1866-wk-Fact-F2BF872258FB8EE71D7ED79D0AB7623E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1892-wk-Fact-8C8E399A74E518183B8AD79D0ACD0646" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">279,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1911-wk-Fact-42516807E5F557A53F9AD79D0AC39841" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94595409e1930-wk-Fact-6D5764F1780589C2323DD79D0AD0FEE3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1951-wk-Fact-8ED07EC256752A548CABEC1B97EDAC94" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">280,327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e1981-wk-Fact-B11600A6DE999AC6E679D79D0ABDBD7D" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,780</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2000-wk-Fact-80DC40F32990C64A76C0D79D0AC9AAB5" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">483</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94595409e2020-wk-Fact-59D2CA4FBC04BD26CBD9D79D0AD08B32" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2040-wk-Fact-B12A789AF85F87E1CFDAD79D0ACE0069" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">382,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2239-wk-Fact-1AA8E5ECF574BA742C6DD79D0ABD6466" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2258-wk-Fact-A24A370B76E7FAF8C5C71468E51D0708" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2278-wk-Fact-68806504514238EEB75014717A906A0D" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2297-wk-Fact-83A652373730471D1766D79D0ACF55C3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2317-wk-Fact-CE303FA2ECAD9E9FD41DD79D0AB99268" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2336-wk-Fact-148FDD67A97D02F75D2314690357DCE9" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2355-wk-Fact-87B35BD218D1C3FD6BE41471D8C0F775" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2375-wk-Fact-7C289C5E67099E2404FED79D0AD0ED7D" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2487-wk-Fact-F818216A5E2A1C015A0ED79D0ABAAC31" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">177,353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2506-wk-Fact-BEF212C77EC32C9FFC861463E9BCF0A5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94595409e2525-wk-Fact-E9926C45A63FA1FF5F98D79D0ACC4CD5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2546-wk-Fact-5211661D08F7C505D644D79D0ABC45D9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">177,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2571-wk-Fact-4CA63B748AF52413F55ED79D0AC25CAA" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2590-wk-Fact-4BD9822C778CFC770E271463EAFD1886" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94595409e2609-wk-Fact-024E469B4C022472164AD79D0ACD204D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2630-wk-Fact-2E28C245197052F2191DD79D0AB79141" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2655-wk-Fact-52501671D3F55D8203CDD79D0AC75455" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2674-wk-Fact-146FE23241FD95876AF41463EC488996" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94595409e2693-wk-Fact-CD59BABF3B60E7D53ABFD79D0AD1C11D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2714-wk-Fact-CF84CE1849B4A3753711D79D0AC64024" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2739-wk-Fact-4E4D1B666E0FBE472CC0D79D0ABEFBF3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,974</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2758-wk-Fact-CD2633160F7D657881F11463ED9620F6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94595409e2777-wk-Fact-8F3B752DFB1DB81E12ADD79D0AC9B712" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259</ix:nonFraction></span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2798-wk-Fact-7106F358A95F66EB8CB3EC2080626E13" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2829-wk-Fact-57FEABCE5DDBBFAA4699D79D0ACF84D9" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">363,265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2848-wk-Fact-D4192E7F07AF0C7AF09D1463EE8F99D1" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94595409e2868-wk-Fact-CE8781486DCF45931595D79D0AC96DF0" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259</ix:nonFraction></span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2888-wk-Fact-084B36762719BF136913D79D0AC5A0E8" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">363,006</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-FB086D6DE04F32FD8B94EC11D8B5093C-0-wk-Fact-0EF27C3B91CE9486F0D2EC126CD742E9" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e2982-wk-Fact-EC0490B732979C4535684E7367AB83C0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,877</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e3001-wk-Fact-9084C64A557E39420EAE4E7367B094D4" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e3021-wk-Fact-74A9F15D9A654CC8F9ED4E7367A02D93" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e3040-wk-Fact-2CC81BCA2A9994DCAA464E7367B3E089" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e3070-wk-Fact-8ED07EC256752A548CABEC1B97EDAC94" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">280,327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e3089-wk-Fact-7106F358A95F66EB8CB3EC2080626E13" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e3100-wk-Fact-39172447BB8ED933327FD79D0AAB2C36" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> material realized losses of its available-for-sale securities for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. Sangamo has the intent and ability to hold its investments for a period of time sufficient to allow for any anticipated recovery in market value. </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595409e3116-wk-Fact-C998CCC2C9E9CC652E03D79D0AB89ED0" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" contextRef="FD2019Q2YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> investments were other-than-temporarily impaired at either </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><a id="s07CFB12DADA158F6B3B1E1700BACCC53"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 4&#8212;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-8802E76C03B2E864F50AD79D0AE8DCC8-0-wk-Fact-DEC5C23577242E3B0B76D79D0A9DE8BB" continuedAt="TextSelection-8802E76C03B2E864F50AD79D0AE8DCC8-1" escape="true">BASIC AND DILUTED NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8802E76C03B2E864F50AD79D0AE8DCC8-1"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total number of shares subject to stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding and the employee stock purchase plan (&#8220;ESPP&#8221;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> totaled </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591861e469-wk-Fact-101605F786AEB4214C02D79D0A9E5F14" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" contextRef="FI2019Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,155,033</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591861e473-wk-Fact-BF118165442071A463E9D79D0A9CEC26" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" contextRef="FI2018Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,757,528</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><a id="s23AD1DE59CF55E8FBA9A0783725DC121"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 5&#8212;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-0-wk-Fact-302FA87061FC5C456429D79D0ADD6708" continuedAt="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-1" escape="true">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-1" continuedAt="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-2"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration Agreements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Kite Pharma, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the Company entered into a global collaboration and license agreement with Kite for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing ZFNs and adeno-associated viral vectors (&#8220;AAVs&#8221;) to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors, T-cell receptors, and NK-cell receptors directed to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products and has announced that they expect to initiate a clinical trial evaluating KITE-037, an allogeneic anti-CD19 CAR-T cell therapy, in 2020. The Kite agreement became effective on </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d94597376e464-wk-Fact-766E6B613E6DE5D2F3DFD79D0ACDB610" name="sgmo:CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective" contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" format="ixt:datemonthdayyearen">April 5, 2018</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;"> when the waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions were completed.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</span><span style="font-family:inherit;font-size:10pt;"> using selected zinc finger nucleases (&#8220;ZFNs&#8221;) and AAVs developed under the research program to express chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;) or NK-cell receptors (&#8220;NKRs&#8221;) directed to candidate targets.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</span><span style="font-family:inherit;font-size:10pt;"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</span><span style="font-family:inherit;font-size:10pt;"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following the effective date, in April 2018, the Company received a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e489-wk-Fact-5E4EA07164A71C298A95D79D0ADCCA1A" name="sgmo:MilestonePaymentsReceived" contextRef="D2018Q2Apr01-Apr30_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment from Kite. In addition, Kite will reimburse the Company&#8217;s direct costs to conduct the joint research program, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e493-wk-Fact-851B6615AA3A4935F8EBD79D0AD1863C" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">3.01</ix:nonFraction>&#160;billion</span></span><span style="font-family:inherit;font-size:10pt;"> if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e497-wk-Fact-627B1329F8369C3C92A5D79D0ADD1F28" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">1.26</ix:nonFraction>&#160;billion</span></span><span style="font-family:inherit;font-size:10pt;"> relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e501-wk-Fact-3EF44EB85D5DB4606D6AD79D0AD70512" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">1.75</ix:nonFraction>&#160;billion</span></span><span style="font-family:inherit;font-size:10pt;"> relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The initial research term in the agreement is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94597376e508-wk-Fact-AB91863903D8AE060804D79D0ADB08B5" name="sgmo:InitialResearchTermOfAgreement" contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" format="ixt-sec:durwordsen">six years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. Kite has an option to extend the research term of the agreement for up to </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> additional one-year periods for a separate upfront fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e516-wk-Fact-D702B290B18890BD0690D79D0ADCD3F1" name="sgmo:SeparateUpfrontFee" contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The Company concluded the transaction price under this agreement is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e520-wk-Fact-72B35152ED519FD2F688D79D0AD2734E" name="sgmo:CollaborativeArrangementTransactionPrice" contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">185.9</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and includes the upfront license fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e524-wk-Fact-E771E4F4B47A2EE8451FD79D0AD1633B" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e529-wk-Fact-277D82BD0BAE4C9E1F36D79D0A958A33" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.9</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has identified the primary performance obligations within the Kite agreement as a license to the technology and on-going services. The Company concluded that the license is not discrete as it does not have stand-alone value to </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-2" continuedAt="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-3"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Kite apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment on a straight-line basis through June 2024, the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e550-wk-Fact-F0E072FE7757889C2DEED79D0ADC3CEA" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q2_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">119.1</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e554-wk-Fact-3C6F0B37EE9C26567B32D79D0AD7E5FC" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.5</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to this agreement.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-37D72B6C1D496E7A6026D79D0AE81228-0-wk-Fact-C4EDD10FA72F3FDA1C42D79D0ADD8BB4" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue related to Kite agreement:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e858-wk-Fact-621E044306B33743CE55EC22080F2856" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e877-wk-Fact-9FD838292FA479139EE4D79D0AAB0A9D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e896-wk-Fact-26CD29BA32D328D485B3EC220813EB2C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,386</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e916-wk-Fact-014C8B1BD441E0E59984D79D0AC564F6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research services</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e931-wk-Fact-493FCAA6E0BC2E218E8FEC220805A0B9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e950-wk-Fact-BB82177DFDDB521D3C13D79D0AABA489" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,562</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e969-wk-Fact-358F8199A6F2F11B970FEC22081F3DB2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e989-wk-Fact-B367B724F4B0CC972D79D79D0AC6D75E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,562</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1014-wk-Fact-E087EE135CC235F5D722D79D0AADCA37" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1033-wk-Fact-6A56A511071CA8802146D79D0AAD1F65" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1052-wk-Fact-8EDFE950D81451DD17E0D79D0AADEE2F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,372</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1072-wk-Fact-B9894ED7250DC119578AD79D0AAC315B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pfizer Inc.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">SB</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">-525</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"> Global Collaboration and License Agreement</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of SB-525, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company originally received an upfront fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1100-wk-Fact-44A1448895EBBB29B976D79D0AD7FE67" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and is eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. In addition, Sangamo is eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1104-wk-Fact-5DF64DDA51965B24B703D79D0A93848A" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">208.5</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1108-wk-Fact-C26F4024183FDFA58000D79D0AD88C5A" name="sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember_srt_RangeAxis_srt_MaximumMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">266.5</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments upon first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the hemophilia A Pfizer agreement, is up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1112-wk-Fact-B9D21CEED2B8C28B4DDBD79D0AD3C2FE" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">475.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1116-wk-Fact-CB716F3E82F35FB1B56DD79D0AD3C4DD" name="sgmo:MilestoneRevenueReceivable" contextRef="I2017Q1May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember_srt_RangeAxis_srt_MaximumMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for SB-525 and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1121-wk-Fact-2AE63E1E3384F54BB83DD79D0ADAFA1C" name="sgmo:MilestoneRevenueReceivable" contextRef="I2017Q1May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_OtherProductsMember_srt_RangeAxis_srt_MaximumMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">175.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1125-wk-Fact-B34687583C851F133D49656F2BB1183E" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="D2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> milestone payments have been received and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1129-wk-Fact-D25FB7BC40BA5ECB6D54D79D0ADB45ED" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" contextRef="D2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember" unitRef="U_sgmoProduct" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> products have been approved and therefore </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1133-wk-Fact-1B355BD6CC36563D76AFD79D0ADD7263" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> royalty fees have been earned under the hemophilia A Pfizer agreement. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None of the clinical or regulatory milestones have been included in the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1140-wk-Fact-44A1448895EBBB29B976D79D0AD7FE67" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-3" continuedAt="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-4"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;fifteen years after the first commercial sale of a product in a country Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has identified the performance obligations within the hemophilia A Pfizer agreement as a license to the technology and on-going services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services through 2020, the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1161-wk-Fact-928A471804077D3E52CDD79D0AD1ED2D" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.3</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1165-wk-Fact-229C4F058DE945EFAF26D79D0AD2D11A" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4_srt_CounterpartyNameAxis_sgmo_PfizerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to this agreement.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-C238C39AED0303BB3225EC49C55374B8-0-wk-Fact-A1F7496A5634D26B9CCBEC4AFE8D88BA" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee related to Pfizer SB-525 agreement</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1386-wk-Fact-4C87BE36EFAE7B832069EC51C9BBCD40" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,635</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1405-wk-Fact-8BCBAEE49B5770750069EC51CC01A05A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1424-wk-Fact-F27863F33DF543134F0AEC51CE4AD724" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,595</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1444-wk-Fact-EEE8A739D0A611B20BC5EC51D090E653" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,841</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March&#160;2019, the Company received new data results in the hemophilia A collaboration agreement with Pfizer, and expansion of patients for the ongoing trial. As a result, the estimated project cost increased and the proportional performance was updated based on the actual services delivered to Pfizer as a percentage of the updated project cost as of March&#160;31, 2019. The increase in project cost resulted in a decrease in the measure of the proportional cumulative performance. During the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1463-wk-Fact-DA1794B7EA31F028893B5F8E6B203669" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in revenues related to the Pfizer SB-525 agreement which were net of the approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1467-wk-Fact-6EB3D416558BCB5A7726D79D0AD65838" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" contextRef="FD2019Q1YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> reduction in revenues recorded in the three months ended March&#160;31, 2019 related to the updated estimated project cost.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">C</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">9</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">ORF</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">72</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"> Research Collaboration and License Agreement</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">December 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP transcription factors (&#8220;TFs&#8221;) to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal lobar degeneration (&#8220;FTLD&#8221;) linked to mutations of the C</span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;">ORF</span><span style="font-family:inherit;font-size:10pt;">72</span><span style="font-family:inherit;font-size:10pt;"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop&#160;ZFP TFs&#160;that bind to and specifically reduce expression of the mutant form of the C</span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;">ORF</span><span style="font-family:inherit;font-size:10pt;">72</span><span style="font-family:inherit;font-size:10pt;"> gene.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company received a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1508-wk-Fact-F42617D38F36548B8913EC599040DE77" name="sgmo:MilestonePaymentsReceived" contextRef="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment from Pfizer and is eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1512-wk-Fact-81CB7DF3766A8077EE87D79D0ADEBC1C" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" contextRef="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1516-wk-Fact-CC153AB76A62879F54DAD79D0ADE99ED" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" contextRef="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfCommercialMilestonesMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">90.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1521-wk-Fact-63BCD04392F30DC0B9FCD79D0A935DB3" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" contextRef="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember" unitRef="milestone" decimals="INF" scale="0" format="ixt-sec:numwordsen">None</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of the clinical or regulatory milestones have been included in the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1525-wk-Fact-F42617D38F36548B8913EC599040DE77" name="sgmo:MilestonePaymentsReceived" contextRef="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know&#8209;how to develop, manufacture and commercialize gene therapy products that use </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-4" continuedAt="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-5"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">resulting ZFP&#160;TFs that satisfy pre&#8209;agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the C9ORF72 gene.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;fifteen years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the C</span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;">ORF</span><span style="font-family:inherit;font-size:10pt;">72</span><span style="font-family:inherit;font-size:10pt;"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the C</span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;">ORF</span><span style="font-family:inherit;font-size:10pt;">72</span><span style="font-family:inherit;font-size:10pt;"> gene for a period of time.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has identified the performance obligations within this agreement as a license to the technology and on-going services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services, over the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1569-wk-Fact-B928F5B3332355138C4BD79D0AD28322" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.7</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1573-wk-Fact-EA34E22D8981F79A322FD79D0ADC36BF" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.8</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to this agreement.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-B42576846D233421A618D79D0AE83C04-0-wk-Fact-C2FD3F76FA29CA58F318D79D0AD68F14" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee related to Pfizer C9ORF72 agreement</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1794-wk-Fact-6BA88CDA606569849412EC220FABF714" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1813-wk-Fact-272C23BC220456A60105D79D0A98FD2C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1832-wk-Fact-F6B52FB59FAC27741701EC220FA78753" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,070</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1852-wk-Fact-7E6B1997051FCFB60CDBD79D0A9BEC44" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,076</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sanofi Genzyme</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with Biogen MA Inc., who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1867-wk-Fact-84DCA6F5C5AC1CCB1A60D79D0AD35544" name="sgmo:NumberOfResearchProgram" contextRef="D2014Q1Jan01-Jan31" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an investigational new drug (&#8220;IND&#8221;) application for ZFP therapeutics intended to treat SCD.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-5" continuedAt="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-6"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the agreement, the Company received an upfront license fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1877-wk-Fact-CD6DC40BB6F5A745AFF2D79D0ADF0AE1" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and is eligible to receive development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. In addition, the Company will also be eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1881-wk-Fact-33966C47E82FFD55E572D79D0ADDC0FA" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.8</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1885-wk-Fact-4C4B3938BF0F7680A64ED79D0ACC6AD6" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.5</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1889-wk-Fact-AC0DD14888034A644F19D79D0AD179E1" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">276.3</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1893-wk-Fact-923B2382B979EEC6B7C3D79D0AD8763D" name="sgmo:MilestonePaymentsReceived" contextRef="D2019Q3SD_srt_CounterpartyNameAxis_sgmo_BioverativIncMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> milestone payments have been received and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1898-wk-Fact-4DFB1E03D4718EAF7991D79D0AD6E685" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" contextRef="D2019Q3SD_srt_CounterpartyNameAxis_sgmo_BioverativIncMember" unitRef="U_sgmoProduct" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> products have been approved and therefore </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e1902-wk-Fact-15EBDDADF53C32848E7FD79D0AD8C25C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2019Q3SD_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> royalty fees have been earned under the Sanofi agreement.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon </span><span style="font-family:inherit;font-size:10pt;">180</span><span style="font-family:inherit;font-size:10pt;"> days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1916-wk-Fact-689A63D4B3673D689895D79D0A93E124" name="sgmo:CollaborativeArrangementTransactionPrice" contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.7</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> includes the upfront license fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1920-wk-Fact-942D2DE8F3529BC6B45DD79D0AD2F443" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1924-wk-Fact-9B0604A9FDB4D0959F8FD79D0ADCC96C" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.7</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> estimated reimbursable service costs for identified research projects over the estimated performance period, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the clinical or regulatory milestones have been included in the transaction price.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has identified the performance obligations within this arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1939-wk-Fact-292FB81F14E55608F92AD79D0A955C39" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q2_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e1943-wk-Fact-BF70DF13D8ED7E27ABC2D79D0ADBD8A0" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to this agreement.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-0C3B92DCB4BE8D93D923D79D0AE98B28-0-wk-Fact-929650F7D2CD6DEDE196D79D0ADEC0D7" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue related to Sanofi agreement:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2247-wk-Fact-66F09D9DC53B946C590FD79D0AA20325" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2266-wk-Fact-0B6C8BAAEA937C5D0244D79D0A9F90F8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2285-wk-Fact-2C623DE5E95018F3FCDCEC220C15F6CE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2305-wk-Fact-34C82964658361F9B0FED79D0AA01AAD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research services</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2320-wk-Fact-6AD0F70F6A3B7D5078FED79D0A9E50F1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2339-wk-Fact-7B7E66389C1EA8875F8CD79D0A9F0F4E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2358-wk-Fact-6D123DE265A3DE4B6B8EEC220C24B411" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2378-wk-Fact-14997E0985AD0088C0C7D79D0A9FDDAC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,560</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2403-wk-Fact-BD49466ACC3CB2FDAD8FD79D0A9E8DC0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2422-wk-Fact-D74D3591156DA1710DFBD79D0A9EC67B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2441-wk-Fact-C6A0F08CEABCEEF4B4F6EC220C1B7463" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,009</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94597376e2461-wk-Fact-EE3AAF88852545748ADCD79D0A9D83D2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">California Institute for Regenerative Medicine</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e2476-wk-Fact-CD04CDACBD93B94EA9BFD79D0ADA124E" name="sgmo:GrantFundingAmount" contextRef="D2018Q2May01-May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had received </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e2488-wk-Fact-C389DB8F2875658E0077D79D0A934FC3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2019Q2SD_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e2492-wk-Fact-7CDA1BAF5F377529213AEC2FD29EE120" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, under the award.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. In the event that the Company terminates a CIRM-funded clinical trial, it will be obligated to repay the remaining CIRM funds on hand, therefore as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e2507-wk-Fact-49C3DB194CFF4F3FCFBFD79D0AD0D9A3" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94597376e2511-wk-Fact-771B6E4592FEE874FD10D79D0AD620BB" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, including interest, related to </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-6"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts with the next 12 months.</span></div></ix:continuation><div><a id="s80C6631549A35E61A93F4FDD749CE806"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 6&#8212;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-A242D78A5D042269C653D79D0AE9E26D-0-wk-Fact-EEC6B6F31C284CE01393D79D0A96455E" continuedAt="TextSelection-A242D78A5D042269C653D79D0AE9E26D-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A242D78A5D042269C653D79D0AE9E26D-1"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo&#8217;s history of losses. Accordingly, the Company&#8217;s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.</span></div></ix:continuation><div><a id="sE8F16B0F46C15731865A96AD08D86E19"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 7&#8212;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-FF941575463DD0B524F0D79D0AE9D0BF-0-wk-Fact-0D7E35DF3B87AAA7A837D79D0A99F70B" continuedAt="TextSelection-FF941575463DD0B524F0D79D0AE9D0BF-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-25F4A9C506285C19D65DD79D0AE96E16-0-wk-Fact-E8AB837F80A5EEF6337CD79D0A98564D" escape="true"><ix:continuation id="TextSelection-FF941575463DD0B524F0D79D0AE9D0BF-1"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e666-wk-Fact-7F7DD6FB3E874F2D7082D79D0AA1FE52" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,763</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e684-wk-Fact-A92FF196F6283EEE867BD79D0AA244DD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e702-wk-Fact-37E65EE4A11B46E3C93711A7190A65DC" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,061</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e721-wk-Fact-440DBF7A6F8C5E4563FAD79D0AA0B9C3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e736-wk-Fact-148BB63DDF4CD2DECC80D79D0AA310D7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e754-wk-Fact-DAF31DECD01E1BDF3267D79D0AA0964F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e772-wk-Fact-E935F641307A6888B65811A7190ADC9D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,329</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e791-wk-Fact-939381144589CE565154D79D0A9FC06C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e816-wk-Fact-F1EDCBFC01F39C83CADED79D0AA2BA3F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e834-wk-Fact-9D709B151FD61354D4B8D79D0A9FDB6E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e852-wk-Fact-B3187B89BA4588A77D9FD79D0AA3AACD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94591828e871-wk-Fact-63A52490FE2DE5CEA78ED79D0AA1EA0E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="s7B62539A3F8657F3A3EA1B3AA2128EEC"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 8&#8212;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-8127E64BAD175E717B73D79D0AE9C361-0-wk-Fact-88196C56952590C0496CD79D0AA41C1A" continuedAt="TextSelection-8127E64BAD175E717B73D79D0AE9C361-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8127E64BAD175E717B73D79D0AE9C361-1" continuedAt="TextSelection-8127E64BAD175E717B73D79D0AE9C361-2"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo occupies approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e461-wk-Fact-19C5423E9D86EE29C01E6321740C4D64" name="us-gaap:LandSubjectToGroundLeases" contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeAndLaboratoryMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">87,700</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office and research and development laboratory facilities in Brisbane, CA pursuant to a lease that expires in </span><span style="font-family:inherit;font-size:10pt;">May 2029</span><span style="font-family:inherit;font-size:10pt;">. Sangamo also leases approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e469-wk-Fact-6F82C8B393A198661063D79D0A95B3A9" name="us-gaap:LandSubjectToGroundLeases" contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeAndLaboratoryMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">37,900</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in Richmond, CA through August 2026. The Company leases approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e473-wk-Fact-61EF34C3A203E4864AAFD79D0ADD288A" name="us-gaap:LandSubjectToGroundLeases" contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">7,700</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of additional research and office space located in Richmond, CA pursuant to a lease that expires in December 2019. In addition, the Company leases </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e477-wk-Fact-019DFF4F86CBB5CD53B462812CE6013F" name="sgmo:LesseeOperatingLeaseNumberOfContracts" contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember" unitRef="contract" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> properties in Valbonne, France. The first lease is for approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e482-wk-Fact-1879D54CA3CEE07F56ABD79D0A94F1C8" name="us-gaap:LandSubjectToGroundLeases" contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">14,036</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of research and office space that expires in </span><span style="font-family:inherit;font-size:10pt;">June 2025</span><span style="font-family:inherit;font-size:10pt;">. The second lease, which commenced on </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d94592364e490-wk-Fact-C227CD95D9C2F38BF51ED79D0AD9BBF3" name="sgmo:LeaseCommencementDate" contextRef="FD2019Q1YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseTwoMember" format="ixt:datemonthdayyearen">April 1, 2019</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;">, is for approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e494-wk-Fact-B5863FB3EAF860A3E872D79D0AC9F5D2" name="us-gaap:LandSubjectToGroundLeases" contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseTwoMember" unitRef="sqft" decimals="INF" scale="0" format="ixt:numdotdecimal">6,800</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office space and expires in </span><span style="font-family:inherit;font-size:10pt;">March 2028</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94592364e509-wk-Fact-7B761157B14A4A2F1CDBD79D0AC427D6" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to the Brisbane lease, the commencement date for approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e516-wk-Fact-0A18DB87CB4E3CCD862AD79D0AC5E96B" name="sgmo:CommencementLandSubjectToGroundLeases" contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember" unitRef="sqft" decimals="INF" scale="0" format="ixt:numdotdecimal">35,080</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of the office space occurred in January 2019 while the commencement date for the remaining approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e520-wk-Fact-7A9618B8C99FE19C5D99D79D0A9CC908" name="sgmo:RemainingCommencementLandSubjectToGroundLeases" contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember" unitRef="sqft" decimals="INF" scale="0" format="ixt:numdotdecimal">52,620</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet occurred in June 2019. The Company has the right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94592364e524-wk-Fact-ADBFF72238D2C8F981E7D79D0A93B357" name="sgmo:LesseeOperatingLeaseLiabilityTenantImprovementAllowance" contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.8</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> on the first portion of the space occupied and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94592364e528-wk-Fact-440957D15216A888B57CD79D0A97765D" name="sgmo:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> on the portion of the lease that commenced in June 2019. This lease includes </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e532-wk-Fact-40D1AF270F8E61561AEDD79D0ADFAE55" name="sgmo:OperatingLeasesNumberOfExtensionOptions" contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember" unitRef="renewal_option" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> renewal options at the election of the Company to extend the lease for an additional </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94592364e537-wk-Fact-20DC3E2F7086FC09DDE2D79D0ADE38C4" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> each. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company incurred </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$<ix:nonFraction id="d94592364e552-wk-Fact-C3783F67B8AE97944B47ECB64418B2F7" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94592364e556-wk-Fact-7D175DB20BA8BE5C6663ECB6D96FFEDB" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of lease costs included in operating expenses in the Condensed Consolidated Statements of Operations in relation to these operating leases. Variable lease expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94592364e560-wk-Fact-28A638C069BE22BC630E453D6EA3ACCE" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94592364e565-wk-Fact-16BF40255446560C9152D79D0A95A4AC" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and was not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94592364e588-wk-Fact-8192EBBCF3C3CDBCA856D79D0AA3BCAD" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and was included in net cash used in operating activities in the Company&#8217;s Condensed Consolidated Statements of Cash Flows.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-8127E64BAD175E717B73D79D0AE9C361-2"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-325B54E53F086B8D1038D79D0AE9322E-0-wk-Fact-F9A7CD647780D4C72F00D79D0ADE75AB" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:89%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six months ending December&#160;31, 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e647-wk-Fact-ECE2D4C043908EC68C6DD79D0AC89337" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,135</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e662-wk-Fact-8CC2DD7058E28ADD8950D79D0AC738DC" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,065</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e682-wk-Fact-6ACC6290A9F5E3CC79FED79D0AB0B1EE" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e702-wk-Fact-CAEA1DD60B2793C75EB3D79D0AC4FB05" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e722-wk-Fact-550C1CE9B3CDECE16B1CD79D0AC20B22" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e742-wk-Fact-57203D8FFEDF27CE90F6D79D0AC9EF59" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e762-wk-Fact-0F1771949EC1D56B2794D79D0AC739E5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,704</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Imputed interest</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94592364e803-wk-Fact-8477D49382B988D245F1D79D0ACB4362" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,669</ix:nonFraction></span></span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e829-wk-Fact-DD30DE08743CCB115093D79D0AD058D0" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,035</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reported as of June&#160;30, 2019:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed    Consolidated Balance Sheet)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e892-wk-Fact-95A45F1D5FB3C90F6BCCD79D0ACD90C4" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - long-term</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e907-wk-Fact-5376ED04C4E343E95870D79D0AB9B12A" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e932-wk-Fact-DD30DE08743CCB115093D79D0AD058D0" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,035</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the weighted-average remaining lease term is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d94592364e948-wk-Fact-C8687F20337839BC1B3BD79D0AC235E0" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q2" format="ixt-sec:duryear">9.3</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;years and the weighted-average incremental borrowing rate used to determine the operating lease liability was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94592364e952-wk-Fact-686422C52DC5FB86350DD79D0A9B95BF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q2" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">6.9</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the Company&#8217;s operating leases.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not have any financing leases.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo is not party to any material pending legal proceedings or contingencies. From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business.</span></div></ix:continuation><div><a id="s53CB031AC3EA581CB02D55F6A3AD38C4"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 9&#8212;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-035F2BFD3F3527ABFAEAD79D0AE9A8A1-0-wk-Fact-59695B10F554D3D183E5D79D0AA5BCA1" continuedAt="TextSelection-035F2BFD3F3527ABFAEAD79D0AE9A8A1-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="TextSelection-035F2BFD3F3527ABFAEAD79D0AE9A8A1-1"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">April 2019</span><span style="font-family:inherit;font-size:10pt;">, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595400e465-wk-Fact-ADBB1794D1D98212CB80D79D0AA706D3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2019Q2Apr1-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at a public offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94595400e469-wk-Fact-88D4E30A34C0E9445F2BD79D0AA4CB1D" name="us-gaap:SharesIssuedPricePerShare" contextRef="I2019Q2Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.50</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94595400e473-wk-Fact-9FEA3889093C22E7F1C1D79D0AA32157" name="sgmo:NetProceedsFromIssuancePublicOffering" contextRef="D2019Q2Apr1-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">136.3</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">April 2018</span><span style="font-family:inherit;font-size:10pt;">, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94595400e484-wk-Fact-E2977F6962E610B57E1AD79D0AA63A99" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2018Q2Apr01-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.2</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at a public offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94595400e488-wk-Fact-55B20C09909A6091A9C4D79D0AA5CE46" name="us-gaap:SharesIssuedPricePerShare" contextRef="I2018Q2Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.25</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94595400e492-wk-Fact-639B02B7319545294B23D79D0AA1051F" name="sgmo:NetProceedsFromIssuancePublicOffering" contextRef="D2018Q2Apr01-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">215.8</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">At-the-Market Offering Agreement</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the Company entered into an amended and restated &#8220;at-the-market&#8221; offering program sales agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;), pursuant to which the Company may issue and sell from time to time up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94595400e502-wk-Fact-928AD52B7D4828D1B9CCD79D0AA42708" name="sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance" contextRef="I2016Q1Dec07_us-gaap_SubsidiarySaleOfStockAxis_sgmo_AtTheMarketOfferingAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s common stock through Cowen as the sales agent (the &#8220;ATM Agreement&#8221;). Sales of the Company&#8217;s common stock, if any, will be made at market prices by any method that is deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 under the Securities Act of 1933, as amended. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has not sold any common stock under the ATM Agreement and the full </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94595400e510-wk-Fact-C8D4076914F3CA7A93AED79D0AA40C2D" name="sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance" contextRef="FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_sgmo_AtTheMarketOfferingAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> remained available for sale, subject to certain conditions as specified in the agreement.</span></div></ix:continuation><div><a id="sF9087DCA113254C29CAF2BF562458419"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 10&#8212;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-18E6F25E859B4D80C98CD79D0AE9F3FA-0-wk-Fact-5CD955B5670D0BCAC86FD79D0AA5A077" continuedAt="TextSelection-18E6F25E859B4D80C98CD79D0AE9F3FA-1" escape="true">ACQUISITION OF TXCELL S.A.</ix:nonNumeric></span></div><ix:continuation id="TextSelection-18E6F25E859B4D80C98CD79D0AE9F3FA-1" continuedAt="TextSelection-18E6F25E859B4D80C98CD79D0AE9F3FA-2"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July&#160;20, 2018, Sangamo entered into several agreements with TxCell S.A. (&#8220;TxCell&#8221;), a French publicly-listed company specialized in the development of cellular immunotherapy products based on regulator T-cells (&#8220;Tregs&#8221;) to treat severe autoimmune and inflammatory diseases, and certain of its shareholders, with the goal of eventually acquiring </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e458-wk-Fact-DEEE8F9412954C1365C7D79D0AA9895A" name="sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" contextRef="I2018Q3July20_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of TxCell&#8217;s share capital.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-18E6F25E859B4D80C98CD79D0AE9F3FA-2" continuedAt="TextSelection-18E6F25E859B4D80C98CD79D0AE9F3FA-3"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under a Share Purchase Agreement (&#8220;SPA&#8221;) signed with certain shareholders of TxCell, the Company acquired </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e465-wk-Fact-ACA5AD7D4DF3A84E2B2DD79D0A9E2126" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,519,036</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> ordinary shares of TxCell (&#8220;TxCell Ordinary Shares&#8221;), representing approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e469-wk-Fact-9457235D7C47FB746441D79D0AD2C2BA" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">53</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding share capital and voting rights of TxCell, (the &#8220;Block Transaction&#8221;) at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;<ix:nonFraction id="d94598408e473-wk-Fact-9FBA169E05D72C08CBCCD79D0AAB6D0C" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2018Q4Oct01_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="eurPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.58</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The Block Transaction closed on October&#160;1, 2018 (the &#8220;Acquisition Date&#8221;).</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, the Company and TxCell entered into a Tender Offer Agreement (&#8220;TOA&#8221;), pursuant to which the Company agreed to acquire </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e480-wk-Fact-6D4B5AD660186F394C9BD79D0AABEEA5" name="sgmo:BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" contextRef="I2018Q4Nov23" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,981,867</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> TxCell Ordinary Shares not acquired as part of the Block Transaction following a public tender offer (the &#8220;Tender Offer&#8221;) at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;<ix:nonFraction id="d94598408e484-wk-Fact-9FBA169E05D72C08CBCCD79D0AAB6D0C" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2018Q4Oct01_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="eurPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.58</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. The Tender Offer closed on November&#160;23, 2018.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following the Block Transaction and the Tender Offer, the Company owns </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e491-wk-Fact-5D3CB30A063EC9FCCD1BD79D0ACEEDFE" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">98.2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of TxCell Ordinary Shares.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the Company also entered into arrangements with the holders of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e498-wk-Fact-8BCA9FF2B4C38883C8E2D79D0ACB5793" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="shares" decimals="-3" scale="0" format="ixt:numdotdecimal">477,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> &#8220;free shares&#8221; of TxCell pursuant to which the Company has the right to purchase such shares from the holders thereof (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#8220;Free Shares Options&#8221;) so as to increase the Company&#8217;s ownership of TxCell to 100% should all free shares be acquired following through the exercise of either the call or the put options.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purchase price for each such free share acquired by the Company upon exercise of a Free Shares Option will be based on the performance of the Company&#8217;s stock price from the announcement of the transactions contemplated by the SPA and TOA through the Acquisition Date. At the Acquisition Date, the Free Shares Options purchase price was valued at </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;<ix:nonFraction id="d94598408e505-wk-Fact-9FBA169E05D72C08CBCCD79D0AAB6D0C" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2018Q4Oct01_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="eurPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.58</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share or approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e509-wk-Fact-22FCD91D569B9F182109D79D0A9FD35B" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">2.99</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share using an exchange rate of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e513-wk-Fact-301E4C5D2025A70B600BD79D0ACBC1BA" name="sgmo:BusinessAcquisitionExchangeRateOnPurchasePrice" contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="number" decimals="2" scale="0" format="ixt:numdotdecimal">1.16</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">. If the Company&#8217;s stock price increases during that time period, the Free Shares Options purchase price per share will proportionately increase. If the Company&#8217;s stock price decreases, the Free Shares Options purchase price will proportionately decrease, the minimum purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;<ix:nonFraction id="d94598408e517-wk-Fact-1DAE67AE92FCE5191D48D79D0AA25051" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="eurPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.58</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share only applies to vested Free Shares Options that are not yet transferable shares, subject to certain exceptions.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e524-wk-Fact-345B39B6665800828047D79D0AD4702B" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> based on an option pricing method. The value was included in the purchase consideration and is recorded as a non-controlling interest on the Condensed Consolidated Balance Sheets. The fair value of the Free Shares Options will vary based on future changes in the Company&#8217;s stock price during the option period. The Company assesses this fair value on a quarterly basis with changes in fair value being recognized in operations. The fair value of the Free Shares Options was estimated to be an asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e528-wk-Fact-EBC79AD34AB86E47CE4653C5FF4A775D" name="sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company provided TxCell with a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e539-wk-Fact-90DBB998B8C26BF7AF5ED79D0ACFE98D" name="sgmo:BusinessCombinationLoanAdjustedInPurchaseConsideration" contextRef="D2018Q3Sep1-Sep30_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> loan (the &#8220;TxCell Loan&#8221;) that was deemed to be part of the purchase consideration for accounting purposes. The TxCell Loan, together with </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e543-wk-Fact-94A5D402925A38F49BCDD79D0AA50CC2" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2018Q3Sep1-Sep30_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.5</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> cash paid to acquire the TxCell Ordinary Shares and the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e547-wk-Fact-D03007B0D2FECFF9CB27D79D0AA84D1D" name="sgmo:BusinessAcquisitionEstimatedFairValueOfFreeShares" contextRef="D2018Q3Sep1-Sep30_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> estimated fair value of the Free Shares Options, comprise the aggregate purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e551-wk-Fact-124579E406567A80E512D79D0AACC9F3" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2018Q3Sep1-Sep30_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.9</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> as of the Acquisition Date.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible), liabilities assumed, as well as tax-related matters. During the measurement period, the Company may record adjustments to the provisional amounts recognized. There were no adjustments to the provisional values subsequent to the Acquisition Date.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The acquisition of TxCell was accounted for as a business combination in accordance with ASC Topic 805, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</span><span style="font-family:inherit;font-size:10pt;">. The operating results of TxCell after the Acquisition Date have been included in the Company&#8217;s Condensed Consolidated Statements of Operations. In June 2019, TxCell became a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">soci&#233;te par actions simplifi&#233;e </span><span style="font-family:inherit;font-size:10pt;">(S.A.S.) and was renamed &#8220;Sangamo Therapeutics France.&#8221;</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Estimate of Assets Acquired and Liabilities Assumed</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC Topic 805, an acquirer recognizes and consolidates assets acquired, liabilities assumed, and any non-controlling interest at </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e576-wk-Fact-A90BE283AE5D7BCCBE02D79D0AA0376D" name="sgmo:BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of their fair values as of the acquisition date (regardless of the acquirer&#8217;s percentage ownership in the acquiree). As goodwill is calculated as a residual, all goodwill of the acquired business, not just the acquirer&#8217;s share, is recognized under this &#8220;full-goodwill&#8221; approach. Recognized goodwill is allocated between the controlling and non-controlling interests. Although this allocation is not presented separately on the acquirer&#8217;s balance sheet, it is necessary so that a goodwill impairment charge recognized in a period following the business combination by an acquirer is appropriately allocated between controlling and non-controlling interests. There were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e580-wk-Fact-89B812EBFEFF8CF2D485D79D0ACE4B6C" name="us-gaap:GoodwillImpairmentLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> goodwill impairments during the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> or during </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-18E6F25E859B4D80C98CD79D0AE9F3FA-3"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="TextSelection-11B15B5E586A41D2AB0CD79D0AEA0042-0-wk-Fact-9A0518E7827D3288C391D79D0A9C35F1" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the estimated fair value of the net assets acquired as of the Acquisition Date (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:89%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">October 1, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consideration transferred</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e656-wk-Fact-B0BFEDA84C8518909DA4D79D0AA7A045" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e671-wk-Fact-168AF0D12C6A96A5AAE0D79D0AD4666B" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of TxCell</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e696-wk-Fact-9CD1C118F090901B94CAD79D0A9BA697" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e737-wk-Fact-AFFA2E9C7E23504FCF22D79D0A9C48FF" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,779</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e752-wk-Fact-962C9E0F9F80C6300C3FD79D0A9ABB5B" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e772-wk-Fact-59F5BA9A24E372E972FBD79D0A9FBB76" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e792-wk-Fact-0B1E1DD8BEB5987471B6D79D0AA669E2" name="sgmo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,019</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e812-wk-Fact-7769BD58127558A388A1D79D0A9F39D7" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94598408e832-wk-Fact-B506AE369100E613A2A0D79D0AD2EB57" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,761</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assumed debt liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94598408e854-wk-Fact-349EF1505DCED87E1C1FD79D0A96B47C" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94598408e875-wk-Fact-2729CE0030FFACDCCFD1D79D0A968632" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,798</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e896-wk-Fact-EDE3A6444905787F0C65D79D0A9E7787" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42,745</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e916-wk-Fact-5B53AF00DD58AA3B3FDDD79D0AA94FEE" name="us-gaap:Goodwill" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total fair value of net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e941-wk-Fact-9CD1C118F090901B94CAD79D0A9BA697" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consideration Transferred</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consideration transferred as of October&#160;1, 2018 consisted of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e956-wk-Fact-B0649D405E1FED35C94FEC3FB14D68AD" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,519,036</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> TxCell Ordinary Shares acquired by the Company on the Acquisition Date of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e960-wk-Fact-53A03C1702E4E01209DAD79D0ACD2B48" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.99</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e964-wk-Fact-420C688FA92558512F89D79D0ACB720F" name="sgmo:BusinessCombinationLoanAdjustedInPurchaseConsideration" contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> TxCell Loan and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e968-wk-Fact-345B39B6665800828047D79D0AD4702B" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for the fair value of the Free Shares Options.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Non-controlling Interest</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the non-controlling interest at the Acquisition Date was based on the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e978-wk-Fact-A9055918EFD75EE77112D79D0AA5BEAC" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2018Q4Oct01" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.99</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> acquisition price per share for the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e982-wk-Fact-6D4B5AD660186F394C9BD79D0AABEEA5" name="sgmo:BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" contextRef="I2018Q4Nov23" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,981,867</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> Ordinary Shares that were not purchased by the Company on the Acquisition Date.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November&#160;1, 2018, pursuant to the TOA, the Company commenced a cash tender offer (the &#8220;Offer&#8221;) to acquire all of the TxCell Ordinary Shares not held by the Company for the same per share price paid in the Block Transaction. Following the completion of the Offer on November&#160;23, 2018, the Company initiated compulsory squeeze-out procedures applicable to French public companies to acquire the remaining TxCell Ordinary Shares, other than the free shares that were subject to the Free Shares Options. Subsequent to the Acquisition Date and through </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company acquired </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e993-wk-Fact-15F95B32426E9AFBF39BD79D0AA451D4" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" contextRef="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,528,635</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;TxCell Ordinary Shares which, when aggregated with the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e997-wk-Fact-B0649D405E1FED35C94FEC3FB14D68AD" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,519,036</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> Ordinary Shares acquired at the Acquisition Date, resulted in the Company owning </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e1001-wk-Fact-5D3CB30A063EC9FCCD1BD79D0ACEEDFE" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">98.2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of all TxCell Ordinary Shares as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e1010-wk-Fact-15F95B32426E9AFBF39BD79D0AA451D4" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" contextRef="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,528,635</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares acquired subsequent to the Acquisition Date were acquired for total consideration of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e1014-wk-Fact-52E0945A2457BDDDD24BD79D0A9DA681" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.9</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e1018-wk-Fact-0D3D3CA014F91F85F7E3D79D0AAACF2C" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.94</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the aggregate purchase consideration was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e1026-wk-Fact-BECD25FB4F2076CD64D0D79D0ACC1DB2" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.4</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> through the completion of this purchase, with approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e1030-wk-Fact-E3FFD2C41446A16F644FD79D0AC902E2" name="sgmo:BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="shares" decimals="-3" scale="0" format="ixt:numdotdecimal">453,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> Ordinary Shares (vested free shares), which remain outstanding and are subject to purchase by the Company as noted above, with an estimated fair value of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d94598408e1035-wk-Fact-17F7DF9693E92C6D3D78654592E03125" name="sgmo:BusinessAcquisitionEstimatedFairValueOfFreeShares" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="sgmo:ScheduleOfNoncontrollingInterestTableTextBlock" id="TextSelection-1BAD86C96554BC73AAB0D79D0AEAA5DB-0-wk-Fact-1EDC2069D782022EE7D2D79D0AA44F81" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was as follows (in thousands):</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:89%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e1077-wk-Fact-86C300C1BF11F4C5CF30D79D0A94D764" name="us-gaap:MinorityInterest" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at Acquisition Date</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e1092-wk-Fact-E9A7C96E47C7F819D3B9D79D0A972A56" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares acquired post acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94598408e1112-wk-Fact-BF8CF5D87321469DE588D79D0A956085" name="sgmo:PostBusinessAcquisitionSharesAcquiredAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest of acquired entity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e1133-wk-Fact-DA2D3A3DB423C639ABFED79D0A961CCC" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency effect</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94598408e1153-wk-Fact-7CFFB26A3FC4ABEB559AD79D0A981D50" name="sgmo:NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss attributable to non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94598408e1174-wk-Fact-F0C12CBECCBAFAF3CEF9D79D0A961436" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">555</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at December&#160;31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e1195-wk-Fact-5BC2E4BF3B544D9C0A16D79D0ACC2989" name="us-gaap:MinorityInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss attributable to non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d94598408e1215-wk-Fact-C398701DA594F86769A7E7D7F73F1EDD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d94598408e1241-wk-Fact-1930E75AE6EC2D9A44FDD79D0AC4175A" name="us-gaap:MinorityInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sDA0017B46BA05D38AE8971FB23ED7049"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160; 2.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, without limitation, statements containing the words &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;continue,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will&#8221; and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially from those set forth in such forward-looking statements as a result of, but not limited to the &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. You should read the following discussion and analysis along with the financial statements and notes attached to those statements included elsewhere in this report and in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, or the </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report, as filed with the Securities and Exchange Commission, or SEC, on March&#160;1, 2019.</span></div><div><a id="s55E2BF964D8559FC848546D19FAED288"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a clinical stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients&#8217; lives using our platform technologies in gene therapy, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</span><span style="font-family:inherit;font-size:10pt;"> gene-edited cell therapy, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:10pt;"> genome editing and gene regulation.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our strategy is to maximize the value and therapeutic use of our technology platforms. In certain therapeutic areas we intend to capture the value of our proprietary gene therapy and genome editing products by forward integrating into manufacturing, development and commercial operations. In other therapeutic areas we intend to partner with biopharmaceutical companies to develop products as appropriate. Decisions to partner product candidates or not will be based on the best way to bring new medicines to patients and on an evaluation of our capacity to bring such products to commercial stage rapidly and efficiently on our own. For our proprietary clinical development programs, we are focused on three therapeutic areas: inherited metabolic diseases, or IMDs, central nervous system diseases and inflammatory and autoimmune diseases.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. We have used our knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors, or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, we have accrued significant scientific, manufacturing and development capabilities and know-how that are generally applicable in the broader field of gene therapy and have capitalized this knowledge into a conventional gene therapy platform.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a substantial intellectual property position including the design, selection, manufacture, composition and use of engineered ZFPs, CAR-Tregs and cell therapies to support our research and development activities. We continue to license and file new patent applications that strengthen our patent portfolio. We believe that our intellectual property position is a critical element in our ability to research, develop, manufacture and commercialize gene therapy, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</span><span style="font-family:inherit;font-size:10pt;"> gene-edited cell therapy, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:10pt;"> genome editing and gene regulation products and services.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gene therapy programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are conducting the Phase 1/2 Alta study, an open-label, ascending-dose clinical trial to evaluate investigational SB-525 gene therapy for severe hemophilia A. SB-525 is being developed under global collaboration with Pfizer Inc., or Pfizer, for the research, development and commercialization of gene therapy product candidates for hemophilia A. Under this agreement, we are responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2019, we and Pfizer announced updated initial data from 10 patients treated in the Alta study. Across the four dosage cohorts evaluated, patients demonstrated a dose-dependent increase in Factor VIII, or FVIII, levels, and a dose-dependent reduction in the use of FVIII replacement therapy was also observed, with patients in the highest dose cohort not requiring factor replacement therapy after initial use of prophylactic factor and experiencing no bleeding events as of the data cut-off date. For the four patients in the highest dose (3e13 vg/kg) cohort, FVIII activity data were available through 24, 19, 6, and 4 weeks of follow-up, respectively. The first two patients treated in the 3e13 vg/kg cohort (Patients 7 and 8) remained in the normal range, as measured using a chromogenic assay, through 24 and 19 weeks of follow-up, respectively. The next two patients in the 3e13 vg/</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">kg cohort (Patients 9 and 10), with 6 and 4 weeks of follow-up, respectively, demonstrated rapid FVIII activity kinetics that appear consistent with Patients 7 and 8 at similar early time points. SB-525 was generally well-tolerated, with one patient (treated with the 3e13 vg/kg dose) reporting a treatment-related serious adverse event of hypotension and fever, which occurred following vector infusion and resolved with treatment within 24 hours of completion of vector infusion. The fifth patient in the 3e13 vg/kg cohort (Patient 11) was treated in July 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on the accumulating results from the Alta study, the U.S. Food and Drug Administration, or FDA, has granted regenerative medicine advanced therapy, or RMAT, designation for SB-525 gene therapy to treat severe hemophilia A. RMAT designation is granted to regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition, for which preliminary clinical evidence indicates that the medicine has the potential to address an unmet medical need. The RMAT designation includes all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with the FDA.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently working with Pfizer on plans to advance SB-525 to a registrational study. Pfizer will assume responsibility for SB-525 late-stage development and manufacturing and we have initiated the transfer of the SB-525 manufacturing process to Pfizer.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also evaluating our wholly-owned investigational ST-920 gene therapy for Fabry disease, an inherited metabolic disease. An investigational new drug application, or IND, was accepted by the FDA in February 2019. We have activated the first clinical site for a Phase 1/2 clinical trial and expect to treat the first subject in the study by the end of 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ex vivo gene edited cell therapy programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are conducting the Phase 1/2 THALES study, an open-label, single arm clinical trial to evaluate the safety and efficacy of ST-400 in up to six subjects with beta thalassemia. ST-400 is an </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</span><span style="font-family:inherit;font-size:10pt;"> gene-edited beta thalassemia cell therapy that involves gene editing of a patient&#8217;s own hematopoietic stem progenitor cells using non-viral delivery of ZFN technology. ST-400 is being developed in collaboration with Sanofi Genzyme, or Sanofi, to research, develop and commercialize therapeutic gene-edited cell therapy products in hemoglobinopathies, including beta thalassemia and sickle cell disease, or SCD. Sanofi is responsible for subsequent development, manufacturing and commercialization of licensed products. The collaboration includes a related program evaluating BIVV003 for the treatment of SCD. BIVV003 uses the same technology as ST-400 and is currently being evaluated in a Phase 1/2 clinical trial conducted by Sanofi.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019, we announced early preliminary data from the first patient enrolled in the study. Recruitment of this study is ongoing, with four of six patients enrolled. We expect to present preliminary data from the first patients enrolled in the study in the fourth quarter of 2019. Until that time, we are not planning to report additional clinical data from the program. More complete results will become available and presented once enrollment is complete and patients have been followed for a longer period. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, we entered into a global collaboration and license agreement with Kite Pharma, Inc., or Kite, a wholly owned subsidiary of Gilead Sciences, Inc., for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, we are working together with Kite on a research program under which we are designing ZFNs and adeno-associated viral vectors, or AAVs, to disrupt and insert certain genes in T-cells and natural killer cells, or NK-cells, including the insertion of genes that encode chimeric antigen receptors, T-cell receptors, and NK-cell receptors directed to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products and has announced that they expect to initiate a clinical trial evaluating KITE-037, an allogeneic anti-CD19 CAR-T cell therapy, in 2020.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2018, we completed our acquisition of 98.2% of the outstanding share capital and voting rights of TxCell S.A., or TxCell, which was renamed Sangamo Therapeutics France in June 2019. With the acquisition of TxCell, or the TxCell Acquisition, we believe we can now accelerate our research and development of innovative, personalized T-cell immunotherapies for the treatment of inflammatory and autoimmune diseases with high unmet medical need. In this regard, we expect the TxCell Acquisition will accelerate our entry into the clinic with a CAR-Treg (which is a regulatory T-cell, or Treg, genetically modified with a chimeric antigen receptor, or CAR) therapy. We are evaluating the potential of CAR-Tregs in solid organ transplantation as well as a range of autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases and inflammatory skin diseases. In addition, we intend to use our ZFN gene editing technology to potentially develop next-generation autologous and allogeneic CAR-Treg cell therapies for use in treating autoimmune diseases. In 2019, we anticipate submitting a clinical trial application in Europe for TX-200, an autologous CAR&#8209;Treg cell therapy for the prevention of solid organ transplant rejection.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">In vivo genome editing and gene regulation programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have three proprietary </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:10pt;"> genome editing programs being evaluated in Phase 1/2 clinical trials: SB-913 (Mucopolysaccharidosis type II, or MPS II), SB-318 (MPS I), and SB-FIX (hemophilia B). In April 2019, we announced that we expect that no additional patients will be treated with first-generation ZFNs in the SB-913, SB-318 and SB-FIX clinical programs </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">given that clinical benefit has not been demonstrated in analyses conducted to date in the ongoing clinical trials and the expected near-term clinical development of second-generation ZFNs.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are planning a new clinical trial for SB-913 to treat MPS III to evaluate second-generation ZFNs and other potential modifications to enhance the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo </span><span style="font-family:inherit;font-size:10pt;">delivery of the ZFNs. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In vitro</span><span style="font-family:inherit;font-size:10pt;"> preclinical data presented last year showed three potential advantages of second-generation ZFNs for use in the clinic: (1)&#160;improvements in efficiency and potency due to structural modifications to the ZFN architecture and expression vector; (2)&#160;the ability to function equally well in the patients with a single nucleotide polymorphism, or SNP, in the target locus in the albumin gene (~20% of the population); and (3)&#160;improvements in specificity. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to initiate this next clinical trial by year end 2020. We expect to use data from the new study evaluating second generation ZFNs to make a Phase III decision for the SB-913 program and to define the next steps for the SB-318 and SB&#8209;FIX programs.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have several preclinical programs evaluating our zinc finger protein transcription factor, or ZFP TF, gene regulation technology. ZFP TFs act at the DNA level to selectively repress or activate the expression of specific genes to achieve a desired therapeutic effect. Gene regulation differs from other genome editing approaches as it is designed to enable precise, robust, and long-term repression of a selected gene following a single administration of AAV and does not cut or modify the target DNA.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March and April 2019, we presented new preclinical data describing the effects of tau-targeted ZFP TFs, delivered with AAVs in the mouse and nonhuman primate, or NHP, brain. Intrahippocampal ZFP TF delivery to adult mice resulted in more than 80% tau reduction, and intravenous ZFP TF administration reduced tau levels by 50-70% across the entire mouse brain. AAV ZFP TFs targeting tau were administered to the adult NHP hippocampus using real-time MRI-guided stereotaxic infusion. The lowering of tau in the hippocampus and entorhinal cortex of NHP was correlated with the transgene expression levels. The treatment was well tolerated for the duration of the study. We believe that together, these preclinical data from mice and NHPs highlight the potential for a single administration of ZFP TF to lower tau as a treatment for tauopathies, including Alzheimer&#8217;s disease.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2017, we entered into a research collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP TFs to treat amyotrophic lateral sclerosis, or ALS, and frontotemporal lobar degeneration, or FTLD, linked to mutations of the C9ORF72 gene. Under this agreement, we are working with Pfizer on a research program to identify, characterize and preclinically develop ZFP TFs that satisfy pre-agreed criteria. Pfizer is responsible for subsequent development, manufacturing and commercialization of licensed products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our revenues have consisted primarily of revenues from our corporate partners, contractual payments from strategic partners for research services and milestones and research grant funding. We expect revenues to continue to fluctuate from period to period and there can be no assurance that new collaborations or partner funding will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred net losses since inception and expect to incur losses in the future as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities, revenues from corporate collaborations and research grants.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our gene therapy and our genome editing programs in the clinic and, if we are able, to progress our earlier stage product candidates into clinical trials. Pursuant to the terms of the agreements with Kite and Sanofi, certain expenses related to research and development activities will be reimbursed to us. The reimbursement funds to be received from Kite and Sanofi will be recognized as revenue as the costs are incurred and collection is reasonably assured.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparability</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We adopted Accounting Standards Codification Topic 842</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8212;Leases</span><span style="font-family:inherit;font-size:10pt;">, or ASC Topic 842, on January&#160;1, 2019, resulting in changes to our accounting policy for leases. We used the modified retrospective approach and recognized the cumulative effect of initially applying ASC Topic 842 as an adjustment to the opening balances of the lease related accounts and accumulated deficit at January&#160;1, 2019. Accordingly, comparative information has not been adjusted and continues to be reported under previous accounting standards. Refer to Note 1 in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information and details on lease related accounts impacted by ASC Topic 842.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Critical Accounting Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements and the related disclosures, which have been prepared in accordance with accounting </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our condensed consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Except for the change in estimate for revenue reversal related to our Pfizer agreement as described in Note 1, Item 1 of this Quarterly Report on Form 10-Q, and for the change to our accounting policy for leases as a result of adopting ASC Topic 842, there have been no significant changes in our critical accounting policies and estimates disclosed in our </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report, as filed with the SEC on March&#160;1, 2019.</span></div><div><a id="s9A9B9F836CE55ADDBF6C23CF4BAF780C"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations for the Three and Six Months Ended June 30, 2019 and 2018</span></div><div style="line-height:120%;padding-top:8px;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except percentage values)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except percentage values)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17,548</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,416</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3,868</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(18%)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,619</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34,053</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(8,434</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(25%)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues consisted of revenues from collaboration agreements and research grants. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Kite, Pfizer and Sanofi as we continue to recognize in revenues upfront and milestone payments received under such agreements over time.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The decrease of $3.9 million in revenues for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, was primarily due to a decrease of $3.7&#160;million in revenues related to our agreements with Pfizer due to a change in estimate as a result of the expansion of the project scope in 2019, and a $1.5&#160;million decrease in revenues related to Sanofi, partially offset by an increase of $1.5&#160;million in revenue related to our agreement with Kite, which took effect in April 2018.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The decrease of $8.4&#160;million in revenues for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, was primarily attributable to a decrease of $14.2&#160;million in revenues related to the hemophilia A Pfizer Agreement due to a change in estimate and a $3.9&#160;million decrease in revenues related to our agreement with Sanofi, partially offset by an increase of $9.9&#160;million in revenue related to our agreement with Kite, which took effect in April 2018.</span></div><div style="line-height:120%;padding-top:8px;padding-left:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Expenses</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except percentage values)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except percentage values)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,455</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,255</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,200</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71,305</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52,802</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18,503</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,597</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,301</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,296</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31,715</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,388</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,327</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51,052</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40,556</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,496</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">103,020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74,190</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28,830</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses consist primarily of salaries and personnel-related expenses including stock-based compensation, laboratory supplies, preclinical and clinical studies, manufacturing clinical supply expenses, allocated facilities expenses, contracted research expenses and expenses for technology licenses. We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our clinical programs and if we are able to progress our earlier stage product candidates into clinical trials. Overall increases in the current period include activities attributed to TxCell, which was acquired on October 1, 2018.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The increase of $7.2&#160;million in research and development expenses for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, was primarily driven by a $4.3&#160;million increase in compensation costs due to headcount growth in our development and technical operations teams to support clinical development trials, a $1.3&#160;million increase in lab supplies, and a $1.2&#160;million increase in facility expense primarily related to our Brisbane facility. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The increase of $18.5&#160;million in research and development expenses for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, was primarily driven by a $9.6&#160;million increase in compensation cost due to headcount growth in our development and technical operations teams to support clinical development trials, $2.5&#160;million increase in research, preclinical </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and clinical expenses, $2.2&#160;million increase in manufacturing related cost as our programs move into the clinic, $2.0&#160;million increase in lab supply expense, and $1.8&#160;million increase in facility expense primarily related to our Brisbane facility.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative personnel, stock-based compensation expenses, professional fees, allocated facilities expenses, patent prosecution expenses and other general corporate expenses. As we continue to build out our product portfolio and advance our product candidates into and through the clinic, we expect the growth of our business to require increased general and administrative expenses. Overall increases in the current period include activities attributed to TxCell, which was acquired on October 1, 2018.</span></div><div style="line-height:120%;padding-top:8px;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The increase of $3.3&#160;million in general and administrative expenses for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, was primarily due to $3.4&#160;million higher compensation costs due to headcount growth and $0.8&#160;million increased facility expense primarily related to our new Brisbane facility, partially offset by a decrease of $1.0 million in consulting and professional fees, which in 2018 included costs to support the TxCell Acquisition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The increase of $10.3&#160;million in general and administrative expenses for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, was primarily due to increases of $6.3&#160;million in compensation related costs due to headcount growth, $0.9&#160;million in legal expense, $1.1&#160;million in consultant expenses, and $1.8 million in facility expense primarily related to our new Brisbane facility. The increases were primarily due to the growth of our business to support the continued advancement of our product candidates into clinical trials.</span></div><div style="line-height:120%;padding-top:8px;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest and other income, net</span></div><div style="line-height:120%;padding-top:8px;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The increases of $0.6&#160;million and $1.5 million in interest and other income, net, for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, were primarily due to higher interest income resulting from our treasury strategy.</span></div><div><a id="s452FBC3E4C105C4CAFCC4D03DF516A1F"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants. Our most significant use of capital pertains to funding our preclinical and clinical research and development programs, as well as employee compensation.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents, marketable securities and interest receivable totaling </span><span style="font-family:inherit;font-size:10pt;">$450.3&#160;million</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$400.5&#160;million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, with the increase primarily attributable to the proceeds from the underwritten public offering completed in April 2019, partially offset by operating expenditures. Our most significant use of capital pertains to our employee compensation and external research and development expenses, such as manufacturing, clinical trials and preclinical activity related to our therapeutic programs. Our cash and investment balances are held in a variety of interest-bearing instruments, including U.S. government-sponsored entity debt securities, corporate debt securities, commercial paper securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">April 2019</span><span style="font-family:inherit;font-size:10pt;">, we completed an underwritten public offering of our common stock, in which we sold an aggregate of </span><span style="font-family:inherit;font-size:10pt;">12.7&#160;million</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock at a public offering price of </span><span style="font-family:inherit;font-size:10pt;">$11.50</span><span style="font-family:inherit;font-size:10pt;"> per share. The net proceeds to us from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately </span><span style="font-family:inherit;font-size:10pt;">$136.3&#160;million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, we entered into an amended and restated sales agreement with Cowen and Company, LLC, or Cowen, pursuant to which we may offer and sell, in our sole discretion, shares of common stock having an aggregate offering price of up to $75.0&#160;million through Cowen acting as our sales agent, or the ATM Facility. Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule&#160;415 under the Securities Act of 1933, as amended. We have not sold any common stock under the ATM Facility. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the full $75.0&#160;million provided for under the ATM Facility remained available for sale, subject to certain conditions as specified in the agreement.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since the beginning of 2017, we have received significant amounts of capital as upfront payments under the following collaboration arrangements: $70.0&#160;million received in May 2017 from Pfizer under our hemophilia A agreement, $12.0&#160;million received in January 2018 from Pfizer under our C9ORF72 agreement, and $150.0&#160;million received in April 2018 under our collaboration agreement with Kite. Our collaboration agreements provide for the payment of development, regulatory, and commercial milestones. For more information see Note 5 &#8212; Major Customers, Partnerships and Strategic Alliances in the condensed consolidated financial statements of this Quarterly Report on Form 10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities was </span><span style="font-family:inherit;font-size:10pt;">$84.7&#160;million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> primarily reflecting our net loss of </span><span style="font-family:inherit;font-size:10pt;">$72.6&#160;million</span><span style="font-family:inherit;font-size:10pt;">, a decrease in deferred revenues of $10.8&#160;million, an increase in accounts receivable of $7.4&#160;million and an increase in prepaid expenses and other assets of $5.4&#160;million, partially offset by stock-based compensation of </span><span style="font-family:inherit;font-size:10pt;">$9.4&#160;million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities of </span><span style="font-family:inherit;font-size:10pt;">$104.3&#160;million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily reflected the increase in deferred revenue due to the $150.0&#160;million upfront license payment from Kite, partially offset by the net loss for the period as well as an increase in prepaid expenses and increased business activities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investing activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;">$27.2&#160;million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$323.7&#160;million</span><span style="font-family:inherit;font-size:10pt;">, respectively. The decrease in net cash used in the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, was due primarily to a net decrease in purchases and maturities of marketable securities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financing activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$140.1&#160;million</span><span style="font-family:inherit;font-size:10pt;"> primarily related to our April 2019&#160;underwritten public offering of our common stock, which generated net proceeds of approximately </span><span style="font-family:inherit;font-size:10pt;">$136.3&#160;million</span><span style="font-family:inherit;font-size:10pt;">, with the remainder primarily related to the </span><span style="font-family:inherit;font-size:10pt;">$4.1&#160;million</span><span style="font-family:inherit;font-size:10pt;"> from the issuance of common stock upon exercise of stock options.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$229.0&#160;million</span><span style="font-family:inherit;font-size:10pt;"> primarily related to our April 2018 underwritten public offering of our common stock, which generated net proceeds of approximately </span><span style="font-family:inherit;font-size:10pt;">$215.8&#160;million</span><span style="font-family:inherit;font-size:10pt;">, with the remainder primarily related to the </span><span style="font-family:inherit;font-size:10pt;">$13.3&#160;million</span><span style="font-family:inherit;font-size:10pt;"> from the issuance of common stock upon exercise of stock options.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Capital and Capital Expenditure Requirements</span></div><div style="line-height:120%;padding-top:8px;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We anticipate continuing to incur operating losses for at least the next several years. While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we believe that the available cash resources, as well as funds received from corporate collaborators, strategic partners and research grants will enable us to maintain our currently planned operations through at least the next twelve months from the date the financial statements are issued. Future capital requirements will be substantial and if our capital resources are insufficient to meet future capital requirements, we will need to raise additional capital to fund our operations through equity or debt financing. We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to advance our product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities, including any sales under our ATM Facility, may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our future capital requirements will depend on many factors and include, but are not limited to the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the outcome, timing and cost of regulatory approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success of our collaboration agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays that may be caused by changing regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number of product candidates that we pursue;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing and terms of future in-licensing and out-licensing transactions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of procuring clinical and commercial supplies of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which we acquire or invest in businesses, products or technologies, including the costs associated with such acquisitions and investments; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the possible costs of litigation.</span></div></td></tr></table><div><a id="s5617D833C12251059053EE4D0284F543"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have any off-balance sheet arrangements as defined in Regulation S-K, Item 303(a)(4)(ii) of Regulation S-K.</span></div><div><a id="sFDFB87E7E92E5274BD66F8DB51F513C4"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations and Commercial Commitments</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our future minimum contractual commitments were reported in our </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report and there have been no material changes outside the ordinary course of business in the previously disclosed contractual commitments during the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. See Note 1 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for a discussion of the Option Agreement with Brammer Bio MA, which may increase our contractual commitments in the future.</span></div><div><a id="s3F7FD72C54EF518B963D3665389488A3"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our exposure to market risk relates to our cash, cash equivalents and investments. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We select investments that maximize interest income to the extent possible within these guidelines. To achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The securities in our investment portfolio are not leveraged, are classified as available-for-sale and are, due to their short-term nature, subject to minimal interest rate risk. Our investments currently consist of U.S. government-sponsored entity debt securities, corporate debt securities, commercial paper securities and money market funds. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. All investments have a fixed interest rate and are carried at market value, which approximates cost. We do not use derivative financial instruments in our investment portfolio. We do not believe that a change in interest rates would have a material negative impact on the value of our investment portfolio. Our market risks at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> have not changed materially from those discussed in Item 7A of our </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report.</span></div><div><a id="s19BBE428BD095AE987B80F64DE2A2EBE"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTROLS AND PROCEDURES</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the supervision of our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. Based on that evaluation, as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inherent Limitations on Controls and Procedures</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There has been no change in our internal control over financial reporting that occurred during the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2F0B23FFAF9751579E38BB51335A4737"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</span></div><div><a id="s56357AA9935459389F163F2E9DC7AD0C"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160; 1.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL PROCEEDINGS</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</span></div><div><a id="s386BC9595F5D5649A8D5A09AF4D5C243"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160; 1A.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An investment in our common stock involves significant risk. This Form 10-Q contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements made by or on our behalf, this section includes a discussion of important factors that could affect our actual future results, including, but not limited to, our revenues, expenses, net loss and net loss per share. You should carefully consider the information described in the following risk factors, together with the other information appearing elsewhere in this report, before making an investment decision regarding our common stock.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Development, Commercialization and Regulatory Approval of our Products and Technology</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our success depends substantially on the results of clinical trials of our lead therapeutic programs, and we may not be able to demonstrate safety and efficacy of our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have any products that have gained regulatory approval, and we are therefore substantially dependent on the results of clinical trials of our lead therapeutic programs. Our failure to enroll sufficient patients to conduct these clinical trials, demonstrate safety or obtain positive clinical trial results, or our inability to meet the expected timeline of these clinical trials or release of data for these programs, would have a material adverse effect on our business operations and financial conditions, which may cause a significant decline in our stock price.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to conduct and complete clinical trials successfully and on a timely basis for these programs is subject to a number of additional risks, including but are not limited to the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disagreement with the design or implementation of our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to identify and recruit sufficient number of acceptable patients to complete enrollment of trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure to demonstrate that a product candidate is safe and effective for its proposed indication;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the occurrence of unexpected adverse events or toxicity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disagreement with the U.S. Food and Drug Administration, or FDA, or foreign regulatory authorities, on the interpretation of data from preclinical studies or our clinical trial results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure of clinical trials to meet the level of statistical significance required for approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a biologics license application, or BLA, or other submission or to obtain regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure to obtain approval of our manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies or our own manufacturing facility;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">defects in the preparation and manufacturing of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure by third parties, including vendors, manufacturers and clinical trial organizations, to provide timely and adequate supplies and services;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">development of similar gene therapies by our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unexpected costs and expenses and lack of sufficient funding for these programs; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">loss of licenses to critical intellectual properties.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have ongoing Phase 1/2 clinical trials evaluating product candidates for the treatment of hemophilia A (SB-525), hemophilia B (SB-FIX), MPS I (SB-318), MPS II (SB-913), and beta thalassemia (ST-400). We have initiated clinical sites in a Phase 1/2 clinical trial of ST-920, an investigational gene therapy product candidate for Fabry disease, and we expect to treat the first subject by year end 2019. We also plan to initiate a Phase 1/2 clinical trial of TxCell&#8217;s first CAR-Treg (which is a regulatory T-cell, or Treg, genetically modified with a chimeric antigen receptor, or CAR) investigational product candidate for solid organ transplant, or TX-200, in 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we are able to complete our Phase 1/2 clinical trials for these programs successfully, we will be required to conduct additional clinical trials with larger patient populations, before obtaining the necessary regulatory approval to commercialize any products, which involves significantly greater resources, commitments and expertise. We also have limited experience in conducting later stage clinical trials and may not possess the necessary resources and expertise to complete such trials. Therefore, we may be required to scale up our operations and enter into collaborative relationships with pharmaceutical companies that could assume responsibility for late-stage development and commercialization. In this regard, while we have </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">entered into collaborative agreements to provide funding and assistance in the development of certain product candidates through the clinical trial process, there is no guarantee that we will be able to enter into future collaborative relationships with third parties that can provide us with the funding and expertise for later stage trials. In addition, there is no guarantee that any positive results achieved in our Phase 1/2 clinical trials will be indicative of long-term efficacy and safety in later stage clinical trials. If a larger patient population does not demonstrate an acceptable safety and efficacy profile, or if any positive results in our Phase 1/2 clinical trials are not reproducible, our products may not receive approval from the FDA or foreign regulatory authorities, which could have a material adverse effect on our business that would cause our stock price to decline significantly.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we have not yet reached agreement with regulatory authorities on the development pathway for our product candidates. As a result, we have not yet determined what endpoints would support approval for certain of our programs. Due to the novelty of certain programs, such as SB-913 and SB-318, the endpoints needed to support regulatory approvals may be different than originally anticipated. For example, in order to support regulatory approval for SB-913 and SB-318, we may be required to detect certain levels of enzymes in patients. In this regard, in September 2018, we announced preliminary safety and efficacy data from the Phase 1/2 clinical trial evaluating SB-913, or the CHAMPIONS study. In cohort 2 of the CHAMPIONS study, at 16 weeks post-dosing, mean reductions were observed in total urinary glycosaminoglycans, or GAGs (which is a key biomarker of MPS II disease pathophysiology), dermatan sulfate, and heparan sulfate of 51%, 32%, and 61%, respectively. Due to the sensitivity of the assay we used to measure plasma iduronate-2-sulfatase, or IDS, enzyme levels, we were unable to detect IDS in any of the patients over the 16 weeks following treatment with SB-913. In February 2019, we announced interim results of the CHAMPIONS Study. A newly developed sensitive quantitative assay (lower limit of quantification of 0.78 nmol/hour/mL) was used to measure plasma IDS activity for these interim results. Small increases in IDS enzyme activity compared to baseline were recorded in the two patients receiving the mid-dose and in one patient receiving the high-dose. At 24 weeks post-dosing, these measurements remained within the expected range for baseline values (less than 10 nmol/hour/mL, as compared to the normal range, which is estimated at greater than 82 nmol/hour/mL). While the newly developed, more sensitive assay was able to detect IDS at lower levels, there can be no guarantee that we will be able to continue to be able to detect IDS in patients or otherwise show direct evidence of efficacy or gene editing. Moreover, these interim results cast doubt with regard to whether there will be evidence of a clinical benefit, and it is possible that we may never see a clinical benefit to patients treated with SB-913. This may delay or preclude continued development and/or any regulatory approvals for SB-913. In April 2019, we provided an update on the SB-318, SB-913 and SB-FIX trials, announcing that no additional patients are expected to be treated with first-generation ZFNs given that clinical benefit has not been demonstrated in analyses conducted to date in the ongoing clinical trials and the expected near-term clinical development of second-generation ZFNs. We are planning a new clinical trial to evaluate second-generation ZFNs and other potential modifications to enhance the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo </span><span style="font-family:inherit;font-size:10pt;">delivery of the ZFNs</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for SB-913 to treat MPS II, which is planned to begin by year end 2020. While we expect to use data from this study to make a Phase III decision for the SB-913 program in 2020 and to define the next steps for the SB-318 and SB-FIX programs, there can be no assurance that we will be able to effectively deliver second-generation ZFNs to produce a clinical benefit to patients treated with SB-913, SB-318 and SB-FIX or any of our other product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if a product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for one of our product candidates in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding to continue the development of that product or generate revenues attributable to that product candidate. Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution since the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Results from preclinical studies or previous clinical trials are not necessarily predictive of future clinical trial results, and interim results of a clinical trial are not necessarily indicative of final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials or preliminary stages of clinical trials. From time to time, we have and may in the future publish or report preliminary, initial or interim data from our clinical trials, such as the preliminary, initial and interim data we have announced from the CHAMPIONS Study (SB-913), the Alta Study (SB-525), the EMPOWERS Study (SB-318) and the THALES Study (SB-400, which involved very early data from the first dosed patient). Preliminary, initial or interim data from our clinical trials and those of our partners may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit but as patients continue to be followed and more patient data becomes available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have ongoing Phase 1/2 clinical trials evaluating product candidates for the treatment of hemophilia A (SB-525), hemophilia B (SB-FIX), MPS I (SB-318), MPS II (SB-913), and beta thalassemia (ST-400), and there is no guarantee that we can achieve positive final safety and efficacy results in our Phase 1/2 clinical trials for these product candidates. Moreover, the interim results recently announced for SB-913 and SB318 cast doubt with regard to whether there will be evidence of a clinical benefit of either product candidate. In April 2019, we provided an update on the SB-318, SB-913 and SB-FIX trials, announcing that no additional patients are expected to be treated with first-generation ZFNs given that clinical benefit has not been demonstrated in analyses conducted to date in the ongoing clinical trials and the expected near-term clinical development of second-generation ZFNs. We are planning a new clinical trial to evaluate second-generation ZFNs and other potential modifications to enhance the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo </span><span style="font-family:inherit;font-size:10pt;">delivery of the ZFNs for SB-913 to treat MPS II, which is planned to begin by year end 2020. While we expect to use data from this study to make a Phase III decision for the SB-913 program in 2020 and to define the next steps for the SB-318 and SB-FIX programs, there can be no assurance that we will be able to effectively deliver second-generation ZFNs to produce a clinical benefit to patients treated with SB-913, SB-318 and SB-FIX or any of our other product candidates. Furthermore, these programs (other than TX-200 that we acquired through the acquisition of TxCell, or the TxCell Acquisition) are novel </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in-vivo</span><span style="font-family:inherit;font-size:10pt;"> gene therapy or genome editing therapies that utilize adeno-associated viral, or AAV, vector to deliver therapeutic levels of zinc finger nuclease, or ZFN, into the patient&#8217;s blood stream. The AAV delivery system has not been validated in human clinical trials previously, and if such delivery system does not meet the safety criteria or cannot produce the desirable efficacy results we expect, we may be forced to suspend or terminate the affected program.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is a high failure rate for drugs, biologic products and cell therapies proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including due to changes in regulatory policy during the period of our product candidate development. Any such delays could materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our potential products are subject to a lengthy and uncertain regulatory approval process in each jurisdiction where approval is sought.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A regulatory authority such as the FDA or the European Medicines Agency, or EMA, must approve any human therapeutic product before it can be marketed in such jurisdiction. The process for receiving regulatory approval is long and uncertain, and a potential product may not withstand the rigors of testing under the regulatory approval processes.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Before commencing clinical trials in humans, we must submit an Investigational New Drug application, or IND, to the FDA. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the European Union, for example, a clinical trial authorization application, or CTA, must be submitted for each clinical protocol to each country&#8217;s national health authority and an independent ethics committee. Only after an IND becomes effective and/or the applicable CTA has been accepted may clinical trials begin. While we have stated our intention to submit additional IND and CTA applications in the future, this is only a statement of intent, and we may not be able to do so because the associated product candidates may not meet the necessary preclinical requirements. In addition, there can be no assurance that, once submitted, an IND or CTA will result in the actual initiation of clinical trials or that we will be able to meet our targeted timeline for the initiation of clinical trials. Clinical trials are subject to oversight by institutional review boards, or IRBs, and the applicable regulatory authority. In addition to FDA and IRB oversight, under guidelines promulgated by the National Institutes of Health, or NIH, gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH guidelines voluntarily follow them. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical trials:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">must be conducted in conformance with the FDA&#8217;s good clinical practices, within the guidelines of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, or ICH, and other applicable regulations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">must meet requirements for IRB oversight;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">must follow IBC and NIH guidelines where applicable;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">must meet requirements for informed consent;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">are subject to continuing FDA or similar foreign government oversight;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">may require oversight by a Data Monitoring Committee, or DMC;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">may require large numbers of test subjects; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">may be suspended by a commercial partner, the FDA, applicable foreign regulatory authorities or us at any time if it is believed that the subjects participating in these trials are being exposed to unacceptable health risks or if the FDA or applicable foreign regulatory authorities find deficiencies in our INDs or their foreign equivalents or the conduct of these trials.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are not able to obtain the necessary regulatory approval to commercialize our products or if such approval is delayed or suspended, it would have a material adverse effect on our business operations and trading price of our common stock.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may encounter difficulties that may delay, suspend or scale back our efforts to advance additional early research programs through preclinical development, IND and foreign equivalent submissions and into clinical development.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We intend to advance early research programs through preclinical development and to submit new INDs, CTAs and equivalent filings in foreign regulatory jurisdictions necessary to commence and conduct human clinical trials evaluating the preclinical candidates in our pipeline. The preparation and submission of INDs and their foreign equivalents requires us to conduct rigorous and time-consuming preclinical testing, studies, and prepare documentation relating to, among other things, the toxicity, safety, manufacturing, chemistry and clinical protocol of our product candidates. We may experience unforeseen difficulties that could delay or otherwise prevent us from executing this strategy successfully. For example, we may encounter problems in the manufacturing of our products and fail to demonstrate consistency in the formulation of the drug. Our preclinical tests may produce negative or inconclusive results, which may lead us to decide, or regulators may require us, to conduct additional preclinical testing. If we cannot obtain positive results in preclinical testing, we may decide to abandon the projects altogether. In addition, our ability to complete and submit certain IND applications and foreign equivalent filings depends on the support of our partners and the timely performance of their obligations under relevant collaboration agreements. If our partners are not able to perform such obligations or if they choose to slow down or delay the progress, we may not be able to prepare and submit the intended INDs or their foreign equivalents on a timely basis or at all. Furthermore, the submission of several INDs and their foreign equivalents involves significant cost and labor, and we may not have sufficient resources and personnel to complete the filing of all intended INDs and their foreign equivalents, which may force us to scale back the number of INDs and their foreign equivalents or forego potential INDs and foreign equivalents that we believe are promising. Any delay, suspension or reduction of our efforts to pursue our preclinical and IND strategy could have a material adverse effect on our business and cause our stock price to decline.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not successfully identify, acquire, develop or commercialize new potential product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Part of our business strategy is to expand our product candidate pipeline by identifying and validating new product candidates, which we may develop ourselves, in-license or otherwise acquire from others. For example, through the TxCell Acquisition, we acquired the rights, among others, to TxCell&#8217;s first CAR-Treg product candidate, TX-200, and its CAR&#8209;Treg technology and know-how. In this regard, we intend to use our ZFN gene editing technology to potentially develop next-generation autologous and allogeneic CAR-Treg cell therapies for use in treating autoimmune diseases, and expect that the TxCell Acquisition will accelerate our entry into the clinic with a CAR-Treg therapy. However, we are new to the field of immunology and to the use of CARs with Tregs, and we may not be successful at developing a CAR-Treg therapy that can be used in patients. Moreover, we may not achieve the expected accelerated development timeline. If we are unable to successfully develop and obtain regulatory approval for TX-200 or other CAR-Treg therapies and effectively commercialize them, or if we are unable to achieve the expected accelerated development timeline, we may not realize the anticipated benefits from the TxCell Acquisition, resulting in possible impairments or other charges or losses which may materially and adversely affect our results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, in the event that our existing product candidates do not receive regulatory approval or are not successfully commercialized, then the success of our business will depend on our ability to continue to expand our product pipeline through in-licensing or other acquisitions. We may be unable to identify relevant product candidates. If we do identify such product candidates, we may be unable to reach acceptable terms with any third party from which we desire to in-license or acquire them. Even if we are able to successfully identify and acquire such product candidates, we may not be able to successfully manage the risks associated with integrating acquired or in-licensed product candidates or technologies or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing transaction. Further, while we seek to mitigate risks and liabilities of potential acquisitions and in-licensing transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in identifying and managing these risks and uncertainties effectively, including in connection with the TxCell Acquisition, would have a material adverse effect on our business. Additionally, we may not realize the anticipated benefits of such </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">transactions for a variety of reasons, including the possibility that acquired product candidates, such as TX-200, prove not to be safe or effective in clinical trials, the integration of an acquired product candidate, technology or business gives rise to unforeseen difficulties and expenditures, or that the expected benefits will not otherwise be realized or will not be realized within the expected timeframe.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates. Clinical testing is expensive, time consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in reaching a consensus with regulatory authorities on trial design;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in opening clinical trial sites or obtaining required IRB or independent ethics committee approval at each clinical trial site;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in recruiting suitable subjects to participate in our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or after an inspection of our clinical trial operations or trial sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure to perform in accordance with FDA good clinical practices, or GCP, or applicable regulatory guidelines in the European Union and other countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in having subjects complete participation in a trial or return for post-treatment follow-up;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinical trial sites or subjects dropping out of a trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019, we provided an update on the SB-318, SB-913 and SB-FIX trials, announcing that no additional patients are expected to be treated with first-generation ZFNs given that clinical benefit has not been demonstrated in analyses conducted to date in the ongoing clinical trials and the expected near-term clinical development of second-generation ZFNs. We are planning a new clinical trial to evaluate second-generation ZFNs and other potential modifications to enhance the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo </span><span style="font-family:inherit;font-size:10pt;">delivery of the ZFNs for SB-913 to treat MPS II, which is planned to begin by year end 2020. While we expect to use data from this study to make a Phase&#160;III decision for the SB-913 program in 2020 and to define the next steps for the SB-318 and SB-FIX programs, there can be no assurance that we will be able to effectively deliver second-generation ZFNs to produce a clinical benefit to patients treated with SB-913, SB-318 and SB-FIX or any of our other product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be delayed in obtaining marketing approval for our product candidates, if at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be subject to changes in the way the product is administered;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be subject to the addition of labeling statements, such as warnings or contraindications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be sued; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">experience damage to our reputation.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to find acceptable patients or may experience delays in enrolling patients for our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on our ability to recruit patients to participate as well as completion of required follow-up periods. For example, hemophilia trials often take longer to enroll due to the availability of existing treatments. We infused the first patient in the Phase 1/2 clinical trial evaluating ST-400 for the treatment of beta thalassemia in the first quarter of 2019. Moreover, we had recently begun to enroll patients into the Phase 1/2 clinical trials evaluating SB-FIX for the treatment of hemophilia B, SB-318 for the treatment of MPS I and SB-913 for MPS II, none of which are enrolling additional patients due to our decision to plan a new clinical trial to evaluate second-generation ZFNs and other potential modifications to enhance the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo </span><span style="font-family:inherit;font-size:10pt;">delivery of the ZFNs for SB-913 to treat MPS II, which we expect to begin by year end 2020. If we are not able to enroll the necessary number of patients in a timely manner, we may not be able to complete these clinical trials. We may face similar challenges or delays in our other or potential future clinical trials. If patients are unwilling to participate in our gene therapy studies because of negative publicity from adverse events related to the biotechnology or gene therapy fields, competitive clinical trials for similar patient populations or for other reasons, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of our product candidates may be delayed. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment and trial completion is affected by factors including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">size of the patient population and process for identifying subjects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">design of the trial protocol;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">eligibility and exclusion criteria;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">perceived risks and benefits of the product candidate under study;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">perceived risks and benefits of gene therapy-based approaches to treatment of diseases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">availability of competing therapies and clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">severity of the disease under investigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">availability of genetic testing for potential patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">proximity and availability of clinical trial sites for prospective subjects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ability to obtain and maintain subject consent;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">risk that enrolled subjects will drop out before completion of the trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patient referral practices of physicians; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ability to monitor subjects adequately during and after treatment.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our current product candidates are being developed to treat rare conditions. We may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by regulatory authorities. We may need to expand the conduct of our clinical trials to foreign countries so that we may be better able to access and enroll subjects. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">difficulty in establishing or managing relationships with contract research organizations, or CROs, and physicians;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">different standards for the conduct of clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">absence in some countries of established groups with sufficient regulatory expertise for review of gene therapy protocols;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our inability to locate qualified local consultants, physicians and partners; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations and prospects.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions, particularly as many of the diseases we are studying have complex comorbidities. If clinical experience indicates that our product candidates have side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">As we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, we cannot predict the timing of any future revenue from these product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot commercialize any of our product candidates to generate revenue until the appropriate regulatory authorities have reviewed and approved the marketing applications for the product candidates. We cannot ensure that the regulatory agencies will complete their review processes in a timely manner or that we will obtain regulatory approval for any product candidate that we or our collaborators develop. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. Regulatory approval processes outside the United States include all of the risks associated with the FDA approval process. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in FDA policy during the period of product development, clinical trials and FDA regulatory review.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to obtain additional orphan drug designations or orphan drug exclusivity for any product. If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an Orphan Drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA&#8217;s Committee for Orphan Medicinal Products grants such designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, orphan designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biologic product.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our four most advanced product candidates, SB-525, SB-FIX, SB-318 and SB-913 have all been granted Orphan Drug Designation by the FDA, and SB-525 and SB-318 and SB-913 have also been designated Orphan Medicinal Products by the EMA. If we request such designation for our other current or future product candidates, there can be no assurances that the FDA or the EMA will grant any of our product candidates such designation. Additionally, such designation does not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve, that product candidate, nor does it limit the ability of any regulatory agency to grant such designation to product candidates of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the United States and 10 years in the European Union. The </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">exclusivity period in the United States can be extended by six months if the BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the European Union, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regenerative Medicine Advanced Therapy, or RMAT, designation, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that SB-525 will receive marketing approval.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have received Regenerative Medicine Advanced Therapy, or RMAT, designation for SB-525 to treat severe hemophilia A. RMAT designation is intended to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with the FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review of the related BLA. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. There is no assurance that we will be able to obtain additional RMAT designations for any of our other product candidates. RMAT designation does not change the FDA&#8217;s standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commercialization of our technologies will depend, in part, on strategic partnering with other companies. If we are not able to find partners in the future or if our partners do not diligently pursue product development efforts, we may not be able to develop our technologies or product candidates, which could slow our growth and decrease the value of our stock.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to rely, to some extent, on our strategic partners to provide funding in support of our research and to perform independent research and preclinical and clinical testing. Our technology is broad-based, and we do not currently possess the resources necessary to fully develop and commercialize potential products that may result from our technologies or the resources or capabilities to complete the lengthy marketing approval processes that may be required for the products. Therefore, we plan to rely on strategic partnerships to help us develop and commercialize our products. We have entered into collaborative agreements to provide funding and assistance in the development of certain product candidates through the clinical trial process. For example, we have an agreement with Kite for potential engineered cell therapies for cancer, two separate agreements with Pfizer, one for SB-525 for hemophilia A, and another for amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">C9ORF72 </span><span style="font-family:inherit;font-size:10pt;">gene, and an agreement with Sanofi for our beta thalassemia and sickle cell disease product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are unable to find additional partners or if the partners are unable or unwilling to advance our programs, or if they do not diligently pursue product approval, this may slow our progress and adversely affect our ability to generate revenues. In addition, our partners may sublicense or abandon development programs or we may have disagreements or disputes with our partners, which would cause associated product development to slow or cease. In addition, the business or operations of our partners may change significantly through restructuring, acquisition or other strategic transactions or decisions that may negatively impact their ability to advance our programs.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There can be no assurance that we will be able to establish further strategic collaborations for our products. We may require significant time to secure collaborations or partners because we need to effectively market the benefits of our technology to these future collaborators and partners, which may direct the attention and resources of our research and development personnel and management away from our primary business operations. Further, each collaboration or partnering arrangement </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">will involve the negotiation of terms that may be unique to each collaborator or partner. These business development efforts may not result in a collaboration or partnership.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The loss of partnering agreements may delay or terminate the potential development or commercialization of products we may derive from our technologies, but it may also delay or terminate our ability to test our product candidates. If any partner fails to conduct the collaborative activities successfully or in a timely manner, the preclinical or clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under typical partnering agreements, we would expect to receive revenue for the research and development of our product candidates based on achievement of specific milestones, as well as royalties based on a percentage of sales of the commercialized products. Achieving these milestones will depend, in part, on the efforts of our partner as well as our own. If we, or any partner, fail to meet specific milestones, then the partnership may be terminated, which could reduce our revenues. For more information on risks relating to our third-party collaborative agreements, see &#8220;Risks Relating to our Relationships with Collaborators and Strategic Partners.&#8221;</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to license gene transfer technologies that we may need to commercialize our zinc finger protein technology.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to regulate or modify a gene in a cell, the zinc finger protein, or ZFP, must be efficiently delivered to the cell. We have licensed certain gene transfer technologies for our ZFP in research including AAV and mRNA technology. We are evaluating these systems and other technologies that may need to be used in the delivery of ZFP into cells for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:10pt;"> applications. However, we may not be able to license the gene transfer technologies required to develop and commercialize our product candidates. We have not developed our own gene transfer technologies, and we rely on our ability to enter into license agreements to provide us with rights to the necessary gene transfer technology. Our approach has been to license appropriate technology as required. The inability to obtain a license to use gene transfer technologies with entities that own such technology on reasonable commercial terms, if at all, could delay or prevent the preclinical evaluation, drug development collaborations, clinical testing, and/or commercialization of our therapeutic product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our gene regulation and genome editing technology is relatively new, and if we are unable to use this technology in all our intended applications, it would limit our revenue opportunities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our technology involves a relatively new approach to gene regulation and genome editing. Although we have generated ZFPs for thousands of gene sequences, we have not created ZFPs for all gene sequences and may not be able do so, which could limit the usefulness of our technology. In addition, while we have demonstrated the function of engineered ZFNs and ZFP transcription factors, or ZFP TFs, in mammalian cells, yeast, insects, plants and animals, we have not yet demonstrated clinical efficacy of this technology in a controlled clinical trial in humans, and the failure to do so could restrict or preclude our ability to develop commercially viable products. If we, and our collaborators or strategic partners, are unable to extend our results to new commercially important genes, experimental animal models, and human clinical studies, we may be unable to use our technology in all its intended applications.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The expected value and utility of our ZFNs and ZFP TFs is in part based on our belief that the targeted editing of genes or specific regulation of gene expression may enable us to develop a new therapeutic approach as well as to help scientists better understand the role of genes in disease, and to aid their efforts in drug discovery and development. We also believe that ZFP-mediated targeted genome editing and gene regulation will have utility in agricultural applications. There is only a limited understanding of the role of specific genes in all these fields. Life sciences companies have developed or commercialized only a few products in any of these fields based on results from genomic research or the ability to regulate gene expression. We, our collaborators or our strategic partners, may not be able to use our technology to identify and validate drug targets or to develop commercial products in the intended markets.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective delivery of ZFNs and ZFP TFs into the appropriate target cells and tissues is critical to the success of the therapeutic applications of our ZFP technology. In order to have a meaningful therapeutic effect, product candidates using ZFNs or ZFP TFs must be delivered to sufficient numbers of cells in the targeted tissue. The ZFN or ZFP TF must be present in that tissue for sufficient time to effect either modification of a therapeutically relevant gene or regulation of its expression. In our current clinical and preclinical programs, we administer these product candidates as a nucleic acid that encodes the ZFN or ZFP TF. We use different formulations to deliver the ZFN or ZFP TF depending on the required duration of expression, the targeted tissue and the indication that we intend to treat, including our proprietary AAV delivery system. However, there can be no assurances that we will be able to effectively deliver our ZFNs and ZFP TFs to produce a clinical benefit.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, we announced our development of second generation, potentially more potent ZFN constructs designed to increase editing efficiency. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In vitro</span><span style="font-family:inherit;font-size:10pt;"> data of these second-generation ZFNs were reviewed by the FDA. The </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;"> data showed three potential advantages for use in the clinic: (1)&#160;a five to thirty-fold improvement in efficiency and potency due to structural changes; (2)&#160;the ability to function equally well in the patients who have a single nucleotide polymorphism in the target locus in the albumin gene (approximately 20% of the population); and (3)&#160;improvements in specificity. The second-generation </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ZFNs are being manufactured and we are planning a new clinical trial to evaluate second-generation ZFNs for SB-913 to treat MPS II, which is planned to begin by year end 2020; however, there can be no assurances that we will be able to effectively deliver this second-generation ZFN to produce a clinical benefit to patients treated with SB-913, SB-318 and SB-FIX or any of our other product candidates. Additional data from our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:10pt;"> genome editing programs will be assessed before potential integration plans for the second-generation ZFNs are finalized.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are conducting proprietary research to discover new product candidates. These programs increase our financial risk of product failure, may significantly increase our research expenditures, and may involve conflicts with future collaborators and strategic partners.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our proprietary research programs consist of research that is funded solely by us or by grant funding and in which we retain exclusive rights to therapeutic products generated by such research. This is in contrast to certain of our research programs that may be funded by corporate partners in which we may share rights to any resulting products. Conducting proprietary research programs may not generate corresponding revenue and may create conflicts with our collaborators or strategic partners over rights to our intellectual property with respect to our proprietary research activities. Any conflict with our collaborators or strategic partners could reduce our ability to enter into future collaborations or partnering agreements and negatively impact our relationship with existing collaborators and partners that could reduce our revenue and delay or terminate our product development. As we continue to focus our strategy on proprietary research and therapeutic development, we expect to experience greater business risks, expend significantly greater funds and require substantial commitments of time from our management and staff.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if our technology proves to be effective, it still may not lead to commercially viable products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we, our collaborators or strategic partners are successful in using our ZFP technology in drug discovery, protein production, therapeutic development or other areas in which we have licensed our technology, such as plant agriculture, they may not be able to commercialize the resulting products or may decide to use other methods competitive with this technology. To date, no company has received marketing approval or has developed or commercialized any therapeutic or agricultural products based on our ZFP technology. Should our technology fail to provide safe, effective, useful or commercially viable approaches to the discovery and development of these product candidates, this would significantly limit our business and future growth and would adversely affect our value.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if our product development efforts are successful and even if the requisite regulatory approvals are obtained, our products may not gain market acceptance among physicians, patients, healthcare payors and the medical community.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the applicable product may not gain market acceptance among physicians, healthcare payors, patients or the medical community. Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the efficacy and safety of such product candidates as demonstrated in clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the clinical indications and patient populations for which the product candidate is approved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acceptance by physicians, major cancer treatment centers and patients of the drug as a safe and effective treatment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the adoption of novel gene therapies by physicians, hospitals and third-party payors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential and perceived advantages of product candidates over alternative treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the safety of product candidates seen in a broader patient group, including its use outside the approved indications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any restrictions on use together with other medications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the prevalence and severity of any side effects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing of market introduction of our products as well as competitive products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the development of manufacturing and distribution processes for our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of treatment in relation to alternative treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the availability of coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket in the absence of coverage or inadequacy of reimbursement by third-party payors and government authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">relative convenience and ease of administration; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effectiveness of our sales and marketing efforts and those of our collaborators.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any of our product candidates are approved but fail to achieve market acceptance among physicians, patients, healthcare payors or treatment centers, we will not be able to generate significant revenues, which would compromise our ability to become profitable.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which we seek to commercialize our products, which could harm our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. A primary trend in the healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek additional clinical evidence, beyond the data required to obtain regulatory approval, demonstrating clinical benefits and value in specific patient populations before covering our products for those patients. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain regulatory approval. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain regulatory approval.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors in the United States often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain regulatory approval. In particular, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the Affordable Care Act, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act and its implementing regulations, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including products similar to our product candidates, that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, created a new Patient Centered Outcomes Research Institute, which provides incentives to programs that increase the federal government&#8217;s comparative effectiveness research, established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (and 70% as of January&#160;1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D, and created a licensure framework for follow-on biologic products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of the provisions of the Affordable Care Act have yet to be fully implemented, and there have been legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, there have been two signed executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Concurrently, Congress has considered legislation that would repeal, or repeal and replace, all or part of the Affordable Care Act. While Congress has not passed repeal legislation, two bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision that repealed, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on January&#160;22, 2018, there was a signed continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care Act-mandated fees. Further, the Bipartisan Budget Act of 2018, among other things, amended the Affordable Care Act, effective January&#160;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; More recently, in December 2018, the Centers for Medicare &amp; Medicaid Services, or CMS, published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December&#160;14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by the U.S. Congress as part of the Tax Cuts and Jobs Act of 2017 Act. While the Texas U.S. District Court Judge, as well as the current administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2&#160;trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013, and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2027 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products, some of which are included in the current administration&#8217;s budget proposal for fiscal year 2019. Additionally, the current administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services, or the HHS, has begun the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. Although a number of these, and other potential, proposed measures will require additional authorization to become effective. Congress and the executive branch have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, have been designed to encourage importation from other countries and bulk purchasing.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the demand for our product candidates, if we obtain regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to set a price that we believe is fair for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to generate revenue and achieve or maintain profitability;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the level of taxes that we are required to pay; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the availability of capital.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the regulatory approvals of our product candidates, if any, may be.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the United States, the European Union and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Price controls may be imposed in foreign markets, which may adversely affect our future profitability.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we, or our collaborators, may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if we complete the necessary preclinical and clinical studies, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate or the approval may be for a more narrow indication than we expect.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical studies, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory advisory group or authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical studies and the review process. Regulatory agencies also may approve a treatment candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our treatment candidates. For example, the development of certain product candidates for pediatric use is an important part of our current business strategy, and if we are unable to obtain regulatory approval for the desired age ranges, our business may suffer.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies, post-market surveillance or patient or drug restrictions. For example, the FDA typically advises that patients treated with gene therapy undergo follow-up observations for potential adverse events for a 15-year period. Additionally, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, products are subject to payment of annual program user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with good manufacturing practices, or GMP, and adherence to commitments made in the BLA. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, if any of our product candidates is approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA and foreign regulatory authorities strictly regulate the promotional claims that may be made about drug and biologic products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">issue a warning letter asserting that we are in violation of the law;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspend or withdraw regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspend any ongoing clinical studies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refuse to approve a pending marketing application, such as a BLA or supplements to a BLA submitted by us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seize product; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refuse to allow us to enter into supply contracts, including government contracts.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure to obtain regulatory approval in international jurisdictions would prevent our product candidates from being marketed abroad.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to regulations in the United States, to market and sell our products in the European Union, many Asian countries and other jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. Clinical trials accepted in one country may not be accepted by regulatory authorities in other countries. In addition, many countries outside the United States require that a product be approved for reimbursement before it can be approved for sale in that country. A product candidate that has been approved for sale in a particular country may not receive reimbursement approval in that country. We may not be able to obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of any of our product candidates by the FDA or regulatory authorities in the European Union, Asia or elsewhere, the commercial prospects of that product candidate may be significantly diminished, our business prospects could decline and this could materially adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our current and future relationships with healthcare providers, customers and third-party payors subject us to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations. If we fail to comply with federal, state and foreign laws and regulations, including healthcare, privacy and data security laws and regulations, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our current and future arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. As a biotechnology company, even though we will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. Restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate include the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal healthcare Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:108px;"><span style="font-family:inherit;font-size:10pt;">fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, and individuals and entities that perform services for them that involve individually identifiable health information, known as business associates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal Physician Payments Sunshine Act created under the Affordable Care Act requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the CMS information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, require drug manufacturers to report information related to payments and other transfers of value to other healthcare providers and healthcare entities, marketing expenditures; or drug pricing; and/or ensure the registration and compliance of sales personnel; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">state and foreign laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies, healthcare providers and other third parties, including charitable foundations, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, personal imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union Member States, such as the UK Bribery Act. Infringement of these laws could result in substantial fines and imprisonment. Moreover, payments made to physicians in certain European Union Member States must be publicly disclosed. Agreements with physicians often must also be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the EU General Data Protection Regulation, or the GDPR, which became effective on May&#160;25, 2018. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the control over personal data by individuals to whom the personal data relates, the information provided to the individuals, the documentation we must maintain, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union, provides an enforcement authority and authorizes the imposition of large penalties for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenues of the non-compliant company, whichever is greater. The GDPR requirements apply not only to third-party transactions, but also to transfers of information between us and our subsidiaries such as TxCell, including employee information. The GDPR has increased our responsibility and potential liability in relation to personal data that we process compared to prior European Union law, particularly in light of the TxCell Acquisition, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#8217;s attention and increase our cost of doing business. However, despite our ongoing efforts to bring our practices into compliance with the GDPR, we may not be successful either due to various factors within our control or other factors outside our control. It is also possible that local data protection authorities may have different interpretations of the GDPR, leading to potential inconsistencies amongst various European Union Member States. Any failure or alleged failure (including as a result of deficiencies in our policies, procedures or measures relating to privacy, data security, marketing or communications) by us to comply with laws, regulations, policies, legal or contractual obligations, industry standards or regulatory guidance relating to privacy or data security, may result in governmental investigations and enforcement actions, litigation, fines and penalties or adverse publicity. In addition, new regulation, legislative actions or changes in interpretation of existing laws or regulations regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the European Union and other jurisdictions, such as the California Consumer Privacy Act of 2018 that will go into effect beginning January&#160;1, 2020, and we cannot determine the impact such future laws, regulations and standards will have on our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, personal imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">decreased demand for any product candidates or products that we may develop;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">termination of clinical trial sites or entire trial programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">injury to our reputation and significant negative media attention;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significant costs to defend the related litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">substantial monetary awards to trial subjects or patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">loss of revenue;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">diversion of management and scientific resources from our business operations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the inability to commercialize any products that we may develop.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently hold product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently rely on third parties to conduct some or all aspects of manufacturing of our product candidates for preclinical and clinical development. If one of our third-party manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts, to find new suppliers or manufacturers.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have limited experience in clinical-scale manufacturing of our product candidates and we rely upon third-party contract manufacturing organizations to manufacture and supply drug product for our preclinical and clinical studies. The manufacture of pharmaceutical products in compliance with the FDA&#8217;s current good manufacturing practices, or cGMP, requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced cGMP requirements, other federal and state regulatory requirements and foreign regulations. If our manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations to us or under applicable regulations, our ability to provide study biologics in our clinical studies would be jeopardized. Any delay or interruption in the supply of clinical study materials could delay the completion of our clinical studies, increase the costs associated with maintaining our clinical study programs and, depending upon the period of delay, require us to commence new studies at significant additional expense or terminate the studies completely.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All manufacturers of our product candidates must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Manufacturers of our product candidates may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. The FDA or similar foreign regulatory agencies may also implement new standards at any time, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. We have limited control over our manufacturers&#8217; compliance with these regulations and standards. Failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall or withdrawal of product approval. If the safety of any product supplied is compromised due to our manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical studies, regulatory submissions, approvals or commercialization of our product candidates, entail higher costs or impair our reputation.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our current agreements with our suppliers do not provide for the entire supply of the drug product necessary for all anticipated clinical studies or for full scale commercialization. If we and our suppliers cannot agree to the terms and conditions for them to provide the drug product necessary for our clinical and commercial supply needs, we may not be able to manufacture the product candidate until a qualified alternative supplier is identified, which could also delay the development of, and impair our ability to commercialize, our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers, which could have a material adverse effect on our business. New suppliers of any product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are building a manufacturing facility that could support future clinical production of our product candidates. We have no experience as a company manufacturing pharmaceutical products, and there can be no assurance that we will be able to build a compliant manufacturing facility or, if built, we will be able to successfully manufacture any of our product candidates. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to utilize both contract manufacturing organizations, or CMOs, and our own facility to meet our projected needs for clinical supply. We intend to expand our manufacturing capacity by designing and building a manufacturing facility that we plan to initially use to support our clinical supply needs. To meet these objectives we will need to transition manufacturing processes and know-how of our product candidates to our own facility. Transferring manufacturing processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. Additional studies may also need to be conducted to support the transfer of certain manufacturing processes and process improvements. We cannot be certain that all relevant know-how and data has been adequately incorporated into the manufacturing process until the completion of studies (and the related evaluations) intended to demonstrate the comparability of material previously produced with that generated by our CMOs. Although some of our employees have experience in the manufacturing of pharmaceutical products from prior employment at other companies, we, as a company, have no prior experience in pharmaceutical product manufacturing, and operating this facility will require us to comply with complex regulations and to continue to hire and retain experienced scientific, quality control, quality assurance and manufacturing personnel. Designing and building a manufacturing facility has been and will continue to be time-consuming and expensive, and we may experience delays or cost overruns. In addition, government approvals will be required for us to operate a manufacturing facility and can be time-consuming to obtain. As a manufacturer of pharmaceutical products, we also will be required to demonstrate and maintain cGMP compliance. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Furthermore, establishing manufacturing operations will require a reallocation of other resources, particularly the time and attention of our senior management. Even if we are able to establish our own manufacturing capabilities, we could encounter challenges in operating the manufacturing facility in compliance with cGMP, regulatory or other applicable requirements, resulting in potential negative consequences, including regulatory actions, which could undermine our ability to utilize this facility for our own manufacturing needs. Any failure or delay in the development of our manufacturing capabilities could adversely impact the development of our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">There are risks associated with manufacturing for clinical and commercial use. Manufacturing biological components at the appropriate scale and quality is complex and difficult.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are risks associated with manufacturing our product candidates including, among others, cGMP compliance, cost overruns, technical problems with process scale-up, process reproducibility, stability issues, lot consistency, yields and timely availability of raw materials. Even if efficacy and safety data from our clinical trials would otherwise support regulatory approval for a product candidate, there is no assurance that we or any third-party manufacturer will be able to manufacture our product candidates to specifications at levels necessary to support or maintain regulatory approval by the FDA or other regulatory authorities. In addition, we may not be able to manufacture our product candidates in sufficient quantities to meet the requirements for a potential launch or to meet potential future demand. If we or our third-party manufacturers are unable to produce sufficient quantities of the approved product for commercialization, either on a timely basis or at all, our commercialization efforts would be impaired, which would have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We face uncertainties and risks associated with the manufacture of our product candidates. Our product candidates are biologics and their manufacture involves complex processes, including the development of cell lines or cell systems to produce the biologic, with the challenge of significant variability. Further, there are difficulties in growing large quantities of such cells, consistently and sufficiently isolating certain types of cells and harvesting and purifying the biologic produced by them. The cost to manufacture biologics is generally far higher than traditional small molecule chemical compounds, and the manufacturing process can be difficult to reproduce. There is no guarantee we will be successful in establishing a larger-scale commercial manufacturing process for our pipeline product candidates or obtaining the needed manufacturing capacity. Due to the high cost to manufacture, inherent uncertainty related to manufacturing costs, and uncertainty in our patient population, there is risk that some of our product candidates may not be commercially viable.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not currently have the infrastructure or capability to manufacture, market and sell therapeutic products on a commercial scale.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order for us to commercialize our therapeutic products directly, we would need to develop, or obtain through outsourcing arrangements, the capability to manufacture, market and sell our products on a commercial scale. Currently, we do not have the ability nor the financial resources to establish the infrastructure and organizations needed to execute these functions, including such infrastructure needed for the commercialization of any product based on our ZFP technology, which can be </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">complex and costly. If we are unable to establish adequate manufacturing, sales, marketing and distribution capabilities, we will not be able to directly commercialize our therapeutics products, which would limit our future growth.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not currently have an organization for the sale, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the FDA and comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. There are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any approved products. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenues and may not become profitable. We will be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies. If we are not successful in commercializing our current or future product candidates either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of February&#160;15, 2019, we had 302 full-time employees. We need to grow the size of our organization in order to support our continued development and potential commercialization of our product candidates. In particular, we will need to add substantial numbers of additional personnel and other resources to support our development and potential commercialization of our product candidates. In addition, we may not be able to attract or retain employees with the appropriate levels of experience and skills to accomplish our objectives. As our development and commercialization plans and strategies continue to develop, or as a result of any future acquisitions, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other resources will increase. Our management, personnel and systems currently in place may not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">managing our preclinical studies and clinical trials effectively;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">identifying, recruiting, maintaining, motivating and integrating additional employees;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">improving our managerial, development, operational, information technology, and finance systems; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expanding our facilities.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As our operations expand, we will also need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and preclinical studies and clinical trials effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and sales and marketing personnel. Our failure to accomplish any of these tasks could prevent us from successfully growing our company.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to our Industry</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our competitors develop, acquire, or market technologies or products that are more effective than ours, this would reduce or eliminate our commercial opportunity.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any products that we or our collaborators or strategic partners develop by using our ZFP technology platform will enter into highly competitive markets. Even if we are able to generate products that are safe and effective for their intended use, competing technologies may prove to be more effective or less expensive, which, to the extent these competing technologies achieve market acceptance, will limit our revenue opportunities. In some cases, competing technologies have proven to be effective and less expensive. Competing technologies may include other methods of regulating gene expression or modifying genes. ZFNs and ZFP TFs have broad application in the life sciences industry and compete with a broad array of new technologies and approaches being applied to genetic research by many companies. Competing proprietary technologies with our product development focus include but are not limited to:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For genome editing and gene therapy products:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">recombinant proteins;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">other gene therapy/cDNAs;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">antisense;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">siRNA and microRNA approaches, exon skipping;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">small molecule drugs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">monoclonal antibodies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CRISPR/Cas technology; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TALE proteins, meganucleases, and MegaTALs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our non-therapeutic applications compete against similar technologies:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For protein production:&#160;gene amplification, CRISPR/Cas technology, TALE technology, insulator technology, and mini-chromosomes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For target validation:&#160;antisense, siRNA, TALE technology and CRISPR/Cas technology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For plant agriculture:&#160;recombination approaches, mutagenesis approaches, TALE technology, CRISPR/Cas technology, mini-chromosomes; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For transgenic animals:&#160;somatic nuclear transfer, embryonic stem cell, TALE, CRISPR/Cas technology and transposase technologies.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to possessing competing technologies, our competitors include pharmaceutical and biotechnology companies with:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">substantially greater capital resources than ours;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">larger research and development staffs and facilities than ours; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">greater experience in product development and in obtaining regulatory approvals and patent protection.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These organizations also compete with us to:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">attract qualified personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">attract parties for acquisitions, joint ventures or other collaborations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">license the proprietary technologies of academic and research institutions that are competitive with our technology, which may preclude us from pursuing similar opportunities.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, our competitors may succeed in obtaining patent protection or commercializing products before us. In addition, any products that we develop may compete with existing products or services that are well established in the marketplace.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our product candidates are based on novel technologies, which makes it difficult to predict the timing and costs of development and of subsequently obtaining regulatory approval.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have concentrated our research and development efforts on genome editing, gene therapy, gene regulation and cell therapy. The regulatory approval process for novel product candidates such as ours is unclear and may be lengthier and more expensive than the process for other, better-known or more extensively studied product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These regulatory review committees and advisory groups, and any new guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our current or future product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be harmed. Even if our product candidates are approved, we expect that the FDA will require us to submit follow-up data regarding our clinical trial subjects for a number of years after any approval. If this follow-up data shows negative long-term safety or efficacy outcomes for these patients, the FDA may revoke its approval or change the label of our products in a manner that could have an adverse impact on our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, adverse developments in clinical trials of gene therapy or cell therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates. The FDA and EMA have only very recent and limited experience in the approval of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:10pt;"> gene therapy products. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our gene therapy approach utilizes vectors derived from viruses, which may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may damage public </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">perception of the safety of our product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gene therapy remains a novel technology, with only one </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:10pt;"> gene therapy product approved for a genetic disease to date in the United States and only two </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:10pt;"> gene therapy products for genetic diseases approved to date in the European Union. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians who specialize in the treatment of genetic diseases targeted by our product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. For example, earlier gene therapy trials led to several well-publicized adverse events, including cases of leukemia and death seen in other trials using other vectors. Serious adverse events in our clinical trials, or other clinical trials involving gene therapy products or our competitors&#8217; products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Laws or public sentiment may limit the production of genetically modified agricultural products, and these laws could reduce our partner&#8217;s ability to sell such products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Genetically modified products are currently subject to public debate and heightened regulatory scrutiny, either of which could prevent or delay production of agricultural products. We have exclusive right to use our ZFP technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants or plant cell cultures. The field-testing, production and marketing of genetically modified plants and plant products are subject to federal, state, local and foreign governmental regulation. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of our genetically modified products in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays or other impediments to our product development programs or the commercialization of resulting products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA currently applies the same regulatory standards to foods developed through genetic engineering as those applied to foods developed through traditional plant breeding. Genetically engineered food products, however, will be subject to pre-market review if these products raise safety questions or are deemed to be food additives. Governmental authorities could also, for social or other purposes, limit the use of genetically modified products created with our gene regulation technology.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if the regulatory approval for genetically modified products developed using our ZFP technology is obtained, our success will also depend on public acceptance of the use of genetically modified products including drugs, plants, and plant products. Claims that genetically modified products are unsafe for consumption or pose a danger to the environment may influence public attitudes. Our genetically modified products may not gain public acceptance. The subject of genetically modified organisms has received negative publicity in the United States and particularly in Europe, and such publicity has aroused public debate. The adverse publicity in Europe could lead to greater regulation and trade restrictions on imports of genetically altered products. Similar adverse public reaction or sentiment in the United States to genetic research and its resulting products could result in greater domestic regulation and could decrease the demand for our technology and products.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to our Finances</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have generated operating losses since we began operations in 1995. Our net losses for the years ended December&#160;31, 2018, 2017 and 2016 were $68.9&#160;million, $54.6&#160;million and $71.7&#160;million, respectively. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have been engaged in developing our ZFP technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities, revenues derived from collaboration agreements, other strategic partnerships in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> we had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$634.2&#160;million</span><span style="font-family:inherit;font-size:10pt;">. Since our initial public offering in 2000, we have generated an aggregate of approximately $794.2&#160;million in gross proceeds from the sale of our equity securities. We expect to continue to incur additional operating losses for the next several years as we continue to advance our product candidates. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to curtail or suspend our operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to raise additional capital, which would harm our ability to develop our technology and product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure and research and product development activities. While we believe our financial resources will be adequate to fund our current operations for at least the next twelve months, we will need to raise substantial additional capital to fund the development, manufacturing and potential commercialization of our product candidates. We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek FDA approvals of potential products, a process that could cost in excess of hundreds of millions of dollars per product. We may experience difficulties in accessing the capital market due to external factors beyond our control such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will materially adversely affect our business and our ability to develop our technology and products candidates and to realize the anticipated benefits of the TxCell Acquisition. Furthermore, any sales of additional equity securities may result in dilution to our stockholders and any debt financing may include business and financial covenants that restricts our operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are at the development phase of operations and may not succeed or become profitable.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We began operations in 1995, are in the early phases of product development for the most advanced candidates in our therapeutics pipeline, and we have incurred significant losses since inception. To date, our revenues have been generated from collaboration agreements, other collaborations in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. Our focus on higher-value therapeutic product development and related collaboration requires us to incur substantial expenses associated with product development. In addition, the preclinical or clinical failure of any single product may have a significant effect on the actual or perceived value of our stock. Our business is subject to all of the risks inherent in the development of a new technology, which includes the need to:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">attract and retain qualified scientific and technical staff and management, particularly scientific staff with expertise to develop our early-stage technology into therapeutic products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain sufficient capital to support the expense of developing our technology platform and developing, testing and commercializing products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">develop a market for our products; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">successfully transition from a company with a research focus to a company capable of supporting commercial activities.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive U.S. tax reform legislation could increase the tax burden on our orphan drug programs and adversely affect our business and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The U.S. government enacted comprehensive tax legislation in 2017 that included significant changes to the taxation of business entities. These changes included, among others, (i)&#160;a permanent reduction to the corporate income tax rate from a top marginal rate of 35% to a flat rate of 21%, (ii)&#160;a partial limitation on the deductibility of business interest expense and net operating loss carryforwards, (iii)&#160;a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain rules designed to prevent erosion of the U.S. income tax base) and (iv)&#160;a one-time tax on accumulated offshore earnings held in cash and illiquid assets, with the latter taxed at a lower rate. Further, the comprehensive tax legislation, among other things, reduced the orphan drug tax credit from 50% to 25% of qualifying expenditures. When and if we become profitable, this reduction in tax credits may result in an increased federal income tax burden on our orphan drug programs as it may cause us to pay federal income taxes earlier under the revised tax law than under the prior law and, despite being partially off-set by a reduction in the corporate tax rate as described above, may increase our total federal tax liability attributable to such programs.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notwithstanding the reduction in the corporate income tax rate, the overall impact of this comprehensive tax legislation resulted in an overall reduction in our deferred tax assets, and our business and financial condition could still be adversely affected as additional guidance and regulations are issued with respect to the original tax law change. In addition, it is uncertain if and to what extent various states will conform to this comprehensive tax legislation. The impact of this comprehensive tax legislation on holders of our common stock is also uncertain and could be adverse. Investors should consult with their legal and tax advisors with respect to this comprehensive tax legislation and the potential tax consequences of investing in or holding our common stock.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to our Relationships with Collaborators and Strategic Partners</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If conflicts arise between us and our collaborators or strategic partners, these parties may act in their self-interest, which may limit our ability to implement our strategies and otherwise harm our business and prospects.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in its self-interest, which may limit our ability to implement our strategies. Some of our academic collaborators and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop or invest in competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of product candidates covered by the applicable agreement.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, conflicts could arise between us and our collaborators resulting from disputes regarding our or our collaborators&#8217; or strategic partners&#8217; performance under the applicable agreement, including disputes arising from alleged breaches of our agreements with our collaborators and strategic partners. For example, we have certain confidentiality obligations to our collaborators and strategic partners under our agreements with them, and it is possible that, in connection with the data security incident we disclosed in April 2018, we could be subject to claims that we have breached our confidentiality obligations, which could result in damages payable by us and/or the affected collaborator or strategic partner seeking to terminate its agreement with us.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these developments could harm our product development efforts and otherwise adversely affect our business and prospects.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our collaborators and strategic partners may control aspects of our clinical trials, which could result in delays and other obstacles in the commercialization of our proposed products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We depend on third-party collaborators and strategic partners to design and conduct our clinical trials for some of our therapeutic programs. As a result, we may not be able to conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations. In addition, if any of these collaborators or strategic partners withdraws support for our programs or proposed products or otherwise impair their development; our business could be negatively affected.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For example, under our agreements with Kite, Pfizer and Sanofi, they have control and broad discretion over all or certain aspects of the clinical development and commercialization of any product developed under the agreement, and we will have little, if any, influence on how these programs will be conducted. Our lack of control over the clinical development in such agreements could cause delays or other difficulties in the development and commercialization of our product candidates, which may prevent us from completing the intended IND filings in a timely fashion and receiving any milestone, royalty payments and other benefits under the agreement. In addition, under their respective agreements, our third-party collaborators have certain rights to terminate the agreements by providing us with advance notices, therefore, the actual milestone payments that we may receive under these agreements may be substantially lower than the full amounts provided for under these agreements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our collaborators or strategic partners may decide to adopt alternative technologies or may be unable to develop commercially viable products with our technology, which would negatively impact our revenues and our strategy to develop these products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our collaborators or strategic partners may adopt alternative technologies, which could decrease the marketability of ZFP technology. Additionally, because many of our collaborators or strategic partners are likely to be working on more than one development project, they could choose to shift their resources to projects other than those they are working on with us. If they do so, this would delay our ability to test our technology and would delay or terminate the development of potential products based on our ZFP technology. Further, our collaborators and strategic partners may elect not to develop products arising out of our collaborative and strategic partnering arrangements or to devote sufficient resources to the development, manufacturing, marketing or sale of these products. If they terminate the collaborative relationship with us, we will be required to seek the support of other partners or collaborators. We may not have sufficient resources and expertise to develop these programs by ourselves, and we may not be able to identify a suitable partner or negotiate a favorable collaboration agreement to allow us to continue the development of these programs. If any of these events occur, we may not be able to develop our technologies or commercialize our products.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the licensed products under our non-therapeutic license agreements are not successfully commercialized, or our third-party licensees terminate our agreements, our ability to generate revenue under these license agreements may be limited.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a number of collaboration agreements with third parties whereby we licensed our ZFP technologies to develop products in non-therapeutic fields, such as laboratory research reagents, protein pharmaceuticals, and, transgenic animals, as well as plant agriculture.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot be certain that we or our collaboration partners will succeed in the development of commercially viable products in these non-therapeutic fields of use, and there is no guarantee that we or our collaboration partners will achieve the milestones set forth in the respective license agreements. To the extent we or our collaboration partners do not succeed in developing and commercializing products or if we or our collaboration partners fail to achieve such milestones, our revenues and benefits under the license agreements will be limited. In the event our third party licensees decide to terminate the license agreements, our ability to generate revenue under such license agreements will cease.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our collaborations with outside scientists may be subject to change, which could limit our access to their expertise.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We work with scientific advisors and collaborators at academic research institutions. These scientists are not our employees and may have other commitments that would limit their availability to us. Although our scientific advisors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. Although our scientific advisors and academic collaborators sign agreements not to disclose our confidential information, it is possible that some of our valuable proprietary knowledge may become publicly known through them, which may cause competitive harm to our business.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to our Intellectual Property</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because it is difficult and costly to protect our proprietary rights, and third parties may have filed patent applications that are similar to ours, we cannot guarantee the proprietary protection of our technologies and products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial success may depend in part on obtaining and enforcing patent protection for our technology and successfully defending any of our patents that may be challenged. Obtaining and enforcing pharmaceutical and biotechnology patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and can involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims that may issue from any patent applications that we own or license, nor are we able to predict whether any third-party patents might issue with claims that are relevant to our product candidates or technologies.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to various license agreements that grant us rights under specified patents and patent applications. We are also party to various license agreements by which we grant third parties rights under specified patents and patent applications. Our current licenses contain performance obligations. If we fail to meet those obligations, the licenses could be terminated. If we are unable to continue to license these technologies on commercially reasonable terms, or at all, we may be forced to delay or terminate aspects of our product development and research activities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to our present and any future sublicenses, because our rights derive from those granted to our sublicensor, we are subject to the risk that our sublicensor may fail to perform its obligations under the master license or fail to inform us of useful improvements in, or additions to, the underlying intellectual property owned by the original licensor.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are unable to exercise the same degree of control over intellectual property that we license from third parties as we exercise over our internally developed intellectual property. We do not control the prosecution of certain of the patent applications that we license from third parties; therefore, the patent applications may not be prosecuted as we desire or in a timely manner.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we or our licensors were the first to make the inventions covered by each of our pending patent applications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we or our licensors were the first to file patent applications for these inventions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the patents of others will not have an adverse effect on our ability to do business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">others will not independently develop similar or alternative technologies or reverse engineer any of our products, processes or technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any of our pending patent applications will result in issued patents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any patents issued or licensed to us, our collaborators or strategic partners will provide a basis for commercially viable products or will provide us with any competitive advantages;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any patents issued or licensed to us will not be challenged and invalidated by third parties; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we will develop additional products, processes or technologies that are patentable.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Others have filed and in the future are likely to file patent applications that are similar to ours. We are aware that there are academic groups and other companies that are attempting to develop technology that is based on the use of zinc finger, TALE, CRISPR/Cas and other DNA-binding proteins, and that these groups and companies have filed patent applications. Several patents with claims directed to this technology have issued, although we have no current plans to use the claimed inventions. If these or other patent applications issue as patents, it is possible that the holder of any patent or patents granted on these applications may bring an infringement action against us, our collaborators, or strategic partners claiming damages and seeking to enjoin commercial activities relating to the affected products and processes. The costs of litigating the claim could be substantial regardless of outcome. Moreover, we cannot predict whether we, our collaborators, or strategic partners would prevail in any actions. In addition, if the relevant patent claims were upheld as valid and enforceable and our products or processes were found to infringe a patent or patents, we or our collaborators may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, and we may be prevented from making, using, or selling the relevant product or process unless we or our collaborators could obtain a license or were able to design around the patent claims. We can give no assurance that such a license would be available to us or our collaborators on commercially reasonable terms, or at all, or that we would be able to successfully design around the relevant patent claims. There may be significant litigation in the genomics or cell therapy industry regarding patent and other intellectual property rights, which could subject us to litigation. If we become involved in litigation, it could consume a substantial portion of managerial and financial resources.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on trade secrets to protect technology where we believe patent protection is not appropriate or obtainable. Trade secrets, however, are difficult to protect. While we require employees, academic collaborators and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information or enforce these confidentiality agreements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our collaborators, strategic partners, and scientific advisors have rights to publish data and information in which we may have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations and strategic partnerships, then we may not be able to receive patent protection or protect our proprietary information.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to obtain or protect intellectual property rights related to our product candidates, we may not be able to compete effectively in the intended markets.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Our competitors may be able to circumvent our patents by developing similar or alternative product candidates in a non-infringing manner. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. We have filed several patent applications covering our product candidates recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications, an interference or derivation proceeding in the United States can be initiated by a third party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date or from the filing date of the corresponding international application. Various extensions </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">may be available. However, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures have been and may in the future be breached, and we may not have adequate remedies for any breach. See also the risk factor titled, &#8220;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span><span style="font-family:inherit;font-size:10pt;">&#8221; In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ex part</span><span style="font-family:inherit;font-size:10pt;">e reexaminations, post-grant review, and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review proceedings before the U.S. Patent and Trademark Office, or U.S. PTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third parties may assert that we are employing their proprietary technology without authorization, and such parties may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, we are aware of certain patents held by a third party related to certain vector manufacturing methods that are currently being used in certain of our product candidates. We have not yet finalized the commercial scale manufacturing process for any of our product candidates. If our commercial scale manufacturing process utilizes these vector manufacturing methods, and if these third-party patents are in force at the time of commercialization, we may need to use or develop a non-infringing manufacturing method or seek a license to these patents. In any event, if any third-party patents were held by a court of competent jurisdiction to cover the manufacturing methods </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license, or until such patents expires. In either case, such a license may not be available on commercially reasonable terms or at all. The inability to obtain required licenses on reasonable commercial terms, if at all, could delay or prevent the preclinical evaluation, drug development collaborations, clinical testing, and/or commercialization of the affected product candidates. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary rights to gene or cell therapy product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Presently, we believe we have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our gene and cell therapy product candidates. Because our programs may involve additional product candidates, such as TX-200 and potential future CAR-Treg therapies that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify on commercially reasonable terms, if at all. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist that might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In many cases, patent prosecution of our in-licensed technology is controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the sublicensing of patent and other rights under our collaborative development relationships;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the priority of invention of patented technology.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. As an example, TxCell has exclusively licensed the right to the CAR for use in TX-200 from the University of British Columbia, or UBC. Should UBC terminate this license agreement, we may have to develop or acquire the appropriate CAR which would extend our anticipated development timeline and add expense, and which could result in our failure to realize the anticipated benefits of the TxCell Acquisition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be involved in lawsuits or similar proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable, in whole or in part, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Moreover, if we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidate. For example, TxCell has exclusively licensed the rights to technology related to redirected Treg cells from the Yeda Research and Development Company, or Yeda. A patent included in this exclusive license agreement with Yeda was granted in Europe in July 2016. Subsequent to this grant, the patent was opposed by several parties in May 2017 and revoked in November 2018. The outcome following legal assertions of invalidity and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the U.S. PTO may be necessary to determine the priority of inventions or other matters of inventorship with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation, interference, derivation, or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the U.S. PTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The U.S. PTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or in other jurisdictions in which we seek patent protection could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The United States enacted the Leahy-Smith America Invents Act, or the America Invents Act, which includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the U.S. PTO during patent prosecution and additional procedures to attack the validity of a patent by U.S. PTO administered post-grant proceedings, including post-grant review, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review, and derivation proceedings. Because of a lower evidentiary standard in U.S. PTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a U.S. PTO proceeding sufficient for the U.S. PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. In addition, the challenged patents are not accorded the presumption of validity as they are in Federal District Court. Accordingly, a third party may attempt to use the U.S. PTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the U.S. PTO, and similar legislative, judicial and regulatory bodies in other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to our Business Operations</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sensitive information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our computer networks or our confidential information. In addition, many of those third parties in turn subcontract or outsource some of their responsibilities to third parties. As a result, our information technology systems, including the functions of third parties that are involved or have access to those systems, is very large and complex. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and exposures, the size, complexity, accessibility and distributed nature of our information technology systems, and the large amounts of sensitive information stored on those systems, make such systems potentially vulnerable to unintentional or malicious, internal and external attacks on our technology environment. Potential vulnerabilities can be exploited from inadvertent or intentional actions of our employees, third-party vendors, business partners, or by malicious third parties. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; nation states and others. In addition to the extraction of sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. In addition, the prevalent use of mobile devices increases the risk of data security incidents.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant disruptions of our, our third-party vendors&#8217; and/or business partners&#8217; information technology systems or other similar data security incidents could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive information, which could result in financial, legal, regulatory, business and reputational harm to us. For example, in April 2018, we announced a data security incident involving the compromise of a then senior executive&#8217;s company email account. Upon learning of the incident on March&#160;28, 2018, external network security experts were promptly engaged, and the incident response team worked diligently to investigate the incident. We also promptly notified federal law enforcement of the incident. The investigation concluded that the incident was limited to the compromise of the then senior executive&#8217;s company email account for approximately 11 weeks. The investigation did not reveal any evidence that our network or other information technology systems were otherwise compromised in connection with the incident or that the incident resulted in the disclosure of or access to personal information about patients or other individuals besides the holder of the company email account that was affected. However, proprietary, confidential and other sensitive information of ours and that of other entities was accessed and may have been compromised as a result of the incident. Unforeseen developments related to this incident could occur, which could have a further adverse impact on us. We do not maintain cyber liability insurance and will therefore have no coverage for any losses resulting from this data security incident. Any litigation or regulatory review arising from this incident could result in significant legal exposure to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While we aware of the company email incident described above, there is no way of knowing with certainty whether we have experienced any other data security incidents that have not been discovered. While we have no reason to believe this to be the case, attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not aware that they have been attacked. Any event, including the company email incident described above, that leads to unauthorized access, use or disclosure of personal information, including but not limited to personal information regarding our patients or employees, could disrupt our business, harm our reputation, compel us to comply with applicable federal and/or state breach notification laws and foreign law equivalents, subject us to time consuming, distracting and expensive litigation, regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise subject us to liability under laws, regulations and contractual obligations, including those that protect the privacy and security of personal information. This could result in increased costs to us, and result in significant legal and financial exposure and/or reputational harm. In addition, any failure or perceived failure by us or our vendors or business partners to comply with our privacy, confidentiality or data security-related legal or other obligations to third parties, or any further security incidents&#160;or other inappropriate access events that result in the unauthorized access, release or transfer of sensitive information, which could include personally identifiable information, may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us by advocacy groups or others, and could cause third parties, including clinical sites, regulators or current and potential partners, to lose trust in us or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related obligations, which could materially and adversely affect our business and prospects. In addition, failure to maintain effective internal accounting controls related to security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and subject us to regulatory scrutiny. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures intended to protect our information </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or further security incidents.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not realize the anticipated benefits of the TxCell Acquisition or be able to successfully integrate the acquired TxCell operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The TxCell Acquisition involves numerous uncertainties and risks, and has required, and will continue to require, significant efforts and expenditures, including with respect to integrating the acquired TxCell operations with our operations. We may not be able to accomplish this integration process smoothly or successfully. The integration of certain of the acquired TxCell operations will take time and will require the dedication of significant management resources, which may temporarily distract our management&#8217;s attention from the routine business of the combined company. In any event, we may encounter unexpected difficulties, or incur unexpected costs, in connection with our transition activities and integration efforts, which include:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential disruption of our historical core business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the risk that our relative lack of historical experience in CAR-Treg development and developing product candidates and technology for immunological diseases will not allow us to advance the development of CAR&#8209;Treg therapies, including TX-200, on the timeframes we expect, or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the strain on, and need to continue to expand, our existing operational, technical, financial and administrative infrastructure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the difficulties in assimilating employees and corporate cultures;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the difficulties in effectively managing transition and integration activities given the distance between our headquarters and U.S.-based management team and TxCell&#8217;s offices in France;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the failure to retain key managers and other personnel, including the employees from the acquired TxCell business who might experience uncertainty about their future roles with us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the challenges in controlling additional costs and expenses in connection with and as a result of the TxCell Acquisition;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the diversion of our management&#8217;s attention to integration of operations and corporate and administrative infrastructures; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any unanticipated liabilities for activities of or related to TxCell or its operations, technologies or product candidates.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any of these factors impairs our ability to integrate successfully, we may be required to spend time or money on integration activities that otherwise would be spent on the development and expansion of our business. If we fail to integrate or otherwise manage the acquired TxCell business successfully and in a timely manner, the combined company&#8217;s potential to achieve the anticipated long-term strategic benefits of the TxCell Acquisition could be compromised and resulting operating inefficiencies could increase costs and expenses more than we planned, could negatively impact the market price of our common stock and could otherwise distract us from execution of our strategy. Failure to maintain effective financial controls and reporting systems and procedures could also adversely affect our ability to produce timely and accurate financial statements. In addition, while we intend to avail ourselves of the French tax credit for certain research and development related expenses, we may not receive the anticipated amount and we may also be required to make corrective actions upon any audit by the French tax authority with respect to such tax credit.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In any event, there can be no assurance that we will integrate or otherwise manage the acquired TxCell business successfully or otherwise do so without experiencing operating inefficiencies or control deficiencies. In addition, because the historical business operations of TxCell differ from our historical business operations, and the combined company has a different business mix than our historical business, we face different operational risks and challenges and the complexity of our company has increased. Significant management time and effort is required to effectively manage the increased complexity of our company following the TxCell Acquisition, and our failure to successfully do so could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to acquire 100% of the equity interests of TxCell, our business, financial condition and results of operations could be adversely affected.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we completed the TxCell Acquisition, we may not be able to acquire the remaining ordinary shares of TxCell for some period of time, if ever. As of February&#160;15, 2019, we have acquired a total of 25,047,671 ordinary shares of TxCell, representing approximately 98.2% of the outstanding share capital and voting rights of TxCell. Until such time, if ever, that we acquire 100% of the equity interests of TxCell, we will need to consider the rights of, and duties owed to, the minority shareholders of TxCell under French law when making future decisions that might impact TxCell, its business or its operations, which could adversely affect our business and our ability to realize the anticipated benefits of the TxCell Acquisition.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We plan to continue to operate the acquired TxCell business in France, which may expose us to unanticipated costs or events.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TxCell&#8217;s historical operations have been based in France and we plan to continue to operate the acquired TxCell business in France. Our operation of the acquired TxCell business in France involves significant risks, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">difficulty hiring and retaining appropriate personnel due to intense competition for such limited resources;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disruptions in relations with our employees, including legacy TxCell employees; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">compliance with regulatory requirements, including local French employment regulations and organized labor in France.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as a result of our operations in France, we have become more exposed to fluctuations in currency exchange rates between the Euro and the U.S. dollar. Given the volatility of currency exchange rates, there is no assurance that we will be able to effectively manage currency transaction and/or conversion risks. To date, we have not entered into derivative instruments to offset the impact of foreign exchange fluctuations, which fluctuations could have a material adverse effect on our financial condition and results of operations. In any event, difficulties resulting from these and other risks related to our anticipated operations in France could expose us to increased expenses, impair our development efforts, adversely affect our financial condition and results of operations, and harm our competitive position.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are also exposed to general risks associated with our operations outside of the United States, which could adversely affect our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to our French operations as a result of the TxCell Acquisition, we also have operations and conduct business in other countries outside the United States, and have a UK subsidiary. We may plan to expand these activities or in to additional countries in the future. Consequently, we are, and will continue to be, subject to risks inherent with operating in foreign countries, in addition to those specific risks associated with TxCell, which include:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the increased complexity and costs inherent in managing international operations, including in geographically disparate locations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">diverse regulatory, financial and legal requirements, and any future changes to such requirements, in one or more countries where we are located or do business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adverse tax consequences, including changes in applicable tax laws and regulations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">applicable trade laws, tariffs, export quotas, custom duties or other trade restrictions, and any changes to them;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">economic weakness, including inflation, or political or economic instability in particular foreign economies and markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">foreign currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to doing business or operating in another country;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">liabilities for activities of, or related to, our international operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">challenges inherent in efficiently managing employees in diverse geographies, including the need to adapt systems, policies, benefits and compliance programs to differing labor and other regulations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">workforce uncertainty in countries where labor unrest is more common than in the United States; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">laws and regulations relating to data security and the unauthorized use of, or access to, commercial and personal information.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The expected withdrawal of the United Kingdom from the European Union, commonly referred to as &#8220;Brexit,&#8221; may adversely impact our ability to obtain regulatory approvals of our product candidates in the European Union and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the European Union.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, UK voters approved a referendum to withdraw from the European Union, commonly referred to as &#8220;Brexit.&#8221; Pursuant to Article 50 of the Treaty on European Union, the United Kingdom will cease to be a European Union Member State either on the effective date of a withdrawal agreement (which requires UK parliamentary approval) or, failing that, two years following the United Kingdom&#8217;s notification of its intention to leave the European Union, unless extended. Although the United Kingdom formally notified the European Council of its intention to leave the European Union in March 2017,several extensions have been granted (most recently until October 31, 2019). Given that no formal withdrawal agreements have been agreed and there have been several extensions granted, the United Kingdom has yet to formally leave the European Union, and it is uncertain as to when it will occur, if ever.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brexit could adversely affect European or worldwide political, regulatory, economic or market conditions and could contribute to instability in global political institutions, regulatory agencies and financial markets. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the European Union for our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Because a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from European Union directives and regulations, Brexit could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom or the European Union. In the near term, there is a risk of disrupted import and export processes due to a lack of administrative processing capacity by the respective UK and European Union customs agencies that may delay time-sensitive shipments and may negatively impact our product supply chain. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the European Union.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we use biological and hazardous materials in a manner that causes injury or violates laws, we may be liable for damages.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals, and various radioactive compounds typically employed in the study of molecular and cellular biology. We routinely use cells in culture and gene delivery vectors, and we employ small amounts of radioisotopes in trace experiments. Although we maintain up-to-date licensing and training programs, we cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling, or disposal of these materials. In the event of contamination or injury, we could be held liable for damages that result, and any liability could exceed our resources. We currently carry insurance covering certain claims arising from our use of these materials. However, if we are unable to maintain our insurance coverage at a reasonable cost and with adequate coverage, our insurance may not cover any liability that may arise. We are subject to federal, state, and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure to attract, retain, and motivate skilled personnel and cultivate key academic collaborations will delay our product development programs and our research and development efforts.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success depends on our continued ability to attract, retain, and motivate highly qualified management and scientific personnel and our ability to develop and maintain important relationships with leading research and academic institutions and scientists. Competition for skilled and qualified personnel and academic and other research collaborations is intense. If we lose the services of personnel with the necessary skills, including the members of our senior management team, it could significantly impede the achievement of our research and development objectives. In addition, we expect to rely on the experience and expertise of TxCell&#8217;s historical management team and other key personnel in the development of TX-200 and potential future CAR-Treg therapies. If we were to lose the services of a significant portion or key individuals of this team, such development and our business could be adversely affected. Moreover, if we fail to negotiate additional acceptable collaborations with academic and other research institutions and scientists, or if our existing collaborations are unsuccessful, our development programs may be delayed or may not succeed.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third parties on which we rely and we may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and may not prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to our Common Stock and Corporate Organization</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our stock price has been volatile and may continue to be volatile, which could result in substantial losses for investors.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our stock price has been volatile and may continue to be volatile, which could cause stockholders to incur substantial losses. An active public market for our common stock may not be sustained, and the market price of our common stock may continue to be highly volatile. The market price of our common stock has fluctuated significantly in response to various factors, some of which are beyond our control, including but not limited to the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements by us or collaborators providing updates on the progress or development status of product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">data from clinical trials;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">initiation or termination of clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in market valuations of similar companies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">overall market and economic conditions, including the equity markets for emerging biotechnology companies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">deviations in our results of operations from the guidance given by us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements by us or our competitors of new or enhanced products, technologies or services or significant contracts, acquisitions, strategic relationships, joint ventures or capital commitments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcement of changes in business and operations by our collaborators and partners, or changes in our existing collaboration agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory developments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes, by one or more of our security analysts, in recommendations, ratings or coverage of our stock;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">additions or departures of key personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">future sales of our common stock or other securities by us, management or directors, liquidation of institutional funds that comprised large holdings of our stock; and decreases in our cash balances.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Actual or potential sales of our common stock by our employees, including our executive officers, pursuant to pre-arranged stock trading plans could cause our stock price to fall or prevent it from increasing for numerous reasons, and actual or potential sales by such persons could be viewed negatively by other investors.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and our policies regarding stock transactions, a number of our employees, including executive officers and members of our board of directors, have adopted and may continue to adopt stock trading plans pursuant to which they have arranged to sell shares of our common stock from time to time in the future. Generally, sales under such plans by our executive officers and directors require public filings. Actual or potential sales of our common stock by such persons could cause the price of our common stock to fall or prevent it from increasing for numerous reasons.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our stock price is also influenced by public perception of gene therapy and government regulation of potential products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reports of serious adverse events in a retroviral gene transfer trial for infants with X-linked severe combined immunodeficiency (X-linked SCID) in France and subsequent FDA actions putting related trials on hold in the United States had a significant negative impact on the public perception and stock price of certain companies involved in gene therapy. Stock prices of these companies declined whether or not the specific company was involved with retroviral gene transfer for the treatment of infants with X-linked SCID, or whether the specific company&#8217;s clinical trials were placed on hold in connection with these events. Other potential adverse events in the field of gene therapy may occur in the future that could result in greater governmental regulation of our potential products and potential regulatory delays relating to the testing or approval of our potential products. These external events may have a negative impact on public perception of our business, which could cause our stock price to decline.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. In the event securities or industry analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our certificate of incorporation, Delaware law and our bylaws could make an acquisition of our company more difficult and could prevent attempts by our stockholders to remove or replace current management.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-takeover provisions of Delaware law and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in control of our company, even if a change in control would be beneficial to our stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. In particular, under our certificate of incorporation our board of directors may issue up to 5,000,000 shares of preferred stock with rights and privileges that might be senior to our common stock, without the consent of the holders of the common stock. Moreover, without any further vote or action on the part of the stockholders, the board of directors would have the authority to determine the price, rights, preferences, privileges, and restrictions of the preferred stock. This preferred stock, if it is ever issued, may have preference over, and harm the rights of, the holders of common stock. Although the issuance of this preferred stock would provide us with flexibility in connection with possible acquisitions and other corporate purposes, this issuance may make it more difficult for a third party to acquire a majority of our outstanding voting stock.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Similarly, our authorized but unissued common stock is available for future issuance without stockholder approval. Our certificate of incorporation further provides that stockholders may not take action by written consent.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our amended and restated bylaws:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish advance notice requirements for nominations for election to the board of directors or proposing matters that can be acted upon at stockholders&#8217; meetings; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">prohibit stockholders from calling a special meeting of stockholders.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also subject to Section 203 of the General Corporation Law of the State of Delaware, which provides, subject to certain exceptions, that if a person acquires 15% of our voting stock, the person is an &#8220;interested stockholder&#8221; and may not engage in &#8220;business combinations&#8221; with us for a period of three years from the time the person acquired 15% or more or our voting stock. The application of Section 203 may, in some circumstances, deter or prevent a change in control of our company even when such change may be beneficial to our stockholders.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our amended and restated bylaws provide that a state or federal court located within the State of Delaware will be the exclusive forum for the adjudication of certain disputes, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our amended and restated bylaws provide that a state or federal court located within the State of Delaware is the sole and exclusive forum for:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any derivative action or proceeding brought on our behalf;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee or stockholder of Sangamo to us or our stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our charter or our bylaws, as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any action asserting a claim governed by the internal affairs doctrine.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This provision further provides that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of and consented to the provisions of such provision.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find this provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</span></div><div><a id="s85E7210EDBCC5A68BDB671BD504AA158"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><a id="s6AAC6AE0E7BC54FFB0E627DD19B09CDC"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">DEFAULTS UPON SENIOR SECURITIES</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5DEB01E3046A59B68224CC2F5FF1F417"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MINE SAFEY DISCLOSURES</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div><a id="sD9507AAAC7685687AC7FD0C62A3B0FBA"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INFORMATION</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><a id="sCE7763FE3EEB5584B01297D0D8846752"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;-sec-extract:summary;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;6.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBITS</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a)&#160;Exhibits:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.08429118773945%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm"><span style="font-family:inherit;font-size:10pt;">Composite copy of Seventh Amended and Restated Certificate of Incorporation of Sangamo Therapeutics, Inc., as amended (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 000-30171), filed with the SEC on August 9, 2017).</span></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex31_6.htm"><span style="font-family:inherit;font-size:10pt;">Third Amended and Restated Bylaws of Sangamo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 000-30171), filed with the SEC on June 15, 2018).</span></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sgmo-20190630xex311.htm"><span style="font-family:inherit;font-size:10pt;">Rule 13a &#8212; 14(a) Certification of Principal Executive Officer.</span></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sgmo-20190630xex312.htm"><span style="font-family:inherit;font-size:10pt;">Rule 13a &#8212; 14(a) Certification of Principal Financial Officer.</span></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sgmo-20190630xex321.htm"><span style="font-family:inherit;font-size:10pt;">Certifications Pursuant to 18 U.S.C. Section 1350.</span></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cover page from Sangamo&#8217;s Quarterly Report on Form 10-Q for the three months ended June 30, 2019, formatted in Inline XBRL.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_____________________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">* </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended.</span></div></td></tr></table><div style="line-height:120%;padding-left:72px;text-indent:-72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><a id="sCFCF9E91226E53CA8DB39F0B5FCE8CA2"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5283C196704D58199ECD2CC1262E5DB6"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:16px;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dated: August&#160;7, 2019</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:696px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:405px;"></td><td style="width:290px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SANGAMO THERAPEUTICS, INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ ALEXANDER D. MACRAE</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Alexander D. Macrae</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">President and Chief Executive Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Principal Executive Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ PRATHYUSHA DURAIBABU</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Prathyusha Duraibabu</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Vice&#160;President, Finance</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Principal Accounting Officer)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sgmo-20190630xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s16CE4A13AC065F50AF9954413DE2C817"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Alexander D. Macrae, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:100%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;7, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ ALEXANDER D. MACRAE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alexander D. Macrae</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sgmo-20190630xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAEC7F60C94FE5D229CEF0E1088D794C2"></a></div><div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, St&#233;phane Boissel, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;7, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ ST&#201;PHANE BOISSEL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">St&#233;phane Boissel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice&#160;President, Corporate Strategy&#160;and&#160;Interim Chief&#160;Financial&#160;Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>sgmo-20190630xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB824C7C426185C53A5A0E6192922F892"></a></div><div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certifications Pursuant to 18 U.S.C. &#167;1350, as Adopted</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in his capacity as an officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), that, to the best of his knowledge:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;the Company&#8217;s Quarterly Report on Form 10-Q for the period ended June&#160;30, 2019, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act; and</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:80%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ ALEXANDER D. MACRAE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alexander D. Macrae</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;7, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ ST&#201;PHANE BOISSEL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">St&#233;phane Boissel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice&#160;President, Corporate Strategy&#160;and&#160;Interim Chief&#160;Financial&#160;Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;7, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sgmo-20190630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20190630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sgmo="http://www.sangamo.com/20190630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AcquisitionOfTxcellSA" roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSA">
        <link:definition>2110100 - Disclosure - Acquisition of Txcell S.A.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfTxcellSAAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail">
        <link:definition>2410402 - Disclosure - Acquisition of Txcell S.A. - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail" roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail">
        <link:definition>2410403 - Disclosure - Acquisition of Txcell S.A. - Summary of Estimated Fair Value of Net Assets Acquired (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail" roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail">
        <link:definition>2410404 - Disclosure - Acquisition of Txcell S.A. - Summary of Non-controlling Interest (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionOfTxcellSATables" roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSATables">
        <link:definition>2310301 - Disclosure - Acquisition of Txcell S.A. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicAndDilutedNetLossPerShare" roleURI="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShare">
        <link:definition>2104100 - Disclosure - Basic and Diluted Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicAndDilutedNetLossPerShareAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShareAdditionalInformationDetail">
        <link:definition>2404401 - Disclosure - Basic and Diluted Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndMarketableSecurities" roleURI="http://www.sangamo.com/role/CashAndMarketableSecurities">
        <link:definition>2103100 - Disclosure - Cash and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2403405 - Disclosure - Cash and Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2403402 - Disclosure - Cash and Marketable Securities - Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail">
        <link:definition>2403403 - Disclosure - Cash and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails" roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails">
        <link:definition>2403404 - Disclosure - Cash and Marketable Securities Summary of cost and estimated fair value of short-term investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndMarketableSecuritiesTables" roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesTables">
        <link:definition>2303301 - Disclosure - Cash and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.sangamo.com/role/CommitmentsAndContingencies">
        <link:definition>2108100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>2408402 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
        <link:definition>2408403 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2308301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
        <link:definition>0002000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.sangamo.com/role/FairValueMeasurements">
        <link:definition>2102100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>2402403 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail" roleURI="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail">
        <link:definition>2402404 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail" roleURI="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail">
        <link:definition>2402402 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.sangamo.com/role/FairValueMeasurementsTables">
        <link:definition>2302301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.sangamo.com/role/IncomeTaxes">
        <link:definition>2106100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsAndStrategicAlliances" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances">
        <link:definition>2105100 - Disclosure - Major Customers, Partnerships and Strategic Alliances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail">
        <link:definition>2405402 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail">
        <link:definition>2405403 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsAndStrategicAlliancesTables" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables">
        <link:definition>2305301 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2401403 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails" roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails">
        <link:definition>2401404 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.sangamo.com/role/StockBasedCompensation">
        <link:definition>2107100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2407402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.sangamo.com/role/StockBasedCompensationTables">
        <link:definition>2307301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.sangamo.com/role/StockholdersEquity">
        <link:definition>2109100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>2409401 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.sangamo.com/role/SubsequentEvents">
        <link:definition>2111100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail">
        <link:definition>2411401 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="sgmo_AchievementOfCommercialMilestonesMember" name="AchievementOfCommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_AchievementOfFirstCommercialSaleMilestonesMember" name="AchievementOfFirstCommercialSaleMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" name="AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" name="AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" name="AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_AchievementOfSpecifiedSalesMilestonesMember" name="AchievementOfSpecifiedSalesMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_AtTheMarketOfferingAgreementMember" name="AtTheMarketOfferingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_BioverativIncMember" name="BioverativIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_BrammerBioMAMember" name="BrammerBioMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_BrisbaneLeaseMember" name="BrisbaneLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_BuildToSuitLeaseMember" name="BuildToSuitLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" name="BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" name="BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" name="BusinessAcquisitionEstimatedFairValueOfFreeShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice" name="BusinessAcquisitionExchangeRateOnPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" name="BusinessAcquisitionNumberOfFreeSharesHeldByHolders" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="sgmo_BusinessAcquisitionNumberOfSharesAcquired" name="BusinessAcquisitionNumberOfSharesAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" name="BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" name="BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction" name="BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests" name="BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration" name="BusinessCombinationLoanAdjustedInPurchaseConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="sgmo_CNineORFSevenTwoMember" name="CNineORFSevenTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" name="CaliforniaInstituteForRegenerativeMedicineAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_CashEquivalentsAndAvailableForSaleSecurities" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" name="CashEquivalentsGrossUnrealizedGainBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" name="CashEquivalentsGrossUnrealizedLossBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="sgmo_ChangeInCollaborationAgreementScopeMember" name="ChangeInCollaborationAgreementScopeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective" name="CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" name="CollaborativeArrangementEstimatedReimbursableServiceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_CollaborativeArrangementTransactionPrice" name="CollaborativeArrangementTransactionPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_CommencementLandSubjectToGroundLeases" name="CommencementLandSubjectToGroundLeases" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="sgmo_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" name="CommonStockCapitalSharesValueReservedForFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_DeferredRentNoncurrent" name="DeferredRentNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_DepositAssetsNonrefundable" name="DepositAssetsNonrefundable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_ExpectedLeaseCommencementPeriod" name="ExpectedLeaseCommencementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearMonthItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_FreeSharesAssetMember" name="FreeSharesAssetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_FreeSharesLiabilityMember" name="FreeSharesLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_GainOnFreeShares" name="GainOnFreeShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_GrantFundingAmount" name="GrantFundingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" name="IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" name="IncreaseInFairValueOfFreeSharesAssetAndLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_InitialResearchTermOfAgreement" name="InitialResearchTermOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_IntangibleAssetsMember" name="IntangibleAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_KitePharmaIncMember" name="KitePharmaIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_LeaseCommencementDate" name="LeaseCommencementDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_LeaseCommencementPeriod" name="LeaseCommencementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearMonthItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" name="LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" name="LesseeOperatingLeaseLiabilityTenantImprovementAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_LesseeOperatingLeaseNumberOfContracts" name="LesseeOperatingLeaseNumberOfContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_ManufacturingCapabilityEstablishmentMember" name="ManufacturingCapabilityEstablishmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_MeasurementInputExchangeRateMember" name="MeasurementInputExchangeRateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_MeasurementInputStockPriceCorrelationMember" name="MeasurementInputStockPriceCorrelationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_MilestonePaymentsReceived" name="MilestonePaymentsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_MilestoneRevenueReceivable" name="MilestoneRevenueReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="sgmo_NetProceedsFromIssuancePublicOffering" name="NetProceedsFromIssuancePublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect" name="NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_NumberOfResearchProgram" name="NumberOfResearchProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_OfficeAndLaboratoryMember" name="OfficeAndLaboratoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_OfficeSpaceMember" name="OfficeSpaceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_OperatingLeasesNumberOfExtensionOptions" name="OperatingLeasesNumberOfExtensionOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_OtherProductsMember" name="OtherProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_PfizerMember" name="PfizerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_PfizerSB525Member" name="PfizerSB525Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_PostBusinessAcquisitionSharesAcquiredAmount" name="PostBusinessAcquisitionSharesAcquiredAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_PropertySubjectToOperatingLeaseOneMember" name="PropertySubjectToOperatingLeaseOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_PropertySubjectToOperatingLeaseTwoMember" name="PropertySubjectToOperatingLeaseTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_RemainingCommencementLandSubjectToGroundLeases" name="RemainingCommencementLandSubjectToGroundLeases" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element id="sgmo_ResearchAgreementTerm" name="ResearchAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_ResearchAndOfficeSpaceMember" name="ResearchAndOfficeSpaceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_ResearchServicesMember" name="ResearchServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_RichmondAndValbonneLeasesMember" name="RichmondAndValbonneLeasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_RichmondLeaseMember" name="RichmondLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_SBFiveTwoFiveMember" name="SBFiveTwoFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_SanofiMember" name="SanofiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" name="ScheduleOfNoncontrollingInterestTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="sgmo_SeparateUpfrontFee" name="SeparateUpfrontFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" name="SharePurchaseAgreementAndTenderOfferAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_SharePurchaseAgreementMember" name="SharePurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_TxCellSAMember" name="TxCellSAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sgmo_ValbonneLeaseMember" name="ValbonneLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>sgmo-20190630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSA" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSA" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSAAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSATables" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSATables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShare" xlink:href="sgmo-20190630.xsd#BasicAndDilutedNetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#BasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecurities" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesTables" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingencies" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesTables" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:href="sgmo-20190630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurements" xlink:href="sgmo-20190630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsTables" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxes" xlink:href="sgmo-20190630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliances" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensation" xlink:href="sgmo-20190630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="sgmo-20190630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:href="sgmo-20190630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquity" xlink:href="sgmo-20190630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEvents" xlink:href="sgmo-20190630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#SubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSA" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a49f91fe-6036-ab86-6a1a-6ac66f348274" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a49f91fe-6036-ab86-6a1a-6ac66f348274" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_b5509fa8-3d11-8808-1ec7-49e5ec2a39e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_b5509fa8-3d11-8808-1ec7-49e5ec2a39e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_090d08a1-b8fd-3634-47b8-7dcb68699de1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_090d08a1-b8fd-3634-47b8-7dcb68699de1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_5b3410a8-a74b-427c-6dee-d79d19c790db" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_5b3410a8-a74b-427c-6dee-d79d19c790db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_0babce17-76af-948e-bcee-dc3ef7464b2a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_0babce17-76af-948e-bcee-dc3ef7464b2a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_c1d14e08-6047-bdc6-cd0b-14a44c47d9d6" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_c1d14e08-6047-bdc6-cd0b-14a44c47d9d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cc1d8741-0bf1-0f1b-dbad-6859add56d00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_49b08da0-3c0d-5e6e-be00-f4ff19b686d5" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_49b08da0-3c0d-5e6e-be00-f4ff19b686d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a49f91fe-6036-ab86-6a1a-6ac66f348274" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSATables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecurities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9b51435d-78b0-60ad-5d83-343c76eab3d9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9b51435d-78b0-60ad-5d83-343c76eab3d9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_c52e5771-6378-c61c-d41e-d79d19662ea4" xlink:type="locator" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_aa65d383-1535-15b5-b800-d79d196b8e30" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_c52e5771-6378-c61c-d41e-d79d19662ea4" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_aa65d383-1535-15b5-b800-d79d196b8e30" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_909e22d6-a7e2-8a39-4b5e-d79d19c84a7b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_c52e5771-6378-c61c-d41e-d79d19662ea4" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_909e22d6-a7e2-8a39-4b5e-d79d19c84a7b" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_eead9dae-5247-38fa-5191-d79d198adc80" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_c52e5771-6378-c61c-d41e-d79d19662ea4" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_eead9dae-5247-38fa-5191-d79d198adc80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_DD40F0B46A74CC8D64A4EC0CFAC9DF15" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_DD40F0B46A74CC8D64A4EC0CFAC9DF15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="arc" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_aa65d383-1535-15b5-b800-d79d196b8e30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a97722c4-c88e-0258-6d8c-8f5c45929660" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a97722c4-c88e-0258-6d8c-8f5c45929660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ad47d869-5bf7-62ba-8427-e58f9319b050" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ad47d869-5bf7-62ba-8427-e58f9319b050" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47ecca60-0dc8-25b2-6295-72031a21e0cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47ecca60-0dc8-25b2-6295-72031a21e0cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0ecff572-4427-028e-de1a-032fc8792eed" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_0ecff572-4427-028e-de1a-032fc8792eed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1beea529-7ff9-f264-77a3-b82530469f83" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1beea529-7ff9-f264-77a3-b82530469f83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c575cd94-2e5c-db53-1e93-d54553800310" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c575cd94-2e5c-db53-1e93-d54553800310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_a9feabf5-0bf0-3efe-740e-f5e41a4b3194" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_MinorityInterest_a9feabf5-0bf0-3efe-740e-f5e41a4b3194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_81b308b1-c4ff-480c-3942-2317dfd5262a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_RestrictedCashCurrent_81b308b1-c4ff-480c-3942-2317dfd5262a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_5d56e70c-9810-c039-1106-1b4e1bffb76b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InterestReceivableCurrent_5d56e70c-9810-c039-1106-1b4e1bffb76b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0c57e6e5-1856-148a-c665-8f26e53c3400" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0c57e6e5-1856-148a-c665-8f26e53c3400" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3832d5-e2fd-470b-5e04-ece38e7ab02d" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3832d5-e2fd-470b-5e04-ece38e7ab02d" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_GainOnFreeShares" xlink:label="loc_sgmo_GainOnFreeShares_a721d78e-bd89-6b70-ead6-d79d19804d29" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_sgmo_GainOnFreeShares_a721d78e-bd89-6b70-ead6-d79d19804d29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_0dd02170-2711-ee37-d503-fddba2bf5494" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_0dd02170-2711-ee37-d503-fddba2bf5494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_21b2374f-ed59-409a-8c93-50623e6a6908" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_21b2374f-ed59-409a-8c93-50623e6a6908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_37a8994a-91be-4778-8a2f-d79d19720dbf" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_37a8994a-91be-4778-8a2f-d79d19720dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_2be55858-29e4-a6b0-2438-d79d19d470f7" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_2be55858-29e4-a6b0-2438-d79d19d470f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4e0ea51c-d09a-0164-9f15-a1d8d4927a87" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4e0ea51c-d09a-0164-9f15-a1d8d4927a87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ee3fb709-d548-2ee3-f8d1-e07a929829cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ee3fb709-d548-2ee3-f8d1-e07a929829cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_501ceb78-782e-aec9-eff2-2bd0a073c870" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_501ceb78-782e-aec9-eff2-2bd0a073c870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_678cc0a1-75a1-b1b0-39a1-094379144ce2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_678cc0a1-75a1-b1b0-39a1-094379144ce2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714a30d1-878f-1497-8ad1-4b1e113da228" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714a30d1-878f-1497-8ad1-4b1e113da228" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6df44786-4260-4fa4-e123-591abd5e882d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6df44786-4260-4fa4-e123-591abd5e882d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ff106bf5-082b-8f58-cc36-c7f91866b7d3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ff106bf5-082b-8f58-cc36-c7f91866b7d3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_92946da7-0b74-45fc-67f0-5fab8668dd69" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_InterestAndOtherIncome_92946da7-0b74-45fc-67f0-5fab8668dd69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f5ae002e-8316-7bc0-1b41-6cd171b53db3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f5ae002e-8316-7bc0-1b41-6cd171b53db3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sgmo-20190630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSA" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSA" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSAAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSATables" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSATables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShare" xlink:href="sgmo-20190630.xsd#BasicAndDilutedNetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#BasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecurities" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesTables" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingencies" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesTables" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:href="sgmo-20190630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurements" xlink:href="sgmo-20190630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsTables" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxes" xlink:href="sgmo-20190630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliances" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensation" xlink:href="sgmo-20190630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="sgmo-20190630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:href="sgmo-20190630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquity" xlink:href="sgmo-20190630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEvents" xlink:href="sgmo-20190630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#SubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSA" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_TxCellSAMember" xlink:label="loc_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:to="loc_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SharePurchaseAgreementMember" xlink:label="loc_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:to="loc_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:to="loc_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:to="loc_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:to="loc_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:to="loc_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:to="loc_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:to="loc_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:to="loc_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice" xlink:label="loc_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration" xlink:label="loc_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests" xlink:label="loc_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction" xlink:label="loc_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_384C5B51B2F2FECAE1FA11A373ED0EAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_384C5B51B2F2FECAE1FA11A373ED0EAB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_34B8B5E26F84548F860411A373ED16B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_384C5B51B2F2FECAE1FA11A373ED0EAB" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_34B8B5E26F84548F860411A373ED16B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBFBB66872EC0C155B7B11A373EDBF2E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_34B8B5E26F84548F860411A373ED16B2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBFBB66872EC0C155B7B11A373EDBF2E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBFBB66872EC0C155B7B11A373EDBF2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_34B8B5E26F84548F860411A373ED16B2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBFBB66872EC0C155B7B11A373EDBF2E" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_TxCellSAMember" xlink:label="loc_sgmo_TxCellSAMember_6A77867070EA0E04F8FE11A373EDBF22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBFBB66872EC0C155B7B11A373EDBF2E" xlink:to="loc_sgmo_TxCellSAMember_6A77867070EA0E04F8FE11A373EDBF22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_430D85889C666AC8392D11A373ED87F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_430D85889C666AC8392D11A373ED87F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75CA6B8B425BA3F14F5D11A373ED8FF5" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75CA6B8B425BA3F14F5D11A373ED8FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5A1B28C3067D75EFF2EB11A373EDE487" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_Goodwill_5A1B28C3067D75EFF2EB11A373EDE487" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSATables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecurities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7DCC3BBF4B1B694C188364F2CBF511ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7DCC3BBF4B1B694C188364F2CBF511ED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_73B7C587FBE42BC84B7C64F2CBF508EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7DCC3BBF4B1B694C188364F2CBF511ED" xlink:to="loc_us-gaap_FinancialInstrumentAxis_73B7C587FBE42BC84B7C64F2CBF508EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_73B7C587FBE42BC84B7C64F2CBF508EA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_73B7C587FBE42BC84B7C64F2CBF508EA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5092C99CDE2243A0B0E164F2CBF56F9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5092C99CDE2243A0B0E164F2CBF56F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_28176D3569B0664D774E64F2CBF5B7D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:to="loc_us-gaap_CommercialPaperMember_28176D3569B0664D774E64F2CBF5B7D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:to="loc_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_893F141AB85C59A2A2F564F2CBF51DAF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_893F141AB85C59A2A2F564F2CBF51DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6D819C4507531E80CBD264F2CBF5DEC5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6D819C4507531E80CBD264F2CBF5DEC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_21D1D6D27B37FEA4437564F2CBF567A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_21D1D6D27B37FEA4437564F2CBF567A4" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3E7BC0D6456F95A79B3464F2CBF5EBD2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3E7BC0D6456F95A79B3464F2CBF5EBD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B6A4E95511C42513386B64F2CBF58FFB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B6A4E95511C42513386B64F2CBF58FFB" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommitmentsAndContingenciesLineItems" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:type="locator" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommitmentsAndContingenciesTable" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_RichmondLeaseMember" xlink:label="loc_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:to="loc_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ValbonneLeaseMember" xlink:label="loc_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:to="loc_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_RichmondAndValbonneLeasesMember" xlink:label="loc_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:to="loc_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BrisbaneLeaseMember" xlink:label="loc_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:to="loc_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:to="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PropertySubjectToOperatingLeaseTwoMember" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:to="loc_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OfficeAndLaboratoryMember" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ResearchAndOfficeSpaceMember" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OfficeSpaceMember" xlink:label="loc_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:to="loc_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_80D8AD56615511EA034864F2CB584719" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:to="loc_srt_RangeAxis_80D8AD56615511EA034864F2CB584719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49894993416014825C2264F2CB58271F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_80D8AD56615511EA034864F2CB584719" xlink:to="loc_srt_RangeMember_49894993416014825C2264F2CB58271F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49894993416014825C2264F2CB58271F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_80D8AD56615511EA034864F2CB584719" xlink:to="loc_srt_RangeMember_49894993416014825C2264F2CB58271F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F9898F73FBA45678633B64F2CB58FC39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49894993416014825C2264F2CB58271F" xlink:to="loc_srt_MinimumMember_F9898F73FBA45678633B64F2CB58FC39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49894993416014825C2264F2CB58271F" xlink:to="loc_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LesseeOperatingLeaseNumberOfContracts" xlink:label="loc_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LeaseCommencementDate" xlink:label="loc_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommencementLandSubjectToGroundLeases" xlink:label="loc_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LeaseCommencementPeriod" xlink:label="loc_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_RemainingCommencementLandSubjectToGroundLeases" xlink:label="loc_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ExpectedLeaseCommencementPeriod" xlink:label="loc_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OperatingLeasesNumberOfExtensionOptions" xlink:label="loc_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6B540B708B2232464345677430B18D53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BBE1F51AAA7955D4CFB9677430A9A231" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6B540B708B2232464345677430B18D53" xlink:to="loc_us-gaap_StatementTable_BBE1F51AAA7955D4CFB9677430A9A231" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_381E9063FFDEBA54580E677430AA1324" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_BBE1F51AAA7955D4CFB9677430A9A231" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_381E9063FFDEBA54580E677430AA1324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_381E9063FFDEBA54580E677430AA1324" xlink:to="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_381E9063FFDEBA54580E677430AA1324" xlink:to="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:to="loc_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:to="loc_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:to="loc_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6D4AA0B4543061D12599677430B00146" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_BBE1F51AAA7955D4CFB9677430A9A231" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6D4AA0B4543061D12599677430B00146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_86884AC8B4DBC33A13C6677430B006EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6D4AA0B4543061D12599677430B00146" xlink:to="loc_us-gaap_TypeOfAdoptionMember_86884AC8B4DBC33A13C6677430B006EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_86884AC8B4DBC33A13C6677430B006EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6D4AA0B4543061D12599677430B00146" xlink:to="loc_us-gaap_TypeOfAdoptionMember_86884AC8B4DBC33A13C6677430B006EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0C5CD985943365D38892677430B1F481" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_86884AC8B4DBC33A13C6677430B006EA" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_0C5CD985943365D38892677430B1F481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_C87BEBC138A0038AE029677430B10F06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_86884AC8B4DBC33A13C6677430B006EA" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_C87BEBC138A0038AE029677430B10F06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6B540B708B2232464345677430B18D53" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAFA4D426CD42B136B58677430B2C830" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAFA4D426CD42B136B58677430B2C830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95F348987931AB687F28677430B468FB" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95F348987931AB687F28677430B468FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_918E6E72F743185D59ED677430B4E7AB" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_ProfitLoss_918E6E72F743185D59ED677430B4E7AB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_262FCBA6EE364085CEB353E31EEAD015" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:to="loc_us-gaap_ValuationTechniqueAxis_262FCBA6EE364085CEB353E31EEAD015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_8233EFE10A405A48F06753E31EEAC9EC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_262FCBA6EE364085CEB353E31EEAD015" xlink:to="loc_us-gaap_ValuationTechniqueDomain_8233EFE10A405A48F06753E31EEAC9EC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_8233EFE10A405A48F06753E31EEAC9EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_262FCBA6EE364085CEB353E31EEAD015" xlink:to="loc_us-gaap_ValuationTechniqueDomain_8233EFE10A405A48F06753E31EEAC9EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_0249125309674FBF86E653E31EEAA7E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_8233EFE10A405A48F06753E31EEAC9EC" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_0249125309674FBF86E653E31EEAA7E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_93E68C086820FD33101A53E31EEA8D65" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_93E68C086820FD33101A53E31EEA8D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C317CD7EDFD8222E0EFB53E31EEBE794_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93E68C086820FD33101A53E31EEA8D65" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C317CD7EDFD8222E0EFB53E31EEBE794_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C317CD7EDFD8222E0EFB53E31EEBE794" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93E68C086820FD33101A53E31EEA8D65" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C317CD7EDFD8222E0EFB53E31EEBE794" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_TxCellSAMember" xlink:label="loc_sgmo_TxCellSAMember_F89E39A7F655EC53F4AB53E31EEBC3D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C317CD7EDFD8222E0EFB53E31EEBE794" xlink:to="loc_sgmo_TxCellSAMember_F89E39A7F655EC53F4AB53E31EEBC3D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BC3CFD51DA482C3F156053E31EEBCB65" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BC3CFD51DA482C3F156053E31EEBCB65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2EFD5A7961488868A2A853E31EEB1933_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BC3CFD51DA482C3F156053E31EEBCB65" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2EFD5A7961488868A2A853E31EEB1933_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2EFD5A7961488868A2A853E31EEB1933" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BC3CFD51DA482C3F156053E31EEBCB65" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2EFD5A7961488868A2A853E31EEB1933" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_F0746DD0DA7F1052FD8553E31EEC4160" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2EFD5A7961488868A2A853E31EEB1933" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_F0746DD0DA7F1052FD8553E31EEC4160" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_69DEA535B6932B1F686053E31EEC2169" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_69DEA535B6932B1F686053E31EEC2169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_93CB6523A6C98ADC826E53E31EEC829E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_93CB6523A6C98ADC826E53E31EEC829E" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_F141FEEC453228E3238753E31EEDEB21" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_F141FEEC453228E3238753E31EEDEB21" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DC607BCFBA75D5C5856C5463643B8BE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DC607BCFBA75D5C5856C5463643B8BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7613CDF0407CE93DE4E35463643B30BA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DC607BCFBA75D5C5856C5463643B8BE4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7613CDF0407CE93DE4E35463643B30BA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7613CDF0407CE93DE4E35463643B30BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DC607BCFBA75D5C5856C5463643B8BE4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7613CDF0407CE93DE4E35463643B30BA" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_TxCellSAMember" xlink:label="loc_sgmo_TxCellSAMember_FE03C71B99962B129F395463643B2427" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7613CDF0407CE93DE4E35463643B30BA" xlink:to="loc_sgmo_TxCellSAMember_FE03C71B99962B129F395463643B2427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MeasurementInputExchangeRateMember" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="loc_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MeasurementInputStockPriceCorrelationMember" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_C28A21AD8C3932A5ABC0546366A8A221" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_C28A21AD8C3932A5ABC0546366A8A221" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_C1CFAE83710F095D150D54636444ED69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_C1CFAE83710F095D150D54636444ED69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_FreeSharesAssetMember" xlink:label="loc_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_FreeSharesLiabilityMember" xlink:label="loc_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_362BD60C4CF5FF38968264F2CBA7AE4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_srt_CounterpartyNameAxis_362BD60C4CF5FF38968264F2CBA7AE4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_362BD60C4CF5FF38968264F2CBA7AE4C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_362BD60C4CF5FF38968264F2CBA7AE4C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_KitePharmaIncMember" xlink:label="loc_sgmo_KitePharmaIncMember_5F34B0822CEEDE8D728264F2CBA76E72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:to="loc_sgmo_KitePharmaIncMember_5F34B0822CEEDE8D728264F2CBA76E72" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerMember" xlink:label="loc_sgmo_PfizerMember_C9D4AD21AD9179997F3864F2CBA7EDA5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:to="loc_sgmo_PfizerMember_C9D4AD21AD9179997F3864F2CBA7EDA5" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerSB525Member" xlink:label="loc_sgmo_PfizerSB525Member_A8F13E2AC0F14B9394B764F2CBA7308F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:to="loc_sgmo_PfizerSB525Member_A8F13E2AC0F14B9394B764F2CBA7308F" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SanofiMember" xlink:label="loc_sgmo_SanofiMember_31C02EACF1738F29A01D64F2CBA74423" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:to="loc_sgmo_SanofiMember_31C02EACF1738F29A01D64F2CBA74423" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BioverativIncMember" xlink:label="loc_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:to="loc_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BA49E5B7105742EBC3CF64F2CBA7E41A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BA49E5B7105742EBC3CF64F2CBA7E41A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0B3EF259C222ED8780764F2CBA721C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BA49E5B7105742EBC3CF64F2CBA7E41A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0B3EF259C222ED8780764F2CBA721C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0B3EF259C222ED8780764F2CBA721C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BA49E5B7105742EBC3CF64F2CBA7E41A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0B3EF259C222ED8780764F2CBA721C2" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborationAndLicenseAgreementMember" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0B3EF259C222ED8780764F2CBA721C2" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfCommercialMilestonesMember" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:to="loc_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:to="loc_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3AA75B9EB47155E3DE1F64F2CBA75934" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190" xlink:to="loc_srt_MaximumMember_3AA75B9EB47155E3DE1F64F2CBA75934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:to="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:to="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SBFiveTwoFiveMember" xlink:label="loc_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OtherProductsMember" xlink:label="loc_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CNineORFSevenTwoMember" xlink:label="loc_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective" xlink:label="loc_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MilestonePaymentsReceived" xlink:label="loc_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_209FA850F5FCE034778865B6E59AA1F3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_209FA850F5FCE034778865B6E59AA1F3" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ResearchAgreementTerm" xlink:label="loc_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SeparateUpfrontFee" xlink:label="loc_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborativeArrangementTransactionPrice" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MilestoneRevenueReceivable" xlink:label="loc_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_40B15372E6CB3704271364F2CBB6C004" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_40B15372E6CB3704271364F2CBB6C004" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NumberOfResearchProgram" xlink:label="loc_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_GrantFundingAmount" xlink:label="loc_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8557848962FBE288EB60453F760701D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_EF53384B538DE8319999453F75F81C6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8557848962FBE288EB60453F760701D4" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_EF53384B538DE8319999453F75F81C6A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_959B88E1FE96B6FDFBA9453F75F88FD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_EF53384B538DE8319999453F75F81C6A" xlink:to="loc_srt_CounterpartyNameAxis_959B88E1FE96B6FDFBA9453F75F88FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_959B88E1FE96B6FDFBA9453F75F88FD5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_959B88E1FE96B6FDFBA9453F75F88FD5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_KitePharmaIncMember" xlink:label="loc_sgmo_KitePharmaIncMember_2A6EA73032AC622CFD4C453F7607254A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:to="loc_sgmo_KitePharmaIncMember_2A6EA73032AC622CFD4C453F7607254A" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerSB525Member" xlink:label="loc_sgmo_PfizerSB525Member_F627306DA9C60D9A2748453F76070304" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:to="loc_sgmo_PfizerSB525Member_F627306DA9C60D9A2748453F76070304" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerMember" xlink:label="loc_sgmo_PfizerMember_EB449D76DB34CA3ED5A5453F76070A23" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:to="loc_sgmo_PfizerMember_EB449D76DB34CA3ED5A5453F76070A23" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SanofiMember" xlink:label="loc_sgmo_SanofiMember_5A70E91F618E7BED6B85453F76076E30" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:to="loc_sgmo_SanofiMember_5A70E91F618E7BED6B85453F76076E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_597B3D8ED298197FEF8E453F7607FC8D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_EF53384B538DE8319999453F75F81C6A" xlink:to="loc_srt_ProductOrServiceAxis_597B3D8ED298197FEF8E453F7607FC8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C77A1B94112FFD54A85E453F7607AAA0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_597B3D8ED298197FEF8E453F7607FC8D" xlink:to="loc_srt_ProductsAndServicesDomain_C77A1B94112FFD54A85E453F7607AAA0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C77A1B94112FFD54A85E453F7607AAA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_597B3D8ED298197FEF8E453F7607FC8D" xlink:to="loc_srt_ProductsAndServicesDomain_C77A1B94112FFD54A85E453F7607AAA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_805307B3DD46C798AB8E453F76076558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C77A1B94112FFD54A85E453F7607AAA0" xlink:to="loc_us-gaap_LicenseAndServiceMember_805307B3DD46C798AB8E453F76076558" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ResearchServicesMember" xlink:label="loc_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C77A1B94112FFD54A85E453F7607AAA0" xlink:to="loc_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D65E3E24D33BE75F19C4453F76077669" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8557848962FBE288EB60453F760701D4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D65E3E24D33BE75F19C4453F76077669" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:to="loc_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_KitePharmaIncMember" xlink:label="loc_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:to="loc_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerSB525Member" xlink:label="loc_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:to="loc_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerMember" xlink:label="loc_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:to="loc_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SanofiMember" xlink:label="loc_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:to="loc_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:type="locator" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ChangeInCollaborationAgreementScopeMember" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:to="loc_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:to="loc_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ManufacturingCapabilityEstablishmentMember" xlink:label="loc_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:to="loc_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DE71908BC4B9F8505298678AE6539896_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DE71908BC4B9F8505298678AE6539896_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DE71908BC4B9F8505298678AE6539896" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DE71908BC4B9F8505298678AE6539896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DE71908BC4B9F8505298678AE6539896" xlink:to="loc_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_EF1BF89748767644D69B678AE653B645" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_srt_CounterpartyNameAxis_EF1BF89748767644D69B678AE653B645" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_EF1BF89748767644D69B678AE653B645" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_EF1BF89748767644D69B678AE653B645" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerMember" xlink:label="loc_sgmo_PfizerMember_3AB59479F550E164BCA0678AE66315F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:to="loc_sgmo_PfizerMember_3AB59479F550E164BCA0678AE66315F8" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BrammerBioMAMember" xlink:label="loc_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:to="loc_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_KitePharmaIncMember" xlink:label="loc_sgmo_KitePharmaIncMember_D0A18400DD6C12D9F38B678AE6631732" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:to="loc_sgmo_KitePharmaIncMember_D0A18400DD6C12D9F38B678AE6631732" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SanofiMember" xlink:label="loc_sgmo_SanofiMember_335E550BD0AA3006A2A0678AE663D058" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:to="loc_sgmo_SanofiMember_335E550BD0AA3006A2A0678AE663D058" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IntangibleAssetsMember" xlink:label="loc_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:to="loc_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:to="loc_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:to="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:to="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:to="loc_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:to="loc_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:to="loc_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_D72F66C1B4E5F8BDE29D678AE6639536" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_ProfitLoss_D72F66C1B4E5F8BDE29D678AE6639536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_DepositAssetsNonrefundable" xlink:label="loc_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_CFB6567326EC88DCAA984E2D14FBE4A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_CFB6567326EC88DCAA984E2D14FBE4A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_CC2F13A9C302F8A1E7E34E2D14FCCC8A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_CFB6567326EC88DCAA984E2D14FBE4A7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_CC2F13A9C302F8A1E7E34E2D14FCCC8A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_CC2F13A9C302F8A1E7E34E2D14FCCC8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_CFB6567326EC88DCAA984E2D14FBE4A7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_CC2F13A9C302F8A1E7E34E2D14FCCC8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_F7FF986D6AA16EE015DA4E2D14FCDFBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_CC2F13A9C302F8A1E7E34E2D14FCCC8A" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_F7FF986D6AA16EE015DA4E2D14FCDFBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_20000311CE906AC544A24E2D14FC8A7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_20000311CE906AC544A24E2D14FC8A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_1A4EA2E419DFD4A8D8B64E2D14FC2596_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_20000311CE906AC544A24E2D14FC8A7D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_1A4EA2E419DFD4A8D8B64E2D14FC2596_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_1A4EA2E419DFD4A8D8B64E2D14FC2596" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_20000311CE906AC544A24E2D14FC8A7D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_1A4EA2E419DFD4A8D8B64E2D14FC2596" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BuildToSuitLeaseMember" xlink:label="loc_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_1A4EA2E419DFD4A8D8B64E2D14FC2596" xlink:to="loc_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_E725D93B1716D3979B344E2D14FDB9D0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:to="loc_srt_RestatementAxis_E725D93B1716D3979B344E2D14FDB9D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_9022928AE7F38A4FE59B4E2D14FDDBF2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_E725D93B1716D3979B344E2D14FDB9D0" xlink:to="loc_srt_RestatementDomain_9022928AE7F38A4FE59B4E2D14FDDBF2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_9022928AE7F38A4FE59B4E2D14FDDBF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_E725D93B1716D3979B344E2D14FDB9D0" xlink:to="loc_srt_RestatementDomain_9022928AE7F38A4FE59B4E2D14FDDBF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_5E51091D9E3CB872C6F04E2D14FEB62B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_9022928AE7F38A4FE59B4E2D14FDDBF2" xlink:to="loc_srt_RestatementAdjustmentMember_5E51091D9E3CB872C6F04E2D14FEB62B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:to="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:to="loc_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:to="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_DeferredRentNoncurrent" xlink:label="loc_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:to="loc_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_03E383053DEAAEA15B254E2D1505F929" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_03E383053DEAAEA15B254E2D1505F929" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:to="loc_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F214C211699FC252DF0311A374A350F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F214C211699FC252DF0311A374A350F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_CC97290A7C3C349D20FD11A374A3A78B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F214C211699FC252DF0311A374A350F1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_CC97290A7C3C349D20FD11A374A3A78B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_CC97290A7C3C349D20FD11A374A3A78B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F214C211699FC252DF0311A374A350F1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_CC97290A7C3C349D20FD11A374A3A78B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_44DB00597EFD968274AC11A374A365ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_CC97290A7C3C349D20FD11A374A3A78B" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_44DB00597EFD968274AC11A374A365ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DC0E06864CEB32DD4A57145E0CDBC1C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_DC0E06864CEB32DD4A57145E0CDBC1C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C44067F9A527E7ADB25D145E0CDB52F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DC0E06864CEB32DD4A57145E0CDBC1C2" xlink:to="loc_us-gaap_EquityComponentDomain_C44067F9A527E7ADB25D145E0CDB52F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C44067F9A527E7ADB25D145E0CDB52F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DC0E06864CEB32DD4A57145E0CDBC1C2" xlink:to="loc_us-gaap_EquityComponentDomain_C44067F9A527E7ADB25D145E0CDB52F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_55EA2FCDB39300FCDE24145E0CDB3350" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C44067F9A527E7ADB25D145E0CDB52F3" xlink:to="loc_us-gaap_CommonStockMember_55EA2FCDB39300FCDE24145E0CDB3350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D920257104FFD137C9D7145E0CDC1C9C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D920257104FFD137C9D7145E0CDC1C9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_31BBDBEFCF9BE5E830ED145E0CDC0600_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D920257104FFD137C9D7145E0CDC1C9C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_31BBDBEFCF9BE5E830ED145E0CDC0600_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_31BBDBEFCF9BE5E830ED145E0CDC0600" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D920257104FFD137C9D7145E0CDC1C9C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_31BBDBEFCF9BE5E830ED145E0CDC0600" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AtTheMarketOfferingAgreementMember" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_31BBDBEFCF9BE5E830ED145E0CDC0600" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_219E31C4A7BE0B85F11A145E0CDD7F51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_219E31C4A7BE0B85F11A145E0CDD7F51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:label="loc_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:to="loc_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6" xlink:to="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:to="loc_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:to="loc_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sgmo-20190630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_4B4AB3EFAA74B2DB424011A373DF9B0E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_4B4AB3EFAA74B2DB424011A373DF9B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4B4AB3EFAA74B2DB424011A373DF9B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4B4AB3EFAA74B2DB424011A373DF9B0E" xlink:to="lab_us-gaap_SubsequentEventsAbstract_4B4AB3EFAA74B2DB424011A373DF9B0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:to="lab_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB" xlink:to="lab_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6" xlink:to="lab_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F1962F9BEA90A847EDEC66052FE4FE76_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F1962F9BEA90A847EDEC66052FE4FE76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F1962F9BEA90A847EDEC66052FE4FE76_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F1962F9BEA90A847EDEC66052FE4FE76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F1962F9BEA90A847EDEC66052FE4FE76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F1962F9BEA90A847EDEC66052FE4FE76" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F1962F9BEA90A847EDEC66052FE4FE76" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_0716F0EC51D36616878066052FE594C1_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_0716F0EC51D36616878066052FE594C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_0716F0EC51D36616878066052FE594C1_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_0716F0EC51D36616878066052FE594C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_0716F0EC51D36616878066052FE594C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_0716F0EC51D36616878066052FE594C1" xlink:to="lab_us-gaap_UseOfEstimates_0716F0EC51D36616878066052FE594C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_845608563ADC14C2E20466052FE5AE5F_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_845608563ADC14C2E20466052FE5AE5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_845608563ADC14C2E20466052FE5AE5F_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_845608563ADC14C2E20466052FE5AE5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_845608563ADC14C2E20466052FE5AE5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_845608563ADC14C2E20466052FE5AE5F" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_845608563ADC14C2E20466052FE5AE5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A35A9F3F393C888717A066052FE5879F_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A35A9F3F393C888717A066052FE5879F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A35A9F3F393C888717A066052FE5879F_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A35A9F3F393C888717A066052FE5879F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A35A9F3F393C888717A066052FE5879F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A35A9F3F393C888717A066052FE5879F" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A35A9F3F393C888717A066052FE5879F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_76E5A1158710F2EA718D66052FE50396_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_76E5A1158710F2EA718D66052FE50396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_76E5A1158710F2EA718D66052FE50396_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_76E5A1158710F2EA718D66052FE50396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_76E5A1158710F2EA718D66052FE50396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_76E5A1158710F2EA718D66052FE50396" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_76E5A1158710F2EA718D66052FE50396" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_46C153D245178579A46B66052FE56AEF_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_46C153D245178579A46B66052FE56AEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_46C153D245178579A46B66052FE56AEF_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_46C153D245178579A46B66052FE56AEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_46C153D245178579A46B66052FE56AEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_46C153D245178579A46B66052FE56AEF" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_46C153D245178579A46B66052FE56AEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9FACA61929A0D7555EF866052FE5887E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_9FACA61929A0D7555EF866052FE5887E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9FACA61929A0D7555EF866052FE5887E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_9FACA61929A0D7555EF866052FE5887E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9FACA61929A0D7555EF866052FE5887E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_9FACA61929A0D7555EF866052FE5887E" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_9FACA61929A0D7555EF866052FE5887E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_AAC78D57164BF8D054BD66052FE52C94_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_AAC78D57164BF8D054BD66052FE52C94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_AAC78D57164BF8D054BD66052FE52C94_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_AAC78D57164BF8D054BD66052FE52C94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_AAC78D57164BF8D054BD66052FE52C94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_AAC78D57164BF8D054BD66052FE52C94" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_AAC78D57164BF8D054BD66052FE52C94" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8F44066C8F2CB3BF25B566052FE62F5E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_8F44066C8F2CB3BF25B566052FE62F5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8F44066C8F2CB3BF25B566052FE62F5E_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_8F44066C8F2CB3BF25B566052FE62F5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8F44066C8F2CB3BF25B566052FE62F5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_8F44066C8F2CB3BF25B566052FE62F5E" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_8F44066C8F2CB3BF25B566052FE62F5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_30F442EBBA8C4F1F97D366052FE62B11_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_30F442EBBA8C4F1F97D366052FE62B11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_30F442EBBA8C4F1F97D366052FE62B11_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_30F442EBBA8C4F1F97D366052FE62B11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_30F442EBBA8C4F1F97D366052FE62B11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_30F442EBBA8C4F1F97D366052FE62B11" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_30F442EBBA8C4F1F97D366052FE62B11" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7904CBCDB5E5BC816DF666052FE67329_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7904CBCDB5E5BC816DF666052FE67329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7904CBCDB5E5BC816DF666052FE67329_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7904CBCDB5E5BC816DF666052FE67329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7904CBCDB5E5BC816DF666052FE67329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7904CBCDB5E5BC816DF666052FE67329" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7904CBCDB5E5BC816DF666052FE67329" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_02E39730D823C2BC027711A374D24EA5_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_02E39730D823C2BC027711A374D24EA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_02E39730D823C2BC027711A374D24EA5_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_02E39730D823C2BC027711A374D24EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_02E39730D823C2BC027711A374D24EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_02E39730D823C2BC027711A374D24EA5" xlink:to="lab_us-gaap_ProfitLoss_02E39730D823C2BC027711A374D24EA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CAE6158D5AD65FC749A511A374D2D563_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CAE6158D5AD65FC749A511A374D2D563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CAE6158D5AD65FC749A511A374D2D563_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CAE6158D5AD65FC749A511A374D2D563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CAE6158D5AD65FC749A511A374D2D563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CAE6158D5AD65FC749A511A374D2D563" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CAE6158D5AD65FC749A511A374D2D563" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5D0E0E97D94D00F4287811A374D229A7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5D0E0E97D94D00F4287811A374D229A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in unrealized gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5D0E0E97D94D00F4287811A374D229A7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5D0E0E97D94D00F4287811A374D229A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5D0E0E97D94D00F4287811A374D229A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5D0E0E97D94D00F4287811A374D229A7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5D0E0E97D94D00F4287811A374D229A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_506CBCF1534F87E33F0E11A374D23C38_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_506CBCF1534F87E33F0E11A374D23C38" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_506CBCF1534F87E33F0E11A374D23C38_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_506CBCF1534F87E33F0E11A374D23C38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_506CBCF1534F87E33F0E11A374D23C38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_506CBCF1534F87E33F0E11A374D23C38" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_506CBCF1534F87E33F0E11A374D23C38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BBB4ABDE0FBE274253AF11A374D208CF_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BBB4ABDE0FBE274253AF11A374D208CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BBB4ABDE0FBE274253AF11A374D208CF_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BBB4ABDE0FBE274253AF11A374D208CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BBB4ABDE0FBE274253AF11A374D208CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BBB4ABDE0FBE274253AF11A374D208CF" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BBB4ABDE0FBE274253AF11A374D208CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7F188340EBD33CED287B11A374D2F383_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_7F188340EBD33CED287B11A374D2F383" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7F188340EBD33CED287B11A374D2F383_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_7F188340EBD33CED287B11A374D2F383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7F188340EBD33CED287B11A374D2F383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7F188340EBD33CED287B11A374D2F383" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_7F188340EBD33CED287B11A374D2F383" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_CF1029370926AA3625D664F2CAEB154B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_CF1029370926AA3625D664F2CAEB154B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_CF1029370926AA3625D664F2CAEB154B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_CF1029370926AA3625D664F2CAEB154B" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_CF1029370926AA3625D664F2CAEB154B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:type="arc" />
    <link:label id="lab_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF_terseLabel_en-US" xlink:label="lab_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TxCell S.A.</link:label>
    <link:label id="lab_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF_label_en-US" xlink:label="lab_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tx Cell S A [Member]</link:label>
    <link:label id="lab_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF_documentation_en-US" xlink:label="lab_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TxCell S.A.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_TxCellSAMember" xlink:label="loc_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF" xlink:to="lab_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:to="lab_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:type="arc" />
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0_terseLabel_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement and Tender Offer Agreement</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0_label_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement And Tender Offer Agreement [Member]</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0_documentation_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share purchase agreement and tender offer agreement.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0" xlink:to="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0" xlink:type="arc" />
    <link:label id="lab_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9_terseLabel_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPA</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9_label_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9_documentation_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SharePurchaseAgreementMember" xlink:label="loc_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9" xlink:to="lab_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492_label_en-US" xlink:label="lab_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:to="lab_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C_terseLabel_en-US" xlink:label="lab_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C_label_en-US" xlink:label="lab_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:to="lab_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C_label_en-US" xlink:label="lab_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C" xlink:to="lab_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:to="lab_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:to="lab_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Pricing Method</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Option Pricing Model [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0" xlink:to="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of equity interests agreed to acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Percentage Of Equity Interests Agreed To Acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition, percentage of equity interests agreed to acquire.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7" xlink:to="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of ordinary shares acquired</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Number Of Shares Acquired</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition, number of shares acquired.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of share capital and voting rights acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares not purchased by the acquirer</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Number Of Shares Owned By Sellers Under Block Transaction</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition number of shares owned by sellers under block transaction.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of free shares held by the holders (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Number Of Free Shares Held By Holders</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition, number of free shares held by the holders.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange rate on purchase price</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Exchange Rate On Purchase Price</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition exchange rate on purchase price.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice" xlink:label="loc_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2" xlink:to="lab_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value liability of free shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Estimated Fair Value Liabilities Of Free Shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition estimated fair value liabilities of free shares.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value asset of free shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Estimated Fair Value Assets Of Free Shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition estimated fair value assets of free shares.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2_terseLabel_en-US" xlink:label="lab_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan deemed to be part of purchase consideration</link:label>
    <link:label id="lab_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2_label_en-US" xlink:label="lab_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Loan Adjusted In Purchase Consideration</link:label>
    <link:label id="lab_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2_documentation_en-US" xlink:label="lab_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination, loan adjusted in purchase consideration.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration" xlink:label="loc_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2" xlink:to="lab_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid to ordinary shares acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of consideration payable</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Estimated Fair Value Of Free Shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition, estimated fair value of free shares.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE_terseLabel_en-US" xlink:label="lab_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value percentage at acquirer recognizes and consolidates assets acquired, liabilities assumed, and any non-controlling interest</link:label>
    <link:label id="lab_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE_label_en-US" xlink:label="lab_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Fair Value Percentage At Acquirer Recognizes And Consolidated Assets Liabilities Assumed And Noncontrolling Interests</link:label>
    <link:label id="lab_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE_documentation_en-US" xlink:label="lab_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination, fair value percentage at acquirer recognizes and consolidated assets, liabilities assumed and noncontrolling interests.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests" xlink:label="loc_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE" xlink:to="lab_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_9E95EF73D4478529373864F2CAEB0316_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_9E95EF73D4478529373864F2CAEB0316" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consideration payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9E95EF73D4478529373864F2CAEB0316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9E95EF73D4478529373864F2CAEB0316" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_9E95EF73D4478529373864F2CAEB0316" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of remaining outstanding share owned by sellers</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Remaining Number Of Shares Owned By Seller Under Block Transaction</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition remaining number of shares owned by seller under block transaction.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction" xlink:label="loc_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF" xlink:to="lab_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9798A77E81839225F8F411A373FCC902_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9798A77E81839225F8F411A373FCC902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Txcell S.A.</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9798A77E81839225F8F411A373FCC902_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9798A77E81839225F8F411A373FCC902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9798A77E81839225F8F411A373FCC902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9798A77E81839225F8F411A373FCC902" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9798A77E81839225F8F411A373FCC902" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6DE6B5D6377B352D928C53E31EE98180_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_6DE6B5D6377B352D928C53E31EE98180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6DE6B5D6377B352D928C53E31EE98180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6DE6B5D6377B352D928C53E31EE98180" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_6DE6B5D6377B352D928C53E31EE98180" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_0249125309674FBF86E653E31EEAA7E4_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_0249125309674FBF86E653E31EEAA7E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Valuation Technique, Option Pricing Model [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_0249125309674FBF86E653E31EEAA7E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_0249125309674FBF86E653E31EEAA7E4" xlink:to="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_0249125309674FBF86E653E31EEAA7E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liability recorded on acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC" xlink:type="arc" />
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of free shares</link:label>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02_label_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Fair Value Of Free Shares Asset And Liability</link:label>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02_documentation_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase in fair value of free shares asset and liability.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02" xlink:to="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E76A6EB78C96C66C365631E67E96F41_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E76A6EB78C96C66C365631E67E96F41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E76A6EB78C96C66C365631E67E96F41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E76A6EB78C96C66C365631E67E96F41" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E76A6EB78C96C66C365631E67E96F41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:to="lab_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:type="arc" />
    <link:label id="lab_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0_terseLabel_en-US" xlink:label="lab_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kite Pharma Inc</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0_label_en-US" xlink:label="lab_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kite Pharma Inc [Member]</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0_documentation_en-US" xlink:label="lab_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kite Pharma Inc.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_KitePharmaIncMember" xlink:label="loc_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0" xlink:to="lab_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0" xlink:type="arc" />
    <link:label id="lab_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9_terseLabel_en-US" xlink:label="lab_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9_label_en-US" xlink:label="lab_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9_documentation_en-US" xlink:label="lab_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerSB525Member" xlink:label="loc_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9" xlink:to="lab_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9" xlink:type="arc" />
    <link:label id="lab_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837_terseLabel_en-US" xlink:label="lab_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837_label_en-US" xlink:label="lab_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837_documentation_en-US" xlink:label="lab_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerMember" xlink:label="loc_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837" xlink:to="lab_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837" xlink:type="arc" />
    <link:label id="lab_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3_terseLabel_en-US" xlink:label="lab_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ Inc</link:label>
    <link:label id="lab_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3_label_en-US" xlink:label="lab_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3_documentation_en-US" xlink:label="lab_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SanofiMember" xlink:label="loc_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3" xlink:to="lab_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues Recognized under Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A" xlink:type="arc" />
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1_terseLabel_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1_label_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1_documentation_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:type="arc" />
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517_terseLabel_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Collaboration Agreement Scope</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517_label_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Collaboration Agreement Scope [Member]</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517_documentation_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Collaboration Agreement Scope [Member]</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ChangeInCollaborationAgreementScopeMember" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517" xlink:to="lab_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:to="lab_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:to="lab_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:type="arc" />
    <link:label id="lab_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742_terseLabel_en-US" xlink:label="lab_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing Capability Establishment</link:label>
    <link:label id="lab_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742_label_en-US" xlink:label="lab_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Capability Establishment [Member]</link:label>
    <link:label id="lab_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742_documentation_en-US" xlink:label="lab_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Capability Establishment [Member]</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ManufacturingCapabilityEstablishmentMember" xlink:label="loc_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742" xlink:to="lab_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:to="lab_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE" xlink:to="lab_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE" xlink:type="arc" />
    <link:label id="lab_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D_terseLabel_en-US" xlink:label="lab_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brammer</link:label>
    <link:label id="lab_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D_label_en-US" xlink:label="lab_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brammer Bio MA [Member]</link:label>
    <link:label id="lab_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D_documentation_en-US" xlink:label="lab_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Brammer Bio MA [Member]</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BrammerBioMAMember" xlink:label="loc_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D" xlink:to="lab_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:type="arc" />
    <link:label id="lab_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744_terseLabel_en-US" xlink:label="lab_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744_label_en-US" xlink:label="lab_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets [Member]</link:label>
    <link:label id="lab_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744_documentation_en-US" xlink:label="lab_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IntangibleAssetsMember" xlink:label="loc_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744" xlink:to="lab_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F" xlink:to="lab_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:to="lab_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Topic 606</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Topic 842</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50_verboseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50" xlink:type="arc" />
    <link:label id="lab_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement</link:label>
    <link:label id="lab_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83_label_en-US" xlink:label="lab_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:to="lab_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:type="arc" />
    <link:label id="lab_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement</link:label>
    <link:label id="lab_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4_label_en-US" xlink:label="lab_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:to="lab_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:type="arc" />
    <link:label id="lab_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments Due to the Adoption of ASC Topic 842</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B" xlink:to="lab_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B" xlink:type="arc" />
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B_terseLabel_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B_label_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B_documentation_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F_negatedLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_D72F66C1B4E5F8BDE29D678AE6639536_negatedLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_D72F66C1B4E5F8BDE29D678AE6639536" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increase in net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_D72F66C1B4E5F8BDE29D678AE6639536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_D72F66C1B4E5F8BDE29D678AE6639536" xlink:to="lab_us-gaap_ProfitLoss_D72F66C1B4E5F8BDE29D678AE6639536" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase in basic net loss per share (Usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2" xlink:to="lab_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B_negatedLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustment</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537_terseLabel_en-US" xlink:label="lab_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option deposit</link:label>
    <link:label id="lab_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537_label_en-US" xlink:label="lab_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposit Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537" xlink:to="lab_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537" xlink:type="arc" />
    <link:label id="lab_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451_terseLabel_en-US" xlink:label="lab_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option deposit, nonrefundable</link:label>
    <link:label id="lab_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451_label_en-US" xlink:label="lab_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposit Assets, Nonrefundable</link:label>
    <link:label id="lab_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451_documentation_en-US" xlink:label="lab_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deposit Assets, Nonrefundable</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_DepositAssetsNonrefundable" xlink:label="loc_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451" xlink:to="lab_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB" xlink:to="lab_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:to="lab_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213" xlink:to="lab_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE" xlink:to="lab_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE" xlink:type="arc" />
    <link:label id="lab_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4_terseLabel_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Free shares asset</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4_label_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Free Shares Asset [Member]</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4_documentation_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Free shares asset.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_FreeSharesAssetMember" xlink:label="loc_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4" xlink:to="lab_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4" xlink:type="arc" />
    <link:label id="lab_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38_terseLabel_en-US" xlink:label="lab_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Free shares liability</link:label>
    <link:label id="lab_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38_label_en-US" xlink:label="lab_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Free Shares Liability [Member]</link:label>
    <link:label id="lab_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38_documentation_en-US" xlink:label="lab_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Free shares liability.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_FreeSharesLiabilityMember" xlink:label="loc_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38" xlink:to="lab_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government-sponsored entity debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities and free shares asset</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2FB954505B5053CE8F6B11A374550E29_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_2FB954505B5053CE8F6B11A374550E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2FB954505B5053CE8F6B11A374550E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2FB954505B5053CE8F6B11A374550E29" xlink:to="lab_us-gaap_EarningsPerShareAbstract_2FB954505B5053CE8F6B11A374550E29" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_046B5F349BBF0325263911A374550483_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_046B5F349BBF0325263911A374550483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_046B5F349BBF0325263911A374550483_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_046B5F349BBF0325263911A374550483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_046B5F349BBF0325263911A374550483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_046B5F349BBF0325263911A374550483" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_046B5F349BBF0325263911A374550483" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5AB434D1C55BCFB625FC64F2CC52F239_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_5AB434D1C55BCFB625FC64F2CC52F239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5AB434D1C55BCFB625FC64F2CC52F239_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_5AB434D1C55BCFB625FC64F2CC52F239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5AB434D1C55BCFB625FC64F2CC52F239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_5AB434D1C55BCFB625FC64F2CC52F239" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_5AB434D1C55BCFB625FC64F2CC52F239" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_AEB6599537E4B9A2823B64F2CC525529_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_AEB6599537E4B9A2823B64F2CC525529" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of discount on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_AEB6599537E4B9A2823B64F2CC525529_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_AEB6599537E4B9A2823B64F2CC525529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_AEB6599537E4B9A2823B64F2CC525529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_AEB6599537E4B9A2823B64F2CC525529" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_AEB6599537E4B9A2823B64F2CC525529" xlink:type="arc" />
    <link:label id="lab_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728_negatedLabel_en-US" xlink:label="lab_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on free shares</link:label>
    <link:label id="lab_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728_label_en-US" xlink:label="lab_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain On Free Shares</link:label>
    <link:label id="lab_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728_documentation_en-US" xlink:label="lab_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on free shares.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_GainOnFreeShares" xlink:label="loc_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728" xlink:to="lab_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_C21A924C3A485273A35564F2CC522BB8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_C21A924C3A485273A35564F2CC522BB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_C21A924C3A485273A35564F2CC522BB8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_C21A924C3A485273A35564F2CC522BB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_C21A924C3A485273A35564F2CC522BB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_C21A924C3A485273A35564F2CC522BB8" xlink:to="lab_us-gaap_ShareBasedCompensation_C21A924C3A485273A35564F2CC522BB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_AB9AED39695FAA5C9EAF64F2CC52B8BD_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease_AB9AED39695FAA5C9EAF64F2CC52B8BD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss on lease termination</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_AB9AED39695FAA5C9EAF64F2CC52B8BD_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease_AB9AED39695FAA5C9EAF64F2CC52B8BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_AB9AED39695FAA5C9EAF64F2CC52B8BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease_AB9AED39695FAA5C9EAF64F2CC52B8BD" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease_AB9AED39695FAA5C9EAF64F2CC52B8BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_7575B7A1EBD17DE8794D64F2CC52D09E_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_7575B7A1EBD17DE8794D64F2CC52D09E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_7575B7A1EBD17DE8794D64F2CC52D09E_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_7575B7A1EBD17DE8794D64F2CC52D09E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7575B7A1EBD17DE8794D64F2CC52D09E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_7575B7A1EBD17DE8794D64F2CC52D09E" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_7575B7A1EBD17DE8794D64F2CC52D09E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_31592A687C64F8E5496764F2CC52CF54_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_31592A687C64F8E5496764F2CC52CF54" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_31592A687C64F8E5496764F2CC52CF54_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_31592A687C64F8E5496764F2CC52CF54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_31592A687C64F8E5496764F2CC52CF54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_31592A687C64F8E5496764F2CC52CF54" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_31592A687C64F8E5496764F2CC52CF54" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6433A327354213B6ECE064F2CC5204C3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6433A327354213B6ECE064F2CC5204C3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6433A327354213B6ECE064F2CC5204C3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6433A327354213B6ECE064F2CC5204C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6433A327354213B6ECE064F2CC5204C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6433A327354213B6ECE064F2CC5204C3" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6433A327354213B6ECE064F2CC5204C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C3778CB2E7C33EE5735764F2CC5260A6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C3778CB2E7C33EE5735764F2CC5260A6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C3778CB2E7C33EE5735764F2CC5260A6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C3778CB2E7C33EE5735764F2CC5260A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C3778CB2E7C33EE5735764F2CC5260A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C3778CB2E7C33EE5735764F2CC5260A6" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C3778CB2E7C33EE5735764F2CC5260A6" xlink:type="arc" />
    <link:label id="lab_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994_negatedLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in operating lease right of use asset.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994" xlink:to="lab_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50A9A6F493CC30B923F364F2CC521040_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50A9A6F493CC30B923F364F2CC521040" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50A9A6F493CC30B923F364F2CC521040_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50A9A6F493CC30B923F364F2CC521040" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50A9A6F493CC30B923F364F2CC521040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50A9A6F493CC30B923F364F2CC521040" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50A9A6F493CC30B923F364F2CC521040" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7678E5C33D4410A7D1CB64F2CC52ECBA_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7678E5C33D4410A7D1CB64F2CC52ECBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7678E5C33D4410A7D1CB64F2CC52ECBA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7678E5C33D4410A7D1CB64F2CC52ECBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7678E5C33D4410A7D1CB64F2CC52ECBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7678E5C33D4410A7D1CB64F2CC52ECBA" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7678E5C33D4410A7D1CB64F2CC52ECBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_A47A74336E9BE61609FC64F2CC52A48C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_A47A74336E9BE61609FC64F2CC52A48C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_A47A74336E9BE61609FC64F2CC52A48C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_A47A74336E9BE61609FC64F2CC52A48C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_A47A74336E9BE61609FC64F2CC52A48C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_A47A74336E9BE61609FC64F2CC52A48C" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_A47A74336E9BE61609FC64F2CC52A48C" xlink:type="arc" />
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Long Term Portion Of Lease Liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) in long-term portion of lease liabilities.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF" xlink:to="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_DD3F42DFBB745535618864F2CC520899_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_DD3F42DFBB745535618864F2CC520899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_DD3F42DFBB745535618864F2CC520899_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_DD3F42DFBB745535618864F2CC520899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_DD3F42DFBB745535618864F2CC520899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_DD3F42DFBB745535618864F2CC520899" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_DD3F42DFBB745535618864F2CC520899" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3FA3B984572A8B88F8B164F2CC525E49_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3FA3B984572A8B88F8B164F2CC525E49" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3FA3B984572A8B88F8B164F2CC525E49_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3FA3B984572A8B88F8B164F2CC525E49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3FA3B984572A8B88F8B164F2CC525E49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3FA3B984572A8B88F8B164F2CC525E49" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3FA3B984572A8B88F8B164F2CC525E49" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_E040F84DEDD254490AA964F2CC52C55C_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_E040F84DEDD254490AA964F2CC52C55C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_E040F84DEDD254490AA964F2CC52C55C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_E040F84DEDD254490AA964F2CC52C55C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_E040F84DEDD254490AA964F2CC52C55C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_E040F84DEDD254490AA964F2CC52C55C" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_E040F84DEDD254490AA964F2CC52C55C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A438B79379805912AE3E64F2CC52B058_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A438B79379805912AE3E64F2CC52B058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A438B79379805912AE3E64F2CC52B058_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A438B79379805912AE3E64F2CC52B058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A438B79379805912AE3E64F2CC52B058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A438B79379805912AE3E64F2CC52B058" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A438B79379805912AE3E64F2CC52B058" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F084FFCEAEBCC547A32F64F2CC52A81F_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F084FFCEAEBCC547A32F64F2CC52A81F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F084FFCEAEBCC547A32F64F2CC52A81F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F084FFCEAEBCC547A32F64F2CC52A81F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F084FFCEAEBCC547A32F64F2CC52A81F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F084FFCEAEBCC547A32F64F2CC52A81F" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F084FFCEAEBCC547A32F64F2CC52A81F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_25829258C8D63B9F06AB64F2CC52F0D1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_25829258C8D63B9F06AB64F2CC52F0D1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_25829258C8D63B9F06AB64F2CC52F0D1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_25829258C8D63B9F06AB64F2CC52F0D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25829258C8D63B9F06AB64F2CC52F0D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25829258C8D63B9F06AB64F2CC52F0D1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_25829258C8D63B9F06AB64F2CC52F0D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1E73DE01D832801F5F7364F2CC52DBC1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1E73DE01D832801F5F7364F2CC52DBC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1E73DE01D832801F5F7364F2CC52DBC1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1E73DE01D832801F5F7364F2CC52DBC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1E73DE01D832801F5F7364F2CC52DBC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1E73DE01D832801F5F7364F2CC52DBC1" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1E73DE01D832801F5F7364F2CC52DBC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E9479FE46FCA34F4177664F2CC5201C8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E9479FE46FCA34F4177664F2CC5201C8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E9479FE46FCA34F4177664F2CC5201C8_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E9479FE46FCA34F4177664F2CC5201C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E9479FE46FCA34F4177664F2CC5201C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E9479FE46FCA34F4177664F2CC5201C8" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E9479FE46FCA34F4177664F2CC5201C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_78FDD706F2A5E0F8EBBC64F2CC52ED0E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_78FDD706F2A5E0F8EBBC64F2CC52ED0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_78FDD706F2A5E0F8EBBC64F2CC52ED0E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_78FDD706F2A5E0F8EBBC64F2CC52ED0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_78FDD706F2A5E0F8EBBC64F2CC52ED0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_78FDD706F2A5E0F8EBBC64F2CC52ED0E" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_78FDD706F2A5E0F8EBBC64F2CC52ED0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0EC2FF77B5982C2EA23A64F2CC525450_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0EC2FF77B5982C2EA23A64F2CC525450" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0EC2FF77B5982C2EA23A64F2CC525450_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0EC2FF77B5982C2EA23A64F2CC525450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0EC2FF77B5982C2EA23A64F2CC525450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0EC2FF77B5982C2EA23A64F2CC525450" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0EC2FF77B5982C2EA23A64F2CC525450" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01EC577EE6C389F0DDB664F2CC52CDDA_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01EC577EE6C389F0DDB664F2CC52CDDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of changes in foreign exchange rates</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01EC577EE6C389F0DDB664F2CC52CDDA_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01EC577EE6C389F0DDB664F2CC52CDDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01EC577EE6C389F0DDB664F2CC52CDDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01EC577EE6C389F0DDB664F2CC52CDDA" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01EC577EE6C389F0DDB664F2CC52CDDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4A930C9B5E7FBB43691164F2CC5250AF_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4A930C9B5E7FBB43691164F2CC5250AF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4A930C9B5E7FBB43691164F2CC5250AF_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4A930C9B5E7FBB43691164F2CC5250AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4A930C9B5E7FBB43691164F2CC5250AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4A930C9B5E7FBB43691164F2CC5250AF" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4A930C9B5E7FBB43691164F2CC5250AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_909D4AC251B525946D4B659363E7BF13_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_909D4AC251B525946D4B659363E7BF13" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_909D4AC251B525946D4B659363E7BF13_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_909D4AC251B525946D4B659363E7BF13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_909D4AC251B525946D4B659363E7BF13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_909D4AC251B525946D4B659363E7BF13" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_909D4AC251B525946D4B659363E7BF13" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F2408E76F66BF4DB39C65942EAA698F_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F2408E76F66BF4DB39C65942EAA698F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F2408E76F66BF4DB39C65942EAA698F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F2408E76F66BF4DB39C65942EAA698F" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F2408E76F66BF4DB39C65942EAA698F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E8F6BF0C0B0C1173727A64F2CC52B675_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E8F6BF0C0B0C1173727A64F2CC52B675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment included in accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E8F6BF0C0B0C1173727A64F2CC52B675_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E8F6BF0C0B0C1173727A64F2CC52B675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E8F6BF0C0B0C1173727A64F2CC52B675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E8F6BF0C0B0C1173727A64F2CC52B675" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E8F6BF0C0B0C1173727A64F2CC52B675" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1A6FA17C7891C5F6532164F2CC522599_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1A6FA17C7891C5F6532164F2CC522599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1A6FA17C7891C5F6532164F2CC522599_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1A6FA17C7891C5F6532164F2CC522599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1A6FA17C7891C5F6532164F2CC522599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1A6FA17C7891C5F6532164F2CC522599" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1A6FA17C7891C5F6532164F2CC522599" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D98EE4A1FFC9E211331411A3193E47E9_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D98EE4A1FFC9E211331411A3193E47E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D98EE4A1FFC9E211331411A3193E47E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D98EE4A1FFC9E211331411A3193E47E9" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D98EE4A1FFC9E211331411A3193E47E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6ECB8425D6DF966AC311A3193ECB3A_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6ECB8425D6DF966AC311A3193ECB3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6ECB8425D6DF966AC311A3193ECB3A_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6ECB8425D6DF966AC311A3193ECB3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6ECB8425D6DF966AC311A3193ECB3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6ECB8425D6DF966AC311A3193ECB3A" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6ECB8425D6DF966AC311A3193ECB3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5BF86CD169A3589426A164F2CB4968D9_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5BF86CD169A3589426A164F2CB4968D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5BF86CD169A3589426A164F2CB4968D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5BF86CD169A3589426A164F2CB4968D9" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5BF86CD169A3589426A164F2CB4968D9" xlink:type="arc" />
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommitmentsAndContingenciesTable" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:to="lab_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:type="arc" />
    <link:label id="lab_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D_terseLabel_en-US" xlink:label="lab_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Richmond Lease</link:label>
    <link:label id="lab_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D_label_en-US" xlink:label="lab_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Richmond Lease [Member]</link:label>
    <link:label id="lab_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D_documentation_en-US" xlink:label="lab_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Richmond Lease.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_RichmondLeaseMember" xlink:label="loc_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D" xlink:to="lab_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D" xlink:type="arc" />
    <link:label id="lab_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1_terseLabel_en-US" xlink:label="lab_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valbonne Lease</link:label>
    <link:label id="lab_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1_label_en-US" xlink:label="lab_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valbonne Lease [Member]</link:label>
    <link:label id="lab_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1_documentation_en-US" xlink:label="lab_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valbonne lease.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ValbonneLeaseMember" xlink:label="loc_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1" xlink:to="lab_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1" xlink:type="arc" />
    <link:label id="lab_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B_terseLabel_en-US" xlink:label="lab_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Richmond and Valbonne Leases</link:label>
    <link:label id="lab_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B_label_en-US" xlink:label="lab_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Richmond And Valbonne Leases [Member]</link:label>
    <link:label id="lab_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B_documentation_en-US" xlink:label="lab_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Richmond and Valbonne leases.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_RichmondAndValbonneLeasesMember" xlink:label="loc_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B" xlink:to="lab_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B" xlink:type="arc" />
    <link:label id="lab_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A_terseLabel_en-US" xlink:label="lab_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brisbane Lease</link:label>
    <link:label id="lab_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A_label_en-US" xlink:label="lab_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brisbane Lease [Member]</link:label>
    <link:label id="lab_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A_documentation_en-US" xlink:label="lab_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Brisbane lease.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BrisbaneLeaseMember" xlink:label="loc_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A" xlink:to="lab_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:type="arc" />
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41_terseLabel_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease One</link:label>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41_label_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Subject To Operating Lease One [Member]</link:label>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41_documentation_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property subject to operating lease one.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41" xlink:to="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41" xlink:type="arc" />
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731_terseLabel_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Two</link:label>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731_label_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Subject To Operating Lease Two [Member]</link:label>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731_documentation_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property subject to operating lease two.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PropertySubjectToOperatingLeaseTwoMember" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731" xlink:to="lab_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:type="arc" />
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E_terseLabel_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office and Laboratory</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E_label_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office And Laboratory [Member]</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E_documentation_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office and laboratory.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OfficeAndLaboratoryMember" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E" xlink:to="lab_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E" xlink:type="arc" />
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Office Space</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A_label_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Office Space [Member]</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A_documentation_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and office space</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ResearchAndOfficeSpaceMember" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A" xlink:to="lab_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A" xlink:type="arc" />
    <link:label id="lab_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919_terseLabel_en-US" xlink:label="lab_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office Space</link:label>
    <link:label id="lab_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919_label_en-US" xlink:label="lab_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Space [Member]</link:label>
    <link:label id="lab_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919_documentation_en-US" xlink:label="lab_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office space.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OfficeSpaceMember" xlink:label="loc_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919" xlink:to="lab_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB_label_en-US" xlink:label="lab_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB" xlink:to="lab_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB" xlink:type="arc" />
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommitmentsAndContingenciesLineItems" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="lab_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of space leased (in sqft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42" xlink:to="lab_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42" xlink:type="arc" />
    <link:label id="lab_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional property available under lease</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LesseeOperatingLeaseNumberOfContracts" xlink:label="loc_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2" xlink:to="lab_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease expiration date</link:label>
    <link:label id="lab_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0_label_en-US" xlink:label="lab_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Expiration Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0" xlink:to="lab_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0" xlink:type="arc" />
    <link:label id="lab_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0_terseLabel_en-US" xlink:label="lab_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease commencement date</link:label>
    <link:label id="lab_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0_label_en-US" xlink:label="lab_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Commencement Date</link:label>
    <link:label id="lab_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0_documentation_en-US" xlink:label="lab_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease commencement date.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LeaseCommencementDate" xlink:label="loc_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0" xlink:to="lab_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease agreement, extendable lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30" xlink:type="arc" />
    <link:label id="lab_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD_terseLabel_en-US" xlink:label="lab_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commencement, area of space leased (in sqft)</link:label>
    <link:label id="lab_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD_label_en-US" xlink:label="lab_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commencement Land Subject To Ground Leases</link:label>
    <link:label id="lab_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD_documentation_en-US" xlink:label="lab_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commencement land subject to ground leases.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommencementLandSubjectToGroundLeases" xlink:label="loc_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD" xlink:to="lab_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD" xlink:type="arc" />
    <link:label id="lab_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C_terseLabel_en-US" xlink:label="lab_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease commencement period</link:label>
    <link:label id="lab_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C_label_en-US" xlink:label="lab_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Commencement Period</link:label>
    <link:label id="lab_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C_documentation_en-US" xlink:label="lab_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease commencement period.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LeaseCommencementPeriod" xlink:label="loc_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C" xlink:to="lab_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C" xlink:type="arc" />
    <link:label id="lab_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850_terseLabel_en-US" xlink:label="lab_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining commencement, area of space leased (in sqft)</link:label>
    <link:label id="lab_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850_label_en-US" xlink:label="lab_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Commencement Land Subject To Ground Leases</link:label>
    <link:label id="lab_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850_documentation_en-US" xlink:label="lab_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remaining commencement land subject to ground leases.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_RemainingCommencementLandSubjectToGroundLeases" xlink:label="loc_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850" xlink:to="lab_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850" xlink:type="arc" />
    <link:label id="lab_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8_terseLabel_en-US" xlink:label="lab_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected lease commencement period</link:label>
    <link:label id="lab_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8_label_en-US" xlink:label="lab_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Lease Commencement Period</link:label>
    <link:label id="lab_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8_documentation_en-US" xlink:label="lab_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected lease commencement period.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ExpectedLeaseCommencementPeriod" xlink:label="loc_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8" xlink:to="lab_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8" xlink:type="arc" />
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Liability Tenant Improvement Allowance</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, liability, tenant improvement allowance.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2" xlink:to="lab_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2" xlink:type="arc" />
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease not yet commenced, tenant improvement allowance</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Lease Not Yet Commenced Tenant Improvement Allowance</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, lease not yet commenced, tenant improvement allowance.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE" xlink:to="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE" xlink:type="arc" />
    <link:label id="lab_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41_terseLabel_en-US" xlink:label="lab_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lease term extension options</link:label>
    <link:label id="lab_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41_label_en-US" xlink:label="lab_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases Number Of Extension Options</link:label>
    <link:label id="lab_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41_documentation_en-US" xlink:label="lab_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating leases number of extension options.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OperatingLeasesNumberOfExtensionOptions" xlink:label="loc_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41" xlink:to="lab_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D" xlink:to="lab_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease option to extend</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE" xlink:to="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9" xlink:to="lab_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for operating lease liabilities included net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66" xlink:to="lab_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease option to extend</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_1E5B2CC250B5CB0CAF3911A3740C7DF5_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_1E5B2CC250B5CB0CAF3911A3740C7DF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1E5B2CC250B5CB0CAF3911A3740C7DF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_1E5B2CC250B5CB0CAF3911A3740C7DF5" xlink:to="lab_us-gaap_EquityAbstract_1E5B2CC250B5CB0CAF3911A3740C7DF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F5924F4B4DF628F8797A11A3740CC77D_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F5924F4B4DF628F8797A11A3740CC77D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F5924F4B4DF628F8797A11A3740CC77D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F5924F4B4DF628F8797A11A3740CC77D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F5924F4B4DF628F8797A11A3740CC77D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F5924F4B4DF628F8797A11A3740CC77D" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F5924F4B4DF628F8797A11A3740CC77D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:type="arc" />
    <link:label id="lab_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3_terseLabel_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Build-to-Suit Lease</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3_label_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Build To Suit Lease [Member]</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3_documentation_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Build-to-suit lease.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BuildToSuitLeaseMember" xlink:label="loc_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3" xlink:to="lab_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:to="lab_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid rent</link:label>
    <link:label id="lab_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C_label_en-US" xlink:label="lab_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C" xlink:to="lab_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:to="lab_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB" xlink:type="arc" />
    <link:label id="lab_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387_terseLabel_en-US" xlink:label="lab_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387_label_en-US" xlink:label="lab_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Noncurrent</link:label>
    <link:label id="lab_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387_documentation_en-US" xlink:label="lab_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred rent noncurrent.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_DeferredRentNoncurrent" xlink:label="loc_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387" xlink:to="lab_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7A83C51CC4023C21482D11A374848164_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_7A83C51CC4023C21482D11A374848164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7A83C51CC4023C21482D11A374848164_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_7A83C51CC4023C21482D11A374848164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7A83C51CC4023C21482D11A374848164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_7A83C51CC4023C21482D11A374848164" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_7A83C51CC4023C21482D11A374848164" xlink:type="arc" />
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and RSUs outstanding (in shares)</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044_label_en-US" xlink:label="lab_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:to="lab_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:to="lab_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Adoption of ASC on Condensed Consolidated Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE" xlink:type="arc" />
    <link:label id="lab_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE_terseLabel_en-US" xlink:label="lab_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE_label_en-US" xlink:label="lab_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ Inc [Member]</link:label>
    <link:label id="lab_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE_documentation_en-US" xlink:label="lab_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ Inc.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BioverativIncMember" xlink:label="loc_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE" xlink:to="lab_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE" xlink:type="arc" />
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7_verboseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration and license agreement.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborationAndLicenseAgreementMember" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:type="arc" />
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65" xlink:to="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65" xlink:type="arc" />
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2" xlink:type="arc" />
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Specified Clinical Development Intellectual Property and Regulatory Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C" xlink:type="arc" />
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570_label_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570_documentation_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of first commercial sale milestones.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570" xlink:to="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570" xlink:type="arc" />
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835_verboseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835" xlink:to="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835" xlink:type="arc" />
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8_verboseLabel_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Commercial Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8_label_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Commercial Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8_documentation_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of Commercial Milestones.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfCommercialMilestonesMember" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8" xlink:to="lab_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8" xlink:type="arc" />
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Clinical Development And Regulatory Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Clinical Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of Specified Clinical Development and Regulatory Milestones.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23" xlink:type="arc" />
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of Specified Sales Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Sales Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of Specified Sales Milestones.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C" xlink:type="arc" />
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1_terseLabel_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California Institute For Regenerative Medicine Agreement</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1_label_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">California Institute For Regenerative Medicine Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1_documentation_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">California institute for regenerative medicine agreement.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1" xlink:to="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D_verboseLabel_en-US" xlink:label="lab_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:to="lab_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190_verboseLabel_en-US" xlink:label="lab_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190" xlink:to="lab_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:to="lab_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="lab_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A" xlink:to="lab_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A" xlink:type="arc" />
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SB-525</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">S B Five Two Five [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SB five two five.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SBFiveTwoFiveMember" xlink:label="loc_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182" xlink:to="lab_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182" xlink:type="arc" />
    <link:label id="lab_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6_terseLabel_en-US" xlink:label="lab_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Products</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6_label_en-US" xlink:label="lab_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6_documentation_en-US" xlink:label="lab_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other products.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OtherProductsMember" xlink:label="loc_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6" xlink:to="lab_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Revenues</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B" xlink:to="lab_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B" xlink:type="arc" />
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF_verboseLabel_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">C9ORF72</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF_label_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">C Nine O R F Seven Two [Member]</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF_documentation_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">C nine ORF seven two.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CNineORFSevenTwoMember" xlink:label="loc_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF" xlink:to="lab_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Grants</link:label>
    <link:label id="lab_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B_label_en-US" xlink:label="lab_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B" xlink:to="lab_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B" xlink:type="arc" />
    <link:label id="lab_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration waiting period under HSR expiration date at which time agreement became effective</link:label>
    <link:label id="lab_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E_label_en-US" xlink:label="lab_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Waiting Period Expiration Date At Which Time Agreement Became Effective</link:label>
    <link:label id="lab_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E_documentation_en-US" xlink:label="lab_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration waiting period expiration date at which time agreement became effective.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective" xlink:label="loc_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E" xlink:to="lab_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E" xlink:type="arc" />
    <link:label id="lab_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5_terseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5_label_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payments received.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MilestonePaymentsReceived" xlink:label="loc_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5" xlink:to="lab_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5" xlink:type="arc" />
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289_terseLabel_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289_label_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Contract Liability Milestone Payment Eligible To Receive</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289_documentation_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer contract liability milestone payment eligible to receive.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289" xlink:to="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289" xlink:type="arc" />
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent development - and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments To Be Received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent development and sales based milestone payments to be received.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D" xlink:type="arc" />
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578_terseLabel_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial research term of agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578_label_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578_documentation_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial research term of agreement.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578" xlink:to="lab_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_209FA850F5FCE034778865B6E59AA1F3_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_209FA850F5FCE034778865B6E59AA1F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease agreement, extendable lease term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_209FA850F5FCE034778865B6E59AA1F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_209FA850F5FCE034778865B6E59AA1F3" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_209FA850F5FCE034778865B6E59AA1F3" xlink:type="arc" />
    <link:label id="lab_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research agreement term</link:label>
    <link:label id="lab_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1_label_en-US" xlink:label="lab_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Agreement Term</link:label>
    <link:label id="lab_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1_documentation_en-US" xlink:label="lab_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research agreement term.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ResearchAgreementTerm" xlink:label="loc_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1" xlink:to="lab_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1" xlink:type="arc" />
    <link:label id="lab_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633_terseLabel_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separate upfront fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633_label_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Separate Upfront Fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633_documentation_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Separate upfront fee.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SeparateUpfrontFee" xlink:label="loc_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633" xlink:to="lab_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633" xlink:type="arc" />
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement transaction price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Transaction Price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement transaction price.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborativeArrangementTransactionPrice" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB" xlink:to="lab_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues under agreement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15" xlink:type="arc" />
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C" xlink:to="lab_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C" xlink:type="arc" />
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89_terseLabel_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential amount to be funded for achievement of specified commercialized and sales milestones</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89_label_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89_documentation_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate additional revenue recognition milestone method revenue eligible to receive.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89" xlink:to="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89" xlink:type="arc" />
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone revenue receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25_label_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Revenue Receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25_documentation_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone&#8203; revenue receivable.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MilestoneRevenueReceivable" xlink:label="loc_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25" xlink:to="lab_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25" xlink:type="arc" />
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products approved</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements Number Of Products Approved Under Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration and license agreements number of products approved under agreement.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue reduction due to decrease in measure of proportional cumulative performance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_40B15372E6CB3704271364F2CBB6C004_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_40B15372E6CB3704271364F2CBB6C004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_40B15372E6CB3704271364F2CBB6C004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_40B15372E6CB3704271364F2CBB6C004" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_40B15372E6CB3704271364F2CBB6C004" xlink:type="arc" />
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of milestones included in transaction price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF_label_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Clinical Or Regulatory Milestones Included In Transaction Price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF_documentation_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of clinical or regulatory milestones included in transaction price.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF" xlink:to="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF" xlink:type="arc" />
    <link:label id="lab_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73_label_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Research Program</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73_documentation_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of research program.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NumberOfResearchProgram" xlink:label="loc_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73" xlink:to="lab_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73" xlink:type="arc" />
    <link:label id="lab_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C_terseLabel_en-US" xlink:label="lab_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funds due under the agreement</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C_label_en-US" xlink:label="lab_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Funding Amount</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C_documentation_en-US" xlink:label="lab_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant funding amount.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_GrantFundingAmount" xlink:label="loc_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C" xlink:to="lab_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_985FE8B0789B638A35F064F2CC723C91_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_985FE8B0789B638A35F064F2CC723C91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_985FE8B0789B638A35F064F2CC723C91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_985FE8B0789B638A35F064F2CC723C91" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_985FE8B0789B638A35F064F2CC723C91" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:to="lab_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_512BAC9B6D5EA2E67D4264F2CC720315_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_512BAC9B6D5EA2E67D4264F2CC720315" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_512BAC9B6D5EA2E67D4264F2CC720315_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_512BAC9B6D5EA2E67D4264F2CC720315" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_512BAC9B6D5EA2E67D4264F2CC720315" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_512BAC9B6D5EA2E67D4264F2CC720315" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_512BAC9B6D5EA2E67D4264F2CC720315" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashCurrent_D558B9DC981C49B8212064F2CC72811B_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_D558B9DC981C49B8212064F2CC72811B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, current portion</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_D558B9DC981C49B8212064F2CC72811B_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_D558B9DC981C49B8212064F2CC72811B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_D558B9DC981C49B8212064F2CC72811B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_D558B9DC981C49B8212064F2CC72811B" xlink:to="lab_us-gaap_RestrictedCashCurrent_D558B9DC981C49B8212064F2CC72811B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6AB8B618053CBD86382364F2CC72235E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6AB8B618053CBD86382364F2CC72235E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6AB8B618053CBD86382364F2CC72235E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6AB8B618053CBD86382364F2CC72235E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6AB8B618053CBD86382364F2CC72235E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6AB8B618053CBD86382364F2CC72235E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6AB8B618053CBD86382364F2CC72235E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestReceivableCurrent_009979397F09B449817864F2CC72F723_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent_009979397F09B449817864F2CC72F723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_009979397F09B449817864F2CC72F723_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent_009979397F09B449817864F2CC72F723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_009979397F09B449817864F2CC72F723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent_009979397F09B449817864F2CC72F723" xlink:to="lab_us-gaap_InterestReceivableCurrent_009979397F09B449817864F2CC72F723" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_E43FE34A09910DA20FC564F2CC727D62_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_E43FE34A09910DA20FC564F2CC727D62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_E43FE34A09910DA20FC564F2CC727D62_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_E43FE34A09910DA20FC564F2CC727D62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_E43FE34A09910DA20FC564F2CC727D62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_E43FE34A09910DA20FC564F2CC727D62" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_E43FE34A09910DA20FC564F2CC727D62" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_F7712C504FF336695F0364F2CC724E2A_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_F7712C504FF336695F0364F2CC724E2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_F7712C504FF336695F0364F2CC724E2A_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_F7712C504FF336695F0364F2CC724E2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_F7712C504FF336695F0364F2CC724E2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_F7712C504FF336695F0364F2CC724E2A" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_F7712C504FF336695F0364F2CC724E2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_439164741AFD743F7DC364F2CC72A7BB_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_439164741AFD743F7DC364F2CC72A7BB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_439164741AFD743F7DC364F2CC72A7BB_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_439164741AFD743F7DC364F2CC72A7BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_439164741AFD743F7DC364F2CC72A7BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_439164741AFD743F7DC364F2CC72A7BB" xlink:to="lab_us-gaap_AssetsCurrent_439164741AFD743F7DC364F2CC72A7BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BF98E1F94E5E2A4FF1D964F2CC7214B0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BF98E1F94E5E2A4FF1D964F2CC7214B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BF98E1F94E5E2A4FF1D964F2CC7214B0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BF98E1F94E5E2A4FF1D964F2CC7214B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BF98E1F94E5E2A4FF1D964F2CC7214B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BF98E1F94E5E2A4FF1D964F2CC7214B0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BF98E1F94E5E2A4FF1D964F2CC7214B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2BACDC7CCD6E71D4860F64F2CC728F7B_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2BACDC7CCD6E71D4860F64F2CC728F7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2BACDC7CCD6E71D4860F64F2CC728F7B_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2BACDC7CCD6E71D4860F64F2CC728F7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2BACDC7CCD6E71D4860F64F2CC728F7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2BACDC7CCD6E71D4860F64F2CC728F7B" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2BACDC7CCD6E71D4860F64F2CC728F7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_EF2A2555D5D4C10009FF64F2CC72BD02_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_EF2A2555D5D4C10009FF64F2CC72BD02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_EF2A2555D5D4C10009FF64F2CC72BD02_label_en-US" xlink:label="lab_us-gaap_Goodwill_EF2A2555D5D4C10009FF64F2CC72BD02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_EF2A2555D5D4C10009FF64F2CC72BD02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_EF2A2555D5D4C10009FF64F2CC72BD02" xlink:to="lab_us-gaap_Goodwill_EF2A2555D5D4C10009FF64F2CC72BD02" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0F22EC71C641EC456DF064F2CC724175_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_0F22EC71C641EC456DF064F2CC724175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0F22EC71C641EC456DF064F2CC724175_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_0F22EC71C641EC456DF064F2CC724175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0F22EC71C641EC456DF064F2CC724175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_0F22EC71C641EC456DF064F2CC724175" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_0F22EC71C641EC456DF064F2CC724175" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_95D1B7B4BC249F4BAF6764F2CC729EBD_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_95D1B7B4BC249F4BAF6764F2CC729EBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_95D1B7B4BC249F4BAF6764F2CC729EBD_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_95D1B7B4BC249F4BAF6764F2CC729EBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_95D1B7B4BC249F4BAF6764F2CC729EBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_95D1B7B4BC249F4BAF6764F2CC729EBD" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_95D1B7B4BC249F4BAF6764F2CC729EBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_7EA89C00AB06D661461B64F2CC7277B1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_7EA89C00AB06D661461B64F2CC7277B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_7EA89C00AB06D661461B64F2CC7277B1_label_en-US" xlink:label="lab_us-gaap_Assets_7EA89C00AB06D661461B64F2CC7277B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7EA89C00AB06D661461B64F2CC7277B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_7EA89C00AB06D661461B64F2CC7277B1" xlink:to="lab_us-gaap_Assets_7EA89C00AB06D661461B64F2CC7277B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82F31AB7AB8483EC272864F2CC727DAF_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82F31AB7AB8483EC272864F2CC727DAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82F31AB7AB8483EC272864F2CC727DAF_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82F31AB7AB8483EC272864F2CC727DAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82F31AB7AB8483EC272864F2CC727DAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82F31AB7AB8483EC272864F2CC727DAF" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82F31AB7AB8483EC272864F2CC727DAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_A1E189A602064267FAED64F2CC72FDD0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_A1E189A602064267FAED64F2CC72FDD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_A1E189A602064267FAED64F2CC72FDD0_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_A1E189A602064267FAED64F2CC72FDD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_A1E189A602064267FAED64F2CC72FDD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_A1E189A602064267FAED64F2CC72FDD0" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_A1E189A602064267FAED64F2CC72FDD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_B9874152D4A365BECF3A64F2CC7245B0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_B9874152D4A365BECF3A64F2CC7245B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_B9874152D4A365BECF3A64F2CC7245B0_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_B9874152D4A365BECF3A64F2CC7245B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_B9874152D4A365BECF3A64F2CC7245B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_B9874152D4A365BECF3A64F2CC7245B0" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_B9874152D4A365BECF3A64F2CC7245B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_EEB472EF71161E0B4B3964F2CC724710_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_EEB472EF71161E0B4B3964F2CC724710" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_EEB472EF71161E0B4B3964F2CC724710_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_EEB472EF71161E0B4B3964F2CC724710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_EEB472EF71161E0B4B3964F2CC724710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_EEB472EF71161E0B4B3964F2CC724710" xlink:to="lab_us-gaap_LiabilitiesCurrent_EEB472EF71161E0B4B3964F2CC724710" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_03925051AA7624D95A4964F2CC72D26E_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_03925051AA7624D95A4964F2CC72D26E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenues, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_03925051AA7624D95A4964F2CC72D26E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_03925051AA7624D95A4964F2CC72D26E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_03925051AA7624D95A4964F2CC72D26E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_03925051AA7624D95A4964F2CC72D26E" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_03925051AA7624D95A4964F2CC72D26E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8B8B07F0D771AA984F6264F2CC72DC26_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8B8B07F0D771AA984F6264F2CC72DC26" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8B8B07F0D771AA984F6264F2CC72DC26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8B8B07F0D771AA984F6264F2CC72DC26" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8B8B07F0D771AA984F6264F2CC72DC26" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_FA79032265875245304C65CCFEB24FE2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_FA79032265875245304C65CCFEB24FE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_FA79032265875245304C65CCFEB24FE2_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_FA79032265875245304C65CCFEB24FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_FA79032265875245304C65CCFEB24FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_FA79032265875245304C65CCFEB24FE2" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_FA79032265875245304C65CCFEB24FE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8ACC434FC801BB8896D364F2CC72FEAE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8ACC434FC801BB8896D364F2CC72FEAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8ACC434FC801BB8896D364F2CC72FEAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8ACC434FC801BB8896D364F2CC72FEAE" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_8ACC434FC801BB8896D364F2CC72FEAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_0F214D9D50F7FECD0CD664F2CC729A42_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_0F214D9D50F7FECD0CD664F2CC729A42" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_0F214D9D50F7FECD0CD664F2CC729A42_label_en-US" xlink:label="lab_us-gaap_Liabilities_0F214D9D50F7FECD0CD664F2CC729A42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_0F214D9D50F7FECD0CD664F2CC729A42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_0F214D9D50F7FECD0CD664F2CC729A42" xlink:to="lab_us-gaap_Liabilities_0F214D9D50F7FECD0CD664F2CC729A42" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_BB3DF40955778C14AA3464F2CC72A0B7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_BB3DF40955778C14AA3464F2CC72A0B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_BB3DF40955778C14AA3464F2CC72A0B7_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_BB3DF40955778C14AA3464F2CC72A0B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_BB3DF40955778C14AA3464F2CC72A0B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_BB3DF40955778C14AA3464F2CC72A0B7" xlink:to="lab_us-gaap_CommitmentsAndContingencies_BB3DF40955778C14AA3464F2CC72A0B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_E8A3151A7140D89974F664F2CC7276FA_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_E8A3151A7140D89974F664F2CC7276FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_E8A3151A7140D89974F664F2CC7276FA_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_E8A3151A7140D89974F664F2CC7276FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_E8A3151A7140D89974F664F2CC7276FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_E8A3151A7140D89974F664F2CC7276FA" xlink:to="lab_us-gaap_PreferredStockValue_E8A3151A7140D89974F664F2CC7276FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_B07BF73CF00869C87F9F64F2CC72F651_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_B07BF73CF00869C87F9F64F2CC72F651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_B07BF73CF00869C87F9F64F2CC72F651_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_B07BF73CF00869C87F9F64F2CC72F651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_B07BF73CF00869C87F9F64F2CC72F651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_B07BF73CF00869C87F9F64F2CC72F651" xlink:to="lab_us-gaap_CommonStockValue_B07BF73CF00869C87F9F64F2CC72F651" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6F8A25DBFBCBA6A20CC864F2CC722840_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6F8A25DBFBCBA6A20CC864F2CC722840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6F8A25DBFBCBA6A20CC864F2CC722840_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6F8A25DBFBCBA6A20CC864F2CC722840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6F8A25DBFBCBA6A20CC864F2CC722840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6F8A25DBFBCBA6A20CC864F2CC722840" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6F8A25DBFBCBA6A20CC864F2CC722840" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6F7E1F86DE891A25D5CC64F2CC81DCDA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6F7E1F86DE891A25D5CC64F2CC81DCDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6F7E1F86DE891A25D5CC64F2CC81DCDA_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6F7E1F86DE891A25D5CC64F2CC81DCDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6F7E1F86DE891A25D5CC64F2CC81DCDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6F7E1F86DE891A25D5CC64F2CC81DCDA" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6F7E1F86DE891A25D5CC64F2CC81DCDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_FC960CE125857990400E64F2CC819B04_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_FC960CE125857990400E64F2CC819B04" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Sangamo Therapeutics, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_FC960CE125857990400E64F2CC819B04_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_FC960CE125857990400E64F2CC819B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_FC960CE125857990400E64F2CC819B04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_FC960CE125857990400E64F2CC819B04" xlink:to="lab_us-gaap_StockholdersEquity_FC960CE125857990400E64F2CC819B04" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_FAB899F24A6065A5B20364F2CC819A95_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_FAB899F24A6065A5B20364F2CC819A95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_FAB899F24A6065A5B20364F2CC819A95_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_FAB899F24A6065A5B20364F2CC819A95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_FAB899F24A6065A5B20364F2CC819A95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_FAB899F24A6065A5B20364F2CC819A95" xlink:to="lab_us-gaap_MinorityInterest_FAB899F24A6065A5B20364F2CC819A95" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55AAA54935D7D547F94364F2CC81F48A_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55AAA54935D7D547F94364F2CC81F48A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55AAA54935D7D547F94364F2CC81F48A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55AAA54935D7D547F94364F2CC81F48A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55AAA54935D7D547F94364F2CC81F48A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55AAA54935D7D547F94364F2CC81F48A" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55AAA54935D7D547F94364F2CC81F48A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3B99AE45BAC11BEEE34E64F2CC81A0A4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_3B99AE45BAC11BEEE34E64F2CC81A0A4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3B99AE45BAC11BEEE34E64F2CC81A0A4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_3B99AE45BAC11BEEE34E64F2CC81A0A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3B99AE45BAC11BEEE34E64F2CC81A0A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3B99AE45BAC11BEEE34E64F2CC81A0A4" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_3B99AE45BAC11BEEE34E64F2CC81A0A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_DE85745DFC64095C97BE11A3742B831F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_DE85745DFC64095C97BE11A3742B831F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_DE85745DFC64095C97BE11A3742B831F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_DE85745DFC64095C97BE11A3742B831F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_DE85745DFC64095C97BE11A3742B831F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_DE85745DFC64095C97BE11A3742B831F" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_DE85745DFC64095C97BE11A3742B831F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_EFB6655A73EFD675DDEA11A373E3445C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_EFB6655A73EFD675DDEA11A373E3445C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_EFB6655A73EFD675DDEA11A373E3445C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_EFB6655A73EFD675DDEA11A373E3445C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_EFB6655A73EFD675DDEA11A373E3445C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_EFB6655A73EFD675DDEA11A373E3445C" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_EFB6655A73EFD675DDEA11A373E3445C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_430D85889C666AC8392D11A373ED87F4_positiveTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_430D85889C666AC8392D11A373ED87F4" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_430D85889C666AC8392D11A373ED87F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_430D85889C666AC8392D11A373ED87F4" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_430D85889C666AC8392D11A373ED87F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of TxCell</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730_terseLabel_en-US" xlink:label="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730_label_en-US" xlink:label="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development</link:label>
    <link:label id="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730_documentation_en-US" xlink:label="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730" xlink:to="lab_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75CA6B8B425BA3F14F5D11A373ED8FF5_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75CA6B8B425BA3F14F5D11A373ED8FF5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Assumed debt liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75CA6B8B425BA3F14F5D11A373ED8FF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75CA6B8B425BA3F14F5D11A373ED8FF5" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75CA6B8B425BA3F14F5D11A373ED8FF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair value of net identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_89244B6F3B5847D95BAA11A373ED2112_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_89244B6F3B5847D95BAA11A373ED2112" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total fair value of net assets acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_89244B6F3B5847D95BAA11A373ED2112" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_89244B6F3B5847D95BAA11A373ED2112" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_89244B6F3B5847D95BAA11A373ED2112" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_FF07A61E09480029BA6A11A3742B8F70_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_FF07A61E09480029BA6A11A3742B8F70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FF07A61E09480029BA6A11A3742B8F70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FF07A61E09480029BA6A11A3742B8F70" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_FF07A61E09480029BA6A11A3742B8F70" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_02CF2EC84C8B856B2EAB11A3742B8F8E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_02CF2EC84C8B856B2EAB11A3742B8F8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_02CF2EC84C8B856B2EAB11A3742B8F8E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_02CF2EC84C8B856B2EAB11A3742B8F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_02CF2EC84C8B856B2EAB11A3742B8F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_02CF2EC84C8B856B2EAB11A3742B8F8E" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_02CF2EC84C8B856B2EAB11A3742B8F8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_860EB98DD912E47EB2B211A3742BA864_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_860EB98DD912E47EB2B211A3742BA864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_860EB98DD912E47EB2B211A3742BA864_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_860EB98DD912E47EB2B211A3742BA864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_860EB98DD912E47EB2B211A3742BA864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_860EB98DD912E47EB2B211A3742BA864" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_860EB98DD912E47EB2B211A3742BA864" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8A272ED356840BB955FE677430A9EB51_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_8A272ED356840BB955FE677430A9EB51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8A272ED356840BB955FE677430A9EB51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8A272ED356840BB955FE677430A9EB51" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_8A272ED356840BB955FE677430A9EB51" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337" xlink:to="lab_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879" xlink:to="lab_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non- Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29" xlink:to="lab_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_0C5CD985943365D38892677430B1F481_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_0C5CD985943365D38892677430B1F481" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Topic 842</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0C5CD985943365D38892677430B1F481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_0C5CD985943365D38892677430B1F481" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_0C5CD985943365D38892677430B1F481" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466" xlink:to="lab_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAFA4D426CD42B136B58677430B2C830_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAFA4D426CD42B136B58677430B2C830" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAFA4D426CD42B136B58677430B2C830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAFA4D426CD42B136B58677430B2C830" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAFA4D426CD42B136B58677430B2C830" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative-effect adjustment of ASC</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect on Retained Earnings, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0" xlink:to="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Issuance costs related to public offering and TxCell Acquisition</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95F348987931AB687F28677430B468FB_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95F348987931AB687F28677430B468FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95F348987931AB687F28677430B468FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95F348987931AB687F28677430B468FB" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95F348987931AB687F28677430B468FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_483D4D967449562BE7EC677430B59981_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_483D4D967449562BE7EC677430B59981" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balances (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_483D4D967449562BE7EC677430B59981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_483D4D967449562BE7EC677430B59981" xlink:to="lab_us-gaap_CommonStockSharesIssued_483D4D967449562BE7EC677430B59981" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99BDFAF396D5C9A00D8F677430B5E05C_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99BDFAF396D5C9A00D8F677430B5E05C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99BDFAF396D5C9A00D8F677430B5E05C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99BDFAF396D5C9A00D8F677430B5E05C" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99BDFAF396D5C9A00D8F677430B5E05C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_F58B78F31FD7AB2CACE911A373FC7E8C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_F58B78F31FD7AB2CACE911A373FC7E8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Estimated Fair Value of Net Assets Acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_F58B78F31FD7AB2CACE911A373FC7E8C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_F58B78F31FD7AB2CACE911A373FC7E8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_F58B78F31FD7AB2CACE911A373FC7E8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_F58B78F31FD7AB2CACE911A373FC7E8C" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_F58B78F31FD7AB2CACE911A373FC7E8C" xlink:type="arc" />
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Non-controlling Interest</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82_label_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Noncontrolling Interest Table [Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of noncontrolling interest.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82" xlink:to="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D2DB52EB3974896345D64F2CBF58B94_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D2DB52EB3974896345D64F2CBF58B94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D2DB52EB3974896345D64F2CBF58B94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D2DB52EB3974896345D64F2CBF58B94" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D2DB52EB3974896345D64F2CBF58B94" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_28176D3569B0664D774E64F2CBF5B7D3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_28176D3569B0664D774E64F2CBF5B7D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_28176D3569B0664D774E64F2CBF5B7D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_28176D3569B0664D774E64F2CBF5B7D3" xlink:to="lab_us-gaap_CommercialPaperMember_28176D3569B0664D774E64F2CBF5B7D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF" xlink:to="lab_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_21D1D6D27B37FEA4437564F2CBF567A4_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_21D1D6D27B37FEA4437564F2CBF567A4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_21D1D6D27B37FEA4437564F2CBF567A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_21D1D6D27B37FEA4437564F2CBF567A4" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_21D1D6D27B37FEA4437564F2CBF567A4" xlink:type="arc" />
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents, Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125_label_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125" xlink:to="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125" xlink:type="arc" />
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0_label_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Equivalents, Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0" xlink:to="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3E7BC0D6456F95A79B3464F2CBF5EBD2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3E7BC0D6456F95A79B3464F2CBF5EBD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, Estimated Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3E7BC0D6456F95A79B3464F2CBF5EBD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3E7BC0D6456F95A79B3464F2CBF5EBD2" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3E7BC0D6456F95A79B3464F2CBF5EBD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B6A4E95511C42513386B64F2CBF58FFB_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B6A4E95511C42513386B64F2CBF58FFB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, Estimated Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B6A4E95511C42513386B64F2CBF58FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B6A4E95511C42513386B64F2CBF58FFB" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B6A4E95511C42513386B64F2CBF58FFB" xlink:type="arc" />
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for Sale Securities Amortized Cost</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1" xlink:type="arc" />
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized gain, before tax.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD" xlink:type="arc" />
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977_negatedLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized loss, before Tax</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977" xlink:type="arc" />
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Estimated Fair Value</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649" xlink:type="arc" />
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14_terseLabel_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange Rate</link:label>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14_label_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Exchange Rate [Member]</link:label>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14_documentation_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Exchange Rate [Member]</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MeasurementInputExchangeRateMember" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14" xlink:to="lab_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14" xlink:type="arc" />
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92_terseLabel_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price Correlation</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92_label_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Stock Price Correlation [Member]</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92_documentation_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Stock Price Correlation [Member]</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MeasurementInputStockPriceCorrelationMember" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92" xlink:to="lab_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price Volatility Estimate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EUR / USD Exchange Rate Volatility Estimate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_C28A21AD8C3932A5ABC0546366A8A221_verboseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_C28A21AD8C3932A5ABC0546366A8A221" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition Estimated Fair Value Liabilities Of Free Shares</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_C28A21AD8C3932A5ABC0546366A8A221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_C28A21AD8C3932A5ABC0546366A8A221" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_C28A21AD8C3932A5ABC0546366A8A221" xlink:type="arc" />
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_C1CFAE83710F095D150D54636444ED69_verboseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_C1CFAE83710F095D150D54636444ED69" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition Estimated Fair Value Assets Of Free Shares</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_C1CFAE83710F095D150D54636444ED69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_C1CFAE83710F095D150D54636444ED69" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_C1CFAE83710F095D150D54636444ED69" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Free shares measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAndServiceMember_805307B3DD46C798AB8E453F76076558_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember_805307B3DD46C798AB8E453F76076558" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_805307B3DD46C798AB8E453F76076558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember_805307B3DD46C798AB8E453F76076558" xlink:to="lab_us-gaap_LicenseAndServiceMember_805307B3DD46C798AB8E453F76076558" xlink:type="arc" />
    <link:label id="lab_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA_terseLabel_en-US" xlink:label="lab_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Services</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA_label_en-US" xlink:label="lab_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Services [Member]</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA_documentation_en-US" xlink:label="lab_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research services.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ResearchServicesMember" xlink:label="loc_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA" xlink:to="lab_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D65E3E24D33BE75F19C4453F76077669_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D65E3E24D33BE75F19C4453F76077669" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D65E3E24D33BE75F19C4453F76077669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D65E3E24D33BE75F19C4453F76077669" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D65E3E24D33BE75F19C4453F76077669" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448_label_en-US" xlink:label="lab_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="lab_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_6B6E98A40F52C8DF15DD678AE6B57DAE_verboseLabel_en-US" xlink:label="lab_dei_DocumentType_6B6E98A40F52C8DF15DD678AE6B57DAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_6B6E98A40F52C8DF15DD678AE6B57DAE_label_en-US" xlink:label="lab_dei_DocumentType_6B6E98A40F52C8DF15DD678AE6B57DAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6B6E98A40F52C8DF15DD678AE6B57DAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_6B6E98A40F52C8DF15DD678AE6B57DAE" xlink:to="lab_dei_DocumentType_6B6E98A40F52C8DF15DD678AE6B57DAE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_B50BAB974FCFE74D42C0678AE6B5CF41_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_B50BAB974FCFE74D42C0678AE6B5CF41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_B50BAB974FCFE74D42C0678AE6B5CF41_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_B50BAB974FCFE74D42C0678AE6B5CF41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_B50BAB974FCFE74D42C0678AE6B5CF41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_B50BAB974FCFE74D42C0678AE6B5CF41" xlink:to="lab_dei_DocumentQuarterlyReport_B50BAB974FCFE74D42C0678AE6B5CF41" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_D468ABC6A288E26578BE678AE6B5D77A_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D468ABC6A288E26578BE678AE6B5D77A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_D468ABC6A288E26578BE678AE6B5D77A_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D468ABC6A288E26578BE678AE6B5D77A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D468ABC6A288E26578BE678AE6B5D77A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_D468ABC6A288E26578BE678AE6B5D77A" xlink:to="lab_dei_DocumentPeriodEndDate_D468ABC6A288E26578BE678AE6B5D77A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_BE20B320B1CA1924619A678AE6B5C56F_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_BE20B320B1CA1924619A678AE6B5C56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_BE20B320B1CA1924619A678AE6B5C56F_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_BE20B320B1CA1924619A678AE6B5C56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_BE20B320B1CA1924619A678AE6B5C56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_BE20B320B1CA1924619A678AE6B5C56F" xlink:to="lab_dei_DocumentTransitionReport_BE20B320B1CA1924619A678AE6B5C56F" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_33E8C3F1C27442B67C5F678AE6B57AA0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_33E8C3F1C27442B67C5F678AE6B57AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_33E8C3F1C27442B67C5F678AE6B57AA0_label_en-US" xlink:label="lab_dei_EntityFileNumber_33E8C3F1C27442B67C5F678AE6B57AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_33E8C3F1C27442B67C5F678AE6B57AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_33E8C3F1C27442B67C5F678AE6B57AA0" xlink:to="lab_dei_EntityFileNumber_33E8C3F1C27442B67C5F678AE6B57AA0" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_B06124D37093BDF8DEFC678AE6B53772_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_B06124D37093BDF8DEFC678AE6B53772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_B06124D37093BDF8DEFC678AE6B53772_label_en-US" xlink:label="lab_dei_EntityRegistrantName_B06124D37093BDF8DEFC678AE6B53772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_B06124D37093BDF8DEFC678AE6B53772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_B06124D37093BDF8DEFC678AE6B53772" xlink:to="lab_dei_EntityRegistrantName_B06124D37093BDF8DEFC678AE6B53772" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6B33A239509E9C48F791678AE6B5BD83_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_6B33A239509E9C48F791678AE6B5BD83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6B33A239509E9C48F791678AE6B5BD83_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_6B33A239509E9C48F791678AE6B5BD83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6B33A239509E9C48F791678AE6B5BD83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_6B33A239509E9C48F791678AE6B5BD83" xlink:to="lab_dei_EntityIncorporationStateCountryCode_6B33A239509E9C48F791678AE6B5BD83" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_562F2410453838BEAE4C678AE6B52D94_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_562F2410453838BEAE4C678AE6B52D94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_562F2410453838BEAE4C678AE6B52D94_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_562F2410453838BEAE4C678AE6B52D94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_562F2410453838BEAE4C678AE6B52D94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_562F2410453838BEAE4C678AE6B52D94" xlink:to="lab_dei_EntityTaxIdentificationNumber_562F2410453838BEAE4C678AE6B52D94" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_85C043750D6776D590DE678AE6B5E787_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_85C043750D6776D590DE678AE6B5E787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_85C043750D6776D590DE678AE6B5E787_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_85C043750D6776D590DE678AE6B5E787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_85C043750D6776D590DE678AE6B5E787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_85C043750D6776D590DE678AE6B5E787" xlink:to="lab_dei_EntityAddressAddressLine1_85C043750D6776D590DE678AE6B5E787" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_FBD96D23E2D544ECC34B678AE6B58177_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_FBD96D23E2D544ECC34B678AE6B58177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_FBD96D23E2D544ECC34B678AE6B58177_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_FBD96D23E2D544ECC34B678AE6B58177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_FBD96D23E2D544ECC34B678AE6B58177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_FBD96D23E2D544ECC34B678AE6B58177" xlink:to="lab_dei_EntityAddressCityOrTown_FBD96D23E2D544ECC34B678AE6B58177" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_226547A3BBB87CA7B58A678AE6C5A90F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_226547A3BBB87CA7B58A678AE6C5A90F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_226547A3BBB87CA7B58A678AE6C5A90F_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_226547A3BBB87CA7B58A678AE6C5A90F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_226547A3BBB87CA7B58A678AE6C5A90F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_226547A3BBB87CA7B58A678AE6C5A90F" xlink:to="lab_dei_EntityAddressStateOrProvince_226547A3BBB87CA7B58A678AE6C5A90F" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_95BB41E4C19CC5F4CC77678AE6C5D39F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_95BB41E4C19CC5F4CC77678AE6C5D39F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_95BB41E4C19CC5F4CC77678AE6C5D39F_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_95BB41E4C19CC5F4CC77678AE6C5D39F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_95BB41E4C19CC5F4CC77678AE6C5D39F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_95BB41E4C19CC5F4CC77678AE6C5D39F" xlink:to="lab_dei_EntityAddressPostalZipCode_95BB41E4C19CC5F4CC77678AE6C5D39F" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_0C2EABB023F89B5D810C678AE6C5307C_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_0C2EABB023F89B5D810C678AE6C5307C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_0C2EABB023F89B5D810C678AE6C5307C_label_en-US" xlink:label="lab_dei_CityAreaCode_0C2EABB023F89B5D810C678AE6C5307C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_0C2EABB023F89B5D810C678AE6C5307C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_0C2EABB023F89B5D810C678AE6C5307C" xlink:to="lab_dei_CityAreaCode_0C2EABB023F89B5D810C678AE6C5307C" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_923CA99BCF3A14EE459C678AE6C5A241_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_923CA99BCF3A14EE459C678AE6C5A241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_923CA99BCF3A14EE459C678AE6C5A241_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_923CA99BCF3A14EE459C678AE6C5A241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_923CA99BCF3A14EE459C678AE6C5A241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_923CA99BCF3A14EE459C678AE6C5A241" xlink:to="lab_dei_LocalPhoneNumber_923CA99BCF3A14EE459C678AE6C5A241" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_2F659ADB6F3A2AD1FB6F678AE6C5B991_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_2F659ADB6F3A2AD1FB6F678AE6C5B991" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_2F659ADB6F3A2AD1FB6F678AE6C5B991_label_en-US" xlink:label="lab_dei_Security12bTitle_2F659ADB6F3A2AD1FB6F678AE6C5B991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_2F659ADB6F3A2AD1FB6F678AE6C5B991" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_2F659ADB6F3A2AD1FB6F678AE6C5B991" xlink:to="lab_dei_Security12bTitle_2F659ADB6F3A2AD1FB6F678AE6C5B991" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_4A69ECC8266A34EA01FD678AE6C5188C_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_4A69ECC8266A34EA01FD678AE6C5188C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_4A69ECC8266A34EA01FD678AE6C5188C_label_en-US" xlink:label="lab_dei_TradingSymbol_4A69ECC8266A34EA01FD678AE6C5188C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4A69ECC8266A34EA01FD678AE6C5188C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_4A69ECC8266A34EA01FD678AE6C5188C" xlink:to="lab_dei_TradingSymbol_4A69ECC8266A34EA01FD678AE6C5188C" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_6AFF8CDDECB2E7A55C75678AE6C570E4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_6AFF8CDDECB2E7A55C75678AE6C570E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_6AFF8CDDECB2E7A55C75678AE6C570E4_label_en-US" xlink:label="lab_dei_SecurityExchangeName_6AFF8CDDECB2E7A55C75678AE6C570E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_6AFF8CDDECB2E7A55C75678AE6C570E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_6AFF8CDDECB2E7A55C75678AE6C570E4" xlink:to="lab_dei_SecurityExchangeName_6AFF8CDDECB2E7A55C75678AE6C570E4" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_FC22FBF6E41882C32886678AE6C5DC19_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_FC22FBF6E41882C32886678AE6C5DC19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_FC22FBF6E41882C32886678AE6C5DC19_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_FC22FBF6E41882C32886678AE6C5DC19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_FC22FBF6E41882C32886678AE6C5DC19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_FC22FBF6E41882C32886678AE6C5DC19" xlink:to="lab_dei_EntityCurrentReportingStatus_FC22FBF6E41882C32886678AE6C5DC19" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_981261EC7DD3FD863634678AE6C5AB8E_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_981261EC7DD3FD863634678AE6C5AB8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_981261EC7DD3FD863634678AE6C5AB8E_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_981261EC7DD3FD863634678AE6C5AB8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_981261EC7DD3FD863634678AE6C5AB8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_981261EC7DD3FD863634678AE6C5AB8E" xlink:to="lab_dei_EntityInteractiveDataCurrent_981261EC7DD3FD863634678AE6C5AB8E" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_161254C9EB74559169D4678AE6C51D0D_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_161254C9EB74559169D4678AE6C51D0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_161254C9EB74559169D4678AE6C51D0D_label_en-US" xlink:label="lab_dei_EntityFilerCategory_161254C9EB74559169D4678AE6C51D0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_161254C9EB74559169D4678AE6C51D0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_161254C9EB74559169D4678AE6C51D0D" xlink:to="lab_dei_EntityFilerCategory_161254C9EB74559169D4678AE6C51D0D" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_D5BAF2F7A7AB2EC0E7AB678AE6C54971_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_D5BAF2F7A7AB2EC0E7AB678AE6C54971" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_D5BAF2F7A7AB2EC0E7AB678AE6C54971_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_D5BAF2F7A7AB2EC0E7AB678AE6C54971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_D5BAF2F7A7AB2EC0E7AB678AE6C54971" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_D5BAF2F7A7AB2EC0E7AB678AE6C54971" xlink:to="lab_dei_EntitySmallBusiness_D5BAF2F7A7AB2EC0E7AB678AE6C54971" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2C62430290BD4B189418678AE6C50F07_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_2C62430290BD4B189418678AE6C50F07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2C62430290BD4B189418678AE6C50F07_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_2C62430290BD4B189418678AE6C50F07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_2C62430290BD4B189418678AE6C50F07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_2C62430290BD4B189418678AE6C50F07" xlink:to="lab_dei_EntityEmergingGrowthCompany_2C62430290BD4B189418678AE6C50F07" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_34F22AB5236C932FE1CC678AE6C57C5F_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_34F22AB5236C932FE1CC678AE6C57C5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_34F22AB5236C932FE1CC678AE6C57C5F_label_en-US" xlink:label="lab_dei_EntityShellCompany_34F22AB5236C932FE1CC678AE6C57C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_34F22AB5236C932FE1CC678AE6C57C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_34F22AB5236C932FE1CC678AE6C57C5F" xlink:to="lab_dei_EntityShellCompany_34F22AB5236C932FE1CC678AE6C57C5F" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1951DF60D4A3C3CA76C6678AE6C5DB8E_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_1951DF60D4A3C3CA76C6678AE6C5DB8E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1951DF60D4A3C3CA76C6678AE6C5DB8E_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_1951DF60D4A3C3CA76C6678AE6C5DB8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1951DF60D4A3C3CA76C6678AE6C5DB8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_1951DF60D4A3C3CA76C6678AE6C5DB8E" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_1951DF60D4A3C3CA76C6678AE6C5DB8E" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_D859543B551BCFCA28DC678AE6C5B50B_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_D859543B551BCFCA28DC678AE6C5B50B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_D859543B551BCFCA28DC678AE6C5B50B_label_en-US" xlink:label="lab_dei_AmendmentFlag_D859543B551BCFCA28DC678AE6C5B50B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D859543B551BCFCA28DC678AE6C5B50B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_D859543B551BCFCA28DC678AE6C5B50B" xlink:to="lab_dei_AmendmentFlag_D859543B551BCFCA28DC678AE6C5B50B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_C118E85952B1AE807437678AE6C5641F_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_C118E85952B1AE807437678AE6C5641F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_C118E85952B1AE807437678AE6C5641F_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_C118E85952B1AE807437678AE6C5641F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C118E85952B1AE807437678AE6C5641F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_C118E85952B1AE807437678AE6C5641F" xlink:to="lab_dei_DocumentFiscalYearFocus_C118E85952B1AE807437678AE6C5641F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_E89C68A59AB369679C7B678AE6C5E5BD_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_E89C68A59AB369679C7B678AE6C5E5BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_E89C68A59AB369679C7B678AE6C5E5BD_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_E89C68A59AB369679C7B678AE6C5E5BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_E89C68A59AB369679C7B678AE6C5E5BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_E89C68A59AB369679C7B678AE6C5E5BD" xlink:to="lab_dei_DocumentFiscalPeriodFocus_E89C68A59AB369679C7B678AE6C5E5BD" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_9B1E7C78283273ED0D8D678AE6C5C1C1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_9B1E7C78283273ED0D8D678AE6C5C1C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_9B1E7C78283273ED0D8D678AE6C5C1C1_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_9B1E7C78283273ED0D8D678AE6C5C1C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_9B1E7C78283273ED0D8D678AE6C5C1C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_9B1E7C78283273ED0D8D678AE6C5C1C1" xlink:to="lab_dei_EntityCentralIndexKey_9B1E7C78283273ED0D8D678AE6C5C1C1" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9C79E1F3350161516D48678AE6C5B506_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_9C79E1F3350161516D48678AE6C5B506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9C79E1F3350161516D48678AE6C5B506_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_9C79E1F3350161516D48678AE6C5B506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9C79E1F3350161516D48678AE6C5B506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_9C79E1F3350161516D48678AE6C5B506" xlink:to="lab_dei_CurrentFiscalYearEndDate_9C79E1F3350161516D48678AE6C5B506" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_D95B404E8FFA0069D5E166052FA11597_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_D95B404E8FFA0069D5E166052FA11597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in Restricted cash, current portion</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_D95B404E8FFA0069D5E166052FA11597_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_D95B404E8FFA0069D5E166052FA11597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_D95B404E8FFA0069D5E166052FA11597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_D95B404E8FFA0069D5E166052FA11597" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_D95B404E8FFA0069D5E166052FA11597" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_33F281434CF8B8B5A45C66052FA1F129_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_33F281434CF8B8B5A45C66052FA1F129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_33F281434CF8B8B5A45C66052FA1F129_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_33F281434CF8B8B5A45C66052FA1F129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_33F281434CF8B8B5A45C66052FA1F129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_33F281434CF8B8B5A45C66052FA1F129" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_33F281434CF8B8B5A45C66052FA1F129" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1CD1E817741C5491CCA166052FA17A8C_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1CD1E817741C5491CCA166052FA17A8C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1CD1E817741C5491CCA166052FA17A8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1CD1E817741C5491CCA166052FA17A8C" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1CD1E817741C5491CCA166052FA17A8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_8840E81982B376BFB93A66052FA16680_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_8840E81982B376BFB93A66052FA16680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of credit established as a deposit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_8840E81982B376BFB93A66052FA16680_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_8840E81982B376BFB93A66052FA16680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_8840E81982B376BFB93A66052FA16680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount_8840E81982B376BFB93A66052FA16680" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount_8840E81982B376BFB93A66052FA16680" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_489A3FB451F70FCC810065CF65DFA5F4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_489A3FB451F70FCC810065CF65DFA5F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized losses of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_489A3FB451F70FCC810065CF65DFA5F4_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_489A3FB451F70FCC810065CF65DFA5F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_489A3FB451F70FCC810065CF65DFA5F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_489A3FB451F70FCC810065CF65DFA5F4" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_489A3FB451F70FCC810065CF65DFA5F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_DC3E237C3478AD3979D1653E0EA801F8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_DC3E237C3478AD3979D1653E0EA801F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporarily impaired investments</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_DC3E237C3478AD3979D1653E0EA801F8_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_DC3E237C3478AD3979D1653E0EA801F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_DC3E237C3478AD3979D1653E0EA801F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_DC3E237C3478AD3979D1653E0EA801F8" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_DC3E237C3478AD3979D1653E0EA801F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7294714B4301B0929AE24EB5DB8461A6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7294714B4301B0929AE24EB5DB8461A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7294714B4301B0929AE24EB5DB8461A6_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7294714B4301B0929AE24EB5DB8461A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7294714B4301B0929AE24EB5DB8461A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7294714B4301B0929AE24EB5DB8461A6" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7294714B4301B0929AE24EB5DB8461A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_2031B3B247EC26C2F84864F2CABCDEEF_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_2031B3B247EC26C2F84864F2CABCDEEF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest, beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_2031B3B247EC26C2F84864F2CABCDEEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_2031B3B247EC26C2F84864F2CABCDEEF" xlink:to="lab_us-gaap_MinorityInterest_2031B3B247EC26C2F84864F2CABCDEEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_27CB15FD84A5971C61BA6560CF244CA4_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_27CB15FD84A5971C61BA6560CF244CA4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest at Acquisition Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_27CB15FD84A5971C61BA6560CF244CA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_27CB15FD84A5971C61BA6560CF244CA4" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_27CB15FD84A5971C61BA6560CF244CA4" xlink:type="arc" />
    <link:label id="lab_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA_negatedLabel_en-US" xlink:label="lab_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares acquired post acquisition</link:label>
    <link:label id="lab_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA_label_en-US" xlink:label="lab_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post Business Acquisition Shares Acquired Amount</link:label>
    <link:label id="lab_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA_documentation_en-US" xlink:label="lab_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post business acquisition shares acquired amount.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PostBusinessAcquisitionSharesAcquiredAmount" xlink:label="loc_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA" xlink:to="lab_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_195D709908A25FAFD60264F2CABD59B5_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_195D709908A25FAFD60264F2CABD59B5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest of acquired entity</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_195D709908A25FAFD60264F2CABD59B5_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_195D709908A25FAFD60264F2CABD59B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_195D709908A25FAFD60264F2CABD59B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_195D709908A25FAFD60264F2CABD59B5" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_195D709908A25FAFD60264F2CABD59B5" xlink:type="arc" />
    <link:label id="lab_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7_negatedTerseLabel_en-US" xlink:label="lab_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency effect</link:label>
    <link:label id="lab_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7_label_en-US" xlink:label="lab_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest Increase Decrease From Foreign Currency Effect</link:label>
    <link:label id="lab_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7_documentation_en-US" xlink:label="lab_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase decrease from foreign currency effect.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect" xlink:label="loc_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7" xlink:to="lab_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_534D8D0C909C483C422564F2CABD4708_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_534D8D0C909C483C422564F2CABD4708" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_534D8D0C909C483C422564F2CABD4708_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_534D8D0C909C483C422564F2CABD4708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_534D8D0C909C483C422564F2CABD4708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_534D8D0C909C483C422564F2CABD4708" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_534D8D0C909C483C422564F2CABD4708" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_9452F95651B764C8BAFD64F2CABDCB41_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_9452F95651B764C8BAFD64F2CABDCB41" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_9452F95651B764C8BAFD64F2CABDCB41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_9452F95651B764C8BAFD64F2CABDCB41" xlink:to="lab_us-gaap_MinorityInterest_9452F95651B764C8BAFD64F2CABDCB41" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5B85D21676A40F62357962681966A48C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5B85D21676A40F62357962681966A48C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nine months ending December 31, 2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5B85D21676A40F62357962681966A48C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5B85D21676A40F62357962681966A48C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5B85D21676A40F62357962681966A48C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5B85D21676A40F62357962681966A48C" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5B85D21676A40F62357962681966A48C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20C9379B686B216E86596268196639FF_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20C9379B686B216E86596268196639FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20C9379B686B216E86596268196639FF_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20C9379B686B216E86596268196639FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20C9379B686B216E86596268196639FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20C9379B686B216E86596268196639FF" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20C9379B686B216E86596268196639FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_BE4127D7ED8D7531F08B626819666888_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_BE4127D7ED8D7531F08B626819666888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_BE4127D7ED8D7531F08B626819666888_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_BE4127D7ED8D7531F08B626819666888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_BE4127D7ED8D7531F08B626819666888" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_BE4127D7ED8D7531F08B626819666888" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_BE4127D7ED8D7531F08B626819666888" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C106F4DFF00AAB0CE9C1626819664808_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C106F4DFF00AAB0CE9C1626819664808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C106F4DFF00AAB0CE9C1626819664808_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C106F4DFF00AAB0CE9C1626819664808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C106F4DFF00AAB0CE9C1626819664808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C106F4DFF00AAB0CE9C1626819664808" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C106F4DFF00AAB0CE9C1626819664808" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_C8775DA16EC72CF0122D62681966683A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_C8775DA16EC72CF0122D62681966683A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_C8775DA16EC72CF0122D62681966683A_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_C8775DA16EC72CF0122D62681966683A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_C8775DA16EC72CF0122D62681966683A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_C8775DA16EC72CF0122D62681966683A" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_C8775DA16EC72CF0122D62681966683A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_891632E8DF77A685714B62681967A8C4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_891632E8DF77A685714B62681967A8C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_891632E8DF77A685714B62681967A8C4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_891632E8DF77A685714B62681967A8C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_891632E8DF77A685714B62681967A8C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_891632E8DF77A685714B62681967A8C4" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_891632E8DF77A685714B62681967A8C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_984F7157676679D1BEC262681967152A_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_984F7157676679D1BEC262681967152A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_984F7157676679D1BEC262681967152A_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_984F7157676679D1BEC262681967152A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_984F7157676679D1BEC262681967152A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_984F7157676679D1BEC262681967152A" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_984F7157676679D1BEC262681967152A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0C30CB30D9FB0C8557C962681967EBA1_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0C30CB30D9FB0C8557C962681967EBA1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0C30CB30D9FB0C8557C962681967EBA1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0C30CB30D9FB0C8557C962681967EBA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0C30CB30D9FB0C8557C962681967EBA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0C30CB30D9FB0C8557C962681967EBA1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0C30CB30D9FB0C8557C962681967EBA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8D5009205D4C9331D288626819670A6D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_8D5009205D4C9331D288626819670A6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8D5009205D4C9331D288626819670A6D_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_8D5009205D4C9331D288626819670A6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_8D5009205D4C9331D288626819670A6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_8D5009205D4C9331D288626819670A6D" xlink:to="lab_us-gaap_OperatingLeaseLiability_8D5009205D4C9331D288626819670A6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_EECDD24A39D43C120D8562681967A4C1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_EECDD24A39D43C120D8562681967A4C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheet)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_EECDD24A39D43C120D8562681967A4C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_EECDD24A39D43C120D8562681967A4C1" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_EECDD24A39D43C120D8562681967A4C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5EDA6DA9D1B3B5939F1362681967B1E6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_5EDA6DA9D1B3B5939F1362681967B1E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5EDA6DA9D1B3B5939F1362681967B1E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_5EDA6DA9D1B3B5939F1362681967B1E6" xlink:to="lab_us-gaap_OperatingLeaseLiability_5EDA6DA9D1B3B5939F1362681967B1E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F412313976898BC26FBC11A3745582B7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F412313976898BC26FBC11A3745582B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers, Partnerships and Strategic Alliances</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F412313976898BC26FBC11A3745582B7_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F412313976898BC26FBC11A3745582B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_F412313976898BC26FBC11A3745582B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_F412313976898BC26FBC11A3745582B7" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F412313976898BC26FBC11A3745582B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_16A1B33F93CBC563B98E11A374842AAD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_16A1B33F93CBC563B98E11A374842AAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_16A1B33F93CBC563B98E11A374842AAD_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_16A1B33F93CBC563B98E11A374842AAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_16A1B33F93CBC563B98E11A374842AAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_16A1B33F93CBC563B98E11A374842AAD" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_16A1B33F93CBC563B98E11A374842AAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_149F984C7AE0BC8E14E711A374841723_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_149F984C7AE0BC8E14E711A374841723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Estimated Fair Value of Free Shares Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_149F984C7AE0BC8E14E711A374841723_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_149F984C7AE0BC8E14E711A374841723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_149F984C7AE0BC8E14E711A374841723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_149F984C7AE0BC8E14E711A374841723" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_149F984C7AE0BC8E14E711A374841723" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_30C5A960C274CF4AD84D11A374A37EC7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_30C5A960C274CF4AD84D11A374A37EC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_30C5A960C274CF4AD84D11A374A37EC7_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_30C5A960C274CF4AD84D11A374A37EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_30C5A960C274CF4AD84D11A374A37EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_30C5A960C274CF4AD84D11A374A37EC7" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_30C5A960C274CF4AD84D11A374A37EC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C1BC2B2BEC963DC470C04EB5DB6D79C9_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C1BC2B2BEC963DC470C04EB5DB6D79C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C1BC2B2BEC963DC470C04EB5DB6D79C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C1BC2B2BEC963DC470C04EB5DB6D79C9" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C1BC2B2BEC963DC470C04EB5DB6D79C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3C104BE9019F1D821B414EB5DB6D415F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3C104BE9019F1D821B414EB5DB6D415F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3C104BE9019F1D821B414EB5DB6D415F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3C104BE9019F1D821B414EB5DB6D415F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3C104BE9019F1D821B414EB5DB6D415F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3C104BE9019F1D821B414EB5DB6D415F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3C104BE9019F1D821B414EB5DB6D415F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E3726C83EE795D7071F24EB5DB6EE247_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E3726C83EE795D7071F24EB5DB6EE247" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E3726C83EE795D7071F24EB5DB6EE247_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E3726C83EE795D7071F24EB5DB6EE247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E3726C83EE795D7071F24EB5DB6EE247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E3726C83EE795D7071F24EB5DB6EE247" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E3726C83EE795D7071F24EB5DB6EE247" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_FCA26022A244AA8E187C4EB5DB6EFEF8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_FCA26022A244AA8E187C4EB5DB6EFEF8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_FCA26022A244AA8E187C4EB5DB6EFEF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_FCA26022A244AA8E187C4EB5DB6EFEF8" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_FCA26022A244AA8E187C4EB5DB6EFEF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:to="lab_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85" xlink:to="lab_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9E0D4F5A72D4CE3B3C4C64F2857FD243_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_9E0D4F5A72D4CE3B3C4C64F2857FD243" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9E0D4F5A72D4CE3B3C4C64F2857FD243_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_9E0D4F5A72D4CE3B3C4C64F2857FD243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9E0D4F5A72D4CE3B3C4C64F2857FD243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_9E0D4F5A72D4CE3B3C4C64F2857FD243" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_9E0D4F5A72D4CE3B3C4C64F2857FD243" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_D0800BD7E49F514EFE6764F2857F711F_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_D0800BD7E49F514EFE6764F2857F711F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_D0800BD7E49F514EFE6764F2857F711F_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_D0800BD7E49F514EFE6764F2857F711F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_D0800BD7E49F514EFE6764F2857F711F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_D0800BD7E49F514EFE6764F2857F711F" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_D0800BD7E49F514EFE6764F2857F711F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_74DA7480D3B025A04BCC64F2857FC8BD_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_74DA7480D3B025A04BCC64F2857FC8BD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_74DA7480D3B025A04BCC64F2857FC8BD_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_74DA7480D3B025A04BCC64F2857FC8BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_74DA7480D3B025A04BCC64F2857FC8BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_74DA7480D3B025A04BCC64F2857FC8BD" xlink:to="lab_us-gaap_OperatingExpenses_74DA7480D3B025A04BCC64F2857FC8BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_74E03AC6D303ED29A40F64F2857FBB80_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_74E03AC6D303ED29A40F64F2857FBB80" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_74E03AC6D303ED29A40F64F2857FBB80_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_74E03AC6D303ED29A40F64F2857FBB80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_74E03AC6D303ED29A40F64F2857FBB80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_74E03AC6D303ED29A40F64F2857FBB80" xlink:to="lab_us-gaap_OperatingIncomeLoss_74E03AC6D303ED29A40F64F2857FBB80" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestAndOtherIncome_4274D889489B30DF8C7864F2857F79D2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome_4274D889489B30DF8C7864F2857F79D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_4274D889489B30DF8C7864F2857F79D2_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome_4274D889489B30DF8C7864F2857F79D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_4274D889489B30DF8C7864F2857F79D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome_4274D889489B30DF8C7864F2857F79D2" xlink:to="lab_us-gaap_InterestAndOtherIncome_4274D889489B30DF8C7864F2857F79D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_DFBAB60BCA91583DE63364F2857FFC25_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_DFBAB60BCA91583DE63364F2857FFC25" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_DFBAB60BCA91583DE63364F2857FFC25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_DFBAB60BCA91583DE63364F2857FFC25" xlink:to="lab_us-gaap_ProfitLoss_DFBAB60BCA91583DE63364F2857FFC25" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B40FD366EFE48C95E4DC64F2857FF160_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B40FD366EFE48C95E4DC64F2857FF160" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B40FD366EFE48C95E4DC64F2857FF160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B40FD366EFE48C95E4DC64F2857FF160" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B40FD366EFE48C95E4DC64F2857FF160" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_3A0EDCE973777052862F64F2857FCBA2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3A0EDCE973777052862F64F2857FCBA2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss to Sangamo Therapeutics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3A0EDCE973777052862F64F2857FCBA2_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3A0EDCE973777052862F64F2857FCBA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3A0EDCE973777052862F64F2857FCBA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_3A0EDCE973777052862F64F2857FCBA2" xlink:to="lab_us-gaap_NetIncomeLoss_3A0EDCE973777052862F64F2857FCBA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_2FCC99B29F4DB19DE39D64F2857FB98E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_2FCC99B29F4DB19DE39D64F2857FB98E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_2FCC99B29F4DB19DE39D64F2857FB98E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_2FCC99B29F4DB19DE39D64F2857FB98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2FCC99B29F4DB19DE39D64F2857FB98E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_2FCC99B29F4DB19DE39D64F2857FB98E" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_2FCC99B29F4DB19DE39D64F2857FB98E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4CDC68C46A679DAD125264F2857FC90F_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4CDC68C46A679DAD125264F2857FC90F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4CDC68C46A679DAD125264F2857FC90F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4CDC68C46A679DAD125264F2857FC90F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4CDC68C46A679DAD125264F2857FC90F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4CDC68C46A679DAD125264F2857FC90F" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4CDC68C46A679DAD125264F2857FC90F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:type="arc" />
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At the market offering agreement.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AtTheMarketOfferingAgreementMember" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A" xlink:to="lab_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering price of common stock issued (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028" xlink:type="arc" />
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518_verboseLabel_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock, after deducting offering expenses</link:label>
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518_label_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Issuance Public Offering</link:label>
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518_documentation_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance public offering.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518" xlink:to="lab_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518" xlink:type="arc" />
    <link:label id="lab_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855_terseLabel_en-US" xlink:label="lab_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issuable and sellable under offering agreement</link:label>
    <link:label id="lab_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855_label_en-US" xlink:label="lab_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label id="lab_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855_documentation_en-US" xlink:label="lab_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock capital shares value reserved for future issuance.</link:label>
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:label="loc_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855" xlink:to="lab_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_422431260CAC25E86B7811A3196D453D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_422431260CAC25E86B7811A3196D453D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_422431260CAC25E86B7811A3196D453D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_422431260CAC25E86B7811A3196D453D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_422431260CAC25E86B7811A3196D453D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_422431260CAC25E86B7811A3196D453D" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_422431260CAC25E86B7811A3196D453D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1ED86DC22458F5D90DA54EB5DB816825_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1ED86DC22458F5D90DA54EB5DB816825" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1ED86DC22458F5D90DA54EB5DB816825_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1ED86DC22458F5D90DA54EB5DB816825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1ED86DC22458F5D90DA54EB5DB816825" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1ED86DC22458F5D90DA54EB5DB816825" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1ED86DC22458F5D90DA54EB5DB816825" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_E56A6E4967947EB98D794EB5DB826FB9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_E56A6E4967947EB98D794EB5DB826FB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_E56A6E4967947EB98D794EB5DB826FB9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_E56A6E4967947EB98D794EB5DB826FB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_E56A6E4967947EB98D794EB5DB826FB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_E56A6E4967947EB98D794EB5DB826FB9" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_E56A6E4967947EB98D794EB5DB826FB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_B71D22CAFE3AF1980ADD4EB5DB8277C5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_B71D22CAFE3AF1980ADD4EB5DB8277C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_B71D22CAFE3AF1980ADD4EB5DB8277C5_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_B71D22CAFE3AF1980ADD4EB5DB8277C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_B71D22CAFE3AF1980ADD4EB5DB8277C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock_B71D22CAFE3AF1980ADD4EB5DB8277C5" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock_B71D22CAFE3AF1980ADD4EB5DB8277C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4F2EC9155E5A11734E834EB5DB8227B4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4F2EC9155E5A11734E834EB5DB8227B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4F2EC9155E5A11734E834EB5DB8227B4_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4F2EC9155E5A11734E834EB5DB8227B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4F2EC9155E5A11734E834EB5DB8227B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4F2EC9155E5A11734E834EB5DB8227B4" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4F2EC9155E5A11734E834EB5DB8227B4" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sgmo-20190630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSA" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSA" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSAAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionOfTxcellSATables" xlink:href="sgmo-20190630.xsd#AcquisitionOfTxcellSATables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShare" xlink:href="sgmo-20190630.xsd#BasicAndDilutedNetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#BasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecurities" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CashAndMarketableSecuritiesTables" xlink:href="sgmo-20190630.xsd#CashAndMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingencies" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsAndContingenciesTables" xlink:href="sgmo-20190630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="sgmo-20190630.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:href="sgmo-20190630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurements" xlink:href="sgmo-20190630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementsTables" xlink:href="sgmo-20190630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxes" xlink:href="sgmo-20190630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliances" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:href="sgmo-20190630.xsd#MajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="sgmo-20190630.xsd#OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensation" xlink:href="sgmo-20190630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="sgmo-20190630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:href="sgmo-20190630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquity" xlink:href="sgmo-20190630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEvents" xlink:href="sgmo-20190630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail" xlink:href="sgmo-20190630.xsd#SubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSA" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3B1781B26601B149E7C911A373FC7826" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9798A77E81839225F8F411A373FCC902" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3B1781B26601B149E7C911A373FC7826" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9798A77E81839225F8F411A373FCC902" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_CF1029370926AA3625D664F2CAEB154B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_CF1029370926AA3625D664F2CAEB154B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E43612ACF0473BAD0F6A64F2CAEB1FF5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_TxCellSAMember" xlink:label="loc_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AA4A3C11D6D116A4135264F2CAEB3153" xlink:to="loc_sgmo_TxCellSAMember_43B5B6998533EA595C2C64F2CAEBC4BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6256E3061416695DD3EC64F2CAEBA693" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_982ACB4AF69E2D769B2064F2CAEBE5C0" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SharePurchaseAgreementMember" xlink:label="loc_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_244E560922E6D13666CB64F2CAEBCC7F" xlink:to="loc_sgmo_SharePurchaseAgreementMember_855EADD9CF9251BACE1564F2CAEB36E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:to="loc_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_AE32A3A220A951923E4064F2CAEB6492" xlink:to="loc_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FA9FF7AE6B8706D59D8664F2CAEBEB7C" xlink:to="loc_srt_MinimumMember_2F4798587DFEDEFAFF4264F2CAEBC05C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:to="loc_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_E4EFA22459821E04178564F2CAEBC85E" xlink:to="loc_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_AFB114A6FA722339D52D64F2CAEB88DE" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_5A5F54B66EF8817DDFCE64F2CAEB01F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DCDCF76EC64EE991285364F2CAEB0CA1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_41BF86E528D3F8A62AE264F2CAEB46B7" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_78DDC11BC5BE756424D864F2CAEBDEF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9D2FF851AC33DA809F4D64F2CAEBB6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_6E4C851AEA32D18DB43964F2CAEBFFC1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction_D2D3E931AE7C0B9C6D4164F2CAEBF120" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_5C36DA111F3D9C9BBBBC64F2CAEB05F8" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice" xlink:label="loc_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice_9B257FDC90FC81B7C0D264F2CAEB0CB2" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_F322C863E14BF51C97DA64F2CAEB6CC8" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_BF9361B75325EBD4087564F2CAEB8C89" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration" xlink:label="loc_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration_A952D00D15EAB236247E64F2CAEBFFD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8BF34F773FA851C631B364F2CAEBF301" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares_BE7752A19116BC55336964F2CAEBC722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_D2F4B2D48E57B8342EA164F2CAEB7939" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests" xlink:label="loc_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests_8E5F3014C6ABC156CF6564F2CAEBDBEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_8FC78B421D3C38FED76864F2CAEBAA3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9E95EF73D4478529373864F2CAEB0316" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9E95EF73D4478529373864F2CAEB0316" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction" xlink:label="loc_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_01FBF3D6B67E85F380D264F2CAEBCF8F" xlink:to="loc_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction_D131E819CBD2CBBDB9D564F2CAEB00DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_E10C23202111934FA5E211A373ED77F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_384C5B51B2F2FECAE1FA11A373ED0EAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_E10C23202111934FA5E211A373ED77F9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_384C5B51B2F2FECAE1FA11A373ED0EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_34B8B5E26F84548F860411A373ED16B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_384C5B51B2F2FECAE1FA11A373ED0EAB" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_34B8B5E26F84548F860411A373ED16B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBFBB66872EC0C155B7B11A373EDBF2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_34B8B5E26F84548F860411A373ED16B2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBFBB66872EC0C155B7B11A373EDBF2E" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_TxCellSAMember" xlink:label="loc_sgmo_TxCellSAMember_6A77867070EA0E04F8FE11A373EDBF22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBFBB66872EC0C155B7B11A373EDBF2E" xlink:to="loc_sgmo_TxCellSAMember_6A77867070EA0E04F8FE11A373EDBF22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_384C5B51B2F2FECAE1FA11A373ED0EAB" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_430D85889C666AC8392D11A373ED87F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_430D85889C666AC8392D11A373ED87F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_F528474F0A802CAC440611A373ED302C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_E78B63531D9006DF05CE11A373ED4B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_D49FF2A1E0BB4EE09A7A11A373ED361C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4F82C8774B589BB1E5E911A373ED0541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_E5FE80E35D989043E35511A373ED400B" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_F9EBFFA3119CBA90A7D611A373EDE730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_E113C247A577365ED88711A373ED872E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_82502CD52C360C665D3C11A373EDF7EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75CA6B8B425BA3F14F5D11A373ED8FF5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75CA6B8B425BA3F14F5D11A373ED8FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_439D56A27ED953037E2B11A373EDBCEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92D7D9978108483BF2F11A373EDDAE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5A1B28C3067D75EFF2EB11A373EDE487" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_Goodwill_5A1B28C3067D75EFF2EB11A373EDE487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_89244B6F3B5847D95BAA11A373ED2112" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C62167E2E764919566E11A373ED92B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_89244B6F3B5847D95BAA11A373ED2112" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_541DE934F653EF8CD6E164F2CABCC6E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_541DE934F653EF8CD6E164F2CABCC6E0" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_2031B3B247EC26C2F84864F2CABCDEEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:to="loc_us-gaap_MinorityInterest_2031B3B247EC26C2F84864F2CABCDEEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_27CB15FD84A5971C61BA6560CF244CA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_27CB15FD84A5971C61BA6560CF244CA4" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PostBusinessAcquisitionSharesAcquiredAmount" xlink:label="loc_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:to="loc_sgmo_PostBusinessAcquisitionSharesAcquiredAmount_955CB3CA0EE31DD1522464F2CABDA6EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_195D709908A25FAFD60264F2CABD59B5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_195D709908A25FAFD60264F2CABD59B5" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect" xlink:label="loc_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:to="loc_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect_2C45AB20CC8FF6D39AE664F2CABD0BA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_534D8D0C909C483C422564F2CABD4708" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_534D8D0C909C483C422564F2CABD4708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_9452F95651B764C8BAFD64F2CABDCB41" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_D1EB5604320BCFF5B408655AE712A81F" xlink:to="loc_us-gaap_MinorityInterest_9452F95651B764C8BAFD64F2CABDCB41" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionOfTxcellSATables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_002440CEA2B51FC131BC11A373FC462C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_F58B78F31FD7AB2CACE911A373FC7E8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_002440CEA2B51FC131BC11A373FC462C" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_F58B78F31FD7AB2CACE911A373FC7E8C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_002440CEA2B51FC131BC11A373FC462C" xlink:to="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_C6B12A89C450C33D8CEF11A373FC9E82" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2FB954505B5053CE8F6B11A374550E29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_046B5F349BBF0325263911A374550483" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2FB954505B5053CE8F6B11A374550E29" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_046B5F349BBF0325263911A374550483" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BasicAndDilutedNetLossPerShareAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_82A54FB410E995AD21A311A3745578F1" xlink:type="locator" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_82A54FB410E995AD21A311A3745578F1" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0B0722AA97D4F428DDD611A37455CD85" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecurities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DCD66858A4E6AD8AAACC4EB5DB841AC5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7294714B4301B0929AE24EB5DB8461A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DCD66858A4E6AD8AAACC4EB5DB841AC5" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7294714B4301B0929AE24EB5DB8461A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_42C4668EBE3FA831AE7964F2CBC60844" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_489A3FB451F70FCC810065CF65DFA5F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_42C4668EBE3FA831AE7964F2CBC60844" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_489A3FB451F70FCC810065CF65DFA5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_DC3E237C3478AD3979D1653E0EA801F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_42C4668EBE3FA831AE7964F2CBC60844" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_DC3E237C3478AD3979D1653E0EA801F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_597322F32272CF0A060766052FA03B9F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83BA73986C69B213CCE666052FA0B4A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597322F32272CF0A060766052FA03B9F" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83BA73986C69B213CCE666052FA0B4A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_D95B404E8FFA0069D5E166052FA11597" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597322F32272CF0A060766052FA03B9F" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_D95B404E8FFA0069D5E166052FA11597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_33F281434CF8B8B5A45C66052FA1F129" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597322F32272CF0A060766052FA03B9F" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_33F281434CF8B8B5A45C66052FA1F129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1CD1E817741C5491CCA166052FA17A8C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597322F32272CF0A060766052FA03B9F" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1CD1E817741C5491CCA166052FA17A8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_8840E81982B376BFB93A66052FA16680" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_597322F32272CF0A060766052FA03B9F" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_8840E81982B376BFB93A66052FA16680" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D2DB52EB3974896345D64F2CBF58B94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7DCC3BBF4B1B694C188364F2CBF511ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D2DB52EB3974896345D64F2CBF58B94" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7DCC3BBF4B1B694C188364F2CBF511ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_73B7C587FBE42BC84B7C64F2CBF508EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7DCC3BBF4B1B694C188364F2CBF511ED" xlink:to="loc_us-gaap_FinancialInstrumentAxis_73B7C587FBE42BC84B7C64F2CBF508EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_73B7C587FBE42BC84B7C64F2CBF508EA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5092C99CDE2243A0B0E164F2CBF56F9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5092C99CDE2243A0B0E164F2CBF56F9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_28176D3569B0664D774E64F2CBF5B7D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:to="loc_us-gaap_CommercialPaperMember_28176D3569B0664D774E64F2CBF5B7D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:to="loc_us-gaap_CashEquivalentsMember_CC08B109F7E66248E7DC64F2CBF5E4FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_893F141AB85C59A2A2F564F2CBF51DAF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_893F141AB85C59A2A2F564F2CBF51DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6D819C4507531E80CBD264F2CBF5DEC5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E28397D030BA1FC4CE1564F2CBF572CF" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6D819C4507531E80CBD264F2CBF5DEC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7DCC3BBF4B1B694C188364F2CBF511ED" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_21D1D6D27B37FEA4437564F2CBF567A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_21D1D6D27B37FEA4437564F2CBF567A4" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_C33018894AD1FF33298264F2CBF58125" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_E16FFFE6614ED9F5932B64F2CBF56FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3E7BC0D6456F95A79B3464F2CBF5EBD2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3E7BC0D6456F95A79B3464F2CBF5EBD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_A2051139E5C0EB4062DF64F2CBF50898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B10BCE88B76D44E4AB1864F2CBF53CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C8C9119709D8C8A546C664F2CBF51877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B6A4E95511C42513386B64F2CBF58FFB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_B6A4E95511C42513386B64F2CBF58FFB" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2C70A7696F68511EC3D464F2CBF589B1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_5FEFFE2DF331455C090864F2CBF5BCBD" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_D49726FE95FE0A18878F64F2CBF58977" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_71B7DDFC2C26A5D5C90964F2CBF5C420" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3038ECEC47F2EE64E43764F2CBF51436" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C1BC2B2BEC963DC470C04EB5DB6D79C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3C104BE9019F1D821B414EB5DB6D415F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C1BC2B2BEC963DC470C04EB5DB6D79C9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3C104BE9019F1D821B414EB5DB6D415F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E3726C83EE795D7071F24EB5DB6EE247" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C1BC2B2BEC963DC470C04EB5DB6D79C9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E3726C83EE795D7071F24EB5DB6EE247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_FCA26022A244AA8E187C4EB5DB6EFEF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_C1BC2B2BEC963DC470C04EB5DB6D79C9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_FCA26022A244AA8E187C4EB5DB6EFEF8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashAndMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BA5ECF810374A21DD7074EB5DB81A5A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1ED86DC22458F5D90DA54EB5DB816825" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BA5ECF810374A21DD7074EB5DB81A5A2" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1ED86DC22458F5D90DA54EB5DB816825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_E56A6E4967947EB98D794EB5DB826FB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BA5ECF810374A21DD7074EB5DB81A5A2" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_E56A6E4967947EB98D794EB5DB826FB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_B71D22CAFE3AF1980ADD4EB5DB8277C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BA5ECF810374A21DD7074EB5DB81A5A2" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_B71D22CAFE3AF1980ADD4EB5DB8277C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4F2EC9155E5A11734E834EB5DB8227B4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_BA5ECF810374A21DD7074EB5DB81A5A2" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4F2EC9155E5A11734E834EB5DB8227B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D709060FE21F0EF86ADB11A3742B9D93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_860EB98DD912E47EB2B211A3742BA864" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D709060FE21F0EF86ADB11A3742B9D93" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_860EB98DD912E47EB2B211A3742BA864" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5BF86CD169A3589426A164F2CB4968D9" xlink:type="locator" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommitmentsAndContingenciesTable" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5BF86CD169A3589426A164F2CB4968D9" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_DA61F91531D75689698764F2CB492193" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_RichmondLeaseMember" xlink:label="loc_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:to="loc_sgmo_RichmondLeaseMember_188FE8D6C95C14FA24E064F2CB49FF7D" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ValbonneLeaseMember" xlink:label="loc_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:to="loc_sgmo_ValbonneLeaseMember_B7FCC89635E2EDCFC67464F2CB49DEE1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_RichmondAndValbonneLeasesMember" xlink:label="loc_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:to="loc_sgmo_RichmondAndValbonneLeasesMember_7FC445291E93277CDA2264F2CB49030B" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BrisbaneLeaseMember" xlink:label="loc_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_D3E40FCD41CF1F4DC76C64F2CB495B28" xlink:to="loc_sgmo_BrisbaneLeaseMember_D3B7FCD4EB329BBBA01364F2CB49619A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_77145F11F4D4D1AB6E8564F2CB496431" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:to="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_91475D0688CCDF0A244464F2CB497F41" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PropertySubjectToOperatingLeaseTwoMember" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_A49B9610CE0F92ED99B264F2CB49EA9B" xlink:to="loc_sgmo_PropertySubjectToOperatingLeaseTwoMember_45A12885079BEB6EC4AD64F2CB581731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08DEB3BD62CD56FCB7BB64F2CB58C23B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OfficeAndLaboratoryMember" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_A6510BE3C4A05B3B480B64F2CB58EE0E" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ResearchAndOfficeSpaceMember" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_038584ED2B793E27923D64F2CB584A8A" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OfficeSpaceMember" xlink:label="loc_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6FFB605D49D777279DE464F2CB58CACD" xlink:to="loc_sgmo_OfficeSpaceMember_64CD6AB44BFBA8FEDF4A64F2CB580919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_80D8AD56615511EA034864F2CB584719" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:to="loc_srt_RangeAxis_80D8AD56615511EA034864F2CB584719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_49894993416014825C2264F2CB58271F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_80D8AD56615511EA034864F2CB584719" xlink:to="loc_srt_RangeMember_49894993416014825C2264F2CB58271F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F9898F73FBA45678633B64F2CB58FC39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49894993416014825C2264F2CB58271F" xlink:to="loc_srt_MinimumMember_F9898F73FBA45678633B64F2CB58FC39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49894993416014825C2264F2CB58271F" xlink:to="loc_srt_MaximumMember_3981B401388AC374C48E64F2CB5860CB" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommitmentsAndContingenciesLineItems" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_2E819656029A4B9F5A1964F2CB49253F" xlink:to="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_3CC62CFCB414A39A9F3864F2CB580D42" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LesseeOperatingLeaseNumberOfContracts" xlink:label="loc_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_LesseeOperatingLeaseNumberOfContracts_CB91518734EC5D5ED24665D6951C8CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_LeaseExpirationDate1_DF1465214E811303928964F2CB5885A0" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LeaseCommencementDate" xlink:label="loc_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_LeaseCommencementDate_AAA69E65BA198C3C7DE964F2CB5878B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9A41E2D88EF9EB9E78B064F2CB583F30" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommencementLandSubjectToGroundLeases" xlink:label="loc_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_CommencementLandSubjectToGroundLeases_D525892080895F68FE9D64F2CB5869FD" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LeaseCommencementPeriod" xlink:label="loc_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_LeaseCommencementPeriod_FCC92945FDAAFFF8DDDB64F2CB584E2C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_RemainingCommencementLandSubjectToGroundLeases" xlink:label="loc_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_RemainingCommencementLandSubjectToGroundLeases_7F40EACF6A3130DE075C64F2CB581850" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ExpectedLeaseCommencementPeriod" xlink:label="loc_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_ExpectedLeaseCommencementPeriod_678A88DE731634EA2E5664F2CB58B3D8" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_EE08FE7DCECEC39CFCD064F2CB5889E2" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance_52A4014260B1B615A4DC64F2CB5874FE" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OperatingLeasesNumberOfExtensionOptions" xlink:label="loc_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_sgmo_OperatingLeasesNumberOfExtensionOptions_63C623359C33787E5BB664F2CB58BA41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_OperatingLeaseCost_5C068AC2A5B3BF18CAA864F2CB586A4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_EA2B53381C54F723AD4664F2CB58F2EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_VariableLeaseCost_ADA44493FAC561FB4A7364F2CB582CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_OperatingLeasePayments_D86FC0ED78BF8016C6B864F2CB58CC66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_21909ACC828CC298878164F2CB58418F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78A7C50968D9C694C2B364F2CB58C608" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_132C3F7483CF444685B064F2CB58BE87" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_7B4EB7111FD6350FD0B864F2CB58234C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5B85D21676A40F62357962681966A48C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5B85D21676A40F62357962681966A48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20C9379B686B216E86596268196639FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20C9379B686B216E86596268196639FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_BE4127D7ED8D7531F08B626819666888" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_BE4127D7ED8D7531F08B626819666888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C106F4DFF00AAB0CE9C1626819664808" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_C106F4DFF00AAB0CE9C1626819664808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_C8775DA16EC72CF0122D62681966683A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_C8775DA16EC72CF0122D62681966683A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_891632E8DF77A685714B62681967A8C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_891632E8DF77A685714B62681967A8C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_984F7157676679D1BEC262681967152A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_984F7157676679D1BEC262681967152A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0C30CB30D9FB0C8557C962681967EBA1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0C30CB30D9FB0C8557C962681967EBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_8D5009205D4C9331D288626819670A6D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_OperatingLeaseLiability_8D5009205D4C9331D288626819670A6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_EECDD24A39D43C120D8562681967A4C1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_EECDD24A39D43C120D8562681967A4C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_02EAFB6C978D63E1E69962681967EB07" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_02EAFB6C978D63E1E69962681967EB07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5EDA6DA9D1B3B5939F1362681967B1E6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E1CC64BC2B6E21DE1AEA626819654377" xlink:to="loc_us-gaap_OperatingLeaseLiability_5EDA6DA9D1B3B5939F1362681967B1E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_45B398881D20DFD1928511A3742BCBFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_DE85745DFC64095C97BE11A3742B831F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_45B398881D20DFD1928511A3742BCBFC" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_DE85745DFC64095C97BE11A3742B831F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_985FE8B0789B638A35F064F2CC723C91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_985FE8B0789B638A35F064F2CC723C91" xlink:to="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_512BAC9B6D5EA2E67D4264F2CC720315" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_512BAC9B6D5EA2E67D4264F2CC720315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_D558B9DC981C49B8212064F2CC72811B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:to="loc_us-gaap_RestrictedCashCurrent_D558B9DC981C49B8212064F2CC72811B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6AB8B618053CBD86382364F2CC72235E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6AB8B618053CBD86382364F2CC72235E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_009979397F09B449817864F2CC72F723" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:to="loc_us-gaap_InterestReceivableCurrent_009979397F09B449817864F2CC72F723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_E43FE34A09910DA20FC564F2CC727D62" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_E43FE34A09910DA20FC564F2CC727D62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_F7712C504FF336695F0364F2CC724E2A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_F7712C504FF336695F0364F2CC724E2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_439164741AFD743F7DC364F2CC72A7BB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DFCF6EAD363D6B67093A64F2CC7214A3" xlink:to="loc_us-gaap_AssetsCurrent_439164741AFD743F7DC364F2CC72A7BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BF98E1F94E5E2A4FF1D964F2CC7214B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_BF98E1F94E5E2A4FF1D964F2CC7214B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12D05B691A8CD76E770264F2CC727776" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12D05B691A8CD76E770264F2CC727776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2BACDC7CCD6E71D4860F64F2CC728F7B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2BACDC7CCD6E71D4860F64F2CC728F7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_EF2A2555D5D4C10009FF64F2CC72BD02" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:to="loc_us-gaap_Goodwill_EF2A2555D5D4C10009FF64F2CC72BD02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E51D14293832923DF1C664F2CC72F173" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E51D14293832923DF1C664F2CC72F173" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0F22EC71C641EC456DF064F2CC724175" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0F22EC71C641EC456DF064F2CC724175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_95D1B7B4BC249F4BAF6764F2CC729EBD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_95D1B7B4BC249F4BAF6764F2CC729EBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7EA89C00AB06D661461B64F2CC7277B1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44224BD0F1A708CE702064F2CC72A2E2" xlink:to="loc_us-gaap_Assets_7EA89C00AB06D661461B64F2CC7277B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_985FE8B0789B638A35F064F2CC723C91" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82F31AB7AB8483EC272864F2CC727DAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82F31AB7AB8483EC272864F2CC727DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_A1E189A602064267FAED64F2CC72FDD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_A1E189A602064267FAED64F2CC72FDD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_B9874152D4A365BECF3A64F2CC7245B0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_B9874152D4A365BECF3A64F2CC7245B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_EEB472EF71161E0B4B3964F2CC724710" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B22050D706F57D542CA64F2CC7205D6" xlink:to="loc_us-gaap_LiabilitiesCurrent_EEB472EF71161E0B4B3964F2CC724710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_03925051AA7624D95A4964F2CC72D26E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_03925051AA7624D95A4964F2CC72D26E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8B8B07F0D771AA984F6264F2CC72DC26" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8B8B07F0D771AA984F6264F2CC72DC26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_FA79032265875245304C65CCFEB24FE2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_FA79032265875245304C65CCFEB24FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8ACC434FC801BB8896D364F2CC72FEAE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8ACC434FC801BB8896D364F2CC72FEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_0F214D9D50F7FECD0CD664F2CC729A42" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:to="loc_us-gaap_Liabilities_0F214D9D50F7FECD0CD664F2CC729A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_BB3DF40955778C14AA3464F2CC72A0B7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:to="loc_us-gaap_CommitmentsAndContingencies_BB3DF40955778C14AA3464F2CC72A0B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_E8A3151A7140D89974F664F2CC7276FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:to="loc_us-gaap_PreferredStockValue_E8A3151A7140D89974F664F2CC7276FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_B07BF73CF00869C87F9F64F2CC72F651" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:to="loc_us-gaap_CommonStockValue_B07BF73CF00869C87F9F64F2CC72F651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6F8A25DBFBCBA6A20CC864F2CC722840" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6F8A25DBFBCBA6A20CC864F2CC722840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C4E385C4210154D5CCFA64F2CC72C3E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C4E385C4210154D5CCFA64F2CC72C3E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6F7E1F86DE891A25D5CC64F2CC81DCDA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6F7E1F86DE891A25D5CC64F2CC81DCDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_FC960CE125857990400E64F2CC819B04" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:to="loc_us-gaap_StockholdersEquity_FC960CE125857990400E64F2CC819B04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_FAB899F24A6065A5B20364F2CC819A95" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:to="loc_us-gaap_MinorityInterest_FAB899F24A6065A5B20364F2CC819A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55AAA54935D7D547F94364F2CC81F48A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_38B0B44CFD10AE484CF864F2CC7200D2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55AAA54935D7D547F94364F2CC81F48A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3B99AE45BAC11BEEE34E64F2CC81A0A4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52CAB3AF00B84495E5F964F2CC72855F" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3B99AE45BAC11BEEE34E64F2CC81A0A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_CC3702649DD3BDA9E94464F2CC52F15E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:to="loc_us-gaap_ProfitLoss_CC3702649DD3BDA9E94464F2CC52F15E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5AB434D1C55BCFB625FC64F2CC52F239" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5AB434D1C55BCFB625FC64F2CC52F239" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_AEB6599537E4B9A2823B64F2CC525529" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_AEB6599537E4B9A2823B64F2CC525529" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_GainOnFreeShares" xlink:label="loc_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:to="loc_sgmo_GainOnFreeShares_CB027EF093D1C4EBECAB64F2CC526728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_C21A924C3A485273A35564F2CC522BB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:to="loc_us-gaap_ShareBasedCompensation_C21A924C3A485273A35564F2CC522BB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_AB9AED39695FAA5C9EAF64F2CC52B8BD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_AB9AED39695FAA5C9EAF64F2CC52B8BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7575B7A1EBD17DE8794D64F2CC52D09E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BFF010E86BD61711A1BA64F2CC525A31" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_7575B7A1EBD17DE8794D64F2CC52D09E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_31592A687C64F8E5496764F2CC52CF54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_31592A687C64F8E5496764F2CC52CF54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6433A327354213B6ECE064F2CC5204C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6433A327354213B6ECE064F2CC5204C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C3778CB2E7C33EE5735764F2CC5260A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C3778CB2E7C33EE5735764F2CC5260A6" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:to="loc_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_FFFD4CF28F47A2F7047364F2CC526994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50A9A6F493CC30B923F364F2CC521040" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50A9A6F493CC30B923F364F2CC521040" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7678E5C33D4410A7D1CB64F2CC52ECBA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7678E5C33D4410A7D1CB64F2CC52ECBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_A47A74336E9BE61609FC64F2CC52A48C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_A47A74336E9BE61609FC64F2CC52A48C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8985D7604AE2CCFD3FE564F2CC522DBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_DD3F42DFBB745535618864F2CC520899" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55025D6613F4D63F56F764F2CC521CCE" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_DD3F42DFBB745535618864F2CC520899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3FA3B984572A8B88F8B164F2CC525E49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_02641CA27F1E57D0E8B664F2CC523081" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3FA3B984572A8B88F8B164F2CC525E49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_E040F84DEDD254490AA964F2CC52C55C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_E040F84DEDD254490AA964F2CC52C55C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A438B79379805912AE3E64F2CC52B058" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A438B79379805912AE3E64F2CC52B058" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F084FFCEAEBCC547A32F64F2CC52A81F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F084FFCEAEBCC547A32F64F2CC52A81F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25829258C8D63B9F06AB64F2CC52F0D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1DE2CAAFF36C9807F21F64F2CC52DB2E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25829258C8D63B9F06AB64F2CC52F0D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1E73DE01D832801F5F7364F2CC52DBC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1E73DE01D832801F5F7364F2CC52DBC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E9479FE46FCA34F4177664F2CC5201C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_E9479FE46FCA34F4177664F2CC5201C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_78FDD706F2A5E0F8EBBC64F2CC52ED0E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_78FDD706F2A5E0F8EBBC64F2CC52ED0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0EC2FF77B5982C2EA23A64F2CC525450" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3708D9EF8AB7B86C95F364F2CC52C3C6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0EC2FF77B5982C2EA23A64F2CC525450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01EC577EE6C389F0DDB664F2CC52CDDA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01EC577EE6C389F0DDB664F2CC52CDDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4A930C9B5E7FBB43691164F2CC5250AF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4A930C9B5E7FBB43691164F2CC5250AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_909D4AC251B525946D4B659363E7BF13" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_909D4AC251B525946D4B659363E7BF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F2408E76F66BF4DB39C65942EAA698F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F2408E76F66BF4DB39C65942EAA698F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2A0F2BED1E19F2D77C0764F2CC522BF0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E8F6BF0C0B0C1173727A64F2CC52B675" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E8F6BF0C0B0C1173727A64F2CC52B675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1A6FA17C7891C5F6532164F2CC522599" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1466C9F15951CA31E7FB64F2CC529C48" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1A6FA17C7891C5F6532164F2CC522599" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_02E39730D823C2BC027711A374D24EA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:to="loc_us-gaap_ProfitLoss_02E39730D823C2BC027711A374D24EA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CAE6158D5AD65FC749A511A374D2D563" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CAE6158D5AD65FC749A511A374D2D563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5D0E0E97D94D00F4287811A374D229A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5D0E0E97D94D00F4287811A374D229A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_506CBCF1534F87E33F0E11A374D23C38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_506CBCF1534F87E33F0E11A374D23C38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BBB4ABDE0FBE274253AF11A374D208CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BBB4ABDE0FBE274253AF11A374D208CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7F188340EBD33CED287B11A374D2F383" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C342E9490B0EF96F2EC311A374D250A4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7F188340EBD33CED287B11A374D2F383" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7EB28575EDBE8C15DDD764F2857F53A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7EB28575EDBE8C15DDD764F2857F53A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9E0D4F5A72D4CE3B3C4C64F2857FD243" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9E0D4F5A72D4CE3B3C4C64F2857FD243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_D0800BD7E49F514EFE6764F2857F711F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_D0800BD7E49F514EFE6764F2857F711F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_74DA7480D3B025A04BCC64F2857FC8BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_FC585808EF0A00839B5164F2857F0A85" xlink:to="loc_us-gaap_OperatingExpenses_74DA7480D3B025A04BCC64F2857FC8BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_74E03AC6D303ED29A40F64F2857FBB80" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:to="loc_us-gaap_OperatingIncomeLoss_74E03AC6D303ED29A40F64F2857FBB80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_4274D889489B30DF8C7864F2857F79D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:to="loc_us-gaap_InterestAndOtherIncome_4274D889489B30DF8C7864F2857F79D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_DFBAB60BCA91583DE63364F2857FFC25" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:to="loc_us-gaap_ProfitLoss_DFBAB60BCA91583DE63364F2857FFC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B40FD366EFE48C95E4DC64F2857FF160" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B40FD366EFE48C95E4DC64F2857FF160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3A0EDCE973777052862F64F2857FCBA2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:to="loc_us-gaap_NetIncomeLoss_3A0EDCE973777052862F64F2857FCBA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2FCC99B29F4DB19DE39D64F2857FB98E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2FCC99B29F4DB19DE39D64F2857FB98E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4CDC68C46A679DAD125264F2857FC90F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_898ECE8E5962AB03613364F2857F0BA5" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4CDC68C46A679DAD125264F2857FC90F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8A272ED356840BB955FE677430A9EB51" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BBE1F51AAA7955D4CFB9677430A9A231" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8A272ED356840BB955FE677430A9EB51" xlink:to="loc_us-gaap_StatementTable_BBE1F51AAA7955D4CFB9677430A9A231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_381E9063FFDEBA54580E677430AA1324" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BBE1F51AAA7955D4CFB9677430A9A231" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_381E9063FFDEBA54580E677430AA1324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_381E9063FFDEBA54580E677430AA1324" xlink:to="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:to="loc_us-gaap_CommonStockMember_1BC4792A5E163D99359D677430AA5337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_24EB1CE4629EDC0F2716677430ABD33D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:to="loc_us-gaap_RetainedEarningsMember_2F9C30C5B2F1B0AEB5B6677430ABB879" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_69B587AED43868B26009677430B0C8A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_688DE2628229F62DD7AA677430AA39C8" xlink:to="loc_us-gaap_NoncontrollingInterestMember_8CF65B24D4066CD63FA5677430B03B29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6D4AA0B4543061D12599677430B00146" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BBE1F51AAA7955D4CFB9677430A9A231" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6D4AA0B4543061D12599677430B00146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_86884AC8B4DBC33A13C6677430B006EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6D4AA0B4543061D12599677430B00146" xlink:to="loc_us-gaap_TypeOfAdoptionMember_86884AC8B4DBC33A13C6677430B006EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0C5CD985943365D38892677430B1F481" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_86884AC8B4DBC33A13C6677430B006EA" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_0C5CD985943365D38892677430B1F481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_C87BEBC138A0038AE029677430B10F06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_86884AC8B4DBC33A13C6677430B006EA" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_C87BEBC138A0038AE029677430B10F06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6B540B708B2232464345677430B18D53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BBE1F51AAA7955D4CFB9677430A9A231" xlink:to="loc_us-gaap_StatementLineItems_6B540B708B2232464345677430B18D53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6B540B708B2232464345677430B18D53" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_CommonStockSharesIssued_CE37758011DD64BC8033677430B2B466" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAFA4D426CD42B136B58677430B2C830" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_DAFA4D426CD42B136B58677430B2C830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_33998C53584B718196AB677430B2A7D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7680C2A3F101806C1D0C677430B3F509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_A31E326535177DBF9F6C677430B325F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_E12D23D003CB00B67B51677430B41308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_C7F790BA1629DE78A2C7677430B4B66A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_178C067C048856713DAE677430B40F4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7BB78EA7B82612D9B447677430B45844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B946F53E421CC06BF43E677430B3B8AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9FD191F05BD076A89618677430B30989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_313286D98602956CE256677430B3048C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95F348987931AB687F28677430B468FB" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95F348987931AB687F28677430B468FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_918E6E72F743185D59ED677430B4E7AB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_ProfitLoss_918E6E72F743185D59ED677430B4E7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_483D4D967449562BE7EC677430B59981" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_CommonStockSharesIssued_483D4D967449562BE7EC677430B59981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99BDFAF396D5C9A00D8F677430B5E05C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_677142B87EF4A6F4658D677430B1E601" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99BDFAF396D5C9A00D8F677430B5E05C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6B6E98A40F52C8DF15DD678AE6B57DAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_DocumentType_6B6E98A40F52C8DF15DD678AE6B57DAE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_B50BAB974FCFE74D42C0678AE6B5CF41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_DocumentQuarterlyReport_B50BAB974FCFE74D42C0678AE6B5CF41" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D468ABC6A288E26578BE678AE6B5D77A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_DocumentPeriodEndDate_D468ABC6A288E26578BE678AE6B5D77A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_BE20B320B1CA1924619A678AE6B5C56F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_DocumentTransitionReport_BE20B320B1CA1924619A678AE6B5C56F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_33E8C3F1C27442B67C5F678AE6B57AA0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityFileNumber_33E8C3F1C27442B67C5F678AE6B57AA0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_B06124D37093BDF8DEFC678AE6B53772" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityRegistrantName_B06124D37093BDF8DEFC678AE6B53772" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6B33A239509E9C48F791678AE6B5BD83" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6B33A239509E9C48F791678AE6B5BD83" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_562F2410453838BEAE4C678AE6B52D94" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityTaxIdentificationNumber_562F2410453838BEAE4C678AE6B52D94" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_85C043750D6776D590DE678AE6B5E787" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityAddressAddressLine1_85C043750D6776D590DE678AE6B5E787" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_FBD96D23E2D544ECC34B678AE6B58177" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityAddressCityOrTown_FBD96D23E2D544ECC34B678AE6B58177" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_226547A3BBB87CA7B58A678AE6C5A90F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityAddressStateOrProvince_226547A3BBB87CA7B58A678AE6C5A90F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_95BB41E4C19CC5F4CC77678AE6C5D39F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityAddressPostalZipCode_95BB41E4C19CC5F4CC77678AE6C5D39F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_0C2EABB023F89B5D810C678AE6C5307C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_CityAreaCode_0C2EABB023F89B5D810C678AE6C5307C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_923CA99BCF3A14EE459C678AE6C5A241" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_LocalPhoneNumber_923CA99BCF3A14EE459C678AE6C5A241" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_2F659ADB6F3A2AD1FB6F678AE6C5B991" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_Security12bTitle_2F659ADB6F3A2AD1FB6F678AE6C5B991" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4A69ECC8266A34EA01FD678AE6C5188C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_TradingSymbol_4A69ECC8266A34EA01FD678AE6C5188C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_6AFF8CDDECB2E7A55C75678AE6C570E4" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_SecurityExchangeName_6AFF8CDDECB2E7A55C75678AE6C570E4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_FC22FBF6E41882C32886678AE6C5DC19" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityCurrentReportingStatus_FC22FBF6E41882C32886678AE6C5DC19" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_981261EC7DD3FD863634678AE6C5AB8E" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityInteractiveDataCurrent_981261EC7DD3FD863634678AE6C5AB8E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_161254C9EB74559169D4678AE6C51D0D" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityFilerCategory_161254C9EB74559169D4678AE6C51D0D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_D5BAF2F7A7AB2EC0E7AB678AE6C54971" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntitySmallBusiness_D5BAF2F7A7AB2EC0E7AB678AE6C54971" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_2C62430290BD4B189418678AE6C50F07" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityEmergingGrowthCompany_2C62430290BD4B189418678AE6C50F07" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_34F22AB5236C932FE1CC678AE6C57C5F" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityShellCompany_34F22AB5236C932FE1CC678AE6C57C5F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1951DF60D4A3C3CA76C6678AE6C5DB8E" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1951DF60D4A3C3CA76C6678AE6C5DB8E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D859543B551BCFCA28DC678AE6C5B50B" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_AmendmentFlag_D859543B551BCFCA28DC678AE6C5B50B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C118E85952B1AE807437678AE6C5641F" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_DocumentFiscalYearFocus_C118E85952B1AE807437678AE6C5641F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_E89C68A59AB369679C7B678AE6C5E5BD" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_DocumentFiscalPeriodFocus_E89C68A59AB369679C7B678AE6C5E5BD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_9B1E7C78283273ED0D8D678AE6C5C1C1" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_EntityCentralIndexKey_9B1E7C78283273ED0D8D678AE6C5C1C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9C79E1F3350161516D48678AE6C5B506" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0AD42F0DCBBDCE396078678AE6B55448" xlink:to="loc_dei_CurrentFiscalYearEndDate_9C79E1F3350161516D48678AE6C5B506" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A5261A878A2C08FCE89611A37484C801" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7A83C51CC4023C21482D11A374848164" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A5261A878A2C08FCE89611A37484C801" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7A83C51CC4023C21482D11A374848164" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6DE6B5D6377B352D928C53E31EE98180" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6DE6B5D6377B352D928C53E31EE98180" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_262FCBA6EE364085CEB353E31EEAD015" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:to="loc_us-gaap_ValuationTechniqueAxis_262FCBA6EE364085CEB353E31EEAD015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_8233EFE10A405A48F06753E31EEAC9EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_262FCBA6EE364085CEB353E31EEAD015" xlink:to="loc_us-gaap_ValuationTechniqueDomain_8233EFE10A405A48F06753E31EEAC9EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_0249125309674FBF86E653E31EEAA7E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_8233EFE10A405A48F06753E31EEAC9EC" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_0249125309674FBF86E653E31EEAA7E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_93E68C086820FD33101A53E31EEA8D65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_93E68C086820FD33101A53E31EEA8D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C317CD7EDFD8222E0EFB53E31EEBE794" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93E68C086820FD33101A53E31EEA8D65" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C317CD7EDFD8222E0EFB53E31EEBE794" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_TxCellSAMember" xlink:label="loc_sgmo_TxCellSAMember_F89E39A7F655EC53F4AB53E31EEBC3D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C317CD7EDFD8222E0EFB53E31EEBE794" xlink:to="loc_sgmo_TxCellSAMember_F89E39A7F655EC53F4AB53E31EEBC3D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BC3CFD51DA482C3F156053E31EEBCB65" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BC3CFD51DA482C3F156053E31EEBCB65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2EFD5A7961488868A2A853E31EEB1933" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BC3CFD51DA482C3F156053E31EEBCB65" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2EFD5A7961488868A2A853E31EEB1933" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_F0746DD0DA7F1052FD8553E31EEC4160" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2EFD5A7961488868A2A853E31EEB1933" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_F0746DD0DA7F1052FD8553E31EEC4160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3A6ECC1D3559EA68CA1C53E31EE99BC0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_69DEA535B6932B1F686053E31EEC2169" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_69DEA535B6932B1F686053E31EEC2169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1F89EE9BEC35E10A1FA653E31EECDBCC" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_93CB6523A6C98ADC826E53E31EEC829E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_93CB6523A6C98ADC826E53E31EEC829E" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_BACD2CB162D9BA0E2C7D53E31EEDDB02" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_F141FEEC453228E3238753E31EEDEB21" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_10C2F5C50F9759C6B20D53E31EECE0A9" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_F141FEEC453228E3238753E31EEDEB21" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2225145EB82A6918A66054636437BF76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2225145EB82A6918A66054636437BF76" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DC607BCFBA75D5C5856C5463643B8BE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DC607BCFBA75D5C5856C5463643B8BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7613CDF0407CE93DE4E35463643B30BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DC607BCFBA75D5C5856C5463643B8BE4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7613CDF0407CE93DE4E35463643B30BA" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_TxCellSAMember" xlink:label="loc_sgmo_TxCellSAMember_FE03C71B99962B129F395463643B2427" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7613CDF0407CE93DE4E35463643B30BA" xlink:to="loc_sgmo_TxCellSAMember_FE03C71B99962B129F395463643B2427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_26B75B23A8447B26DCB95463643C17E7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_97F23F60B9293445A50F546364412649" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MeasurementInputExchangeRateMember" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="loc_sgmo_MeasurementInputExchangeRateMember_881E2C426A65FE930F5954636442EF14" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MeasurementInputStockPriceCorrelationMember" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_ACFBBDDBB372AB981D08546364423D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_4D315D5688C167089E3854636442740C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0EDD45F95176190C4ADC5463644189E5" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2A8671769DC9F0FBB62754636442B0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_615BAAC86C75E695719B5463643A42B8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_C28A21AD8C3932A5ABC0546366A8A221" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_C28A21AD8C3932A5ABC0546366A8A221" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_C1CFAE83710F095D150D54636444ED69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_C1CFAE83710F095D150D54636444ED69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_45779189E93769AE850A54636444B46D" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2ABE2F353127DB561C1554636444DC9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_326AB7435FE25D57344364F2CC14663F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_326AB7435FE25D57344364F2CC14663F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_183E700AB8880895AD4964F2CC14B709" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_94BFDD40CFF44BDF2D0364F2CC143A02" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_CDA29DCDC9CB8778041464F2CC14E62E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_607EA2BD8C32738E99BD64F2CC144623" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0F9DDA8BC4F45565247B64F2CC1440C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2C23C3E21BF8957BD80464F2CC235A07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_BD50F9C87D585C4CB40D64F2CC1455BB" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_189FED274A0C70D788AA64F2CC23115E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C940007E75769C6BFD1F64F2CC23E0E6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_us-gaap_MoneyMarketFundsMember_38C6F59AF75CA006A3A664F2CC239213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_us-gaap_CommercialPaperMember_C3F0ED44BB86BF8CCA7264F2CC2381EE" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_FreeSharesAssetMember" xlink:label="loc_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_sgmo_FreeSharesAssetMember_922FFF01AF8DF86ABA9A64F2CC2359F4" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_FreeSharesLiabilityMember" xlink:label="loc_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_sgmo_FreeSharesLiabilityMember_F047008A84CF2C8CB68164F2CC235F38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9DCFD94E86412344E00C64F2CC239B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E69D02A3A6C3397C7E964F2CC2381DF" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32E9EE915EF97B80407564F2CC2375E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CB607F5481D8E3B135EF64F2CC14A3E7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_589ACE2FF4EA46419F0F64F2CC237976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_D566D1ACDC1BBFB84EBB64F2CC238284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_D8DFD66088D9432378B164F2CC2377D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F6E1528D09B941E8128B64F2CC23F0FD" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_B7CF7B72A774D322978364F2CC2340A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54E898C34641C72698D011A37484894B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_16A1B33F93CBC563B98E11A374842AAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54E898C34641C72698D011A37484894B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_16A1B33F93CBC563B98E11A374842AAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_149F984C7AE0BC8E14E711A374841723" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54E898C34641C72698D011A37484894B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_149F984C7AE0BC8E14E711A374841723" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FF07A61E09480029BA6A11A3742B8F70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_02CF2EC84C8B856B2EAB11A3742B8F8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FF07A61E09480029BA6A11A3742B8F70" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_02CF2EC84C8B856B2EAB11A3742B8F8E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71A465697AAA99E67D4311A37455D271" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_F412313976898BC26FBC11A3745582B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71A465697AAA99E67D4311A37455D271" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_F412313976898BC26FBC11A3745582B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5DDD9EF740D7055AAA6664F2CBA74CCA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5DDD9EF740D7055AAA6664F2CBA74CCA" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_362BD60C4CF5FF38968264F2CBA7AE4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_srt_CounterpartyNameAxis_362BD60C4CF5FF38968264F2CBA7AE4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_362BD60C4CF5FF38968264F2CBA7AE4C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_KitePharmaIncMember" xlink:label="loc_sgmo_KitePharmaIncMember_5F34B0822CEEDE8D728264F2CBA76E72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:to="loc_sgmo_KitePharmaIncMember_5F34B0822CEEDE8D728264F2CBA76E72" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerMember" xlink:label="loc_sgmo_PfizerMember_C9D4AD21AD9179997F3864F2CBA7EDA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:to="loc_sgmo_PfizerMember_C9D4AD21AD9179997F3864F2CBA7EDA5" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerSB525Member" xlink:label="loc_sgmo_PfizerSB525Member_A8F13E2AC0F14B9394B764F2CBA7308F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:to="loc_sgmo_PfizerSB525Member_A8F13E2AC0F14B9394B764F2CBA7308F" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SanofiMember" xlink:label="loc_sgmo_SanofiMember_31C02EACF1738F29A01D64F2CBA74423" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:to="loc_sgmo_SanofiMember_31C02EACF1738F29A01D64F2CBA74423" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BioverativIncMember" xlink:label="loc_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_EB8DB6AE4A390140274964F2CBA7C979" xlink:to="loc_sgmo_BioverativIncMember_983A152DD8351EAC3C0964F2CBA79CFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BA49E5B7105742EBC3CF64F2CBA7E41A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BA49E5B7105742EBC3CF64F2CBA7E41A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0B3EF259C222ED8780764F2CBA721C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BA49E5B7105742EBC3CF64F2CBA7E41A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0B3EF259C222ED8780764F2CBA721C2" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborationAndLicenseAgreementMember" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D0B3EF259C222ED8780764F2CBA721C2" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_C77447ED32425369423064F2CBA7CDD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A30FFFCE71DA8D89637664F2CBA7E279" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8DE2002B9D1EFDD09F3564F2CBA73E65" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154DE1D0F580A32783FF64F2CBA7FBB2" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_75CEB27EFECA6C336A1864F2CBA77F6C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_8F3C6B0DDC3F7EADF99B64F2CBA71570" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_52F5538704248596EC8564F2CBA7D835" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfCommercialMilestonesMember" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_135D87BFDC14FF59E5D564F2CBA7FCD8" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_A6D4B747967B0EA0591764F2CBA78D23" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_11386178DC9FDA5B100E64F2CBA7289C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9A6E877A891139010F9164F2CBA781DE" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_25537AAA024489DE5EF464F2CBA7C3B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_CD2D8908B0500FE1E80664F2CBA7DD7D" xlink:to="loc_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3AA75B9EB47155E3DE1F64F2CBA75934" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A038E1C48A4D23F82FCA64F2CBA74190" xlink:to="loc_srt_MaximumMember_3AA75B9EB47155E3DE1F64F2CBA75934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2460AB60C6C8D44DC72A64F2CBA7515D" xlink:to="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_us-gaap_LicenseAndServiceMember_F0D04776432779FF97C764F2CBA7B82A" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SBFiveTwoFiveMember" xlink:label="loc_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_sgmo_SBFiveTwoFiveMember_E72D12B6D7ED8926456864F2CBA76182" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OtherProductsMember" xlink:label="loc_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_sgmo_OtherProductsMember_FFEDC7D44A203F61A83264F2CBA7B0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_us-gaap_RoyaltyMember_71390EBE4FF5A404A99464F2CBA72C5B" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CNineORFSevenTwoMember" xlink:label="loc_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_sgmo_CNineORFSevenTwoMember_0B561106CCD918C7AA0D64F2CBA768EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0FDD6F1156CF9CFFCECB64F2CBA7CA10" xlink:to="loc_us-gaap_GrantMember_06AF56D70CE8E85E2A2E64F2CBA7B12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_53EAB9949948D220449B64F2CBA75948" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective" xlink:label="loc_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective_C8EA27E7484A70543CA664F2CBA7FC6E" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MilestonePaymentsReceived" xlink:label="loc_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_MilestonePaymentsReceived_DBDD23962E6E743D05EB64F2CBA7BDD5" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_1F10CA06CCE40C8B669364F2CBA72289" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_8C8F1C3FF5D330C51F5264F2CBA79F0D" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_8B7DA43FABEAA15E8E0264F2CBA70578" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_209FA850F5FCE034778865B6E59AA1F3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_209FA850F5FCE034778865B6E59AA1F3" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ResearchAgreementTerm" xlink:label="loc_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_ResearchAgreementTerm_D40AE2FC4A2ED615C2E564F2CBB678D1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SeparateUpfrontFee" xlink:label="loc_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_SeparateUpfrontFee_D9BC35FCEF8296CE7A1764F2CBB68633" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborativeArrangementTransactionPrice" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_1EB8DAB7487C0E8EE00664F2CBB627DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_29AC81FDCA604A615B3C64F2CBB60A15" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7CCAC3ED756180F4A64164F2CBB6BEEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_857A01EAC0F4453B356064F2CBB6593C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_72EA5100941D86EFF24364F2CBB63C89" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_MilestoneRevenueReceivable" xlink:label="loc_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_MilestoneRevenueReceivable_FD4432A080B9D13FE50364F2CBB63E25" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0ABD7D71D15F05E1801664F2CBB6C8B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_C70AC4A6B3B8C1BC5ACE64F2CBB6C682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_40B15372E6CB3704271364F2CBB6C004" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_40B15372E6CB3704271364F2CBB6C004" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_49C7672A1DA8ACDC573664F2CBB67DCF" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NumberOfResearchProgram" xlink:label="loc_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_NumberOfResearchProgram_B2DEE62590AFD527706064F2CBB6EA73" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_GrantFundingAmount" xlink:label="loc_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_sgmo_GrantFundingAmount_C120178695F627B5D67E64F2CBB65C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3A76A074FBADC306979364F2CBA754D4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_B905EF6A64BE3C9594B364F2CBB65997" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69EFE23B1B6BAD9EBAC5453F75F8BB2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_EF53384B538DE8319999453F75F81C6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69EFE23B1B6BAD9EBAC5453F75F8BB2D" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_EF53384B538DE8319999453F75F81C6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_959B88E1FE96B6FDFBA9453F75F88FD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_EF53384B538DE8319999453F75F81C6A" xlink:to="loc_srt_CounterpartyNameAxis_959B88E1FE96B6FDFBA9453F75F88FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_959B88E1FE96B6FDFBA9453F75F88FD5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_KitePharmaIncMember" xlink:label="loc_sgmo_KitePharmaIncMember_2A6EA73032AC622CFD4C453F7607254A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:to="loc_sgmo_KitePharmaIncMember_2A6EA73032AC622CFD4C453F7607254A" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerSB525Member" xlink:label="loc_sgmo_PfizerSB525Member_F627306DA9C60D9A2748453F76070304" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:to="loc_sgmo_PfizerSB525Member_F627306DA9C60D9A2748453F76070304" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerMember" xlink:label="loc_sgmo_PfizerMember_EB449D76DB34CA3ED5A5453F76070A23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:to="loc_sgmo_PfizerMember_EB449D76DB34CA3ED5A5453F76070A23" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SanofiMember" xlink:label="loc_sgmo_SanofiMember_5A70E91F618E7BED6B85453F76076E30" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3BFC23B7866FB65C8FEB453F7607370D" xlink:to="loc_sgmo_SanofiMember_5A70E91F618E7BED6B85453F76076E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_597B3D8ED298197FEF8E453F7607FC8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_EF53384B538DE8319999453F75F81C6A" xlink:to="loc_srt_ProductOrServiceAxis_597B3D8ED298197FEF8E453F7607FC8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C77A1B94112FFD54A85E453F7607AAA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_597B3D8ED298197FEF8E453F7607FC8D" xlink:to="loc_srt_ProductsAndServicesDomain_C77A1B94112FFD54A85E453F7607AAA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_805307B3DD46C798AB8E453F76076558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C77A1B94112FFD54A85E453F7607AAA0" xlink:to="loc_us-gaap_LicenseAndServiceMember_805307B3DD46C798AB8E453F76076558" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ResearchServicesMember" xlink:label="loc_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C77A1B94112FFD54A85E453F7607AAA0" xlink:to="loc_sgmo_ResearchServicesMember_FCEAAE3F4F0B5B5995F6453F760701CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8557848962FBE288EB60453F760701D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_EF53384B538DE8319999453F75F81C6A" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8557848962FBE288EB60453F760701D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D65E3E24D33BE75F19C4453F76077669" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8557848962FBE288EB60453F760701D4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D65E3E24D33BE75F19C4453F76077669" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E76A6EB78C96C66C365631E67E96F41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E76A6EB78C96C66C365631E67E96F41" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:to="loc_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_743F143806EF90375335631E67EA7E97" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_KitePharmaIncMember" xlink:label="loc_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:to="loc_sgmo_KitePharmaIncMember_6E63555E7D9F96010844631E67EAB6C0" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerSB525Member" xlink:label="loc_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:to="loc_sgmo_PfizerSB525Member_A2672DD17FC57CE57659631E67EB08B9" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerMember" xlink:label="loc_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:to="loc_sgmo_PfizerMember_DD3BABA8E4689C451BC1631E67EB3837" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SanofiMember" xlink:label="loc_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D25FC0CCE6C946EE16CB631E67EA3051" xlink:to="loc_sgmo_SanofiMember_25B7F7994373BD8C052F631E67EB1AD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_F591C89EBA92C3CBBBB3631E67EA9683" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_E9DDBC87E39EC0173C23631E67EB81F0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_D705AF752888AD23B473631E67EBB39A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BD134F475B20D045B67C11A374A3352F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_30C5A960C274CF4AD84D11A374A37EC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BD134F475B20D045B67C11A374A3352F" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_30C5A960C274CF4AD84D11A374A37EC7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_99C0A6E59A0B3375E0A5678AE653811B" xlink:type="locator" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_99C0A6E59A0B3375E0A5678AE653811B" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D667060EE8CA496770E26792B8CE0A2A" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ChangeInCollaborationAgreementScopeMember" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2F40151388AD66F1E77D679312C86613" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_A56DE54EE9B8EC36DC2167964D336517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_99991B068D294DC40B6C678AE653C5A6" xlink:to="loc_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_ManufacturingCapabilityEstablishmentMember" xlink:label="loc_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_9EC2FB0D58DD716A7B6F678AE653D092" xlink:to="loc_sgmo_ManufacturingCapabilityEstablishmentMember_D48A84EE3A79623366E9678AE6534742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DE71908BC4B9F8505298678AE6539896" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_565164342DB4410D5E62678AE653DB9F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DE71908BC4B9F8505298678AE6539896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DE71908BC4B9F8505298678AE6539896" xlink:to="loc_us-gaap_CollaborativeArrangementMember_AE963B0D984A3D14C95E678AE653A9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_EF1BF89748767644D69B678AE653B645" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_srt_CounterpartyNameAxis_EF1BF89748767644D69B678AE653B645" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_EF1BF89748767644D69B678AE653B645" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_PfizerMember" xlink:label="loc_sgmo_PfizerMember_3AB59479F550E164BCA0678AE66315F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:to="loc_sgmo_PfizerMember_3AB59479F550E164BCA0678AE66315F8" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BrammerBioMAMember" xlink:label="loc_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:to="loc_sgmo_BrammerBioMAMember_8578D1248D4B488615DE678AE663821D" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_KitePharmaIncMember" xlink:label="loc_sgmo_KitePharmaIncMember_D0A18400DD6C12D9F38B678AE6631732" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:to="loc_sgmo_KitePharmaIncMember_D0A18400DD6C12D9F38B678AE6631732" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_SanofiMember" xlink:label="loc_sgmo_SanofiMember_335E550BD0AA3006A2A0678AE663D058" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CF5901830F65EEAC2E57678AE65320E1" xlink:to="loc_sgmo_SanofiMember_335E550BD0AA3006A2A0678AE663D058" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_375C89340F19D0E710F5678AE6630437" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_IntangibleAssetsMember" xlink:label="loc_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F7D61A9F345A4F8043ED678AE6636D8C" xlink:to="loc_sgmo_IntangibleAssetsMember_15AA694DD6C774895070678AE663E744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7A5B0CE63F4EA3737912678AE663567E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1AA2131E02E4B3F8AEDF678AE663F748" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_197DAA8EF669E2E3CD16678AE6635696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4815051E58A51318C1C1678AE6636886" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_A88E93863E3F8961DADC678AE6635781" xlink:to="loc_us-gaap_SalesRevenueNetMember_F53BAABE73EA9B6CC5D6678AE6638B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_10B7489B615FD668943A678AE6637D50" xlink:to="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_96E5F8A02036B6BBFFED678AE6633C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_C90DC0D34F82C1E69C87678AE6637B23" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_A38EB346B2458312D7C5678AE6638406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_20494D35F0D6F8900C94678AE66302FC" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_97A909E20B02137BE3E0678AE6639D1F" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_9AC769F4961971AB55AD678AE663BE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_760F71A6DE5E6225961A678AE663FD83" xlink:to="loc_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1CC8CF465BB5039104D5678AE663F8A4" xlink:to="loc_srt_RestatementAdjustmentMember_F6170BC71D8662BDD7FF678AE663418B" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_77D500F292F1AB3D464A678AE653FAB1" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886D231F31F6B8B4703F678AE663569F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_D72F66C1B4E5F8BDE29D678AE6639536" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_ProfitLoss_D72F66C1B4E5F8BDE29D678AE6639536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_EarningsPerShareBasic_A893AE37B4331775FAE1678AE6639BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_1D72AC88B31C00CC0D13678AE663E36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_DepositAssets_EAC0E5C1163F4FE18B15678AE663B537" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_DepositAssetsNonrefundable" xlink:label="loc_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_sgmo_DepositAssetsNonrefundable_C88EF65556B687358C4D678AE6637451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_OtherCommitment_BFFCB43914550E92BBF0678AE6633EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0630D5CF474543CFD77E678AE66313F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_FC755D270688BB3FDB66678AE663D65B" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FB907A119E9CCB761634678AE663B23C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_10D2AE563A4E43544F2D4E2D14FB9820" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10D2AE563A4E43544F2D4E2D14FB9820" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_CFB6567326EC88DCAA984E2D14FBE4A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_CFB6567326EC88DCAA984E2D14FBE4A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_CC2F13A9C302F8A1E7E34E2D14FCCC8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_CFB6567326EC88DCAA984E2D14FBE4A7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_CC2F13A9C302F8A1E7E34E2D14FCCC8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_F7FF986D6AA16EE015DA4E2D14FCDFBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_CC2F13A9C302F8A1E7E34E2D14FCCC8A" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_F7FF986D6AA16EE015DA4E2D14FCDFBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_20000311CE906AC544A24E2D14FC8A7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_20000311CE906AC544A24E2D14FC8A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_1A4EA2E419DFD4A8D8B64E2D14FC2596" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_20000311CE906AC544A24E2D14FC8A7D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_1A4EA2E419DFD4A8D8B64E2D14FC2596" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_BuildToSuitLeaseMember" xlink:label="loc_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_1A4EA2E419DFD4A8D8B64E2D14FC2596" xlink:to="loc_sgmo_BuildToSuitLeaseMember_218DF6016F7F9BC868CB4E2D14FD17A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_E725D93B1716D3979B344E2D14FDB9D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:to="loc_srt_RestatementAxis_E725D93B1716D3979B344E2D14FDB9D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_9022928AE7F38A4FE59B4E2D14FDDBF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_E725D93B1716D3979B344E2D14FDB9D0" xlink:to="loc_srt_RestatementDomain_9022928AE7F38A4FE59B4E2D14FDDBF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_5E51091D9E3CB872C6F04E2D14FEB62B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_9022928AE7F38A4FE59B4E2D14FDDBF2" xlink:to="loc_srt_RestatementAdjustmentMember_5E51091D9E3CB872C6F04E2D14FEB62B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_920D76DB446753E0EF154E2D14FBCF3B" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:to="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1DF560E75718309821DA4E2D14FE16B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_098401197CF43DA243BD4E2D14FFDF53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9130B947FE63ED6473DC4E2D14FE82B9" xlink:to="loc_us-gaap_PrepaidRent_AEB0E43946FAF9BCD8B74E2D14FF758C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_D0BEF4214172D8FB92E14E2D14FEB19D" xlink:to="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_AC49421A1DF87414FFC44E2D14FF30FB" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_DeferredRentNoncurrent" xlink:label="loc_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:to="loc_sgmo_DeferredRentNoncurrent_BCB9F90AE2F97069E3724E2D15042387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5AC71231AC96667DA5B84E2D1505995D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_03E383053DEAAEA15B254E2D1505F929" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_1FADFFC7BEC0D355E1A74E2D14FFCE9F" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_03E383053DEAAEA15B254E2D1505F929" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F1962F9BEA90A847EDEC66052FE4FE76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F1962F9BEA90A847EDEC66052FE4FE76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_0716F0EC51D36616878066052FE594C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_UseOfEstimates_0716F0EC51D36616878066052FE594C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_845608563ADC14C2E20466052FE5AE5F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_845608563ADC14C2E20466052FE5AE5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A35A9F3F393C888717A066052FE5879F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A35A9F3F393C888717A066052FE5879F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_76E5A1158710F2EA718D66052FE50396" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_76E5A1158710F2EA718D66052FE50396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_46C153D245178579A46B66052FE56AEF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_46C153D245178579A46B66052FE56AEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9FACA61929A0D7555EF866052FE5887E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_9FACA61929A0D7555EF866052FE5887E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_AAC78D57164BF8D054BD66052FE52C94" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_AAC78D57164BF8D054BD66052FE52C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8F44066C8F2CB3BF25B566052FE62F5E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_8F44066C8F2CB3BF25B566052FE62F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_30F442EBBA8C4F1F97D366052FE62B11" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_30F442EBBA8C4F1F97D366052FE62B11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7904CBCDB5E5BC816DF666052FE67329" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED2AC531F53F7D796E9866052FE4680D" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7904CBCDB5E5BC816DF666052FE67329" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D99BC014E1431051D26011A374A3233B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D99BC014E1431051D26011A374A3233B" xlink:to="loc_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F214C211699FC252DF0311A374A350F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F214C211699FC252DF0311A374A350F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_CC97290A7C3C349D20FD11A374A3A78B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_F214C211699FC252DF0311A374A350F1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_CC97290A7C3C349D20FD11A374A3A78B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_44DB00597EFD968274AC11A374A365ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_CC97290A7C3C349D20FD11A374A3A78B" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_44DB00597EFD968274AC11A374A365ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_75683E64FCD235BDCBE311A374A37044" xlink:to="loc_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_61961E970EB5DD9B2BCF11A374A3008B" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_CD8553A9D5F241385B6511A374A33EDE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D98EE4A1FFC9E211331411A3193E47E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6ECB8425D6DF966AC311A3193ECB3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D98EE4A1FFC9E211331411A3193E47E9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6ECB8425D6DF966AC311A3193ECB3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DB320590752186F6410511A31966921B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DB320590752186F6410511A31966921B" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_452C88A6977B010FBF5E11A31966AA08" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_754D792DAA347521B9A011A319675CA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33BE6A02C41A13AE473C11A31967672B" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_55BCD78CD89DE2E5243911A3196755C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6D3B5CAF34BA4A4F4DF611A31966C8C5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_625887B62F102A15AE1A11A319671BE4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_C7B69C2321EBB17B02A111A319678BB8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DEB0903BA6DE5D8734E111A3196D3E55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_422431260CAC25E86B7811A3196D453D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DEB0903BA6DE5D8734E111A3196D3E55" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_422431260CAC25E86B7811A3196D453D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1E5B2CC250B5CB0CAF3911A3740C7DF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F5924F4B4DF628F8797A11A3740CC77D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1E5B2CC250B5CB0CAF3911A3740C7DF5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_F5924F4B4DF628F8797A11A3740CC77D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B6043A53A86B54BBF618145E0CD138E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B6043A53A86B54BBF618145E0CD138E5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DC0E06864CEB32DD4A57145E0CDBC1C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_DC0E06864CEB32DD4A57145E0CDBC1C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C44067F9A527E7ADB25D145E0CDB52F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DC0E06864CEB32DD4A57145E0CDBC1C2" xlink:to="loc_us-gaap_EquityComponentDomain_C44067F9A527E7ADB25D145E0CDB52F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_55EA2FCDB39300FCDE24145E0CDB3350" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C44067F9A527E7ADB25D145E0CDB52F3" xlink:to="loc_us-gaap_CommonStockMember_55EA2FCDB39300FCDE24145E0CDB3350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D920257104FFD137C9D7145E0CDC1C9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D920257104FFD137C9D7145E0CDC1C9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_31BBDBEFCF9BE5E830ED145E0CDC0600" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D920257104FFD137C9D7145E0CDC1C9C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_31BBDBEFCF9BE5E830ED145E0CDC0600" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_AtTheMarketOfferingAgreementMember" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_31BBDBEFCF9BE5E830ED145E0CDC0600" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_29E6843D0D46EAD1B786145E0CDC601A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C3CF95C925EFEB4440E145E0CD1BF00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_219E31C4A7BE0B85F11A145E0CDD7F51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_219E31C4A7BE0B85F11A145E0CDD7F51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_64C5AF43D963209AB1CD145E0CDD1028" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_77E60A554DA59E2A5AD7145E0CDD7518" xlink:type="arc" />
    <link:loc xlink:href="sgmo-20190630.xsd#sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:label="loc_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_384D0499329054681930145E0CDD0477" xlink:to="loc_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_76138BBAA99FB632CC79145E0CDDF855" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_F66BF361D723D764F10711A373E3A651" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_EFB6655A73EFD675DDEA11A373E3445C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_F66BF361D723D764F10711A373E3A651" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_EFB6655A73EFD675DDEA11A373E3445C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4B4AB3EFAA74B2DB424011A373DF9B0E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4B4AB3EFAA74B2DB424011A373DF9B0E" xlink:to="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A9ABFCCD9838B380E06C11A373DFDA21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_CFDFC877088EC3A8CBE911A373DF8447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_FBD6CC51DB85FC90ADD711A373E0869E" xlink:to="loc_us-gaap_EquityComponentDomain_E89A7A02690A5B999E9D11A373E03CCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_50AF5F089247DC52AA9D11A373E0540A" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AA4DEAB50616B68CD1E811A373E0C064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_60A3E151DB1FE4E4135211A373DFB334" xlink:to="loc_us-gaap_SubsequentEventLineItems_EC66521B68D72C9B244911A373E1D5D6" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>sgmo-20190630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgmo="http://www.sangamo.com/20190630"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:utreg="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sgmo-20190630.xsd" xlink:type="simple"/>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-08-02</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_sgmo_ChangeInCollaborationAgreementScopeMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BrammerBioMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember_us-gaap_OtherCommitmentsAxis_sgmo_ManufacturingCapabilityEstablishmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BrammerBioMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingCapabilityEstablishmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_BalanceSheetLocationAxis_sgmo_IntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sgmo:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_sgmo_BuildToSuitLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_LeaseArrangementTypeAxis_sgmo_BuildToSuitLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputStockPriceCorrelationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputExchangeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputExchangeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputStockPriceCorrelationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="I2017Q1May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_OtherProductsMember_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfFirstCommercialSaleMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="I2017Q1May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2018Q4_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2019Q3SD_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-02-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_CounterpartyNameAxis_sgmo_PfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="D2018Q2May01-May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="D2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="D2018Q2Apr01-Apr30_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="D2014Q1Jan01-Jan31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="D2019Q3SD_srt_CounterpartyNameAxis_sgmo_BioverativIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-02-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="D2019Q2SD_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfCommercialMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q2Apr5_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-05</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeAndLaboratoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:ValbonneLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:ValbonneLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:ValbonneLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondAndValbonneLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeAndLaboratoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:ValbonneLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondAndValbonneLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondAndValbonneLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q2Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="D2018Q2Apr01-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="I2016Q1Dec07_us-gaap_SubsidiarySaleOfStockAxis_sgmo_AtTheMarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-07</instant>
        </period>
    </context>
    <context id="I2018Q2Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_sgmo_AtTheMarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="D2019Q2Apr1-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep1-Sep30_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct01_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="I2018Q4Nov23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2018-11-23</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="I2018Q3July20_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-20</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <unit id="renewal_option">
        <measure>sgmo:renewal_option</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="sqft">
        <measure>utreg:sqft</measure>
    </unit>
    <unit id="U_sgmoMilestone">
        <measure>sgmo:Milestone</measure>
    </unit>
    <unit id="U_sgmoProduct">
        <measure>sgmo:Product</measure>
    </unit>
    <unit id="contract">
        <measure>sgmo:contract</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="program">
        <measure>sgmo:program</measure>
    </unit>
    <unit id="milestone">
        <measure>sgmo:milestone</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q2YTD"
      id="Fact-DE37197EC40E86C94CB2D79D0AB82707-wk-Fact-DE37197EC40E86C94CB2D79D0AB82707">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q2YTD"
      id="Fact-FAA312CFA8DE28DC6AB4D79D0AC16214-wk-Fact-FAA312CFA8DE28DC6AB4D79D0AC16214">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q2YTD"
      id="Fact-C04DBAA725D728C4639CD79D0AACB6AD-wk-Fact-C04DBAA725D728C4639CD79D0AACB6AD">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q2YTD"
      id="Fact-11BCE90B3CB0F6E8CE9FD79D0AC2FC8F-wk-Fact-11BCE90B3CB0F6E8CE9FD79D0AC2FC8F">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q2YTD"
      id="Fact-D43E9F458CDFC1EADFA6D79D0ADBB2DF-wk-Fact-D43E9F458CDFC1EADFA6D79D0ADBB2DF">0001001233</dei:EntityCentralIndexKey>
    <sgmo:ExpectedLeaseCommencementPeriod
      contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember"
      id="Fact-C8D045CD64B733F56B58D79D0A936F3D-wk-Fact-C8D045CD64B733F56B58D79D0A936F3D">2019-06</sgmo:ExpectedLeaseCommencementPeriod>
    <sgmo:LeaseCommencementPeriod
      contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember"
      id="Fact-9958028BA8022E13C179D79D0A94D997-wk-Fact-9958028BA8022E13C179D79D0A94D997">2019-01</sgmo:LeaseCommencementPeriod>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember"
      decimals="INF"
      id="Fact-B4661CDD43D96C4E54ADD79D0AA4271D-wk-Fact-B4661CDD43D96C4E54ADD79D0AA4271D"
      unitRef="U_sgmoMilestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="INF"
      id="Fact-6AEF45052DF8892D55E4D79D0AA26D4B-wk-Fact-6AEF45052DF8892D55E4D79D0AA26D4B"
      unitRef="U_sgmoMilestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:ResearchAgreementTerm
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      id="Fact-183466E0F45D03BAC589D79D0AA3D1B1-wk-Fact-183466E0F45D03BAC589D79D0AA3D1B1">an option to extend the research term of the agreement for up to two additional one-year periods for a separate upfront fee of $10.0 million per year.</sgmo:ResearchAgreementTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2018Q2YTD"
      decimals="INF"
      id="Fact-FDA4698EA3763BFD724ED79D0ACF41E2-wk-Fact-FDA4698EA3763BFD724ED79D0ACF41E2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="Fact-9C8E9C9263B843DEA448D79D0A97C09C-wk-Fact-9C8E9C9263B843DEA448D79D0A97C09C"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:LeaseExpirationDate1
      contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember"
      id="Fact-08FFEC6CF2DB0B83C774D79D0AA0D3E9-wk-Fact-08FFEC6CF2DB0B83C774D79D0AA0D3E9">2019-08-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="FD2019Q2YTD"
      id="Fact-E0BF0B7788382EBD8B39D79D0ADA8A75-wk-Fact-E0BF0B7788382EBD8B39D79D0ADA8A75">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember"
      id="Fact-28E745529FE5AE9E73F5D79D0A953DAD-wk-Fact-28E745529FE5AE9E73F5D79D0A953DAD">Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional five to ten years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember"
      id="Fact-C45928B185757F21FAB74ED1713376F8-wk-Fact-C45928B185757F21FAB74ED1713376F8">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="I2018Q2Apr5_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      id="Fact-496882F3A1DA11876B2465B589C93AE3-wk-Fact-496882F3A1DA11876B2465B589C93AE3">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="Fact-B8D9618F95719C0F1728D79D0AD0D82B-wk-Fact-B8D9618F95719C0F1728D79D0AD0D82B"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"
      decimals="-5"
      id="Fact-8EC921C02D025688B42FD79D0AC02FBC-wk-Fact-8EC921C02D025688B42FD79D0AC02FBC"
      unitRef="usd">1100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember"
      decimals="-5"
      id="Fact-72E691CCD4404ACC42F3D79D0AB5A471-wk-Fact-72E691CCD4404ACC42F3D79D0AB5A471"
      unitRef="usd">25600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="Fact-819A5F802B740687A297D79D0AAE8C4F-wk-Fact-819A5F802B740687A297D79D0AAE8C4F"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="FD2019Q2YTD"
      id="Fact-10A6305C0043A65E531ED79D0A9D2D21-wk-Fact-10A6305C0043A65E531ED79D0A9D2D21">&amp;lt;div style="font-family:Times New Roman;font-size:10pt;"&amp;gt;&amp;lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&amp;gt;&amp;lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&amp;gt;SUBSEQUENT EVENTS&amp;lt;/font&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&amp;gt;&amp;lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&amp;gt;[OPEN THROUGH FILING DATE]&amp;lt;/font&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;/div&amp;gt;</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType
      contextRef="FD2019Q2YTD"
      id="d94577764e500-wk-Fact-E542A454A9D03B1B232BD79D0AD4A4F6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2019Q2YTD"
      id="d94577764e523-wk-Fact-542F6A9F5FA375FC87F2E1E6E8A8BCEF">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q2YTD"
      id="d94577764e533-wk-Fact-6052432B98DF8A8F8F72677BB93B05D8">2019-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q2YTD"
      id="d94577764e552-wk-Fact-35CC7E53D7D9DF92E43FE1F14EA62A6A">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q2YTD"
      id="d94577764e572-wk-Fact-5E0701716AB3AA086998E6D3DD5395A9">000-30171</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q2YTD"
      id="d94577764e581-wk-Fact-4FB1F0A0082DC7EC8490D79D0AD455A2">SANGAMO THERAPEUTICS, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q2YTD"
      id="d94577764e607-wk-Fact-E4A9971480AA718F6413E6D519B20B1F">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q2YTD"
      id="d94577764e627-wk-Fact-62B92FDF3569BED8F69BE6D5D32BCE8F">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q2YTD"
      id="d94577764e691-wk-Fact-55E9CB996A10408D8C4124E96EB4DC92">501 Canal Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q2YTD"
      id="d94577764e696-wk-Fact-E518C21F3ED20E7DEE3C24E9DE1426F6">Richmond</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q2YTD"
      id="d94577764e701-wk-Fact-9A844FD4F7DD684EEC9724E9FD8AC3C6">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q2YTD"
      id="d94577764e711-wk-Fact-52C04A22D8498A954946E6D6A4E2C45B">94804</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q2YTD"
      id="d94577764e742-wk-Fact-F7003A45C8836DDF287FE6DC4A3807E2">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q2YTD"
      id="d94577764e747-wk-Fact-76DD2BCC30FD01B41141E6DCFEA11912">970-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q2YTD"
      id="d94577764e801-wk-Fact-96C07E8D62AD4C7D648BE6FFA2A826C1">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q2YTD"
      id="d94577764e811-wk-Fact-6FA112D4832C11F168A9E6FD6821BB8F">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q2YTD"
      id="d94577764e821-wk-Fact-B09B177EF9D0EBBA9B9BE6FEE013D218">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q2YTD"
      id="d94577764e827-wk-Fact-468D686B52BC47CB22DEE6DE337D608C">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q2YTD"
      id="d94577764e840-wk-Fact-4ECE9336E6D202D09ED0E6E06A87BDAD">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q2YTD"
      id="d94577764e868-wk-Fact-56429D0DF3909F77078FE6E171932EB4">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q2YTD"
      id="d94577764e914-wk-Fact-EEB6E0D056165ECD482EE7B953814399">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q2YTD"
      id="d94577764e940-wk-Fact-3039B3874E3F818289B9E7B99F483AB8">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q2YTD"
      id="d94577764e950-wk-Fact-A21AED697297D2EA2315E7C5A30585AF">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q2"
      decimals="INF"
      id="d94577764e963-wk-Fact-A5A60F325F6D3408E60E62DAF131E7F5"
      unitRef="shares">115675077</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e610-wk-Fact-469CE8BB84B262C73103D79D0AC023A8"
      unitRef="usd">169222000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e629-wk-Fact-F26F58192F10765674D2D79D0AB3026E"
      unitRef="usd">140418000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e644-wk-Fact-C8FF7A458F2325F6A97DE7D2B8F490E3"
      unitRef="usd">2000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e663-wk-Fact-9710C75C7B2F20140B6FE7D309FD3FDD"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e683-wk-Fact-DFBC3F61C2215E362C75D79D0ABEE556"
      unitRef="usd">271877000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e702-wk-Fact-EA6990E80FF78DED8F8AD79D0AB3DD16"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e722-wk-Fact-0FF5B5FA23F4029AAACAD79D0AC80446"
      unitRef="usd">766000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e741-wk-Fact-12551A0C8D004E4C3F65D79D0ABD9EAA"
      unitRef="usd">375000</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e761-wk-Fact-D0AD10D95E07B3649524D79D0ABA2828"
      unitRef="usd">12095000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e780-wk-Fact-1F7C0AA9A183C2393ADCD79D0AD06E3A"
      unitRef="usd">4673000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e800-wk-Fact-2AE8514BCD1187F4F235D79D0ACC50D0"
      unitRef="usd">5848000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e819-wk-Fact-C92309ED9A8444BFC101D79D0AD0DDBC"
      unitRef="usd">5340000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e839-wk-Fact-61AF287911C8A3090B0AD79D0ABE7F00"
      unitRef="usd">461808000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e858-wk-Fact-7A267726DB6F5BF6E41CD79D0AC222D3"
      unitRef="usd">410521000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e878-wk-Fact-803182B60E3827BF27F3E7D503D45988"
      unitRef="usd">8450000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e897-wk-Fact-BEE14064AD6605239E9CE7D62590806A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e918-wk-Fact-F2B6E69BBE24A0133386D79D0AD42C41"
      unitRef="usd">21019000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e937-wk-Fact-72F3564834CE2CB30F0BD79D0ABE3437"
      unitRef="usd">78723000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e957-wk-Fact-C5222250B38FFB640975D79D0ACCDE0B"
      unitRef="usd">53892000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e976-wk-Fact-0AC24FA37B16936C2A5FD79D0AB78472"
      unitRef="usd">54243000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e996-wk-Fact-0DAB4FD64ED43BFB22A5D79D0ACF834D"
      unitRef="usd">39795000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1015-wk-Fact-68C55902C4CD583B68B3D79D0ACFF628"
      unitRef="usd">40044000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1035-wk-Fact-6F410EDDA81D8CBE76D2D79D0ACCE53E"
      unitRef="usd">79435000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1074-wk-Fact-AA07633196497B05E92ED79D0AC57158"
      unitRef="usd">7582000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1093-wk-Fact-C258D560131929414DC3D79D0AC235A0"
      unitRef="usd">3364000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1113-wk-Fact-2B69EB158C278134D3A0D79D0AAD634C"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1132-wk-Fact-F8D0E86062637492A54DD79D0AC99B81"
      unitRef="usd">3500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1157-wk-Fact-BC34558D4DA2573085E5D79D0AC964D0"
      unitRef="usd">673481000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1176-wk-Fact-6AE923DCBB19027279BFD79D0AB0941A"
      unitRef="usd">590395000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1278-wk-Fact-E7688D0BE907E6B8EA6ED79D0AC8CB4A"
      unitRef="usd">22505000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1297-wk-Fact-5CEC5428DAFA0DDB177CD79D0AC498A3"
      unitRef="usd">21457000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1312-wk-Fact-0DA4997DA96961E29E8AD79D0ABA6BEA"
      unitRef="usd">8714000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1331-wk-Fact-11EA634C7F0CDD29E3FED79D0AC37EBB"
      unitRef="usd">9490000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1352-wk-Fact-A0344213EDDE36541BC9D79D0AD1412D"
      unitRef="usd">50826000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1371-wk-Fact-AAA23BA81D6D602CCA50D79D0ABAE648"
      unitRef="usd">47564000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1391-wk-Fact-40CF06639CDCF1840851D79D0AC9184D"
      unitRef="usd">82045000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1410-wk-Fact-19CBF409F604A870A0ACD79D0ACF4816"
      unitRef="usd">78511000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1430-wk-Fact-933527C99A9433EE90BFD79D0ABE8A8E"
      unitRef="usd">94189000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1449-wk-Fact-BD718900C7026E05594AD79D0AD11F5A"
      unitRef="usd">108273000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1469-wk-Fact-5376ED04C4E343E95870D79D0AB9B12A"
      unitRef="usd">41550000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1488-wk-Fact-9AD4C333EF37D9C4EAC3D79D0AB29B17"
      unitRef="usd">27689000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1508-wk-Fact-09D3E0275C015DBE4308D79D0ABC94C2"
      unitRef="usd">6661000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1527-wk-Fact-BE4422E3C3076F4B4C14D79D0AB9E8E7"
      unitRef="usd">6705000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1547-wk-Fact-0352D0FB09341A8106B8D79D0AB952B8"
      unitRef="usd">3288000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1566-wk-Fact-48B9E843EDD439EB48D4D79D0AC87F08"
      unitRef="usd">1960000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1586-wk-Fact-64F04C9ADD7EC731B5CAD79D0AC62E37"
      unitRef="usd">227733000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1605-wk-Fact-5C4F7CC09DD083765CD1D79D0ABCAA35"
      unitRef="usd">223138000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q2"
      id="d94603608e1625-wk-Fact-B35A889FC5B402BE51FFD79D0AD305B5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d94603608e1644-wk-Fact-D83BB1B11F6834E7FA44D79D0AD1444C"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1705-wk-Fact-F69554AF524365DC5056D79D0AB41F51"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1724-wk-Fact-EE3409FA1BE57301D313D79D0ABA5B32"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1744-wk-Fact-8BD90D2D11B5CA16187FD79D0AB8C7AC"
      unitRef="usd">1156000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1763-wk-Fact-344B3565BCD646374ED4D79D0AB8A7E8"
      unitRef="usd">1022000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1784-wk-Fact-C18F9197C918D9B2FAB4D79D0AB8D0A0"
      unitRef="usd">1078976000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1803-wk-Fact-7D5FA66BAC9785E31FA8D79D0AC1020D"
      unitRef="usd">929632000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1823-wk-Fact-1D6979039EEDA2150B74D79D0ACCF21E"
      unitRef="usd">-634233000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1843-wk-Fact-8FCDFAB3D8A2196E10BED79D0ABEA42C"
      unitRef="usd">-562696000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1864-wk-Fact-F5DADB605C232397F561D79D0AC91231"
      unitRef="usd">-765000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1884-wk-Fact-0520A7B6080F139363EDD79D0ABE1A78"
      unitRef="usd">-1440000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1905-wk-Fact-39245F6DF04D671371ABD79D0ABEE605"
      unitRef="usd">445134000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1924-wk-Fact-0936B750059FD353E827D79D0AC4634D"
      unitRef="usd">366518000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1944-wk-Fact-1930E75AE6EC2D9A44FDD79D0AC4175A"
      unitRef="usd">614000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e1963-wk-Fact-5BC2E4BF3B544D9C0A16D79D0ACC2989"
      unitRef="usd">739000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e1983-wk-Fact-B5F04749C2EF2E4BE717D79D0AC7FA5D"
      unitRef="usd">445748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e2002-wk-Fact-9498F1B95CD7A6294375D79D0AB77712"
      unitRef="usd">367257000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94603608e2027-wk-Fact-2F5FB8157C89F4827E9BD79D0ACC5E45"
      unitRef="usd">673481000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94603608e2046-wk-Fact-C174C8F1B000D13A6965D79D0AB18303"
      unitRef="usd">590395000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94582075e658-wk-Fact-14AA779FB24F3D00B66DD79D0AA08A82"
      unitRef="usd">17548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94582075e677-wk-Fact-C50E5033FADEF6CF6117D79D0AB7F074"
      unitRef="usd">21416000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94582075e696-wk-Fact-085F3FBCD3C0BBFF5C74E7D7F746D8E1"
      unitRef="usd">25619000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94582075e716-wk-Fact-1FA1328069BE01046F68D79D0AA39396"
      unitRef="usd">34053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94582075e813-wk-Fact-3DDDFD5EE461C788B9B8D79D0AA25424"
      unitRef="usd">36455000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94582075e832-wk-Fact-CC7E1BEFDC18D643D282D79D0AB9BA9F"
      unitRef="usd">29255000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94582075e851-wk-Fact-E26EB5136C9954BD6186E7D7F73B776C"
      unitRef="usd">71305000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94582075e871-wk-Fact-07846BCCB6D4DC3B4287D79D0AC1F81D"
      unitRef="usd">52802000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94582075e891-wk-Fact-C0F27562C8EF2DDD279ED79D0AA2E8D5"
      unitRef="usd">14597000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94582075e910-wk-Fact-6E7883E674AE7AB0BBBDD79D0AB31B3F"
      unitRef="usd">11301000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94582075e929-wk-Fact-CD5675688422578CFD6CE7D7F749EED3"
      unitRef="usd">31715000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94582075e949-wk-Fact-4445445BDA400C731865D79D0A97DD17"
      unitRef="usd">21388000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94582075e969-wk-Fact-4E651BECBE0C27DF2A40D79D0A99ED37"
      unitRef="usd">51052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94582075e988-wk-Fact-5A618A48D23C719EB03BD79D0AA1F171"
      unitRef="usd">40556000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94582075e1007-wk-Fact-1001706181A51839FA6BD79D0AB6DB8A"
      unitRef="usd">103020000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94582075e1027-wk-Fact-CB2DA7F269E236CF0C74D79D0AC1E955"
      unitRef="usd">74190000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94582075e1047-wk-Fact-A4755F752FFD506511ABD79D0A9C3184"
      unitRef="usd">-33504000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94582075e1067-wk-Fact-A36DEE2B4E4D29819B8CD79D0AB05049"
      unitRef="usd">-19140000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94582075e1087-wk-Fact-8061ABF127A296F024F9D79D0AAC1345"
      unitRef="usd">-77401000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94582075e1108-wk-Fact-D72A939BDE86808C12BDD79D0A95A665"
      unitRef="usd">-40137000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94582075e1129-wk-Fact-8C5E22E5FA6DE034AE2AD79D0AA720DF"
      unitRef="usd">3148000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94582075e1148-wk-Fact-93EE227F4D4059028B53D79D0A9D73C2"
      unitRef="usd">2500000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94582075e1167-wk-Fact-57F43E3FE824FDA112C9E7D7F7429080"
      unitRef="usd">4842000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94582075e1187-wk-Fact-303AC8345A95042D0E17D79D0A99891C"
      unitRef="usd">3310000</us-gaap:InterestAndOtherIncome>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94582075e1207-wk-Fact-E6E469E7D668848601EDD79D0AA6963A"
      unitRef="usd">-30356000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94582075e1227-wk-Fact-ED7EC79FAB86196C138ED79D0AB6DB62"
      unitRef="usd">-16640000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94582075e1247-wk-Fact-196061D9DAA4298342ABD79D0AC38062"
      unitRef="usd">-72559000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94582075e1268-wk-Fact-D9287DD0D5B87C14CB22D79D0ABA2F9C"
      unitRef="usd">-36827000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94582075e1289-wk-Fact-1EEBBAFF58FB27E18596D79D0A9780E3"
      unitRef="usd">-72000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94582075e1309-wk-Fact-D259F091182A9D6EF6D0D79D0A9CBAA6"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94582075e1328-wk-Fact-C398701DA594F86769A7E7D7F73F1EDD"
      unitRef="usd">-125000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94582075e1349-wk-Fact-72B4064E24C835452C1AD79D0A9E4B53"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94582075e1375-wk-Fact-524C04F00A6F600F373D64F2821068BF"
      unitRef="usd">-30284000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94582075e1395-wk-Fact-9E8B80E7D9C68B3BAEC9D79D0A96A909"
      unitRef="usd">-16640000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94582075e1415-wk-Fact-5F454D89C0AADD83986ED79D0AAA041F"
      unitRef="usd">-72434000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94582075e1436-wk-Fact-A5E46909F15586123D16D79D0A9902AE"
      unitRef="usd">-36827000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d94582075e1460-wk-Fact-3DD3C47A023492ED6DD4D79D0AAE1DBE"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d94582075e1480-wk-Fact-62D1BCF07F2F4796892DD79D0AA90914"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d94582075e1500-wk-Fact-DC0F7D7B34F97E0942CEE7D7F7384E28"
      unitRef="usdPerShare">-0.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q2YTD"
      decimals="2"
      id="d94582075e1521-wk-Fact-86EE9A1E001F25121A22D79D0A94A2C7"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94582075e1540-wk-Fact-125BA32C097D1DC3719AD79D0AB32604"
      unitRef="shares">114382000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94582075e1559-wk-Fact-42ADE23DA55EC674605FD79D0AA8ADB2"
      unitRef="shares">97267000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94582075e1578-wk-Fact-DF42435B61B623594D6AE7D7F72D094D"
      unitRef="shares">108360000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94582075e1598-wk-Fact-AB51120060878CD44492D79D0AAB0479"
      unitRef="shares">91831000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94577302e659-wk-Fact-E6E469E7D668848601EDD79D0AA6963A"
      unitRef="usd">-30356000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94577302e679-wk-Fact-ED7EC79FAB86196C138ED79D0AB6DB62"
      unitRef="usd">-16640000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94577302e699-wk-Fact-196061D9DAA4298342ABD79D0AC38062"
      unitRef="usd">-72559000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94577302e720-wk-Fact-D9287DD0D5B87C14CB22D79D0ABA2F9C"
      unitRef="usd">-36827000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94577302e736-wk-Fact-EE8977DB94F0070F369BD79D0AD61208"
      unitRef="usd">1442000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94577302e755-wk-Fact-5EDC50C2D2F10CA4068ED79D0AD829E2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94577302e774-wk-Fact-96AD4EB7CBE7308400B9E7EA2C549F78"
      unitRef="usd">-62000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94577302e795-wk-Fact-C67BC7681AE010F176BED79D0ADB3C72"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94577302e815-wk-Fact-5CC85C6B1D1FCB22EACFD79D0AD6D523"
      unitRef="usd">484000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94577302e834-wk-Fact-ADD23CF5EBAC892DB015D79D0AD45BDF"
      unitRef="usd">230000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94577302e853-wk-Fact-36DFA4688BB8D1F7FE7EE7EA2C50F42C"
      unitRef="usd">737000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94577302e873-wk-Fact-E645978D9CE423398C3FD79D0AD50260"
      unitRef="usd">131000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94577302e893-wk-Fact-6DE645BBD2FE64B9FDC9D79D0ADAB0DC"
      unitRef="usd">-28430000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94577302e913-wk-Fact-EDD8873C6710AA4F3165D79D0ADA47CC"
      unitRef="usd">-16410000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94577302e933-wk-Fact-5098DCEAF1C921DD42ADD79D0AD35810"
      unitRef="usd">-71884000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94577302e954-wk-Fact-CD42A610A1628FBB73A7D79D0AD21CA8"
      unitRef="usd">-36696000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94577302e975-wk-Fact-5A37E6433D24F91845F4D79D0ADB318D"
      unitRef="usd">-72000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94577302e995-wk-Fact-43CCE8728075902ECFAAD79D0AD793F7"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94577302e1014-wk-Fact-DE5DA36979CC03A66D92E7EA2C4DBF33"
      unitRef="usd">-125000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94577302e1035-wk-Fact-A19357C55E72AB62B9E4D79D0AD51016"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94577302e1060-wk-Fact-92E5FB47C4BB404FD1F4D79D0AD58EB8"
      unitRef="usd">-28358000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94577302e1080-wk-Fact-DA82AB275826BB4FEE23D79D0ADBF6A3"
      unitRef="usd">-16410000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94577302e1100-wk-Fact-08A0B59588F2AF7C39ACD79D0ACE0042"
      unitRef="usd">-71759000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94577302e1121-wk-Fact-676981C617365AE7EAE0D79D0AD16C37"
      unitRef="usd">-36696000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e808-wk-Fact-28D8BC2E9BEA056C33BFD79D0AAEBF69"
      unitRef="shares">102188</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e827-wk-Fact-BBD7D0B43BD54AD6865CD79D0AB9B9B4"
      unitRef="usd">1022000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e846-wk-Fact-C6A5B8BE9E4E109F766FD79D0AAA8737"
      unitRef="usd">929632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e866-wk-Fact-5E3AAC5FB352D640207CD79D0AA9B18F"
      unitRef="usd">-562696000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e886-wk-Fact-16A4C01D7C388EA0B05CD79D0AA6FE58"
      unitRef="usd">-1440000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d94591244e906-wk-Fact-D8215CA7968732EF2F10D79D0ABDBA48"
      unitRef="usd">739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94591244e926-wk-Fact-9498F1B95CD7A6294375D79D0AB77712"
      unitRef="usd">367257000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1
      contextRef="FD2019Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e994-wk-Fact-69358C537CB769F8A6B8D79D0ABCCAED"
      unitRef="usd">897000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
    <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1
      contextRef="FD2019Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94591244e1052-wk-Fact-8FFDE621A3A26B7C743DD79D0AACE34F"
      unitRef="usd">897000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e1072-wk-Fact-538AF2FC41255E964D95D79D0ABD7BE1"
      unitRef="shares">141</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e1086-wk-Fact-5F17FB2AB40724E3FC75D79D0AAE86EE"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e1105-wk-Fact-6440E2357DE2C92ED569D79D0AB06DDB"
      unitRef="usd">215000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d94591244e1183-wk-Fact-6FE7A581ED557CA9978CD79D0AAFBC2B"
      unitRef="usd">216000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e1236-wk-Fact-84B85B1501C05BF74671D79D0AB759EF"
      unitRef="usd">258000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d94591244e1315-wk-Fact-86B8911A10FBE745B4A1D79D0ABD0C4D"
      unitRef="usd">258000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e1369-wk-Fact-7A1995654C06691250C5D79D0AB5D209"
      unitRef="usd">4523000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d94591244e1447-wk-Fact-A4E5A61456F9E01B7F7DD79D0AA211C3"
      unitRef="usd">4523000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e1539-wk-Fact-CECFFE40AD0A7BCBFA59D79D0AB68999"
      unitRef="usd">1504000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d94591244e1579-wk-Fact-5534DEFB859915846ED9D79D0ABA8FD2"
      unitRef="usd">1504000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e1672-wk-Fact-F5EA134A45339759236DD79D0AB8D666"
      unitRef="usd">253000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d94591244e1711-wk-Fact-E5B885D623E4BCC735FDD79D0AACB2AC"
      unitRef="usd">253000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e1784-wk-Fact-C732B76143EC5C185F19D79D0AA54C05"
      unitRef="usd">-42150000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d94591244e1823-wk-Fact-EBBC1B9BE5350981FD3CD79D0AAA3125"
      unitRef="usd">-53000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d94591244e1844-wk-Fact-1637F39FEBBCE4DF9FBFD79D0AAAD261"
      unitRef="usd">-42203000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e1865-wk-Fact-1B08BCDBDC30A67CAAF7D79D0AAE81E2"
      unitRef="shares">102329</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e1879-wk-Fact-8EDB323E06C03B0B6CEBD79D0AB96A95"
      unitRef="usd">1023000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e1898-wk-Fact-0FD1E7C9D895AD7B7E69D79D0AA911F5"
      unitRef="usd">934112000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e1918-wk-Fact-C4917C29FD221D324A44D79D0AA86CCC"
      unitRef="usd">-603949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e1938-wk-Fact-B733EAAE2B899D42DC0FD79D0ABEE106"
      unitRef="usd">-2691000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d94591244e1958-wk-Fact-0789D4D645317C9574A1D79D0AA97D40"
      unitRef="usd">686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1"
      decimals="-3"
      id="d94591244e1978-wk-Fact-7BF2E015FA7D300655E4D79D0AC0FD85"
      unitRef="usd">329181000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e1999-wk-Fact-860ED203DE331B3EC33AE7EBACE15F2E"
      unitRef="shares">492</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e2013-wk-Fact-00383A463E57D71F34D9E7EBACEEA3AE"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e2032-wk-Fact-A274AA10376B81C47C02E7EBACE5EBCE"
      unitRef="usd">2439000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94591244e2110-wk-Fact-92982039B3F96293C851D79D0ABACF61"
      unitRef="usd">2444000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e2130-wk-Fact-819B5BF81916255A2033E7EBACE916FB"
      unitRef="shares">132</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e2144-wk-Fact-CA7A4D91D55AE7B56B3CE7EBACF6E1BA"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e2163-wk-Fact-B566972FF1C3EDD711C3E7EBACDC0D42"
      unitRef="usd">1137000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94591244e2241-wk-Fact-BAFA77E21AA8E74E26E0D79D0AAF4ECA"
      unitRef="usd">1138000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e2261-wk-Fact-EAD7D58978C56151D10ED79D0AA1B3D4"
      unitRef="shares">12650</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e2275-wk-Fact-8DB1248E64F8AC0C113CD79D0ABE2A75"
      unitRef="usd">127000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e2294-wk-Fact-2DCF75B98671CC55958DE7ED9566BE66"
      unitRef="usd">136439000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94591244e2372-wk-Fact-CD8007C53ADD16C7EF98D79D0AA12BC1"
      unitRef="usd">136566000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e2425-wk-Fact-964109E19A21F222D8E8FB7C653D18BA"
      unitRef="usd">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94591244e2503-wk-Fact-1D050BBB50D7294A1B36FB7C6C0E4C30"
      unitRef="usd">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e2557-wk-Fact-C763E5ADAA28B2D9C72DE7EBACF21414"
      unitRef="usd">4867000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94591244e2635-wk-Fact-32F678DAA9467C083DDAD79D0ABC5A6E"
      unitRef="usd">4867000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e2727-wk-Fact-84E797D463B35CCEBC24E7EBACD715A4"
      unitRef="usd">-1442000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94591244e2766-wk-Fact-030A11474AE9B7CB59EAD79D0AC3370E"
      unitRef="usd">-1442000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e2858-wk-Fact-427F9B211313E75AA8B7E7EBACC71781"
      unitRef="usd">484000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94591244e2897-wk-Fact-5CC85C6B1D1FCB22EACFD79D0AD6D523"
      unitRef="usd">484000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e2970-wk-Fact-D3E053A438A9F55320DB64F476C00845"
      unitRef="usd">-30284000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d94591244e3009-wk-Fact-DD66E5C402CEAAF05E86E7EBACFA7662"
      unitRef="usd">-72000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94591244e3030-wk-Fact-E6E469E7D668848601EDD79D0AA6963A"
      unitRef="usd">-30356000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e3051-wk-Fact-9553FF6BA5D1154785DED79D0AA2B12E"
      unitRef="shares">115603</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e3070-wk-Fact-4452518C4A863A4614CDD79D0AC2F088"
      unitRef="usd">1156000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e3089-wk-Fact-7435E1A1DFCF1AAFB4B8D79D0AB2424E"
      unitRef="usd">1078976000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e3109-wk-Fact-DBD59724B9A989C1171DD79D0AA021C4"
      unitRef="usd">-634233000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e3129-wk-Fact-6EBE5C6C90B7EF040716D79D0AAB804D"
      unitRef="usd">-765000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="d94591244e3149-wk-Fact-15C8F710AA71D2ACAEF4D79D0AAE3394"
      unitRef="usd">614000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94591244e3169-wk-Fact-B5F04749C2EF2E4BE717D79D0AC7FA5D"
      unitRef="usd">445748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e3541-wk-Fact-7BC96A9C117CEBBDF92BD79D0AB2C743"
      unitRef="shares">85598</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e3560-wk-Fact-F6325E466082BECAEEC9D79D0AAA68A8"
      unitRef="usd">856000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e3579-wk-Fact-48A370B290E4491715C7D79D0AAABDC9"
      unitRef="usd">682809000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e3599-wk-Fact-8B419733E3F627E09A53D79D0AA8445C"
      unitRef="usd">-495479000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e3619-wk-Fact-2D651E762E729603989FD79D0AA86A4A"
      unitRef="usd">-286000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4"
      decimals="-3"
      id="d94591244e3659-wk-Fact-EC5C3E68C2CE1E8C9957D79D0AB4BF81"
      unitRef="usd">187900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1
      contextRef="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e3727-wk-Fact-116A4D8EB6FF3D3B61D7D79D0AA68C20"
      unitRef="usd">1117000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
    <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1
      contextRef="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-3"
      id="d94591244e3785-wk-Fact-284508280E6BB3DCE7F7D79D0AA8CD4B"
      unitRef="usd">1117000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e3805-wk-Fact-6C55E67DB594A2231499D79D0AABF06C"
      unitRef="shares">1443</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e3819-wk-Fact-D0CB5CBD22A401E536ABD79D0ABDC2DE"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e3838-wk-Fact-1959570AC238E0AFD505D79D0AAAD666"
      unitRef="usd">10570000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d94591244e3916-wk-Fact-31A92C6B7263DF9AD60CD79D0AAFDB70"
      unitRef="usd">10584000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e3969-wk-Fact-A8A3A113EA9699EC03A7D79D0AC5A3C2"
      unitRef="usd">3050000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d94591244e4047-wk-Fact-E9129DB3D607EF751B1FD79D0AAEBF62"
      unitRef="usd">3050000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e4139-wk-Fact-BFF86EE9B425A2A3C0A8D79D0ABAA877"
      unitRef="usd">-99000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d94591244e4179-wk-Fact-136F6B78810DAEF7D6A4D79D0AAF9C77"
      unitRef="usd">-99000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e4253-wk-Fact-D89227F8DE9DB1D565CAD79D0AACEFFB"
      unitRef="usd">-20187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d94591244e4312-wk-Fact-1BF4D2AD14723FF5F48CD79D0AC6F3C1"
      unitRef="usd">-20187000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e4333-wk-Fact-5B0D7DC1ED7EF18A5243D79D0AB848B9"
      unitRef="shares">87041</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e4347-wk-Fact-C06440E78684D629FE92D79D0AB97BA9"
      unitRef="usd">870000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e4366-wk-Fact-C5A5368F36E69ED83564D79D0AB4172E"
      unitRef="usd">696429000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e4386-wk-Fact-1C7AFA84F26112792441D79D0ABA6B41"
      unitRef="usd">-514549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e4406-wk-Fact-93CC7A0FE5BFFDA29288D79D0AB11BEA"
      unitRef="usd">-385000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q1"
      decimals="-3"
      id="d94591244e4446-wk-Fact-34535606A1AA557EEEAAD79D0AAF2146"
      unitRef="usd">182365000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e4466-wk-Fact-DD3542C982CC48382C03D79D0AB1F168"
      unitRef="shares">263</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e4480-wk-Fact-5725462223923956B3FAD79D0AB8CEE9"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e4499-wk-Fact-80F4311D3642DED13E58D79D0AB4BEDB"
      unitRef="usd">1952000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94591244e4577-wk-Fact-70907F010CBA3F4815EAD79D0AB034B6"
      unitRef="usd">1954000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e4597-wk-Fact-54DC91BD1A1EA45689BCD79D0ABA4CEA"
      unitRef="shares">163</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e4611-wk-Fact-8D24CB51E2BEBA1CDA7ED79D0AC7DC98"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e4630-wk-Fact-84BB0FFB01BBE182CA4CD79D0AC3BAC3"
      unitRef="usd">688000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94591244e4708-wk-Fact-6CBF3CBBFD4BF6F0F700D79D0AB3CC06"
      unitRef="usd">690000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e4729-wk-Fact-DFE7105114DDD3D9B1F6D79D0AB196BF"
      unitRef="shares">14157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e4743-wk-Fact-88E0574940CB05BB70DBD79D0AA7DFAC"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e4762-wk-Fact-85BEBA6E1DD4282BC37BD79D0AB5463B"
      unitRef="usd">215614000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94591244e4839-wk-Fact-3334D182EB5E0B30C86FD79D0AAA58DA"
      unitRef="usd">215756000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e4892-wk-Fact-7BF0B40AD630DC2E7938D79D0AA8F3AC"
      unitRef="usd">3514000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94591244e4970-wk-Fact-8287A838CA7BD2086510D79D0AA98DD5"
      unitRef="usd">3514000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e5062-wk-Fact-75F54DE24340477B05E6D79D0AACFA1D"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94591244e5102-wk-Fact-AB1455AB7A5EF26FC874D79D0AAE3D1D"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e5195-wk-Fact-FF614FE720B607F3D9D2D79D0AB7AC18"
      unitRef="usd">230000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94591244e5234-wk-Fact-ADD23CF5EBAC892DB015D79D0AD45BDF"
      unitRef="usd">230000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e5307-wk-Fact-494AA23CC3621D0CFCB9D79D0AC223E8"
      unitRef="usd">-16640000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94591244e5366-wk-Fact-ED7EC79FAB86196C138ED79D0AB6DB62"
      unitRef="usd">-16640000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d94591244e5387-wk-Fact-DC1A8933C875AD3A269FD79D0AB7AA7A"
      unitRef="shares">101624</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d94591244e5406-wk-Fact-8BC50779C5E50AB8BCFBD79D0ABE26B3"
      unitRef="usd">1016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d94591244e5425-wk-Fact-C0215B6DEDCBA32B0D2ED79D0ABDE770"
      unitRef="usd">918197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d94591244e5445-wk-Fact-92A448CC55525C8E6041D79D0ABA147E"
      unitRef="usd">-531189000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d94591244e5465-wk-Fact-1B78486915494C900AAFD79D0AAEF8C3"
      unitRef="usd">-157000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2"
      decimals="-3"
      id="d94591244e5505-wk-Fact-F49426CF39A7B977B9E1D79D0AAB6515"
      unitRef="usd">387867000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e609-wk-Fact-196061D9DAA4298342ABD79D0AC38062"
      unitRef="usd">-72559000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e629-wk-Fact-D9287DD0D5B87C14CB22D79D0ABA2F9C"
      unitRef="usd">-36827000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e686-wk-Fact-9D67BF31B60FF965B8BAD79D0AB58BF1"
      unitRef="usd">1583000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e705-wk-Fact-434E8D60B5BE124DDA64D79D0AB467FD"
      unitRef="usd">1207000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e725-wk-Fact-730630A17E3F963D72EBD79D0AC60AC8"
      unitRef="usd">2455000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e745-wk-Fact-77EB0F5EFD6841E6FE7AD79D0AC176B5"
      unitRef="usd">1656000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <sgmo:GainOnFreeShares
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e766-wk-Fact-0741745EAE772C8CC863D79D0ABA276A"
      unitRef="usd">551000</sgmo:GainOnFreeShares>
    <sgmo:GainOnFreeShares
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e786-wk-Fact-22C6DFE5F1140D4F00DED79D0ABE8BF6"
      unitRef="usd">0</sgmo:GainOnFreeShares>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e806-wk-Fact-FA4AB85B4052116CD1AED79D0AC4027C"
      unitRef="usd">9390000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e825-wk-Fact-2B2579233A728D46B16FD79D0AB6B46C"
      unitRef="usd">6564000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e845-wk-Fact-2044221FAB16FEF54E10D79D0ACCAEEF"
      unitRef="usd">-218000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e864-wk-Fact-70F04990B02E57664B8AD79D0AB15AB2"
      unitRef="usd">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e884-wk-Fact-ABF328D9AA13C462ED6DD79D0AB48AA7"
      unitRef="usd">-11000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e903-wk-Fact-CA2A93A18B732FBA5F04D79D0AC0BD50"
      unitRef="usd">-465000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e965-wk-Fact-7FC4E351CD0EC68B6A31D79D0ACCAEFA"
      unitRef="usd">391000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e985-wk-Fact-DB955E0175DAB7094981D79D0ABC79D0"
      unitRef="usd">322000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1006-wk-Fact-5DE2BAA6AA3AB36E514DD79D0ABDD228"
      unitRef="usd">7422000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1026-wk-Fact-3D413B97475E2A145079D79D0AC9BDA2"
      unitRef="usd">1634000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1047-wk-Fact-AD6A1535883945135B7ED79D0ABC8D5C"
      unitRef="usd">5449000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1067-wk-Fact-BF0A13457002FF832A23D79D0AB52799"
      unitRef="usd">3564000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sgmo:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1088-wk-Fact-D8707E9BA61D6326806AD79D0AB55D34"
      unitRef="usd">-1923000</sgmo:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <sgmo:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1107-wk-Fact-1B6EEBD76B05396F2CB9D79D0AC6C956"
      unitRef="usd">0</sgmo:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1127-wk-Fact-2E763E762900948F8465D79D0AB70F9D"
      unitRef="usd">1811000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1146-wk-Fact-4F620AFE09501032A35CD79D0ABAC97F"
      unitRef="usd">2733000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1166-wk-Fact-818E6D71DC3EEC7101E9D79D0AB2FCF4"
      unitRef="usd">-764000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1186-wk-Fact-79F7145AADF3CB83AA96D79D0ACCA8E6"
      unitRef="usd">-1133000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1207-wk-Fact-31FE44694C362166C655D79D0AC1140E"
      unitRef="usd">-10821000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1227-wk-Fact-16B80DEE0FEB9430969DD79D0AB0BA56"
      unitRef="usd">138474000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1247-wk-Fact-4DB8009C4F6AC8640C9AD79D0ACC6E16"
      unitRef="usd">-563000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1267-wk-Fact-EA3076AC0B50F6581AD5D79D0AC9F418"
      unitRef="usd">0</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1287-wk-Fact-3F02AF9FC26CAB9FAD6BD79D0ACCC82D"
      unitRef="usd">1327000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1306-wk-Fact-0B0DDF087104253E33E4D79D0ACB017D"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1326-wk-Fact-1BB91A03B2D30F9EE6ACD79D0AC7FFCC"
      unitRef="usd">-84712000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1346-wk-Fact-AA8BDBA9D7325D1CD7B2D79D0AC8AE82"
      unitRef="usd">104307000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1408-wk-Fact-2605385787671D0B22B1D79D0AB0DF1C"
      unitRef="usd">244306000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1428-wk-Fact-4EC444EC863B21BA42D3D79D0AB56C27"
      unitRef="usd">451240000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1449-wk-Fact-9DE40F541C3395DDFD4ED79D0AB3AB91"
      unitRef="usd">226884000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1468-wk-Fact-AE2B8019DBAC99497AE2D79D0AC8D77A"
      unitRef="usd">133297000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1488-wk-Fact-558AB24DA0C29F067445D79D0AC5AABE"
      unitRef="usd">9760000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1508-wk-Fact-FEA05576E936AC1FEBA0D79D0ABE8B08"
      unitRef="usd">5768000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1529-wk-Fact-2105E81ED4AC1364F0B2D79D0ABE38B8"
      unitRef="usd">-27182000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1549-wk-Fact-48D9E8B9F9AC1DFF8EC0D79D0AB4DA17"
      unitRef="usd">-323711000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1611-wk-Fact-12337DAD009FC84A10B0F06E1D22F76B"
      unitRef="usd">136308000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1630-wk-Fact-B287C64D6A186241C8E8D79D0AC47F8A"
      unitRef="usd">215756000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1650-wk-Fact-6358FFC31F4CD108DA8EF06E1D61B23F"
      unitRef="usd">296000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1670-wk-Fact-CDB1E878478D1CF89E0ED79D0AB06CA3"
      unitRef="usd">57000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1691-wk-Fact-362F2AB8191C3F7AB873F06E1D51C980"
      unitRef="usd">4094000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1710-wk-Fact-3222AC8410A57913947DD79D0AC461B0"
      unitRef="usd">13285000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1730-wk-Fact-B2F0133BAEB11E142127F06E1D32E958"
      unitRef="usd">140106000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1749-wk-Fact-D86F17918236C3D35849D79D0AB35703"
      unitRef="usd">228984000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1769-wk-Fact-5104D35577C0DE09ED9AF06E1D134DF6"
      unitRef="usd">592000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1788-wk-Fact-1867ED115FA69BB3A30ED79D0AC914FC"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1809-wk-Fact-C7269B6EB1E396E87CFDF06E1D70A3A0"
      unitRef="usd">28804000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1828-wk-Fact-A37A746B03BD7D11E0C6D79D0AC5DFED"
      unitRef="usd">9580000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94580089e1848-wk-Fact-DAE7BEBFA9BAF982F94AF06E1D51D7A7"
      unitRef="usd">143918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d94580089e1867-wk-Fact-71D33DAE8A4A1514D091D79D0AB294EE"
      unitRef="usd">53326000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94580089e1892-wk-Fact-88773D36DF82CA5AD75EF06E1D419FBE"
      unitRef="usd">172722000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q2"
      decimals="-3"
      id="d94580089e1911-wk-Fact-1A8FAD1695C801E7B622D79D0AB60F67"
      unitRef="usd">62906000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e1972-wk-Fact-12A3BAAD8E072E2EB895F06E1D418850"
      unitRef="usd">1679000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e1991-wk-Fact-6FFFBAB17AAD697250AFD79D0AC1BE44"
      unitRef="usd">1836000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94580089e2011-wk-Fact-830FA104E50225467601F06ED1009FB1"
      unitRef="usd">29671000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94580089e2030-wk-Fact-FD62260D919876954EF6D79D0AC6CEEB"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-4C702B131013D17116DCD79D0AE751A0-0-wk-Fact-A9DB694DD9765C67C89ED79D0AB59F53">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo Therapeutics, Inc. (&#x201c;Sangamo&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is focused on the research, development and commercialization of novel therapeutic strategies for unmet medical needs. Sangamo&#x2019;s genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins (&#x201c;ZFPs&#x201d;). Potential applications of Sangamo&#x2019;s technology include development of human therapeutics, plant agriculture and enhancement of pharmaceutical protein production.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next twelve months from the date the financial statements are issued. Sangamo will require additional financial resources to complete the development and commercialization of its products including ZFP Therapeutic products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#x2019;s business and ability to develop its technology and ZFP Therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#x2019;s stockholders, and any debt financing may include covenants that restrict the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The condensed consolidated balance sheet data at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was derived from the audited consolidated financial statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (the &#x201c;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Annual Report&#x201d;) as filed with the SEC on March&#160;1, 2019. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and footnotes thereto for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, included in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;) as result of a decision made in a joint steering committee of Pfizer and Sangamo in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to increase the project scope and related project cost, which resulted in a decrease in the measure of the proportional performance. This adjustment decreased revenue by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, increased net loss by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and increased the Company&#x2019;s basic net loss per share by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.03&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;adjustments are recorded as a component of Accumulated Other Comprehensive Income (Loss) (&#x201c;AOCI&#x201d;) within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain prior period amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.6&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from Intangible assets to Other non-current assets on the Condensed Consolidated Balance Sheet as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three months or less&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in AOCI.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the condensed consolidated balance sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2019, the Company entered into an Option Agreement (the &#x201c;Option&#x201d;) with Brammer Bio MA (&#x201c;Brammer&#x201d;) whereby Brammer granted an option to secure dedicated capacity for Sangamo for manufacturing in Brammer&#x2019;s facilities. The Company paid &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the Option, which expires on July&#160;31, 2020, and which is included in other non-current assets on the Condensed Consolidated Balance Sheets. If the Company exercises the option, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; will be applied towards future manufacturing services. If the Company does not exercise the option, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the deposit is non-refundable. The remainder will be applied towards future services initiated within five years. In addition, the Company will pay Brammer &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to assist it in establishing its manufacturing capabilities in Brisbane, CA.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&#x2019;s investment securities consist of the U.S. government-sponsored entities and various major corporations and financial institutions with high credit ratings. The free share asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective January&#160;1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606 - &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASC Topic 606&#x201d;) using the modified retrospective method, resulting in a change to its accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s contract revenues consist of strategic partnering collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, revenues related to Kite Pharma, Inc. (&#x201c;Kite&#x201d;), a wholly-owned subsidiary of Gilead Sciences, Inc., the hemoglobinopathies agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#x201c;Sanofi&#x201d;)), and the Company&#x2019;s hemophilia A collaboration agreement with Pfizer represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the Company&#x2019;s total revenue, excluding the above change in estimate. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, revenues related to Kite, the Company&#x2019;s hemophilia A collaboration agreement with Pfizer and the hemoglobinopathies agreement with Sanofi represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the Company&#x2019;s total revenue. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, revenues related to the Company&#x2019;s hemophilia A collaboration agreement with Pfizer, the hemoglobinopathies agreement with Sanofi and the agreement with Kite represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the Company&#x2019;s total revenue. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, revenues related to the Company&#x2019;s hemophilia A collaboration agreement with Pfizer, Kite and the hemoglobinopathies agreement with Sanofi represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the Company&#x2019;s total revenue. Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Funds received from third parties under contract or grant arrangements are recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#x2019;s development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Simplified Disclosure&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No.&#160;33-10532, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Disclosure Update and Simplification&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as updated. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders&#x2019; equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments are effective for all filings made on or after November&#160;5, 2018. As such, the Company adopted these SEC amendments on November&#160;5, 2018 and has presented the analysis of changes in stockholders&#x2019; equity in these interim financial statements for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; presented in this Quarterly Report on Form 10-Q. The Company&#x2019;s adoption of these SEC amendments had no material effect on the Company&#x2019;s reporting of financial position, results of operations, cash flows or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Accounting for Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-2&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASC Topic 842&#x201d;). ASC Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a ROU asset and corresponding liability, measured at the present value of the lease payments. On January&#160;1, 2019, the Company adopted ASC Topic 842 using the modified retrospective approach with a cumulative-effect adjustment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.9&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflected as a decrease to the opening balance of accumulated deficit as of the adoption date. Results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are presented under ASC Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 &#x2014; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASC Topic 840&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASC Topic 842 provides a number of optional practical expedients in transition. The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the effective date and did not elect the practical expedient pertaining to land easements as this is not applicable to the current contract portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The impact of the adoption of ASC Topic 842 on the accompanying Condensed Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Adjustments Due to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;the Adoption of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC Topic 842&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;January 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(62,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid rent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-indent:9px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-indent:9px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred rent&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;271&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(271&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-indent:9px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Build-to-suit lease obligation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(27,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-indent:9px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(562,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(561,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Operating lease liabilities &#x2013; current and deferred rent are included in accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Build-to-suit lease obligation and operating lease liabilities &#x2013; long-term are included in long-term portion of lease liabilities on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The adjustments due to the adoption of ASC Topic 842 primarily related to the recognition of operating lease ROU assets and operating lease liabilities for the Company&#x2019;s leases. In addition, the adoption of ASC Topic 842 resulted in a change in accounting of the build-to-suit component of two leases under ASC Topic 840 to operating leases under ASC Topic 842 and as a result the Company derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as the Company had been deemed to own these buildings under ASC Topic 840. For additional discussion of the build-to-suit properties, see &#x201c;Note 7 &#x2013; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property and equipment, net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x201d; to the Company&#x2019;s consolidated financial statements included in its Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; filed with the SEC on March&#160;1, 2019. For a description of the leases, see &#x201c;Note 8 &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&#x2013; Commitments and Contingencies &#x2013; Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x201d; in these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASC Topic 808&#x201d;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January&#160;1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the FASB issued ASU No. 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASU 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x201d;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the goodwill impairment test. ASU 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; requires goodwill impairment to be measured as the amount by which a reporting unit&#x2019;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-148DF0E835350A3306F2D79D0AE7919E-0-wk-Fact-4F90F0E8204CBA37AE0DD79D0A995226">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The condensed consolidated balance sheet data at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was derived from the audited consolidated financial statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (the &#x201c;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Annual Report&#x201d;) as filed with the SEC on March&#160;1, 2019. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and footnotes thereto for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, included in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Annual Report.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q2YTD"
      id="TextSelection-D0843D8BA68FD8E8FA9FD79D0AE75A54-0-wk-Fact-C8C359F4CF6D0C30CE7AD79D0AB4FDB5">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;) as result of a decision made in a joint steering committee of Pfizer and Sangamo in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to increase the project scope and related project cost, which resulted in a decrease in the measure of the proportional performance. This adjustment decreased revenue by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, increased net loss by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and increased the Company&#x2019;s basic net loss per share by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.03&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_sgmo_ChangeInCollaborationAgreementScopeMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d94582067e528-wk-Fact-331D9CE3AD9326851825D79D0AB934A1"
      unitRef="usd">-3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_sgmo_ChangeInCollaborationAgreementScopeMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d94582067e532-wk-Fact-F9B1914B5F0B464EBC46D79D0AAEB0E9"
      unitRef="usd">-3000000.0</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_sgmo_ChangeInCollaborationAgreementScopeMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d94582067e536-wk-Fact-A4535B7A140596800744D79D0AB6CDDF"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-ACD2ECAF9B6439127AA6D79D0AE6A487-0-wk-Fact-F78D984A3C488131BB1CD79D0AAD5599">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;adjustments are recorded as a component of Accumulated Other Comprehensive Income (Loss) (&#x201c;AOCI&#x201d;) within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="FD2019Q2YTD"
      id="TextSelection-3964764824D48808E003D79D0AE77BAD-0-wk-Fact-F0133A85021A6F24E72BD79D0AB1B5D7">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain prior period amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.6&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from Intangible assets to Other non-current assets on the Condensed Consolidated Balance Sheet as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:PriorPeriodReclassificationAdjustment
      contextRef="FD2018Q4YTD_us-gaap_BalanceSheetLocationAxis_sgmo_IntangibleAssetsMember"
      decimals="-5"
      id="d94582067e573-wk-Fact-2EEAE80528ECE3B2EBEFD79D0AA1CB79"
      unitRef="usd">-600000</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-9FB097BAC53B5FB7037ED79D0AE65E9E-0-wk-Fact-84189C8D155F9F29190FD79D0AB34338">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three months or less&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="FD2019Q2YTD"
      id="TextSelection-E03A141FF7B95F85A885D79D0AE6A79F-0-wk-Fact-BF1EE5C705FAA49399D4D79D0AAF72E6">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in AOCI.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="FD2019Q2YTD"
      id="TextSelection-429466946C3CCD79D674256A0E86BABD-0-wk-Fact-D50B276EA02CA31FCE6E2570FA7278EC">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the condensed consolidated balance sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2019, the Company entered into an Option Agreement (the &#x201c;Option&#x201d;) with Brammer Bio MA (&#x201c;Brammer&#x201d;) whereby Brammer granted an option to secure dedicated capacity for Sangamo for manufacturing in Brammer&#x2019;s facilities. The Company paid &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the Option, which expires on July&#160;31, 2020, and which is included in other non-current assets on the Condensed Consolidated Balance Sheets. If the Company exercises the option, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; will be applied towards future manufacturing services. If the Company does not exercise the option, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the deposit is non-refundable. The remainder will be applied towards future services initiated within five years. In addition, the Company will pay Brammer &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to assist it in establishing its manufacturing capabilities in Brisbane, CA.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DepositAssets
      contextRef="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember"
      decimals="-5"
      id="d94582067e624-wk-Fact-281B596E578173D49273626F7C07844D"
      unitRef="usd">3000000.0</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember"
      decimals="-5"
      id="d94582067e628-wk-Fact-281B596E578173D49273626F7C07844D"
      unitRef="usd">3000000.0</us-gaap:DepositAssets>
    <sgmo:DepositAssetsNonrefundable
      contextRef="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember"
      decimals="-5"
      id="d94582067e632-wk-Fact-AAB672EC8B0854F1E7BC6270CD92EA60"
      unitRef="usd">1500000</sgmo:DepositAssetsNonrefundable>
    <us-gaap:OtherCommitment
      contextRef="I2019Q2Apr30_srt_CounterpartyNameAxis_sgmo_BrammerBioMAMember_us-gaap_OtherCommitmentsAxis_sgmo_ManufacturingCapabilityEstablishmentMember"
      decimals="-5"
      id="d94582067e636-wk-Fact-D2179F2EFD1F2B6B457C631BD62DF10F"
      unitRef="usd">2000000.0</us-gaap:OtherCommitment>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-7EFD3A14BA1BBECB84BCD79D0AE6EB97-0-wk-Fact-F6E367578CA22C96EE9AD79D0AB66444">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&#x2019;s investment securities consist of the U.S. government-sponsored entities and various major corporations and financial institutions with high credit ratings. The free share asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-648FE0E52A8B54918764D79D0AE60D7F-0-wk-Fact-1E19345C7E334F6CA205D79D0AB1C41E">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-D24F68CEFD815B0FFAE4D79D0AE7DFA0-0-wk-Fact-245EBA40AF39872BB9BCD79D0AB1B8E4">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective January&#160;1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606 - &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASC Topic 606&#x201d;) using the modified retrospective method, resulting in a change to its accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s contract revenues consist of strategic partnering collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, revenues related to Kite Pharma, Inc. (&#x201c;Kite&#x201d;), a wholly-owned subsidiary of Gilead Sciences, Inc., the hemoglobinopathies agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#x201c;Sanofi&#x201d;)), and the Company&#x2019;s hemophilia A collaboration agreement with Pfizer represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the Company&#x2019;s total revenue, excluding the above change in estimate. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, revenues related to Kite, the Company&#x2019;s hemophilia A collaboration agreement with Pfizer and the hemoglobinopathies agreement with Sanofi represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the Company&#x2019;s total revenue. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, revenues related to the Company&#x2019;s hemophilia A collaboration agreement with Pfizer, the hemoglobinopathies agreement with Sanofi and the agreement with Kite represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the Company&#x2019;s total revenue. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, revenues related to the Company&#x2019;s hemophilia A collaboration agreement with Pfizer, Kite and the hemoglobinopathies agreement with Sanofi represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the Company&#x2019;s total revenue. Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Funds received from third parties under contract or grant arrangements are recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#x2019;s development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e713-wk-Fact-85BED998E3CD5E85E286D79D0AB27020"
      unitRef="number">0.61</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e717-wk-Fact-90E3A4AADE915B6584DDD79D0AB1DE04"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e721-wk-Fact-2277ECC0407C04A6AEB2EB8235422D50"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e734-wk-Fact-9B1D53637E45EA5FA873491A714D0474"
      unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e738-wk-Fact-38D52B276DB79F94B688491AA9EC4396"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e742-wk-Fact-AD8E4C8F18D5B33B9FC9491ACD10FD3C"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e755-wk-Fact-A04BB5DA10CFFAA46009D79D0AB65ED1"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e759-wk-Fact-7F48C83BAAAF5FD49B8FD79D0AAF2391"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e763-wk-Fact-70B0CAB3E4AF8953FB6ED79D0AB2357A"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e776-wk-Fact-7ECA6C6E4867385B5BBC491CA738DACE"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e780-wk-Fact-4E6B653E5ADE3E41DB40491D1C6AE0E2"
      unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d94582067e784-wk-Fact-26952926C853EC0006E5491D45C33B8C"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-849DD3E7599E2B1E0CECD79D0AE7614A-0-wk-Fact-AEAEE6A9228F607A43EFD79D0AB59E7A">&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Simplified Disclosure&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No.&#160;33-10532, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Disclosure Update and Simplification&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as updated. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders&#x2019; equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments are effective for all filings made on or after November&#160;5, 2018. As such, the Company adopted these SEC amendments on November&#160;5, 2018 and has presented the analysis of changes in stockholders&#x2019; equity in these interim financial statements for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; presented in this Quarterly Report on Form 10-Q. The Company&#x2019;s adoption of these SEC amendments had no material effect on the Company&#x2019;s reporting of financial position, results of operations, cash flows or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Accounting for Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-2&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASC Topic 842&#x201d;). ASC Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a ROU asset and corresponding liability, measured at the present value of the lease payments. On January&#160;1, 2019, the Company adopted ASC Topic 842 using the modified retrospective approach with a cumulative-effect adjustment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.9&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflected as a decrease to the opening balance of accumulated deficit as of the adoption date. Results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are presented under ASC Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 &#x2014; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASC Topic 840&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ASC Topic 842 provides a number of optional practical expedients in transition. The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the effective date and did not elect the practical expedient pertaining to land easements as this is not applicable to the current contract portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASC Topic 808&#x201d;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January&#160;1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the FASB issued ASU No. 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;ASU 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x201d;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the goodwill impairment test. ASU 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; requires goodwill impairment to be measured as the amount by which a reporting unit&#x2019;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-4&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d94582067e833-wk-Fact-E3D7F9540A8AE62834F4D79D0AA7D1EC"
      unitRef="usd">900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-BBFE8CA8E501CA1E6361D79D0AE7D490-0-wk-Fact-4CD08C06BC43A9394B6ED79D0AAD31EB">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The impact of the adoption of ASC Topic 842 on the accompanying Condensed Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Adjustments Due to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;the Adoption of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC Topic 842&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;January 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(62,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid rent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-indent:9px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-indent:9px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred rent&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;271&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(271&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-indent:9px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Build-to-suit lease obligation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(27,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-indent:9px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(562,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(561,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Operating lease liabilities &#x2013; current and deferred rent are included in accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Build-to-suit lease obligation and operating lease liabilities &#x2013; long-term are included in long-term portion of lease liabilities on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94582067e1029-wk-Fact-72F3564834CE2CB30F0BD79D0ABE3437"
      unitRef="usd">78723000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1048-wk-Fact-9085195DBE9B96121186D79D0A9DF89B"
      unitRef="usd">-62500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1068-wk-Fact-7F3771F37E4BD6C3F459D79D0A9A6896"
      unitRef="usd">16223000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1103-wk-Fact-02FAD1B2901E49240DD1D79D0A9A703D"
      unitRef="usd">8753000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1122-wk-Fact-F6F53C6E0F83E751408CD79D0A98C858"
      unitRef="usd">8753000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidRent
      contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1162-wk-Fact-6EB419470AEE73895F58D79D0A992B05"
      unitRef="usd">36025000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1181-wk-Fact-43F510B2DBAA0F7D412DD79D0A9C47FE"
      unitRef="usd">36025000</us-gaap:PrepaidRent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1347-wk-Fact-71EBEAD5C0138A2F6956D79D0A9D994A"
      unitRef="usd">1408000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1366-wk-Fact-EFEF8D33FC3B396291C9D79D0A99B0F2"
      unitRef="usd">1408000</us-gaap:OperatingLeaseLiabilityCurrent>
    <sgmo:DeferredRentNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94582067e1389-wk-Fact-C77EEF3804C40866D6ADD79D0A9A8199"
      unitRef="usd">271000</sgmo:DeferredRentNoncurrent>
    <sgmo:DeferredRentNoncurrent
      contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1408-wk-Fact-0EA8574F16263EF7FB5FD79D0A9BCE85"
      unitRef="usd">-271000</sgmo:DeferredRentNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4_us-gaap_LeaseArrangementTypeAxis_sgmo_BuildToSuitLeaseMember"
      decimals="-3"
      id="d94582067e1451-wk-Fact-ACC03E9573B41CA1A5F1D79D0A98FBFA"
      unitRef="usd">27689000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_LeaseArrangementTypeAxis_sgmo_BuildToSuitLeaseMember"
      decimals="-3"
      id="d94582067e1470-wk-Fact-B3FDB4993827F73D75D4D79D0A97561F"
      unitRef="usd">-27689000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1532-wk-Fact-0F9E0FFDD15C3B6E5013D79D0A9D981F"
      unitRef="usd">7933000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1551-wk-Fact-810A7B1D5C74074312BFD79D0A98EAF3"
      unitRef="usd">7933000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94582067e1635-wk-Fact-8FCDFAB3D8A2196E10BED79D0ABEA42C"
      unitRef="usd">-562696000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I2019Q1Jan01_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1655-wk-Fact-B0C057104C8D891BEC96D79D0A9877CD"
      unitRef="usd">897000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d94582067e1674-wk-Fact-E2BA0DCD58F9119D9DCAD79D0A9BE490"
      unitRef="usd">-561799000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-CA76499ABE164490D3BAD79D0AE80315-0-wk-Fact-E23056E65531E19527B1D79D0ACB4EDC">FAIR VALUE MEASUREMENTS&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale marketable securities and the free share asset/liability. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;padding-left:96px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;padding-left:96px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;padding-left:96px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, available-for-sale marketable securities and the free share asset/liability are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, 2019&lt;br/&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;170,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;170,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;280,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;280,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;382,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;310,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Free shares asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;br/&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;177,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;177,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;363,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Free shares liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Free Share Asset/Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a result of the July&#160;20, 2018 Share Purchase Agreement (&#x201c;SPA&#x201d;) with TxCell S.A., a French &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;soci&#xe9;t&#xe9; anonyme&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (&#x201c;TxCell&#x201d;) (see Note 10 &#x2014; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Acquisition of TxCell S.A.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;), the Company entered into arrangements with the holders of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;477,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &#x201c;free shares&#x201d; of TxCell pursuant to which the Company has the right to purchase such shares from the holders thereof (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#x201c;Monte Carlo simulation model&#x201d;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Condensed Consolidated Statements of Operations. The number of free shares has not changed since the Acquisition Date. The free shares liability was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and the Company recognized a gain due to an increase in the fair value of the free shares of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.5&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; bringing the balance to an asset of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Free Shares valuation assumptions:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo Stock Price (USD)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;TxCell Stock Price (EUR)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;EUR / USD Exchange Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Estimated Correlation Sangamo and TxCell Stock Prices&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;72.2%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo Stock Price (USD) Volatility Estimate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77.6%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79.9%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;TxCell Stock Price (EUR) Volatility Estimate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76.2%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.6%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;EUR / USD Exchange Rate Volatility Estimate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.7%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk Free Rate and Cost of Debt by Expected Exercise Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Varies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Varies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-E3C30E72C8008F417CF4D79D0AE7172D-0-wk-Fact-ECA7BD8C4B04FE2CBD50D79D0ACCC5C2">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, available-for-sale marketable securities and the free share asset/liability are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, 2019&lt;br/&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;170,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;170,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;280,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;280,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;382,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;310,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Free shares asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;br/&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;177,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;177,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;363,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Free shares liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94585328e837-wk-Fact-44BB882107E0F381E95ED79D0AD91E52"
      unitRef="usd">71490000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94585328e856-wk-Fact-13D237A45105768899C2D79D0AD49A9F"
      unitRef="usd">71490000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94585328e875-wk-Fact-0EA13261F28DE2FF021D165EBA9E94FA"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94585328e895-wk-Fact-95DAC46929354ECE17E0165E6AABFA4C"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e910-wk-Fact-5D9F3A6CF34C6261093CD79D0AD6423F"
      unitRef="usd">30441000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e929-wk-Fact-7F7E2AFD05C4FC2745B5165DE0830A7E"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e948-wk-Fact-3785F827E1673F8F6EEBD79D0AD9A511"
      unitRef="usd">30441000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e968-wk-Fact-E79ABA0EAEDF26FD224E165E70110399"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e988-wk-Fact-EF43C30DE4F40235477CD79D0AD54B68"
      unitRef="usd">101931000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1007-wk-Fact-6786CF8C804FEDD0A689D79D0AD93D08"
      unitRef="usd">71490000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1026-wk-Fact-CF05E28C8DCAAA8EA47BD79D0AD3D759"
      unitRef="usd">30441000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1046-wk-Fact-E2B80D095A8F360FDC79165E7554E87F"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e1148-wk-Fact-0D5620D859E1BA8AE6F4D79D0AD40A88"
      unitRef="usd">170953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e1167-wk-Fact-1920DC809005411C3B13165F8E39403D"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e1186-wk-Fact-6DE509C5CD0B64759D6DD79D0AD6B8EA"
      unitRef="usd">170953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e1206-wk-Fact-3CAC3327B080BF4D24A0166026CD8ED8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e1226-wk-Fact-A76EEC92B78AB3966868D79D0AD492AC"
      unitRef="usd">71383000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e1245-wk-Fact-DB9234446FAA12F84C31165F92D1F1B6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e1264-wk-Fact-AB2A36244AF2BEBFBF67D79D0AD958F5"
      unitRef="usd">71383000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e1284-wk-Fact-4A57069CA41E280E0A2716602B59A893"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e1304-wk-Fact-0EFA6101044078F5B374D79D0AD74129"
      unitRef="usd">37991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e1323-wk-Fact-AE4C0E2861D601478A2F165F989BBBB7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e1342-wk-Fact-993BBD2E88919FD7960CD79D0AD7965D"
      unitRef="usd">37991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e1362-wk-Fact-7D2F5885E3CCD2380B3916602FDC52D1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1383-wk-Fact-E4F7A3992DD514A6B821D79D0AD88F86"
      unitRef="usd">280327000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1402-wk-Fact-2E2B18A0B15C9F037541165F9E63F24C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1421-wk-Fact-656BB36B32BD37918668D79D0AD3EC01"
      unitRef="usd">280327000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1441-wk-Fact-0ECC28F00CFA1CAE3AD61660347E17DA"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1466-wk-Fact-005D34D6311D380189AFD79D0AD49866"
      unitRef="usd">382258000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1485-wk-Fact-DE69800E086FFBC8D398D79D0AD5C71F"
      unitRef="usd">71490000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1504-wk-Fact-06E5296174A007CF76A6D79D0AD8BE5D"
      unitRef="usd">310768000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e1524-wk-Fact-4B87E019D6373062E87D166038157A67"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember"
      decimals="-3"
      id="d94585328e1626-wk-Fact-2B6B134FE292C41292ADD79D0AD7905B"
      unitRef="usd">361000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember"
      decimals="-3"
      id="d94585328e1645-wk-Fact-A222215C9E92A7B0D4C91660C5008892"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember"
      decimals="-3"
      id="d94585328e1664-wk-Fact-1F724A32775AAAE3A3E61660CBFC2763"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesAssetMember"
      decimals="-3"
      id="d94585328e1684-wk-Fact-A7B66B03D3C4BC91CA8BD79D0AD7DADC"
      unitRef="usd">361000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94585328e2055-wk-Fact-E99D7D61A677C45268DED79D0ADB5E46"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94585328e2074-wk-Fact-26C0A527F26748FE2125D79D0ADC5A69"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94585328e2093-wk-Fact-FF91F2C4CD1ABD273F33165C758DE5D4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94585328e2113-wk-Fact-A864B28B099FED160C9F165C7F318601"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2128-wk-Fact-ADEFF80580F1C41039ADD79D0ADEBCB6"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2147-wk-Fact-6691C7D18D91F7FB3A69D79D0AC6679C"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2166-wk-Fact-8CBF1531D0CB03122F6F165C83A62C19"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2186-wk-Fact-9316B23A5C78AF09D805165C8A07E28A"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e2288-wk-Fact-565344D7198B5AF922AFD79D0ADB3026"
      unitRef="usd">177224000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e2307-wk-Fact-600E961310278992E9691662DDB90A66"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e2326-wk-Fact-9951C1138669A094A8AFD79D0ADD51F3"
      unitRef="usd">177224000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94585328e2346-wk-Fact-4D66B70D55EB805927D616624DC914C9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e2366-wk-Fact-CE0C96FFED9A5F5C32C2D79D0ADC158B"
      unitRef="usd">63870000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e2385-wk-Fact-B6FFD2204135EF0254671662E1FE3CD8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e2404-wk-Fact-FB1A22C10A794B98EE46D79D0AD98D2C"
      unitRef="usd">63870000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e2424-wk-Fact-89EF59ACC111E7C09F301662530898EA"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e2444-wk-Fact-ABE74AB470FFC929355FD79D0ADE6DC8"
      unitRef="usd">18621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e2463-wk-Fact-2A1197A2E25B537561F81662E6C13AB1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e2482-wk-Fact-146E276D5A1F94ECA19CD79D0ADD231D"
      unitRef="usd">18621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94585328e2502-wk-Fact-A575576FB2C73ED6F8201662584097C4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2522-wk-Fact-BE4835F3A775F3833AE6D79D0ADC44F7"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2541-wk-Fact-BDE74379EE7EF252AC271662EBDCDA66"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2560-wk-Fact-444C3294D7DAA1238900D79D0ADE390E"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2580-wk-Fact-5C8B7B9B1C99B63E118A16625D9E3036"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2606-wk-Fact-F19F36E782D1D3977757D79D0ACFC5DC"
      unitRef="usd">363006000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2625-wk-Fact-6D4460C47BFE5FAEB086D79D0AD6E1EC"
      unitRef="usd">103291000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2644-wk-Fact-67CC27EB3C50B4776737D79D0ACEABA1"
      unitRef="usd">259715000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d94585328e2664-wk-Fact-74083BBBE7014941669D166261C6516E"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember"
      decimals="-3"
      id="d94585328e2766-wk-Fact-A498397E118C7AD7D9F1D79D0ADAD67C"
      unitRef="usd">154000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember"
      decimals="-3"
      id="d94585328e2785-wk-Fact-D21FB4756DF70D3261531661AACB8644"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember"
      decimals="-3"
      id="d94585328e2804-wk-Fact-8352DECA97B63957E33A1661B4A5A3CC"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_sgmo_FreeSharesLiabilityMember"
      decimals="-3"
      id="d94585328e2824-wk-Fact-02F48719FC8B8D01B219D79D0AD94941"
      unitRef="usd">154000</us-gaap:LiabilitiesFairValueDisclosure>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="-3"
      id="d94585328e2857-wk-Fact-8BCA9FF2B4C38883C8E2D79D0ACB5793"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="-5"
      id="d94585328e2861-wk-Fact-374D501EDA35AFE8D7B9D79D0ACCC8AF"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember"
      decimals="-5"
      id="d94585328e2865-wk-Fact-B56A88B2BE17B4ABC85353C77319C889"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="-5"
      id="d94585328e2874-wk-Fact-74636B55B1710CABF070D79D0ACB51B5"
      unitRef="usd">500000</sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability>
    <sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="-5"
      id="d94585328e2886-wk-Fact-EBC79AD34AB86E47CE4653C5FF4A775D"
      unitRef="usd">400000</sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-DE0F72B781A5103CB19FD79D0AE86973-0-wk-Fact-1A4E789B6580F6809CA6D79D0ACDCE0F">&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Free Shares valuation assumptions:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo Stock Price (USD)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;TxCell Stock Price (EUR)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x20ac;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;EUR / USD Exchange Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Estimated Correlation Sangamo and TxCell Stock Prices&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;72.2%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo Stock Price (USD) Volatility Estimate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77.6%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;79.9%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;TxCell Stock Price (EUR) Volatility Estimate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76.2%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.6%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;EUR / USD Exchange Rate Volatility Estimate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.7%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk Free Rate and Cost of Debt by Expected Exercise Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Varies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Varies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember"
      decimals="2"
      id="d94585328e2975-wk-Fact-9CC88978D1D87B613C10D79D0AC75215"
      unitRef="usdPerShare">9.65</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember"
      decimals="2"
      id="d94585328e2993-wk-Fact-D13A18728A4CAC9BAC05D79D0ACC5EEC"
      unitRef="usdPerShare">11.48</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember"
      decimals="2"
      id="d94585328e3017-wk-Fact-38620D403835209AAACCD79D0AC9342A"
      unitRef="eurPerShare">2.24</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember"
      decimals="2"
      id="d94585328e3035-wk-Fact-B0EC7F69EB721A5DAAE0D79D0AC85D9E"
      unitRef="eurPerShare">2.58</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2019Q2_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputExchangeRateMember"
      decimals="2"
      id="d94585328e3054-wk-Fact-F01E9E9F9C1F11DF6910D79D0ACDD444"
      unitRef="number">0.89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2018Q4_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputExchangeRateMember"
      decimals="2"
      id="d94585328e3072-wk-Fact-71B68DCB2BE65C05D5BBD79D0ACD7168"
      unitRef="number">0.87</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputStockPriceCorrelationMember"
      decimals="1"
      id="d94585328e3096-wk-Fact-D83B2C5FE44394314982D79D0ACEDC07"
      unitRef="number">72.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_sgmo_MeasurementInputStockPriceCorrelationMember"
      decimals="1"
      id="d94585328e3114-wk-Fact-15CAAFEA8302829A36551060E67C34A5"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="1"
      id="d94585328e3138-wk-Fact-084E13A5CB09FF1097BED79D0AC531E3"
      unitRef="number">77.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="1"
      id="d94585328e3156-wk-Fact-CB8A8AB3BA949E0D9527D79D0ACE9B51"
      unitRef="number">79.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="1"
      id="d94585328e3180-wk-Fact-F70D12146B726F8AC300D79D0AC99C02"
      unitRef="number">76.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="1"
      id="d94585328e3198-wk-Fact-719855BB7519570B1766D79D0ACBBCDB"
      unitRef="number">8.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="1"
      id="d94585328e3222-wk-Fact-A92AACB509A712CA7D5DD79D0AC99030"
      unitRef="number">7.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="FI2018Q4_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="1"
      id="d94585328e3240-wk-Fact-1085B38A22BC842E994DD79D0AC70C0A"
      unitRef="number">7.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-A3F14F16AFC0AE5AB5E9D79D0AE868B6-0-wk-Fact-14B3B0D3A77EA7F47761D79D0AA38803">CASH AND MARKETABLE SECURITIES&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;169,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;140,418&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash included in Restricted cash, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash included in Non-current restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;172,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;143,918&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash consists of a letter of credit for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.5&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; established as a deposit for the Brisbane lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash Equivalents and Available-for-sale Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The table below summarizes the Company&#x2019;s cash equivalents and available-for-sale securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;170,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;170,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;279,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;280,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381,780&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;382,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;177,353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;177,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,974&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;363,265&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;363,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;271,877&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;280,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; material realized losses of its available-for-sale securities for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Sangamo has the intent and ability to hold its investments for a period of time sufficient to allow for any anticipated recovery in market value. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;No&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; investments were other-than-temporarily impaired at either &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1705D338CC3A352EB19DEB90831EEB46-0-wk-Fact-B58E656F3E5D78AF6BB6EBC32B23B7B0">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;169,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;140,418&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash included in Restricted cash, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash included in Non-current restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;172,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;143,918&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-58E05D56CB8A9BFFC4BCEBC3794D37D2-0-wk-Fact-4AA919D23C1EEFCDE112EBC3E9EA1B65">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;169,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;140,418&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash included in Restricted cash, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash included in Non-current restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;172,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;143,918&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;62,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e584-wk-Fact-469CE8BB84B262C73103D79D0AC023A8"
      unitRef="usd">169222000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e603-wk-Fact-F26F58192F10765674D2D79D0AB3026E"
      unitRef="usd">140418000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q2"
      decimals="-3"
      id="d94595409e622-wk-Fact-C52421ED692E66C248FCEBD0C3C84ACE"
      unitRef="usd">59406000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d94595409e642-wk-Fact-317B04E7E62722C03D89EBD0E395CD51"
      unitRef="usd">49826000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e657-wk-Fact-CFBDCDF444868A9DC9EAEBCC645D3A52"
      unitRef="usd">2000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e676-wk-Fact-C6C0BF06F7A7C28C5FC5EBD0A1A10EB7"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q2"
      decimals="-3"
      id="d94595409e695-wk-Fact-C331C34C6B209CAF8B86EBD0C47BC9D5"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d94595409e715-wk-Fact-2E8059BFC37034CC5BC2EBD0E44AAFC1"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e735-wk-Fact-E647C4F45EEDCA08D26DEBCC840ADE77"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e754-wk-Fact-15363CC6223AA218C202EBD0A243562F"
      unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2018Q2"
      decimals="-3"
      id="d94595409e773-wk-Fact-93B1B77AE03DBE31E82DEBD0C51EDE46"
      unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d94595409e793-wk-Fact-9451556B5A5B71EBB755EBD0E5165594"
      unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e818-wk-Fact-88773D36DF82CA5AD75EF06E1D419FBE"
      unitRef="usd">172722000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e837-wk-Fact-DAE7BEBFA9BAF982F94AF06E1D51D7A7"
      unitRef="usd">143918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q2"
      decimals="-3"
      id="d94595409e856-wk-Fact-1A8FAD1695C801E7B622D79D0AB60F67"
      unitRef="usd">62906000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d94595409e876-wk-Fact-71D33DAE8A4A1514D091D79D0AB294EE"
      unitRef="usd">53326000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="FI2019Q2"
      decimals="-5"
      id="d94595409e888-wk-Fact-3035D79704FA6D24934CEBD813F54B9F"
      unitRef="usd">3500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-C9C5F0D29E37A3F203C1D79D0AE8FCAC-0-wk-Fact-79B1A443EF7ACC5F381FD79D0AAC7C1E">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The table below summarizes the Company&#x2019;s cash equivalents and available-for-sale securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;vertical-align:top;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;101,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;170,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;170,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;71,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;279,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;280,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381,780&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;382,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;177,353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;177,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,974&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;363,265&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;363,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94595409e1310-wk-Fact-90DB97609D8C03664D20D79D0AC38660"
      unitRef="usd">71490000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94595409e1329-wk-Fact-D4621694D8589C6B8EAB1467D4DF0910"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94595409e1349-wk-Fact-D9B02DAE2A4C4105CA23146ED0B5FA54"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94595409e1368-wk-Fact-00AB876CF8FD29CCFCABD79D0AC8E897"
      unitRef="usd">71490000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e1388-wk-Fact-DAD3B38C1B8F8892D3D7D79D0ABE6DD6"
      unitRef="usd">30439000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e1407-wk-Fact-5BA96F3F1853D7A8E73EEC08C6E82DDD"
      unitRef="usd">2000</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e1426-wk-Fact-478F3E298EA648F87BA2146F5EE88322"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e1446-wk-Fact-A405EF678F5EAB45E1DCD79D0ACD8FD0"
      unitRef="usd">30441000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember"
      decimals="-3"
      id="d94595409e1471-wk-Fact-864352824D66DA0EF3CFD79D0AD0E491"
      unitRef="usd">101929000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember"
      decimals="-3"
      id="d94595409e1490-wk-Fact-9B9BA8CA3A412F5D2AC7EC0D386A49CA"
      unitRef="usd">2000</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember"
      decimals="-3"
      id="d94595409e1509-wk-Fact-E221F17080577C3D1D6A146FD52E68BF"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember"
      decimals="-3"
      id="d94595409e1529-wk-Fact-B33E43778DBC65F12131D79D0ABCF0CD"
      unitRef="usd">101931000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e1641-wk-Fact-79FC21FCCB275107DCCED79D0AC332A0"
      unitRef="usd">170598000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e1660-wk-Fact-C88048EB74FF600FBD69D79D0AC3E4DC"
      unitRef="usd">355000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e1679-wk-Fact-4B0ECD183874EDF5150E146AED56C42E"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e1699-wk-Fact-5F91A3807F7874552242D79D0AC857CC"
      unitRef="usd">170953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e1724-wk-Fact-AB96E4095C0123F4D200D79D0AC2AAB5"
      unitRef="usd">71280000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e1743-wk-Fact-845533BD1B1AB33EEC58D79D0AD31958"
      unitRef="usd">108000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e1762-wk-Fact-235F7F1EFB3710DC1D9FD79D0AD2725A"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e1783-wk-Fact-67208BE55EA368272F8BD79D0AC10FBB"
      unitRef="usd">71383000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e1808-wk-Fact-49EFCE4A266F1952802FD79D0AB9F96C"
      unitRef="usd">37973000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e1827-wk-Fact-F5AAED09FDF2130BC4E2EBEE41D9A791"
      unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e1846-wk-Fact-5A6DDDB53AEFE70DB9DE146AEFDDE750"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e1866-wk-Fact-F2BF872258FB8EE71D7ED79D0AB7623E"
      unitRef="usd">37991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e1892-wk-Fact-8C8E399A74E518183B8AD79D0ACD0646"
      unitRef="usd">279851000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e1911-wk-Fact-42516807E5F557A53F9AD79D0AC39841"
      unitRef="usd">481000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e1930-wk-Fact-6D5764F1780589C2323DD79D0AD0FEE3"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e1951-wk-Fact-8ED07EC256752A548CABEC1B97EDAC94"
      unitRef="usd">280327000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e1981-wk-Fact-B11600A6DE999AC6E679D79D0ABDBD7D"
      unitRef="usd">381780000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e2000-wk-Fact-80DC40F32990C64A76C0D79D0AC9AAB5"
      unitRef="usd">483000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e2020-wk-Fact-59D2CA4FBC04BD26CBD9D79D0AD08B32"
      unitRef="usd">5000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e2040-wk-Fact-B12A789AF85F87E1CFDAD79D0ACE0069"
      unitRef="usd">382258000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94595409e2239-wk-Fact-1AA8E5ECF574BA742C6DD79D0ABD6466"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94595409e2258-wk-Fact-A24A370B76E7FAF8C5C71468E51D0708"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94595409e2278-wk-Fact-68806504514238EEB75014717A906A0D"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d94595409e2297-wk-Fact-83A652373730471D1766D79D0ACF55C3"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember"
      decimals="-3"
      id="d94595409e2317-wk-Fact-CE303FA2ECAD9E9FD41DD79D0AB99268"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember"
      decimals="-3"
      id="d94595409e2336-wk-Fact-148FDD67A97D02F75D2314690357DCE9"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember"
      decimals="-3"
      id="d94595409e2355-wk-Fact-87B35BD218D1C3FD6BE41471D8C0F775"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashEquivalentsMember"
      decimals="-3"
      id="d94595409e2375-wk-Fact-7C289C5E67099E2404FED79D0AD0ED7D"
      unitRef="usd">103291000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e2487-wk-Fact-F818216A5E2A1C015A0ED79D0ABAAC31"
      unitRef="usd">177353000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e2506-wk-Fact-BEF212C77EC32C9FFC861463E9BCF0A5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e2525-wk-Fact-E9926C45A63FA1FF5F98D79D0ACC4CD5"
      unitRef="usd">129000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d94595409e2546-wk-Fact-5211661D08F7C505D644D79D0ABC45D9"
      unitRef="usd">177224000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e2571-wk-Fact-4CA63B748AF52413F55ED79D0AC25CAA"
      unitRef="usd">63981000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e2590-wk-Fact-4BD9822C778CFC770E271463EAFD1886"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e2609-wk-Fact-024E469B4C022472164AD79D0ACD204D"
      unitRef="usd">111000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e2630-wk-Fact-2E28C245197052F2191DD79D0AB79141"
      unitRef="usd">63870000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e2655-wk-Fact-52501671D3F55D8203CDD79D0AC75455"
      unitRef="usd">18640000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e2674-wk-Fact-146FE23241FD95876AF41463EC488996"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e2693-wk-Fact-CD59BABF3B60E7D53ABFD79D0AD1C11D"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
      decimals="-3"
      id="d94595409e2714-wk-Fact-CF84CE1849B4A3753711D79D0AC64024"
      unitRef="usd">18621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e2739-wk-Fact-4E4D1B666E0FBE472CC0D79D0ABEFBF3"
      unitRef="usd">259974000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e2758-wk-Fact-CD2633160F7D657881F11463ED9620F6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e2777-wk-Fact-8F3B752DFB1DB81E12ADD79D0AC9B712"
      unitRef="usd">259000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e2798-wk-Fact-7106F358A95F66EB8CB3EC2080626E13"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e2829-wk-Fact-57FEABCE5DDBBFAA4699D79D0ACF84D9"
      unitRef="usd">363265000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e2848-wk-Fact-D4192E7F07AF0C7AF09D1463EE8F99D1"
      unitRef="usd">0</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e2868-wk-Fact-CE8781486DCF45931595D79D0AC96DF0"
      unitRef="usd">259000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e2888-wk-Fact-084B36762719BF136913D79D0AC5A0E8"
      unitRef="usd">363006000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-FB086D6DE04F32FD8B94EC11D8B5093C-0-wk-Fact-0EF27C3B91CE9486F0D2EC126CD742E9">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;271,877&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;280,327&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;259,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e2982-wk-Fact-EC0490B732979C4535684E7367AB83C0"
      unitRef="usd">271877000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e3001-wk-Fact-9084C64A557E39420EAE4E7367B094D4"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e3021-wk-Fact-74A9F15D9A654CC8F9ED4E7367A02D93"
      unitRef="usd">8450000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e3040-wk-Fact-2CC81BCA2A9994DCAA464E7367B3E089"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94595409e3070-wk-Fact-8ED07EC256752A548CABEC1B97EDAC94"
      unitRef="usd">280327000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94595409e3089-wk-Fact-7106F358A95F66EB8CB3EC2080626E13"
      unitRef="usd">259715000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d94595409e3100-wk-Fact-39172447BB8ED933327FD79D0AAB2C36"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d94595409e3116-wk-Fact-C998CCC2C9E9CC652E03D79D0AB89ED0"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-8802E76C03B2E864F50AD79D0AE8DCC8-0-wk-Fact-DEC5C23577242E3B0B76D79D0A9DE8BB">BASIC AND DILUTED NET LOSS PER SHARE&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The total number of shares subject to stock options and restricted stock units (&#x201c;RSUs&#x201d;) outstanding and the employee stock purchase plan (&#x201c;ESPP&#x201d;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; totaled &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,155,033&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,757,528&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
      contextRef="FI2019Q2"
      decimals="INF"
      id="d94591861e469-wk-Fact-101605F786AEB4214C02D79D0A9E5F14"
      unitRef="shares">10155033</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
      contextRef="FI2018Q2"
      decimals="INF"
      id="d94591861e473-wk-Fact-BF118165442071A463E9D79D0A9CEC26"
      unitRef="shares">8757528</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-808A0AAA2CEBD0A02943D79D0AE997AB-0-wk-Fact-302FA87061FC5C456429D79D0ADD6708">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2018, the Company entered into a global collaboration and license agreement with Kite for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing ZFNs and adeno-associated viral vectors (&#x201c;AAVs&#x201d;) to disrupt and insert certain genes in T-cells and natural killer cells (&#x201c;NK-cells&#x201d;) including the insertion of genes that encode chimeric antigen receptors, T-cell receptors, and NK-cell receptors directed to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products and has announced that they expect to initiate a clinical trial evaluating KITE-037, an allogeneic anti-CD19 CAR-T cell therapy, in 2020. The Kite agreement became effective on &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;span style="white-space:nowrap"&gt;April 5, 2018&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; when the waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions were completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ex vivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; using selected zinc finger nucleases (&#x201c;ZFNs&#x201d;) and AAVs developed under the research program to express chimeric antigen receptors (&#x201c;CARs&#x201d;), T-cell receptors (&#x201c;TCRs&#x201d;) or NK-cell receptors (&#x201c;NKRs&#x201d;) directed to candidate targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ex vivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ex vivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Following the effective date, in April 2018, the Company received a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment from Kite. In addition, Kite will reimburse the Company&#x2019;s direct costs to conduct the joint research program, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.01&#160;billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.26&#160;billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.75&#160;billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The initial research term in the agreement is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Kite has an option to extend the research term of the agreement for up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;two&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; additional one-year periods for a separate upfront fee of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The Company concluded the transaction price under this agreement is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$185.9&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and includes the upfront license fee of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35.9&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has identified the primary performance obligations within the Kite agreement as a license to the technology and on-going services. The Company concluded that the license is not discrete as it does not have stand-alone value to &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Kite apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment on a straight-line basis through June 2024, the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had deferred revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$119.1&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$131.5&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues recognized under the agreement for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,562&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,562&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,372&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;SB&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;-525&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt; Global Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of SB-525, its gene therapy product candidate for hemophilia A, and closely related products.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company originally received an upfront fee of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$70.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and is eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. In addition, Sangamo is eligible to receive up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$208.5&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$266.5&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments upon first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the hemophilia A Pfizer agreement, is up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$475.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which includes up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$300.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for SB-525 and up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$175.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone payments have been received and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; products have been approved and therefore &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; royalty fees have been earned under the hemophilia A Pfizer agreement. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;None of the clinical or regulatory milestones have been included in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$70.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#x2019;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;fifteen years after the first commercial sale of a product in a country Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has identified the performance obligations within the hemophilia A Pfizer agreement as a license to the technology and on-going services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services through 2020, the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had deferred revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.3&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues recognized under the agreement for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Recognition of upfront fee related to Pfizer SB-525 agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,595&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,841&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March&#160;2019, the Company received new data results in the hemophilia A collaboration agreement with Pfizer, and expansion of patients for the ongoing trial. As a result, the estimated project cost increased and the proportional performance was updated based on the actual services delivered to Pfizer as a percentage of the updated project cost as of March&#160;31, 2019. The increase in project cost resulted in a decrease in the measure of the proportional cumulative performance. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in revenues related to the Pfizer SB-525 agreement which were net of the approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reduction in revenues recorded in the three months ended March&#160;31, 2019 related to the updated estimated project cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;C&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;9&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;ORF&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;72&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt; Research Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP transcription factors (&#x201c;TFs&#x201d;) to treat amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;) and frontotemporal lobar degeneration (&#x201c;FTLD&#x201d;) linked to mutations of the C&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;9&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ORF&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;72&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop&#160;ZFP TFs&#160;that bind to and specifically reduce expression of the mutant form of the C&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;9&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ORF&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;72&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company received a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment from Pfizer and is eligible to receive up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$90.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;None&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the clinical or regulatory milestones have been included in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#x2019;s relevant patents and know&#x2011;how to develop, manufacture and commercialize gene therapy products that use &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;resulting ZFP&#160;TFs that satisfy pre&#x2011;agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the C9ORF72 gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;fifteen years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Following termination by the Company for Pfizer&#x2019;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the C&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;9&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ORF&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;72&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; gene for a period of time. Following termination by Pfizer for the Company&#x2019;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the C&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;9&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ORF&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;72&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; gene for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has identified the performance obligations within this agreement as a license to the technology and on-going services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services, over the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had deferred revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.7&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.8&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues recognized under the agreement for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Recognition of upfront fee related to Pfizer C9ORF72 agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,076&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#x201c;SCD&#x201d;). The agreement was originally signed with Biogen MA Inc., who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an investigational new drug (&#x201c;IND&#x201d;) application for ZFP therapeutics intended to treat SCD.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#x2019;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#x2019;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the agreement, the Company received an upfront license fee of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and is eligible to receive development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. In addition, the Company will also be eligible to receive up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$115.8&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$160.5&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$276.3&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone payments have been received and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; products have been approved and therefore &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; royalty fees have been earned under the Sanofi agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;180&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days&#x2019; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75.7&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; includes the upfront license fee of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$55.7&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; estimated reimbursable service costs for identified research projects over the estimated performance period, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the clinical or regulatory milestones have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has identified the performance obligations within this arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had deferred revenue of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.9&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.6&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues recognized under the agreement for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,338&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,560&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,059&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,009&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;California Institute for Regenerative Medicine&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2018, the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) granted a Strategic Partnership Award for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#x2019;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had received &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, under the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. In the event that the Company terminates a CIRM-funded clinical trial, it will be obligated to repay the remaining CIRM funds on hand, therefore as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.3&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.8&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, including interest, related to &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts with the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <sgmo:CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective
      contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      id="d94597376e464-wk-Fact-766E6B613E6DE5D2F3DFD79D0ACDB610">2018-04-05</sgmo:CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective>
    <sgmo:MilestonePaymentsReceived
      contextRef="D2018Q2Apr01-Apr30_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e489-wk-Fact-5E4EA07164A71C298A95D79D0ADCCA1A"
      unitRef="usd">150000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-7"
      id="d94597376e493-wk-Fact-851B6615AA3A4935F8EBD79D0AD1863C"
      unitRef="usd">3010000000.00</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-7"
      id="d94597376e497-wk-Fact-627B1329F8369C3C92A5D79D0ADD1F28"
      unitRef="usd">1260000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-7"
      id="d94597376e501-wk-Fact-3EF44EB85D5DB4606D6AD79D0AD70512"
      unitRef="usd">1750000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:InitialResearchTermOfAgreement
      contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      id="d94597376e508-wk-Fact-AB91863903D8AE060804D79D0ADB08B5">P6Y</sgmo:InitialResearchTermOfAgreement>
    <sgmo:SeparateUpfrontFee
      contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e516-wk-Fact-D702B290B18890BD0690D79D0ADCD3F1"
      unitRef="usd">10000000.0</sgmo:SeparateUpfrontFee>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e520-wk-Fact-72B35152ED519FD2F688D79D0AD2734E"
      unitRef="usd">185900000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e524-wk-Fact-E771E4F4B47A2EE8451FD79D0AD1633B"
      unitRef="usd">150000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="D2018Q2Apr05-Apr05_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e529-wk-Fact-277D82BD0BAE4C9E1F36D79D0A958A33"
      unitRef="usd">35900000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q2_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e550-wk-Fact-F0E072FE7757889C2DEED79D0ADC3CEA"
      unitRef="usd">119100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e554-wk-Fact-3C6F0B37EE9C26567B32D79D0AD7E5FC"
      unitRef="usd">131500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember"
      id="TextSelection-37D72B6C1D496E7A6026D79D0AE81228-0-wk-Fact-C4EDD10FA72F3FDA1C42D79D0ADD8BB4">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues recognized under the agreement for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,562&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,562&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,372&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e858-wk-Fact-621E044306B33743CE55EC22080F2856"
      unitRef="usd">6227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e877-wk-Fact-9FD838292FA479139EE4D79D0AAB0A9D"
      unitRef="usd">5953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e896-wk-Fact-26CD29BA32D328D485B3EC220813EB2C"
      unitRef="usd">12386000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e916-wk-Fact-014C8B1BD441E0E59984D79D0AC564F6"
      unitRef="usd">5953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember"
      decimals="-3"
      id="d94597376e931-wk-Fact-493FCAA6E0BC2E218E8FEC220805A0B9"
      unitRef="usd">2833000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember"
      decimals="-3"
      id="d94597376e950-wk-Fact-BB82177DFDDB521D3C13D79D0AABA489"
      unitRef="usd">1562000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember"
      decimals="-3"
      id="d94597376e969-wk-Fact-358F8199A6F2F11B970FEC22081F3DB2"
      unitRef="usd">4986000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember"
      decimals="-3"
      id="d94597376e989-wk-Fact-B367B724F4B0CC972D79D79D0AC6D75E"
      unitRef="usd">1562000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember"
      decimals="-3"
      id="d94597376e1014-wk-Fact-E087EE135CC235F5D722D79D0AADCA37"
      unitRef="usd">9060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember"
      decimals="-3"
      id="d94597376e1033-wk-Fact-6A56A511071CA8802146D79D0AAD1F65"
      unitRef="usd">7515000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember"
      decimals="-3"
      id="d94597376e1052-wk-Fact-8EDFE950D81451DD17E0D79D0AADEE2F"
      unitRef="usd">17372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember"
      decimals="-3"
      id="d94597376e1072-wk-Fact-B9894ED7250DC119578AD79D0AAC315B"
      unitRef="usd">7515000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember"
      decimals="-5"
      id="d94597376e1100-wk-Fact-44A1448895EBBB29B976D79D0AD7FE67"
      unitRef="usd">70000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"
      decimals="-5"
      id="d94597376e1104-wk-Fact-5DF64DDA51965B24B703D79D0A93848A"
      unitRef="usd">208500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
      contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember_srt_RangeAxis_srt_MaximumMember"
      decimals="-5"
      id="d94597376e1108-wk-Fact-C26F4024183FDFA58000D79D0AD88C5A"
      unitRef="usd">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfFirstCommercialSaleMilestonesMember"
      decimals="-5"
      id="d94597376e1112-wk-Fact-B9D21CEED2B8C28B4DDBD79D0AD3C2FE"
      unitRef="usd">475000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="I2017Q1May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_SBFiveTwoFiveMember_srt_RangeAxis_srt_MaximumMember"
      decimals="INF"
      id="d94597376e1116-wk-Fact-CB716F3E82F35FB1B56DD79D0AD3C4DD"
      unitRef="usd">300000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="I2017Q1May31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_OtherProductsMember_srt_RangeAxis_srt_MaximumMember"
      decimals="INF"
      id="d94597376e1121-wk-Fact-2AE63E1E3384F54BB83DD79D0ADAFA1C"
      unitRef="usd">175000000.0</sgmo:MilestoneRevenueReceivable>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="D2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember"
      decimals="INF"
      id="d94597376e1125-wk-Fact-B34687583C851F133D49656F2BB1183E"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="D2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember"
      decimals="INF"
      id="d94597376e1129-wk-Fact-D25FB7BC40BA5ECB6D54D79D0ADB45ED"
      unitRef="U_sgmoProduct">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="INF"
      id="d94597376e1133-wk-Fact-1B355BD6CC36563D76AFD79D0ADD7263"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="D2017Q2May01-May31_srt_CounterpartyNameAxis_sgmo_PfizerMember"
      decimals="-5"
      id="d94597376e1140-wk-Fact-44A1448895EBBB29B976D79D0AD7FE67"
      unitRef="usd">70000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember"
      decimals="-5"
      id="d94597376e1161-wk-Fact-928A471804077D3E52CDD79D0AD1ED2D"
      unitRef="usd">14300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4_srt_CounterpartyNameAxis_sgmo_PfizerMember"
      decimals="-5"
      id="d94597376e1165-wk-Fact-229C4F058DE945EFAF26D79D0AD2D11A"
      unitRef="usd">10000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member"
      id="TextSelection-C238C39AED0303BB3225EC49C55374B8-0-wk-Fact-A1F7496A5634D26B9CCBEC4AFE8D88BA">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues recognized under the agreement for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Recognition of upfront fee related to Pfizer SB-525 agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,595&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,841&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e1386-wk-Fact-4C87BE36EFAE7B832069EC51C9BBCD40"
      unitRef="usd">4635000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e1405-wk-Fact-8BCBAEE49B5770750069EC51CC01A05A"
      unitRef="usd">8183000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e1424-wk-Fact-F27863F33DF543134F0AEC51CE4AD724"
      unitRef="usd">1595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e1444-wk-Fact-EEE8A739D0A611B20BC5EC51D090E653"
      unitRef="usd">15841000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerSB525Member_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-5"
      id="d94597376e1463-wk-Fact-DA1794B7EA31F028893B5F8E6B203669"
      unitRef="usd">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="FD2019Q1YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-5"
      id="d94597376e1467-wk-Fact-6EB3D416558BCB5A7726D79D0AD65838"
      unitRef="usd">-3000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <sgmo:MilestonePaymentsReceived
      contextRef="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember"
      decimals="-5"
      id="d94597376e1508-wk-Fact-F42617D38F36548B8913EC599040DE77"
      unitRef="usd">12000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"
      decimals="INF"
      id="d94597376e1512-wk-Fact-81CB7DF3766A8077EE87D79D0ADEBC1C"
      unitRef="usd">60000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfCommercialMilestonesMember"
      decimals="INF"
      id="d94597376e1516-wk-Fact-CC153AB76A62879F54DAD79D0ADE99ED"
      unitRef="usd">90000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember"
      decimals="INF"
      id="d94597376e1521-wk-Fact-63BCD04392F30DC0B9FCD79D0A935DB3"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:MilestonePaymentsReceived
      contextRef="D2017Q4Dec01-Dec31_srt_CounterpartyNameAxis_sgmo_PfizerMember"
      decimals="-5"
      id="d94597376e1525-wk-Fact-F42617D38F36548B8913EC599040DE77"
      unitRef="usd">12000000.0</sgmo:MilestonePaymentsReceived>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q2_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember"
      decimals="-5"
      id="d94597376e1569-wk-Fact-B928F5B3332355138C4BD79D0AD28322"
      unitRef="usd">8700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_sgmo_CNineORFSevenTwoMember"
      decimals="-5"
      id="d94597376e1573-wk-Fact-EA34E22D8981F79A322FD79D0ADC36BF"
      unitRef="usd">9800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember"
      id="TextSelection-B42576846D233421A618D79D0AE83C04-0-wk-Fact-C2FD3F76FA29CA58F318D79D0AD68F14">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues recognized under the agreement for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Recognition of upfront fee related to Pfizer C9ORF72 agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,070&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,076&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e1794-wk-Fact-6BA88CDA606569849412EC220FABF714"
      unitRef="usd">455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e1813-wk-Fact-272C23BC220456A60105D79D0A98FD2C"
      unitRef="usd">617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e1832-wk-Fact-F6B52FB59FAC27741701EC220FA78753"
      unitRef="usd">1070000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_PfizerMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e1852-wk-Fact-7E6B1997051FCFB60CDBD79D0A9BEC44"
      unitRef="usd">1076000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:NumberOfResearchProgram
      contextRef="D2014Q1Jan01-Jan31"
      decimals="INF"
      id="d94597376e1867-wk-Fact-84DCA6F5C5AC1CCB1A60D79D0AD35544"
      unitRef="program">2</sgmo:NumberOfResearchProgram>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember"
      decimals="-5"
      id="d94597376e1877-wk-Fact-CD6DC40BB6F5A745AFF2D79D0ADF0AE1"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e1881-wk-Fact-33966C47E82FFD55E572D79D0ADDC0FA"
      unitRef="usd">115800000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_AchievementOfSpecifiedSalesMilestonesMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e1885-wk-Fact-4C4B3938BF0F7680A64ED79D0ACC6AD6"
      unitRef="usd">160500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e1889-wk-Fact-AC0DD14888034A644F19D79D0AD179E1"
      unitRef="usd">276300000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestonePaymentsReceived
      contextRef="D2019Q3SD_srt_CounterpartyNameAxis_sgmo_BioverativIncMember"
      decimals="INF"
      id="d94597376e1893-wk-Fact-923B2382B979EEC6B7C3D79D0AD8763D"
      unitRef="usd">0</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="D2019Q3SD_srt_CounterpartyNameAxis_sgmo_BioverativIncMember"
      decimals="INF"
      id="d94597376e1898-wk-Fact-4DFB1E03D4718EAF7991D79D0AD6E685"
      unitRef="U_sgmoProduct">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2019Q3SD_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="INF"
      id="d94597376e1902-wk-Fact-15EBDDADF53C32848E7FD79D0AD8C25C"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e1916-wk-Fact-689A63D4B3673D689895D79D0A93E124"
      unitRef="usd">75700000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e1920-wk-Fact-942D2DE8F3529BC6B45DD79D0AD2F443"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="D2014Q1Jan01-Jan31_srt_CounterpartyNameAxis_sgmo_SanofiMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e1924-wk-Fact-9B0604A9FDB4D0959F8FD79D0ADCC96C"
      unitRef="usd">55700000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q2_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e1939-wk-Fact-292FB81F14E55608F92AD79D0A955C39"
      unitRef="usd">2900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4_srt_CounterpartyNameAxis_sgmo_BioverativIncMember_us-gaap_TypeOfArrangementAxis_sgmo_CollaborationAndLicenseAgreementMember"
      decimals="-5"
      id="d94597376e1943-wk-Fact-BF70DF13D8ED7E27ABC2D79D0ADBD8A0"
      unitRef="usd">4600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember"
      id="TextSelection-0C3B92DCB4BE8D93D923D79D0AE98B28-0-wk-Fact-929650F7D2CD6DEDE196D79D0ADEC0D7">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues recognized under the agreement for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,338&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,560&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,059&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,009&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e2247-wk-Fact-66F09D9DC53B946C590FD79D0AA20325"
      unitRef="usd">901000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e2266-wk-Fact-0B6C8BAAEA937C5D0244D79D0A9F90F8"
      unitRef="usd">1184000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e2285-wk-Fact-2C623DE5E95018F3FCDCEC220C15F6CE"
      unitRef="usd">1654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      id="d94597376e2305-wk-Fact-34C82964658361F9B0FED79D0AA01AAD"
      unitRef="usd">2338000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember"
      decimals="-3"
      id="d94597376e2320-wk-Fact-6AD0F70F6A3B7D5078FED79D0A9E50F1"
      unitRef="usd">2158000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember"
      decimals="-3"
      id="d94597376e2339-wk-Fact-7B7E66389C1EA8875F8CD79D0A9F0F4E"
      unitRef="usd">3332000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember"
      decimals="-3"
      id="d94597376e2358-wk-Fact-6D123DE265A3DE4B6B8EEC220C24B411"
      unitRef="usd">3355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember"
      decimals="-3"
      id="d94597376e2378-wk-Fact-14997E0985AD0088C0C7D79D0A9FDDAC"
      unitRef="usd">6560000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember"
      decimals="-3"
      id="d94597376e2403-wk-Fact-BD49466ACC3CB2FDAD8FD79D0A9E8DC0"
      unitRef="usd">3059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_CounterpartyNameAxis_sgmo_SanofiMember"
      decimals="-3"
      id="d94597376e2422-wk-Fact-D74D3591156DA1710DFBD79D0A9EC67B"
      unitRef="usd">4516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember"
      decimals="-3"
      id="d94597376e2441-wk-Fact-C6A0F08CEABCEEF4B4F6EC220C1B7463"
      unitRef="usd">5009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_CounterpartyNameAxis_sgmo_SanofiMember"
      decimals="-3"
      id="d94597376e2461-wk-Fact-EE3AAF88852545748ADCD79D0A9D83D2"
      unitRef="usd">8898000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:GrantFundingAmount
      contextRef="D2018Q2May01-May31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"
      decimals="-5"
      id="d94597376e2476-wk-Fact-CD04CDACBD93B94EA9BFD79D0ADA124E"
      unitRef="usd">8000000.0</sgmo:GrantFundingAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2019Q2SD_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"
      decimals="-5"
      id="d94597376e2488-wk-Fact-C389DB8F2875658E0077D79D0A934FC3"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"
      decimals="-5"
      id="d94597376e2492-wk-Fact-7CDA1BAF5F377529213AEC2FD29EE120"
      unitRef="usd">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"
      decimals="-5"
      id="d94597376e2507-wk-Fact-49C3DB194CFF4F3FCFBFD79D0AD0D9A3"
      unitRef="usd">3300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"
      decimals="-5"
      id="d94597376e2511-wk-Fact-771B6E4592FEE874FD10D79D0AD620BB"
      unitRef="usd">1800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-A242D78A5D042269C653D79D0AE9E26D-0-wk-Fact-EEC6B6F31C284CE01393D79D0A96455E">INCOME TAXES&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo&#x2019;s history of losses. Accordingly, the Company&#x2019;s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-FF941575463DD0B524F0D79D0AE9D0BF-0-wk-Fact-0D7E35DF3B87AAA7A837D79D0A99F70B">STOCK-BASED COMPENSATION&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,061&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-25F4A9C506285C19D65DD79D0AE96E16-0-wk-Fact-E8AB837F80A5EEF6337CD79D0A98564D">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,061&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d94591828e666-wk-Fact-7F7DD6FB3E874F2D7082D79D0AA1FE52"
      unitRef="usd">2763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d94591828e684-wk-Fact-A92FF196F6283EEE867BD79D0AA244DD"
      unitRef="usd">2120000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d94591828e702-wk-Fact-37E65EE4A11B46E3C93711A7190A65DC"
      unitRef="usd">5061000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d94591828e721-wk-Fact-440DBF7A6F8C5E4563FAD79D0AA0B9C3"
      unitRef="usd">3879000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d94591828e736-wk-Fact-148BB63DDF4CD2DECC80D79D0AA310D7"
      unitRef="usd">2104000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d94591828e754-wk-Fact-DAF31DECD01E1BDF3267D79D0AA0964F"
      unitRef="usd">1394000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d94591828e772-wk-Fact-E935F641307A6888B65811A7190ADC9D"
      unitRef="usd">4329000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d94591828e791-wk-Fact-939381144589CE565154D79D0A9FC06C"
      unitRef="usd">2685000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d94591828e816-wk-Fact-F1EDCBFC01F39C83CADED79D0AA2BA3F"
      unitRef="usd">4867000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d94591828e834-wk-Fact-9D709B151FD61354D4B8D79D0A9FDB6E"
      unitRef="usd">3514000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94591828e852-wk-Fact-B3187B89BA4588A77D9FD79D0AA3AACD"
      unitRef="usd">9390000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d94591828e871-wk-Fact-63A52490FE2DE5CEA78ED79D0AA1EA0E"
      unitRef="usd">6564000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-8127E64BAD175E717B73D79D0AE9C361-0-wk-Fact-88196C56952590C0496CD79D0AA41C1A">COMMITMENTS AND CONTINGENCIES&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo occupies approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,700&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of office and research and development laboratory facilities in Brisbane, CA pursuant to a lease that expires in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May 2029&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Sangamo also leases approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,900&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of office and laboratory space in Richmond, CA through August 2026. The Company leases approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,700&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of additional research and office space located in Richmond, CA pursuant to a lease that expires in December 2019. In addition, the Company leases &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; properties in Valbonne, France. The first lease is for approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,036&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of research and office space that expires in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June 2025&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The second lease, which commenced on &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;span style="white-space:nowrap"&gt;April 1, 2019&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, is for approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,800&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of office space and expires in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March 2028&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;With respect to the Brisbane lease, the commencement date for approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,080&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of the office space occurred in January 2019 while the commencement date for the remaining approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,620&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet occurred in June 2019. The Company has the right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.8&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the first portion of the space occupied and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.2&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the portion of the lease that commenced in June 2019. This lease includes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; renewal options at the election of the Company to extend the lease for an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; each. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company incurred &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:right;"&gt;&lt;span&gt;$1.6&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.8&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of lease costs included in operating expenses in the Condensed Consolidated Statements of Operations in relation to these operating leases. Variable lease expense was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.6&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and was not included in the measurement of the Company&#x2019;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#x2019;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense due to the Company&#x2019;s election to not separate lease and non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and was included in net cash used in operating activities in the Company&#x2019;s Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six months ending December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,704&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14,669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Reported as of June&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed    Consolidated Balance Sheet)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the weighted-average remaining lease term is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;years and the weighted-average incremental borrowing rate used to determine the operating lease liability was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company does not have any financing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sangamo is not party to any material pending legal proceedings or contingencies. From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeAndLaboratoryMember"
      decimals="0"
      id="d94592364e461-wk-Fact-19C5423E9D86EE29C01E6321740C4D64"
      unitRef="sqft">87700</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeAndLaboratoryMember"
      decimals="0"
      id="d94592364e469-wk-Fact-6F82C8B393A198661063D79D0A95B3A9"
      unitRef="sqft">37900</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember"
      decimals="0"
      id="d94592364e473-wk-Fact-61EF34C3A203E4864AAFD79D0ADD288A"
      unitRef="sqft">7700</us-gaap:LandSubjectToGroundLeases>
    <sgmo:LesseeOperatingLeaseNumberOfContracts
      contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember"
      decimals="INF"
      id="d94592364e477-wk-Fact-019DFF4F86CBB5CD53B462812CE6013F"
      unitRef="contract">2</sgmo:LesseeOperatingLeaseNumberOfContracts>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_ResearchAndOfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseOneMember"
      decimals="0"
      id="d94592364e482-wk-Fact-1879D54CA3CEE07F56ABD79D0A94F1C8"
      unitRef="sqft">14036</us-gaap:LandSubjectToGroundLeases>
    <sgmo:LeaseCommencementDate
      contextRef="FD2019Q1YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseTwoMember"
      id="d94592364e490-wk-Fact-C227CD95D9C2F38BF51ED79D0AD9BBF3">2019-04-01</sgmo:LeaseCommencementDate>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_ValbonneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_sgmo_PropertySubjectToOperatingLeaseTwoMember"
      decimals="INF"
      id="d94592364e494-wk-Fact-B5863FB3EAF860A3E872D79D0AC9F5D2"
      unitRef="sqft">6800</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_RichmondAndValbonneLeasesMember"
      id="d94592364e509-wk-Fact-7B761157B14A4A2F1CDBD79D0AC427D6">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <sgmo:CommencementLandSubjectToGroundLeases
      contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sgmo_OfficeSpaceMember"
      decimals="INF"
      id="d94592364e516-wk-Fact-0A18DB87CB4E3CCD862AD79D0AC5E96B"
      unitRef="sqft">35080</sgmo:CommencementLandSubjectToGroundLeases>
    <sgmo:RemainingCommencementLandSubjectToGroundLeases
      contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember"
      decimals="INF"
      id="d94592364e520-wk-Fact-7A9618B8C99FE19C5D99D79D0A9CC908"
      unitRef="sqft">52620</sgmo:RemainingCommencementLandSubjectToGroundLeases>
    <sgmo:LesseeOperatingLeaseLiabilityTenantImprovementAllowance
      contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember"
      decimals="-5"
      id="d94592364e524-wk-Fact-ADBFF72238D2C8F981E7D79D0A93B357"
      unitRef="usd">6800000</sgmo:LesseeOperatingLeaseLiabilityTenantImprovementAllowance>
    <sgmo:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance
      contextRef="FI2019Q2_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember"
      decimals="-5"
      id="d94592364e528-wk-Fact-440957D15216A888B57CD79D0A97765D"
      unitRef="usd">10200000</sgmo:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance>
    <sgmo:OperatingLeasesNumberOfExtensionOptions
      contextRef="FD2019Q2YTD_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember"
      decimals="INF"
      id="d94592364e532-wk-Fact-40D1AF270F8E61561AEDD79D0ADFAE55"
      unitRef="renewal_option">2</sgmo:OperatingLeasesNumberOfExtensionOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_LeaseArrangementTypeAxis_sgmo_BrisbaneLeaseMember"
      id="d94592364e537-wk-Fact-20DC3E2F7086FC09DDE2D79D0ADE38C4">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d94592364e552-wk-Fact-C3783F67B8AE97944B47ECB64418B2F7"
      unitRef="usd">1600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d94592364e556-wk-Fact-7D175DB20BA8BE5C6663ECB6D96FFEDB"
      unitRef="usd">2800000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d94592364e560-wk-Fact-28A638C069BE22BC630E453D6EA3ACCE"
      unitRef="usd">400000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d94592364e565-wk-Fact-16BF40255446560C9152D79D0A95A4AC"
      unitRef="usd">600000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d94592364e588-wk-Fact-8192EBBCF3C3CDBCA856D79D0AA3BCAD"
      unitRef="usd">1100000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-325B54E53F086B8D1038D79D0AE9322E-0-wk-Fact-F9A7CD647780D4C72F00D79D0ADE75AB">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six months ending December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,704&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14,669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Reported as of June&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed    Consolidated Balance Sheet)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;44,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e647-wk-Fact-ECE2D4C043908EC68C6DD79D0AC89337"
      unitRef="usd">2135000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e662-wk-Fact-8CC2DD7058E28ADD8950D79D0AC738DC"
      unitRef="usd">6065000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e682-wk-Fact-6ACC6290A9F5E3CC79FED79D0AB0B1EE"
      unitRef="usd">6107000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e702-wk-Fact-CAEA1DD60B2793C75EB3D79D0AC4FB05"
      unitRef="usd">6175000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e722-wk-Fact-550C1CE9B3CDECE16B1CD79D0AC20B22"
      unitRef="usd">6253000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e742-wk-Fact-57203D8FFEDF27CE90F6D79D0AC9EF59"
      unitRef="usd">31969000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e762-wk-Fact-0F1771949EC1D56B2794D79D0AC739E5"
      unitRef="usd">58704000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e803-wk-Fact-8477D49382B988D245F1D79D0ACB4362"
      unitRef="usd">14669000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e829-wk-Fact-DD30DE08743CCB115093D79D0AD058D0"
      unitRef="usd">44035000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e892-wk-Fact-95A45F1D5FB3C90F6BCCD79D0ACD90C4"
      unitRef="usd">2485000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e907-wk-Fact-5376ED04C4E343E95870D79D0AB9B12A"
      unitRef="usd">41550000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94592364e932-wk-Fact-DD30DE08743CCB115093D79D0AD058D0"
      unitRef="usd">44035000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q2"
      id="d94592364e948-wk-Fact-C8687F20337839BC1B3BD79D0AC235E0">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q2"
      decimals="3"
      id="d94592364e952-wk-Fact-686422C52DC5FB86350DD79D0A9B95BF"
      unitRef="number">0.069</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-035F2BFD3F3527ABFAEAD79D0AE9A8A1-0-wk-Fact-59695B10F554D3D183E5D79D0AA5BCA1">STOCKHOLDERS&#x2019; EQUITY&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.7&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a public offering price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$136.3&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.2&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a public offering price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$16.25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$215.8&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;At-the-Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the Company entered into an amended and restated &#x201c;at-the-market&#x201d; offering program sales agreement with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), pursuant to which the Company may issue and sell from time to time up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the Company&#x2019;s common stock through Cowen as the sales agent (the &#x201c;ATM Agreement&#x201d;). Sales of the Company&#x2019;s common stock, if any, will be made at market prices by any method that is deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule 415 under the Securities Act of 1933, as amended. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has not sold any common stock under the ATM Agreement and the full &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75.0&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; remained available for sale, subject to certain conditions as specified in the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="D2019Q2Apr1-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d94595400e465-wk-Fact-ADBB1794D1D98212CB80D79D0AA706D3"
      unitRef="usd">12700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="I2019Q2Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="d94595400e469-wk-Fact-88D4E30A34C0E9445F2BD79D0AA4CB1D"
      unitRef="usdPerShare">11.50</us-gaap:SharesIssuedPricePerShare>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="D2019Q2Apr1-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d94595400e473-wk-Fact-9FEA3889093C22E7F1C1D79D0AA32157"
      unitRef="usd">136300000</sgmo:NetProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="D2018Q2Apr01-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d94595400e484-wk-Fact-E2977F6962E610B57E1AD79D0AA63A99"
      unitRef="usd">14200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="I2018Q2Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="d94595400e488-wk-Fact-55B20C09909A6091A9C4D79D0AA5CE46"
      unitRef="usdPerShare">16.25</us-gaap:SharesIssuedPricePerShare>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="D2018Q2Apr01-Apr30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d94595400e492-wk-Fact-639B02B7319545294B23D79D0AA1051F"
      unitRef="usd">215800000</sgmo:NetProceedsFromIssuancePublicOffering>
    <sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance
      contextRef="I2016Q1Dec07_us-gaap_SubsidiarySaleOfStockAxis_sgmo_AtTheMarketOfferingAgreementMember"
      decimals="-5"
      id="d94595400e502-wk-Fact-928AD52B7D4828D1B9CCD79D0AA42708"
      unitRef="usd">75000000.0</sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance
      contextRef="FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_sgmo_AtTheMarketOfferingAgreementMember"
      decimals="-5"
      id="d94595400e510-wk-Fact-C8D4076914F3CA7A93AED79D0AA40C2D"
      unitRef="usd">75000000.0</sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-18E6F25E859B4D80C98CD79D0AE9F3FA-0-wk-Fact-5CD955B5670D0BCAC86FD79D0AA5A077">ACQUISITION OF TXCELL S.A.&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On July&#160;20, 2018, Sangamo entered into several agreements with TxCell S.A. (&#x201c;TxCell&#x201d;), a French publicly-listed company specialized in the development of cellular immunotherapy products based on regulator T-cells (&#x201c;Tregs&#x201d;) to treat severe autoimmune and inflammatory diseases, and certain of its shareholders, with the goal of eventually acquiring &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of TxCell&#x2019;s share capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under a Share Purchase Agreement (&#x201c;SPA&#x201d;) signed with certain shareholders of TxCell, the Company acquired &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,519,036&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; ordinary shares of TxCell (&#x201c;TxCell Ordinary Shares&#x201d;), representing approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the outstanding share capital and voting rights of TxCell, (the &#x201c;Block Transaction&#x201d;) at a price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x20ac;2.58&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The Block Transaction closed on October&#160;1, 2018 (the &#x201c;Acquisition Date&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additionally, the Company and TxCell entered into a Tender Offer Agreement (&#x201c;TOA&#x201d;), pursuant to which the Company agreed to acquire &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,981,867&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; TxCell Ordinary Shares not acquired as part of the Block Transaction following a public tender offer (the &#x201c;Tender Offer&#x201d;) at a price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x20ac;2.58&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. The Tender Offer closed on November&#160;23, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Following the Block Transaction and the Tender Offer, the Company owns &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of TxCell Ordinary Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition, the Company also entered into arrangements with the holders of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;477,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &#x201c;free shares&#x201d; of TxCell pursuant to which the Company has the right to purchase such shares from the holders thereof (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#x201c;Free Shares Options&#x201d;) so as to increase the Company&#x2019;s ownership of TxCell to 100% should all free shares be acquired following through the exercise of either the call or the put options.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The purchase price for each such free share acquired by the Company upon exercise of a Free Shares Option will be based on the performance of the Company&#x2019;s stock price from the announcement of the transactions contemplated by the SPA and TOA through the Acquisition Date. At the Acquisition Date, the Free Shares Options purchase price was valued at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x20ac;2.58&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share or approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share using an exchange rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.16&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. If the Company&#x2019;s stock price increases during that time period, the Free Shares Options purchase price per share will proportionately increase. If the Company&#x2019;s stock price decreases, the Free Shares Options purchase price will proportionately decrease, the minimum purchase price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x20ac;2.58&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share only applies to vested Free Shares Options that are not yet transferable shares, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; based on an option pricing method. The value was included in the purchase consideration and is recorded as a non-controlling interest on the Condensed Consolidated Balance Sheets. The fair value of the Free Shares Options will vary based on future changes in the Company&#x2019;s stock price during the option period. The Company assesses this fair value on a quarterly basis with changes in fair value being recognized in operations. The fair value of the Free Shares Options was estimated to be an asset of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2018, the Company provided TxCell with a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.2&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; loan (the &#x201c;TxCell Loan&#x201d;) that was deemed to be part of the purchase consideration for accounting purposes. The TxCell Loan, together with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.5&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; cash paid to acquire the TxCell Ordinary Shares and the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; estimated fair value of the Free Shares Options, comprise the aggregate purchase consideration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$45.9&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of the Acquisition Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible), liabilities assumed, as well as tax-related matters. During the measurement period, the Company may record adjustments to the provisional amounts recognized. There were no adjustments to the provisional values subsequent to the Acquisition Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The acquisition of TxCell was accounted for as a business combination in accordance with ASC Topic 805, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Business Combinations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The operating results of TxCell after the Acquisition Date have been included in the Company&#x2019;s Condensed Consolidated Statements of Operations. In June 2019, TxCell became a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;soci&#xe9;te par actions simplifi&#xe9;e &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(S.A.S.) and was renamed &#x201c;Sangamo Therapeutics France.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Estimate of Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under ASC Topic 805, an acquirer recognizes and consolidates assets acquired, liabilities assumed, and any non-controlling interest at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of their fair values as of the acquisition date (regardless of the acquirer&#x2019;s percentage ownership in the acquiree). As goodwill is calculated as a residual, all goodwill of the acquired business, not just the acquirer&#x2019;s share, is recognized under this &#x201c;full-goodwill&#x201d; approach. Recognized goodwill is allocated between the controlling and non-controlling interests. Although this allocation is not presented separately on the acquirer&#x2019;s balance sheet, it is necessary so that a goodwill impairment charge recognized in a period following the business combination by an acquirer is appropriately allocated between controlling and non-controlling interests. There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; goodwill impairments during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or during &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the estimated fair value of the net assets acquired as of the Acquisition Date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;October 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Consideration transferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of non-controlling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of TxCell&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,779&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,427&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,761&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assumed debt liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,798&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of net identifiable assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42,745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total fair value of net assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Consideration Transferred&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Consideration transferred as of October&#160;1, 2018 consisted of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,519,036&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; TxCell Ordinary Shares acquired by the Company on the Acquisition Date of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.2&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; TxCell Loan and approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the fair value of the Free Shares Options.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Non-controlling Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of the non-controlling interest at the Acquisition Date was based on the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; acquisition price per share for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,981,867&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Ordinary Shares that were not purchased by the Company on the Acquisition Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On November&#160;1, 2018, pursuant to the TOA, the Company commenced a cash tender offer (the &#x201c;Offer&#x201d;) to acquire all of the TxCell Ordinary Shares not held by the Company for the same per share price paid in the Block Transaction. Following the completion of the Offer on November&#160;23, 2018, the Company initiated compulsory squeeze-out procedures applicable to French public companies to acquire the remaining TxCell Ordinary Shares, other than the free shares that were subject to the Free Shares Options. Subsequent to the Acquisition Date and through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company acquired &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,528,635&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;TxCell Ordinary Shares which, when aggregated with the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,519,036&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Ordinary Shares acquired at the Acquisition Date, resulted in the Company owning &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of all TxCell Ordinary Shares as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,528,635&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares acquired subsequent to the Acquisition Date were acquired for total consideration of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$33.9&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.94&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregate purchase consideration was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$80.4&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; through the completion of this purchase, with approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;453,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Ordinary Shares (vested free shares), which remain outstanding and are subject to purchase by the Company as noted above, with an estimated fair value of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.6&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest at January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest at Acquisition Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares acquired post acquisition&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(34,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest of acquired entity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign currency effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(555&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;739&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire
      contextRef="I2018Q3July20_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="INF"
      id="d94598408e458-wk-Fact-DEEE8F9412954C1365C7D79D0AA9895A"
      unitRef="number">1</sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementMember"
      decimals="INF"
      id="d94598408e465-wk-Fact-ACA5AD7D4DF3A84E2B2DD79D0A9E2126"
      unitRef="shares">13519036</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementMember"
      decimals="2"
      id="d94598408e469-wk-Fact-9457235D7C47FB746441D79D0AD2C2BA"
      unitRef="number">0.53</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2018Q4Oct01_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="2"
      id="d94598408e473-wk-Fact-9FBA169E05D72C08CBCCD79D0AAB6D0C"
      unitRef="eurPerShare">2.58</us-gaap:BusinessAcquisitionSharePrice>
    <sgmo:BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction
      contextRef="I2018Q4Nov23"
      decimals="INF"
      id="d94598408e480-wk-Fact-6D4B5AD660186F394C9BD79D0AABEEA5"
      unitRef="shares">11981867</sgmo:BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2018Q4Oct01_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="2"
      id="d94598408e484-wk-Fact-9FBA169E05D72C08CBCCD79D0AAB6D0C"
      unitRef="eurPerShare">2.58</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="3"
      id="d94598408e491-wk-Fact-5D3CB30A063EC9FCCD1BD79D0ACEEDFE"
      unitRef="number">0.982</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="-3"
      id="d94598408e498-wk-Fact-8BCA9FF2B4C38883C8E2D79D0ACB5793"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2018Q4Oct01_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="2"
      id="d94598408e505-wk-Fact-9FBA169E05D72C08CBCCD79D0AAB6D0C"
      unitRef="eurPerShare">2.58</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="INF"
      id="d94598408e509-wk-Fact-22FCD91D569B9F182109D79D0A9FD35B"
      unitRef="usdPerShare">2.99</us-gaap:BusinessAcquisitionSharePrice>
    <sgmo:BusinessAcquisitionExchangeRateOnPurchasePrice
      contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="2"
      id="d94598408e513-wk-Fact-301E4C5D2025A70B600BD79D0ACBC1BA"
      unitRef="number">1.16</sgmo:BusinessAcquisitionExchangeRateOnPurchasePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="2"
      id="d94598408e517-wk-Fact-1DAE67AE92FCE5191D48D79D0AA25051"
      unitRef="eurPerShare">2.58</us-gaap:BusinessAcquisitionSharePrice>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember"
      decimals="-5"
      id="d94598408e524-wk-Fact-345B39B6665800828047D79D0AD4702B"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"
      decimals="-5"
      id="d94598408e528-wk-Fact-EBC79AD34AB86E47CE4653C5FF4A775D"
      unitRef="usd">400000</sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares>
    <sgmo:BusinessCombinationLoanAdjustedInPurchaseConsideration
      contextRef="D2018Q3Sep1-Sep30_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-5"
      id="d94598408e539-wk-Fact-90DBB998B8C26BF7AF5ED79D0ACFE98D"
      unitRef="usd">5200000</sgmo:BusinessCombinationLoanAdjustedInPurchaseConsideration>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2018Q3Sep1-Sep30_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-5"
      id="d94598408e543-wk-Fact-94A5D402925A38F49BCDD79D0AA50CC2"
      unitRef="usd">40500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <sgmo:BusinessAcquisitionEstimatedFairValueOfFreeShares
      contextRef="D2018Q3Sep1-Sep30_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-5"
      id="d94598408e547-wk-Fact-D03007B0D2FECFF9CB27D79D0AA84D1D"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueOfFreeShares>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2018Q3Sep1-Sep30_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-5"
      id="d94598408e551-wk-Fact-124579E406567A80E512D79D0AACC9F3"
      unitRef="usd">45900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <sgmo:BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="INF"
      id="d94598408e576-wk-Fact-A90BE283AE5D7BCCBE02D79D0AA0376D"
      unitRef="number">1</sgmo:BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d94598408e580-wk-Fact-89B812EBFEFF8CF2D485D79D0ACE4B6C"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-11B15B5E586A41D2AB0CD79D0AEA0042-0-wk-Fact-9A0518E7827D3288C391D79D0A9C35F1">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the estimated fair value of the net assets acquired as of the Acquisition Date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;October 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Consideration transferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of non-controlling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of TxCell&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,779&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,427&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;155&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,761&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Assumed debt liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,798&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of net identifiable assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;42,745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total fair value of net assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e656-wk-Fact-B0BFEDA84C8518909DA4D79D0AA7A045"
      unitRef="usd">45911000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e671-wk-Fact-168AF0D12C6A96A5AAE0D79D0AD4666B"
      unitRef="usd">35829000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e696-wk-Fact-9CD1C118F090901B94CAD79D0A9BA697"
      unitRef="usd">81740000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e737-wk-Fact-AFFA2E9C7E23504FCF22D79D0A9C48FF"
      unitRef="usd">4779000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e752-wk-Fact-962C9E0F9F80C6300C3FD79D0A9ABB5B"
      unitRef="usd">2427000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e772-wk-Fact-59F5BA9A24E372E972FBD79D0A9FBB76"
      unitRef="usd">1857000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <sgmo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e792-wk-Fact-0B1E1DD8BEB5987471B6D79D0AA669E2"
      unitRef="usd">55019000</sgmo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e812-wk-Fact-7769BD58127558A388A1D79D0A9F39D7"
      unitRef="usd">155000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e832-wk-Fact-B506AE369100E613A2A0D79D0AD2EB57"
      unitRef="usd">9761000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e854-wk-Fact-349EF1505DCED87E1C1FD79D0A96B47C"
      unitRef="usd">4933000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e875-wk-Fact-2729CE0030FFACDCCFD1D79D0A968632"
      unitRef="usd">6798000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e896-wk-Fact-EDE3A6444905787F0C65D79D0A9E7787"
      unitRef="usd">42745000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e916-wk-Fact-5B53AF00DD58AA3B3FDDD79D0AA94FEE"
      unitRef="usd">38995000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e941-wk-Fact-9CD1C118F090901B94CAD79D0A9BA697"
      unitRef="usd">81740000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="INF"
      id="d94598408e956-wk-Fact-B0649D405E1FED35C94FEC3FB14D68AD"
      unitRef="shares">13519036</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="2"
      id="d94598408e960-wk-Fact-53A03C1702E4E01209DAD79D0ACD2B48"
      unitRef="usdPerShare">2.99</us-gaap:BusinessAcquisitionSharePrice>
    <sgmo:BusinessCombinationLoanAdjustedInPurchaseConsideration
      contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-5"
      id="d94598408e964-wk-Fact-420C688FA92558512F89D79D0ACB720F"
      unitRef="usd">5200000</sgmo:BusinessCombinationLoanAdjustedInPurchaseConsideration>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueOptionPricingModelMember"
      decimals="-5"
      id="d94598408e968-wk-Fact-345B39B6665800828047D79D0AD4702B"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2018Q4Oct01"
      decimals="2"
      id="d94598408e978-wk-Fact-A9055918EFD75EE77112D79D0AA5BEAC"
      unitRef="usdPerShare">2.99</us-gaap:BusinessAcquisitionSharePrice>
    <sgmo:BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction
      contextRef="I2018Q4Nov23"
      decimals="INF"
      id="d94598408e982-wk-Fact-6D4B5AD660186F394C9BD79D0AABEEA5"
      unitRef="shares">11981867</sgmo:BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="INF"
      id="d94598408e993-wk-Fact-15F95B32426E9AFBF39BD79D0AA451D4"
      unitRef="shares">11528635</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="D2018Q3Oct1-Oct1_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="INF"
      id="d94598408e997-wk-Fact-B0649D405E1FED35C94FEC3FB14D68AD"
      unitRef="shares">13519036</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="3"
      id="d94598408e1001-wk-Fact-5D3CB30A063EC9FCCD1BD79D0ACEEDFE"
      unitRef="number">0.982</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="INF"
      id="d94598408e1010-wk-Fact-15F95B32426E9AFBF39BD79D0AA451D4"
      unitRef="shares">11528635</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="FD2018Q4QTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-5"
      id="d94598408e1014-wk-Fact-52E0945A2457BDDDD24BD79D0A9DA681"
      unitRef="usd">33900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="2"
      id="d94598408e1018-wk-Fact-0D3D3CA014F91F85F7E3D79D0AAACF2C"
      unitRef="usdPerShare">2.94</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-5"
      id="d94598408e1026-wk-Fact-BECD25FB4F2076CD64D0D79D0ACC1DB2"
      unitRef="usd">80400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <sgmo:BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-3"
      id="d94598408e1030-wk-Fact-E3FFD2C41446A16F644FD79D0AC902E2"
      unitRef="shares">453000</sgmo:BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction>
    <sgmo:BusinessAcquisitionEstimatedFairValueOfFreeShares
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember"
      decimals="-5"
      id="d94598408e1035-wk-Fact-17F7DF9693E92C6D3D78654592E03125"
      unitRef="usd">600000</sgmo:BusinessAcquisitionEstimatedFairValueOfFreeShares>
    <sgmo:ScheduleOfNoncontrollingInterestTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1BAD86C96554BC73AAB0D79D0AEAA5DB-0-wk-Fact-1EDC2069D782022EE7D2D79D0AA44F81">&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest at January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest at Acquisition Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares acquired post acquisition&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(34,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest of acquired entity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign currency effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:start;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(555&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;739&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-controlling interest at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</sgmo:ScheduleOfNoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="FI2017Q4"
      decimals="-3"
      id="d94598408e1077-wk-Fact-86C300C1BF11F4C5CF30D79D0A94D764"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94598408e1092-wk-Fact-E9A7C96E47C7F819D3B9D79D0A972A56"
      unitRef="usd">35829000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <sgmo:PostBusinessAcquisitionSharesAcquiredAmount
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d94598408e1112-wk-Fact-BF8CF5D87321469DE588D79D0A956085"
      unitRef="usd">34516000</sgmo:PostBusinessAcquisitionSharesAcquiredAmount>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d94598408e1133-wk-Fact-DA2D3A3DB423C639ABFED79D0A961CCC"
      unitRef="usd">1313000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <sgmo:NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d94598408e1153-wk-Fact-7CFFB26A3FC4ABEB559AD79D0A981D50"
      unitRef="usd">19000</sgmo:NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d94598408e1174-wk-Fact-F0C12CBECCBAFAF3CEF9D79D0A961436"
      unitRef="usd">-555000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d94598408e1195-wk-Fact-5BC2E4BF3B544D9C0A16D79D0ACC2989"
      unitRef="usd">739000</us-gaap:MinorityInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d94598408e1215-wk-Fact-C398701DA594F86769A7E7D7F73F1EDD"
      unitRef="usd">-125000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q2"
      decimals="-3"
      id="d94598408e1241-wk-Fact-1930E75AE6EC2D9A44FDD79D0AC4175A"
      unitRef="usd">614000</us-gaap:MinorityInterest>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6849633072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Aug. 02, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">501 Canal Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Richmond<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,675,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6829377760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 169,222<span></span>
</td>
<td class="nump">$ 140,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current portion</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">271,877<span></span>
</td>
<td class="nump">259,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">12,095<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">5,340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">461,808<span></span>
</td>
<td class="nump">410,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">8,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,019<span></span>
</td>
<td class="nump">78,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">53,892<span></span>
</td>
<td class="nump">54,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">39,795<span></span>
</td>
<td class="nump">40,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">79,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">7,582<span></span>
</td>
<td class="nump">3,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">673,481<span></span>
</td>
<td class="nump">590,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">22,505<span></span>
</td>
<td class="nump">21,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">8,714<span></span>
</td>
<td class="nump">9,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">50,826<span></span>
</td>
<td class="nump">47,564<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">82,045<span></span>
</td>
<td class="nump">78,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">94,189<span></span>
</td>
<td class="nump">108,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">41,550<span></span>
</td>
<td class="nump">27,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="nump">6,661<span></span>
</td>
<td class="nump">6,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">3,288<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">227,733<span></span>
</td>
<td class="nump">223,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">1,156<span></span>
</td>
<td class="nump">1,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,078,976<span></span>
</td>
<td class="nump">929,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(634,233)<span></span>
</td>
<td class="num">(562,696)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(765)<span></span>
</td>
<td class="num">(1,440)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Sangamo Therapeutics, Inc. stockholders' equity</a></td>
<td class="nump">445,134<span></span>
</td>
<td class="nump">366,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">445,748<span></span>
</td>
<td class="nump">367,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 673,481<span></span>
</td>
<td class="nump">$ 590,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6849717728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 21,416<span></span>
</td>
<td class="nump">$ 25,619<span></span>
</td>
<td class="nump">$ 34,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">36,455<span></span>
</td>
<td class="nump">29,255<span></span>
</td>
<td class="nump">71,305<span></span>
</td>
<td class="nump">52,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,597<span></span>
</td>
<td class="nump">11,301<span></span>
</td>
<td class="nump">31,715<span></span>
</td>
<td class="nump">21,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">51,052<span></span>
</td>
<td class="nump">40,556<span></span>
</td>
<td class="nump">103,020<span></span>
</td>
<td class="nump">74,190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(33,504)<span></span>
</td>
<td class="num">(19,140)<span></span>
</td>
<td class="num">(77,401)<span></span>
</td>
<td class="num">(40,137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">3,148<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">4,842<span></span>
</td>
<td class="nump">3,310<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(30,356)<span></span>
</td>
<td class="num">(16,640)<span></span>
</td>
<td class="num">(72,559)<span></span>
</td>
<td class="num">(36,827)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(72)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss to Sangamo Therapeutics, Inc. stockholders</a></td>
<td class="num">$ (30,284)<span></span>
</td>
<td class="num">$ (16,640)<span></span>
</td>
<td class="num">$ (72,434)<span></span>
</td>
<td class="num">$ (36,827)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in USD per share)</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</a></td>
<td class="nump">114,382<span></span>
</td>
<td class="nump">97,267<span></span>
</td>
<td class="nump">108,360<span></span>
</td>
<td class="nump">91,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6829952944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (30,356)<span></span>
</td>
<td class="num">$ (16,640)<span></span>
</td>
<td class="num">$ (72,559)<span></span>
</td>
<td class="num">$ (36,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain on available-for-sale securities</a></td>
<td class="nump">484<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">737<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(28,430)<span></span>
</td>
<td class="num">(16,410)<span></span>
</td>
<td class="num">(71,884)<span></span>
</td>
<td class="num">(36,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="num">(72)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</a></td>
<td class="num">$ (28,358)<span></span>
</td>
<td class="num">$ (16,410)<span></span>
</td>
<td class="num">$ (71,759)<span></span>
</td>
<td class="num">$ (36,696)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843118160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Non- Controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2017</a></td>
<td class="nump">$ 187,900<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">$ 682,809<span></span>
</td>
<td class="num">$ (495,479)<span></span>
</td>
<td class="num">$ (286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Cumulative-effect adjustment of ASC | Topic 606</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">10,584<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">10,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="num">(99)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(20,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Mar. 31, 2018</a></td>
<td class="nump">182,365<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
<td class="nump">696,429<span></span>
</td>
<td class="num">(514,549)<span></span>
</td>
<td class="num">(385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2017</a></td>
<td class="nump">187,900<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">682,809<span></span>
</td>
<td class="num">(495,479)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(36,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2018</a></td>
<td class="nump">387,867<span></span>
</td>
<td class="nump">$ 1,016<span></span>
</td>
<td class="nump">918,197<span></span>
</td>
<td class="num">(531,189)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Mar. 31, 2018</a></td>
<td class="nump">182,365<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
<td class="nump">696,429<span></span>
</td>
<td class="num">(514,549)<span></span>
</td>
<td class="num">(385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">1,954<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">215,756<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">215,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(16,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2018</a></td>
<td class="nump">387,867<span></span>
</td>
<td class="nump">$ 1,016<span></span>
</td>
<td class="nump">918,197<span></span>
</td>
<td class="num">(531,189)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2018</a></td>
<td class="nump">367,257<span></span>
</td>
<td class="nump">$ 1,022<span></span>
</td>
<td class="nump">929,632<span></span>
</td>
<td class="num">(562,696)<span></span>
</td>
<td class="num">(1,440)<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Cumulative-effect adjustment of ASC | Topic 842</a></td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs related to public offering and TxCell Acquisition</a></td>
<td class="num">(258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(42,203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Mar. 31, 2019</a></td>
<td class="nump">329,181<span></span>
</td>
<td class="nump">$ 1,023<span></span>
</td>
<td class="nump">934,112<span></span>
</td>
<td class="num">(603,949)<span></span>
</td>
<td class="num">(2,691)<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2018</a></td>
<td class="nump">367,257<span></span>
</td>
<td class="nump">$ 1,022<span></span>
</td>
<td class="nump">929,632<span></span>
</td>
<td class="num">(562,696)<span></span>
</td>
<td class="num">(1,440)<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(72,559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2019</a></td>
<td class="nump">445,748<span></span>
</td>
<td class="nump">$ 1,156<span></span>
</td>
<td class="nump">1,078,976<span></span>
</td>
<td class="num">(634,233)<span></span>
</td>
<td class="num">(765)<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Mar. 31, 2019</a></td>
<td class="nump">329,181<span></span>
</td>
<td class="nump">$ 1,023<span></span>
</td>
<td class="nump">934,112<span></span>
</td>
<td class="num">(603,949)<span></span>
</td>
<td class="num">(2,691)<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">2,444<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">136,566<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">136,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs related to public offering and TxCell Acquisition</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="nump">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(30,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2019</a></td>
<td class="nump">$ 445,748<span></span>
</td>
<td class="nump">$ 1,156<span></span>
</td>
<td class="nump">$ 1,078,976<span></span>
</td>
<td class="num">$ (634,233)<span></span>
</td>
<td class="num">$ (765)<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cumulative effect on retained earnings net of related income tax effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6831105200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (72,559)<span></span>
</td>
<td class="num">$ (36,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,583<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on marketable securities</a></td>
<td class="num">(2,455)<span></span>
</td>
<td class="num">(1,656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GainOnFreeShares', window );">Gain on free shares</a></td>
<td class="num">(551)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,390<span></span>
</td>
<td class="nump">6,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Net loss on lease termination</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="num">(391)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,422)<span></span>
</td>
<td class="num">(1,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(5,449)<span></span>
</td>
<td class="num">(3,564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,811<span></span>
</td>
<td class="nump">2,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(764)<span></span>
</td>
<td class="num">(1,133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="num">(10,821)<span></span>
</td>
<td class="nump">138,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities', window );">Long-term portion of lease liabilities</a></td>
<td class="num">(563)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(84,712)<span></span>
</td>
<td class="nump">104,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(244,306)<span></span>
</td>
<td class="num">(451,240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">226,884<span></span>
</td>
<td class="nump">133,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(9,760)<span></span>
</td>
<td class="num">(5,768)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(27,182)<span></span>
</td>
<td class="num">(323,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">136,308<span></span>
</td>
<td class="nump">215,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(296)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">4,094<span></span>
</td>
<td class="nump">13,285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">140,106<span></span>
</td>
<td class="nump">228,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effects of changes in foreign exchange rates</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">28,804<span></span>
</td>
<td class="nump">9,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">143,918<span></span>
</td>
<td class="nump">53,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">172,722<span></span>
</td>
<td class="nump">62,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accrued liabilities</a></td>
<td class="nump">1,679<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 29,671<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GainOnFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GainOnFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in long-term portion of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77888415&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6669604576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization, Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or the &#8220;Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is focused on the research, development and commercialization of novel therapeutic strategies for unmet medical needs. Sangamo&#8217;s genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins (&#8220;ZFPs&#8221;). Potential applications of Sangamo&#8217;s technology include development of human therapeutics, plant agriculture and enhancement of pharmaceutical protein production.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next twelve months from the date the financial statements are issued. Sangamo will require additional financial resources to complete the development and commercialization of its products including ZFP Therapeutic products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and ZFP Therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The condensed consolidated balance sheet data at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was derived from the audited consolidated financial statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (the &#8220;</span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report&#8221;) as filed with the SEC on March&#160;1, 2019. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and footnotes thereto for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, included in the </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In </span><span style="font-family:inherit;font-size:10pt;">March 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) as result of a decision made in a joint steering committee of Pfizer and Sangamo in </span><span style="font-family:inherit;font-size:10pt;">March 2019</span><span style="font-family:inherit;font-size:10pt;"> to increase the project scope and related project cost, which resulted in a decrease in the measure of the proportional performance. This adjustment decreased revenue by </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, increased net loss by </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and increased the Company&#8217;s basic net loss per share by </span><span style="font-family:inherit;font-size:10pt;"><span>$0.03</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adjustments are recorded as a component of Accumulated Other Comprehensive Income (Loss) (&#8220;AOCI&#8221;) within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain prior period amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> from Intangible assets to Other non-current assets on the Condensed Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo considers all highly-liquid investments purchased with original maturities of </span><span style="font-family:inherit;font-size:10pt;">three months or less</span><span style="font-family:inherit;font-size:10pt;"> at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in AOCI.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, net, which are determined using the specific identification method.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the condensed consolidated balance sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019, the Company entered into an Option Agreement (the &#8220;Option&#8221;) with Brammer Bio MA (&#8220;Brammer&#8221;) whereby Brammer granted an option to secure dedicated capacity for Sangamo for manufacturing in Brammer&#8217;s facilities. The Company paid </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Option, which expires on July&#160;31, 2020, and which is included in other non-current assets on the Condensed Consolidated Balance Sheets. If the Company exercises the option, the </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> will be applied towards future manufacturing services. If the Company does not exercise the option, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> of the deposit is non-refundable. The remainder will be applied towards future services initiated within five years. In addition, the Company will pay Brammer </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> to assist it in establishing its manufacturing capabilities in Brisbane, CA.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&#8217;s investment securities consist of the U.S. government-sponsored entities and various major corporations and financial institutions with high credit ratings. The free share asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January&#160;1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 606&#8221;) using the modified retrospective method, resulting in a change to its accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s contract revenues consist of strategic partnering collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, revenues related to Kite Pharma, Inc. (&#8220;Kite&#8221;), a wholly-owned subsidiary of Gilead Sciences, Inc., the hemoglobinopathies agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#8220;Sanofi&#8221;)), and the Company&#8217;s hemophilia A collaboration agreement with Pfizer represented </span><span style="font-family:inherit;font-size:10pt;"><span>61%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>18%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>16%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue, excluding the above change in estimate. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, revenues related to Kite, the Company&#8217;s hemophilia A collaboration agreement with Pfizer and the hemoglobinopathies agreement with Sanofi represented </span><span style="font-family:inherit;font-size:10pt;"><span>52%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>26%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>17%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue. During the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, revenues related to the Company&#8217;s hemophilia A collaboration agreement with Pfizer, the hemoglobinopathies agreement with Sanofi and the agreement with Kite represented </span><span style="font-family:inherit;font-size:10pt;"><span>47%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>26%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>22%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, revenues related to the Company&#8217;s hemophilia A collaboration agreement with Pfizer, Kite and the hemoglobinopathies agreement with Sanofi represented </span><span style="font-family:inherit;font-size:10pt;"><span>38%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>21%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue. Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Funds received from third parties under contract or grant arrangements are recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#8217;s development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Simplified Disclosure</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No.&#160;33-10532, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Update and Simplification</span><span style="font-family:inherit;font-size:10pt;">, as updated. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders&#8217; equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments are effective for all filings made on or after November&#160;5, 2018. As such, the Company adopted these SEC amendments on November&#160;5, 2018 and has presented the analysis of changes in stockholders&#8217; equity in these interim financial statements for </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> presented in this Quarterly Report on Form 10-Q. The Company&#8217;s adoption of these SEC amendments had no material effect on the Company&#8217;s reporting of financial position, results of operations, cash flows or stockholders&#8217; equity.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Accounting for Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016</span><span style="font-family:inherit;font-size:10pt;">-2</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 842&#8221;). ASC Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a ROU asset and corresponding liability, measured at the present value of the lease payments. On January&#160;1, 2019, the Company adopted ASC Topic 842 using the modified retrospective approach with a cumulative-effect adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> reflected as a decrease to the opening balance of accumulated deficit as of the adoption date. Results for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are presented under ASC Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 &#8212; </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 840&#8221;).</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC Topic 842 provides a number of optional practical expedients in transition. The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effective date and did not elect the practical expedient pertaining to land easements as this is not applicable to the current contract portfolio.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact of the adoption of ASC Topic 842 on the accompanying Condensed Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments Due to</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">the Adoption of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC Topic 842</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,723</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(62,500</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid rent</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - current</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred rent</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(271</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Build-to-suit lease obligation</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,689</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - long-term</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(562,696</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>897</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(561,799</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">___________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Operating lease liabilities &#8211; current and deferred rent are included in accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Build-to-suit lease obligation and operating lease liabilities &#8211; long-term are included in long-term portion of lease liabilities on the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The adjustments due to the adoption of ASC Topic 842 primarily related to the recognition of operating lease ROU assets and operating lease liabilities for the Company&#8217;s leases. In addition, the adoption of ASC Topic 842 resulted in a change in accounting of the build-to-suit component of two leases under ASC Topic 840 to operating leases under ASC Topic 842 and as a result the Company derecognized the estimated fair value of the building shells that were included in Property and equipment, net as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, as the Company had been deemed to own these buildings under ASC Topic 840. For additional discussion of the build-to-suit properties, see &#8220;Note 7 &#8211; </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property and equipment, net</span><span style="font-family:inherit;font-size:10pt;">&#8221; to the Company&#8217;s consolidated financial statements included in its Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> filed with the SEC on March&#160;1, 2019. For a description of the leases, see &#8220;Note 8 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#8211; Commitments and Contingencies &#8211; Leases</span><span style="font-family:inherit;font-size:10pt;">&#8221; in these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Not yet adopted</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 808&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January&#160;1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Goodwill Impairment Testing</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;">&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step </span><span style="font-family:inherit;font-size:10pt;">2</span><span style="font-family:inherit;font-size:10pt;"> from the goodwill impairment test. ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;"> requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;"> requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;"> will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838602752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale marketable securities and the free share asset/liability. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="line-height:120%;padding-top:8px;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="line-height:120%;padding-top:8px;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="line-height:120%;padding-top:8px;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value measurements of the Company&#8217;s cash equivalents, available-for-sale marketable securities and the free share asset/liability are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2019<br/>Fair Value Measurements</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,441</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,441</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,931</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,441</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170,953</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170,953</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and marketable securities</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382,258</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>310,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Free shares asset</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018<br/>Fair Value Measurements</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and marketable securities</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>363,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Free shares liability</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Free Share Asset/Liability</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;SPA&#8221;) with TxCell S.A., a French </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">soci&#233;t&#233; anonyme</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;TxCell&#8221;) (see Note 10 &#8212; </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisition of TxCell S.A.</span><span style="font-family:inherit;font-size:10pt;">), the Company entered into arrangements with the holders of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>477,000</span></span><span style="font-family:inherit;font-size:10pt;"> &#8220;free shares&#8221; of TxCell pursuant to which the Company has the right to purchase such shares from the holders thereof (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#8220;Monte Carlo simulation model&#8221;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Condensed Consolidated Statements of Operations. The number of free shares has not changed since the Acquisition Date. The free shares liability was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and the Company recognized a gain due to an increase in the fair value of the free shares of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> bringing the balance to an asset of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Free Shares valuation assumptions:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo Stock Price (USD)</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TxCell Stock Price (EUR)</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR / USD Exchange Rate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated Correlation Sangamo and TxCell Stock Prices</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72.2%</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo Stock Price (USD) Volatility Estimate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.6%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79.9%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TxCell Stock Price (EUR) Volatility Estimate</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.2%</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.6%</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR / USD Exchange Rate Volatility Estimate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.7%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk Free Rate and Cost of Debt by Expected Exercise Date</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varies</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varies</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846415296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash and Marketable Securities</a></td>
<td class="text">CASH AND MARKETABLE SECURITIES<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,418</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in Restricted cash, current portion</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in Non-current restricted cash</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,918</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,906</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash consists of a letter of credit for </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> established as a deposit for the Brisbane lease.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Available-for-sale Securities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the Company&#8217;s cash equivalents and available-for-sale securities (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,441</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,931</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,280</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,383</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>279,851</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381,780</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382,258</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,981</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,640</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,974</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(259</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>363,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(259</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>363,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271,877</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> material realized losses of its available-for-sale securities for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. Sangamo has the intent and ability to hold its investments for a period of time sufficient to allow for any anticipated recovery in market value. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> investments were other-than-temporarily impaired at either </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838597664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text">BASIC AND DILUTED NET LOSS PER SHARE<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total number of shares subject to stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding and the employee stock purchase plan (&#8220;ESPP&#8221;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> totaled </span><span style="font-family:inherit;font-size:10pt;"><span>10,155,033</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>8,757,528</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6835258912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Major Customers, Partnerships and Strategic Alliances</a></td>
<td class="text">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration Agreements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Kite Pharma, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the Company entered into a global collaboration and license agreement with Kite for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing ZFNs and adeno-associated viral vectors (&#8220;AAVs&#8221;) to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors, T-cell receptors, and NK-cell receptors directed to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products and has announced that they expect to initiate a clinical trial evaluating KITE-037, an allogeneic anti-CD19 CAR-T cell therapy, in 2020. The Kite agreement became effective on </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">April 5, 2018</span></span></span><span style="font-family:inherit;font-size:10pt;"> when the waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions were completed.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</span><span style="font-family:inherit;font-size:10pt;"> using selected zinc finger nucleases (&#8220;ZFNs&#8221;) and AAVs developed under the research program to express chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;) or NK-cell receptors (&#8220;NKRs&#8221;) directed to candidate targets.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</span><span style="font-family:inherit;font-size:10pt;"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</span><span style="font-family:inherit;font-size:10pt;"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following the effective date, in April 2018, the Company received a </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment from Kite. In addition, Kite will reimburse the Company&#8217;s direct costs to conduct the joint research program, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to </span><span style="font-family:inherit;font-size:10pt;"><span>$3.01&#160;billion</span></span><span style="font-family:inherit;font-size:10pt;"> if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.26&#160;billion</span></span><span style="font-family:inherit;font-size:10pt;"> relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.75&#160;billion</span></span><span style="font-family:inherit;font-size:10pt;"> relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The initial research term in the agreement is </span><span style="font-family:inherit;font-size:10pt;"><span>six years</span></span><span style="font-family:inherit;font-size:10pt;">. Kite has an option to extend the research term of the agreement for up to </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> additional one-year periods for a separate upfront fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The Company concluded the transaction price under this agreement is </span><span style="font-family:inherit;font-size:10pt;"><span>$185.9&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and includes the upfront license fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$35.9&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has identified the primary performance obligations within the Kite agreement as a license to the technology and on-going services. The Company concluded that the license is not discrete as it does not have stand-alone value to </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Kite apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment on a straight-line basis through June 2024, the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$119.1&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$131.5&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to this agreement.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue related to Kite agreement:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,386</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research services</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,515</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,515</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pfizer Inc.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">SB</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">-525</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"> Global Collaboration and License Agreement</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of SB-525, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company originally received an upfront fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and is eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. In addition, Sangamo is eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$208.5&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$266.5&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments upon first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the hemophilia A Pfizer agreement, is up to </span><span style="font-family:inherit;font-size:10pt;"><span>$475.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes up to </span><span style="font-family:inherit;font-size:10pt;"><span>$300.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for SB-525 and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$175.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payments have been received and </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> products have been approved and therefore </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> royalty fees have been earned under the hemophilia A Pfizer agreement. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None of the clinical or regulatory milestones have been included in the </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;fifteen years after the first commercial sale of a product in a country Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has identified the performance obligations within the hemophilia A Pfizer agreement as a license to the technology and on-going services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services through 2020, the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.3&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to this agreement.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee related to Pfizer SB-525 agreement</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,595</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,841</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March&#160;2019, the Company received new data results in the hemophilia A collaboration agreement with Pfizer, and expansion of patients for the ongoing trial. As a result, the estimated project cost increased and the proportional performance was updated based on the actual services delivered to Pfizer as a percentage of the updated project cost as of March&#160;31, 2019. The increase in project cost resulted in a decrease in the measure of the proportional cumulative performance. During the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in revenues related to the Pfizer SB-525 agreement which were net of the approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> reduction in revenues recorded in the three months ended March&#160;31, 2019 related to the updated estimated project cost.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">C</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">9</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">ORF</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">72</span><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"> Research Collaboration and License Agreement</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">December 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP transcription factors (&#8220;TFs&#8221;) to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal lobar degeneration (&#8220;FTLD&#8221;) linked to mutations of the C</span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;">ORF</span><span style="font-family:inherit;font-size:10pt;">72</span><span style="font-family:inherit;font-size:10pt;"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop&#160;ZFP TFs&#160;that bind to and specifically reduce expression of the mutant form of the C</span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;">ORF</span><span style="font-family:inherit;font-size:10pt;">72</span><span style="font-family:inherit;font-size:10pt;"> gene.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company received a </span><span style="font-family:inherit;font-size:10pt;"><span>$12.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment from Pfizer and is eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$90.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>None</span></span><span style="font-family:inherit;font-size:10pt;"> of the clinical or regulatory milestones have been included in the </span><span style="font-family:inherit;font-size:10pt;"><span>$12.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know&#8209;how to develop, manufacture and commercialize gene therapy products that use </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">resulting ZFP&#160;TFs that satisfy pre&#8209;agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the C9ORF72 gene.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;fifteen years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the C</span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;">ORF</span><span style="font-family:inherit;font-size:10pt;">72</span><span style="font-family:inherit;font-size:10pt;"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the C</span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;">ORF</span><span style="font-family:inherit;font-size:10pt;">72</span><span style="font-family:inherit;font-size:10pt;"> gene for a period of time.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has identified the performance obligations within this agreement as a license to the technology and on-going services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services, over the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.7&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.8&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to this agreement.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee related to Pfizer C9ORF72 agreement</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>617</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,076</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sanofi Genzyme</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with Biogen MA Inc., who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an investigational new drug (&#8220;IND&#8221;) application for ZFP therapeutics intended to treat SCD.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the agreement, the Company received an upfront license fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and is eligible to receive development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. In addition, the Company will also be eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>$115.8&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to </span><span style="font-family:inherit;font-size:10pt;"><span>$160.5&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to </span><span style="font-family:inherit;font-size:10pt;"><span>$276.3&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payments have been received and </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> products have been approved and therefore </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> royalty fees have been earned under the Sanofi agreement.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon </span><span style="font-family:inherit;font-size:10pt;">180</span><span style="font-family:inherit;font-size:10pt;"> days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$75.7&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> includes the upfront license fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$55.7&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> estimated reimbursable service costs for identified research projects over the estimated performance period, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the clinical or regulatory milestones have been included in the transaction price.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has identified the performance obligations within this arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the estimated period the Company will perform research services. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to this agreement.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue related to Sanofi agreement:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>901</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research services</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,158</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,332</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">California Institute for Regenerative Medicine</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had received </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, under the award.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. In the event that the Company terminates a CIRM-funded clinical trial, it will be obligated to repay the remaining CIRM funds on hand, therefore as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, including interest, related to </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts with the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838604768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo&#8217;s history of losses. Accordingly, the Company&#8217;s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846461680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,763</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,120</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,061</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,879</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,329</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,867</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,514</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,564</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6591712976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo occupies approximately </span><span style="font-family:inherit;font-size:10pt;"><span>87,700</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office and research and development laboratory facilities in Brisbane, CA pursuant to a lease that expires in </span><span style="font-family:inherit;font-size:10pt;">May 2029</span><span style="font-family:inherit;font-size:10pt;">. Sangamo also leases approximately </span><span style="font-family:inherit;font-size:10pt;"><span>37,900</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in Richmond, CA through August 2026. The Company leases approximately </span><span style="font-family:inherit;font-size:10pt;"><span>7,700</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of additional research and office space located in Richmond, CA pursuant to a lease that expires in December 2019. In addition, the Company leases </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> properties in Valbonne, France. The first lease is for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>14,036</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of research and office space that expires in </span><span style="font-family:inherit;font-size:10pt;">June 2025</span><span style="font-family:inherit;font-size:10pt;">. The second lease, which commenced on </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">April 1, 2019</span></span></span><span style="font-family:inherit;font-size:10pt;">, is for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>6,800</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office space and expires in </span><span style="font-family:inherit;font-size:10pt;">March 2028</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to the Brisbane lease, the commencement date for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>35,080</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of the office space occurred in January 2019 while the commencement date for the remaining approximately </span><span style="font-family:inherit;font-size:10pt;"><span>52,620</span></span><span style="font-family:inherit;font-size:10pt;"> square feet occurred in June 2019. The Company has the right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.8&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> on the first portion of the space occupied and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.2&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> on the portion of the lease that commenced in June 2019. This lease includes </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> renewal options at the election of the Company to extend the lease for an additional </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> each. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company incurred </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$1.6&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of lease costs included in operating expenses in the Condensed Consolidated Statements of Operations in relation to these operating leases. Variable lease expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and was not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and was included in net cash used in operating activities in the Company&#8217;s Condensed Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:89%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six months ending December&#160;31, 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,065</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,253</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,969</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Imputed interest</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,669</span></span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reported as of June&#160;30, 2019:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed    Consolidated Balance Sheet)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,485</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - long-term</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the weighted-average remaining lease term is </span><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span><span style="font-family:inherit;font-size:10pt;">&#160;years and the weighted-average incremental borrowing rate used to determine the operating lease liability was </span><span style="font-family:inherit;font-size:10pt;"><span>6.9%</span></span><span style="font-family:inherit;font-size:10pt;"> for the Company&#8217;s operating leases.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not have any financing leases.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo is not party to any material pending legal proceedings or contingencies. From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6836802192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">April 2019</span><span style="font-family:inherit;font-size:10pt;">, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>12.7&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at a public offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$136.3&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">April 2018</span><span style="font-family:inherit;font-size:10pt;">, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>14.2&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at a public offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$16.25</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$215.8&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">At-the-Market Offering Agreement</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the Company entered into an amended and restated &#8220;at-the-market&#8221; offering program sales agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;), pursuant to which the Company may issue and sell from time to time up to </span><span style="font-family:inherit;font-size:10pt;"><span>$75.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s common stock through Cowen as the sales agent (the &#8220;ATM Agreement&#8221;). Sales of the Company&#8217;s common stock, if any, will be made at market prices by any method that is deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 under the Securities Act of 1933, as amended. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has not sold any common stock under the ATM Agreement and the full </span><span style="font-family:inherit;font-size:10pt;"><span>$75.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> remained available for sale, subject to certain conditions as specified in the agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6591695088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Txcell S.A.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition of Txcell S.A.</a></td>
<td class="text">ACQUISITION OF TXCELL S.A.<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July&#160;20, 2018, Sangamo entered into several agreements with TxCell S.A. (&#8220;TxCell&#8221;), a French publicly-listed company specialized in the development of cellular immunotherapy products based on regulator T-cells (&#8220;Tregs&#8221;) to treat severe autoimmune and inflammatory diseases, and certain of its shareholders, with the goal of eventually acquiring </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of TxCell&#8217;s share capital.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under a Share Purchase Agreement (&#8220;SPA&#8221;) signed with certain shareholders of TxCell, the Company acquired </span><span style="font-family:inherit;font-size:10pt;"><span>13,519,036</span></span><span style="font-family:inherit;font-size:10pt;"> ordinary shares of TxCell (&#8220;TxCell Ordinary Shares&#8221;), representing approximately </span><span style="font-family:inherit;font-size:10pt;"><span>53%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding share capital and voting rights of TxCell, (the &#8220;Block Transaction&#8221;) at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;2.58</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The Block Transaction closed on October&#160;1, 2018 (the &#8220;Acquisition Date&#8221;).</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, the Company and TxCell entered into a Tender Offer Agreement (&#8220;TOA&#8221;), pursuant to which the Company agreed to acquire </span><span style="font-family:inherit;font-size:10pt;"><span>11,981,867</span></span><span style="font-family:inherit;font-size:10pt;"> TxCell Ordinary Shares not acquired as part of the Block Transaction following a public tender offer (the &#8220;Tender Offer&#8221;) at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;2.58</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The Tender Offer closed on November&#160;23, 2018.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following the Block Transaction and the Tender Offer, the Company owns </span><span style="font-family:inherit;font-size:10pt;"><span>98.2%</span></span><span style="font-family:inherit;font-size:10pt;"> of TxCell Ordinary Shares.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the Company also entered into arrangements with the holders of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>477,000</span></span><span style="font-family:inherit;font-size:10pt;"> &#8220;free shares&#8221; of TxCell pursuant to which the Company has the right to purchase such shares from the holders thereof (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#8220;Free Shares Options&#8221;) so as to increase the Company&#8217;s ownership of TxCell to 100% should all free shares be acquired following through the exercise of either the call or the put options.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purchase price for each such free share acquired by the Company upon exercise of a Free Shares Option will be based on the performance of the Company&#8217;s stock price from the announcement of the transactions contemplated by the SPA and TOA through the Acquisition Date. At the Acquisition Date, the Free Shares Options purchase price was valued at </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;2.58</span></span><span style="font-family:inherit;font-size:10pt;"> per share or approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.99</span></span><span style="font-family:inherit;font-size:10pt;"> per share using an exchange rate of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.16</span></span><span style="font-family:inherit;font-size:10pt;">. If the Company&#8217;s stock price increases during that time period, the Free Shares Options purchase price per share will proportionately increase. If the Company&#8217;s stock price decreases, the Free Shares Options purchase price will proportionately decrease, the minimum purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;2.58</span></span><span style="font-family:inherit;font-size:10pt;"> per share only applies to vested Free Shares Options that are not yet transferable shares, subject to certain exceptions.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on an option pricing method. The value was included in the purchase consideration and is recorded as a non-controlling interest on the Condensed Consolidated Balance Sheets. The fair value of the Free Shares Options will vary based on future changes in the Company&#8217;s stock price during the option period. The Company assesses this fair value on a quarterly basis with changes in fair value being recognized in operations. The fair value of the Free Shares Options was estimated to be an asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company provided TxCell with a </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> loan (the &#8220;TxCell Loan&#8221;) that was deemed to be part of the purchase consideration for accounting purposes. The TxCell Loan, together with </span><span style="font-family:inherit;font-size:10pt;"><span>$40.5&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> cash paid to acquire the TxCell Ordinary Shares and the </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> estimated fair value of the Free Shares Options, comprise the aggregate purchase consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$45.9&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> as of the Acquisition Date.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible), liabilities assumed, as well as tax-related matters. During the measurement period, the Company may record adjustments to the provisional amounts recognized. There were no adjustments to the provisional values subsequent to the Acquisition Date.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The acquisition of TxCell was accounted for as a business combination in accordance with ASC Topic 805, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</span><span style="font-family:inherit;font-size:10pt;">. The operating results of TxCell after the Acquisition Date have been included in the Company&#8217;s Condensed Consolidated Statements of Operations. In June 2019, TxCell became a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">soci&#233;te par actions simplifi&#233;e </span><span style="font-family:inherit;font-size:10pt;">(S.A.S.) and was renamed &#8220;Sangamo Therapeutics France.&#8221;</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Estimate of Assets Acquired and Liabilities Assumed</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC Topic 805, an acquirer recognizes and consolidates assets acquired, liabilities assumed, and any non-controlling interest at </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of their fair values as of the acquisition date (regardless of the acquirer&#8217;s percentage ownership in the acquiree). As goodwill is calculated as a residual, all goodwill of the acquired business, not just the acquirer&#8217;s share, is recognized under this &#8220;full-goodwill&#8221; approach. Recognized goodwill is allocated between the controlling and non-controlling interests. Although this allocation is not presented separately on the acquirer&#8217;s balance sheet, it is necessary so that a goodwill impairment charge recognized in a period following the business combination by an acquirer is appropriately allocated between controlling and non-controlling interests. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> goodwill impairments during the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> or during </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the estimated fair value of the net assets acquired as of the Acquisition Date (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:89%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">October 1, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consideration transferred</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,911</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of TxCell</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,857</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,761</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assumed debt liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,798</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,745</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,995</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total fair value of net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consideration Transferred</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consideration transferred as of October&#160;1, 2018 consisted of the </span><span style="font-family:inherit;font-size:10pt;"><span>13,519,036</span></span><span style="font-family:inherit;font-size:10pt;"> TxCell Ordinary Shares acquired by the Company on the Acquisition Date of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.99</span></span><span style="font-family:inherit;font-size:10pt;"> per share, the </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> TxCell Loan and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for the fair value of the Free Shares Options.</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Non-controlling Interest</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the non-controlling interest at the Acquisition Date was based on the </span><span style="font-family:inherit;font-size:10pt;"><span>$2.99</span></span><span style="font-family:inherit;font-size:10pt;"> acquisition price per share for the </span><span style="font-family:inherit;font-size:10pt;"><span>11,981,867</span></span><span style="font-family:inherit;font-size:10pt;"> Ordinary Shares that were not purchased by the Company on the Acquisition Date.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November&#160;1, 2018, pursuant to the TOA, the Company commenced a cash tender offer (the &#8220;Offer&#8221;) to acquire all of the TxCell Ordinary Shares not held by the Company for the same per share price paid in the Block Transaction. Following the completion of the Offer on November&#160;23, 2018, the Company initiated compulsory squeeze-out procedures applicable to French public companies to acquire the remaining TxCell Ordinary Shares, other than the free shares that were subject to the Free Shares Options. Subsequent to the Acquisition Date and through </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company acquired </span><span style="font-family:inherit;font-size:10pt;"><span>11,528,635</span></span><span style="font-family:inherit;font-size:10pt;">&#160;TxCell Ordinary Shares which, when aggregated with the </span><span style="font-family:inherit;font-size:10pt;"><span>13,519,036</span></span><span style="font-family:inherit;font-size:10pt;"> Ordinary Shares acquired at the Acquisition Date, resulted in the Company owning </span><span style="font-family:inherit;font-size:10pt;"><span>98.2%</span></span><span style="font-family:inherit;font-size:10pt;"> of all TxCell Ordinary Shares as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;"><span>11,528,635</span></span><span style="font-family:inherit;font-size:10pt;"> shares acquired subsequent to the Acquisition Date were acquired for total consideration of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$33.9&#160;million</span></span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;"><span>$2.94</span></span><span style="font-family:inherit;font-size:10pt;"> per share. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the aggregate purchase consideration was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$80.4&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> through the completion of this purchase, with approximately </span><span style="font-family:inherit;font-size:10pt;"><span>453,000</span></span><span style="font-family:inherit;font-size:10pt;"> Ordinary Shares (vested free shares), which remain outstanding and are subject to purchase by the Company as noted above, with an estimated fair value of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was as follows (in thousands):</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:89%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at Acquisition Date</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,829</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares acquired post acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest of acquired entity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency effect</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss attributable to non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(555</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at December&#160;31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>739</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss attributable to non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(125</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>614</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838582448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffff00;"&gt;[OPEN THROUGH FILING DATE]&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843744208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The condensed consolidated balance sheet data at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was derived from the audited consolidated financial statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (the &#8220;</span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report&#8221;) as filed with the SEC on March&#160;1, 2019. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and footnotes thereto for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, included in the </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Annual Report.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. In </span><span style="font-family:inherit;font-size:10pt;">March 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) as result of a decision made in a joint steering committee of Pfizer and Sangamo in </span><span style="font-family:inherit;font-size:10pt;">March 2019</span><span style="font-family:inherit;font-size:10pt;"> to increase the project scope and related project cost, which resulted in a decrease in the measure of the proportional performance. This adjustment decreased revenue by </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, increased net loss by </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> and increased the Company&#8217;s basic net loss per share by </span><span style="font-family:inherit;font-size:10pt;"><span>$0.03</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adjustments are recorded as a component of Accumulated Other Comprehensive Income (Loss) (&#8220;AOCI&#8221;) within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain prior period amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> from Intangible assets to Other non-current assets on the Condensed Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo considers all highly-liquid investments purchased with original maturities of </span><span style="font-family:inherit;font-size:10pt;">three months or less</span><span style="font-family:inherit;font-size:10pt;"> at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in AOCI.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, net, which are determined using the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the condensed consolidated balance sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019, the Company entered into an Option Agreement (the &#8220;Option&#8221;) with Brammer Bio MA (&#8220;Brammer&#8221;) whereby Brammer granted an option to secure dedicated capacity for Sangamo for manufacturing in Brammer&#8217;s facilities. The Company paid </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Option, which expires on July&#160;31, 2020, and which is included in other non-current assets on the Condensed Consolidated Balance Sheets. If the Company exercises the option, the </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> will be applied towards future manufacturing services. If the Company does not exercise the option, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> of the deposit is non-refundable. The remainder will be applied towards future services initiated within five years. In addition, the Company will pay Brammer </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> to assist it in establishing its manufacturing capabilities in Brisbane, CA.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&#8217;s investment securities consist of the U.S. government-sponsored entities and various major corporations and financial institutions with high credit ratings. The free share asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January&#160;1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 606&#8221;) using the modified retrospective method, resulting in a change to its accounting policy for revenue recognition. ASC Topic 606 establishes a unified model to determine how revenue is recognized.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s contract revenues consist of strategic partnering collaboration agreements and research activity grants and licensing. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are recognized when the related qualified research expenses are incurred. Deferred revenue represents the portion of research or license payments received but not earned.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, revenues related to Kite Pharma, Inc. (&#8220;Kite&#8221;), a wholly-owned subsidiary of Gilead Sciences, Inc., the hemoglobinopathies agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#8220;Sanofi&#8221;)), and the Company&#8217;s hemophilia A collaboration agreement with Pfizer represented </span><span style="font-family:inherit;font-size:10pt;"><span>61%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>18%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>16%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue, excluding the above change in estimate. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, revenues related to Kite, the Company&#8217;s hemophilia A collaboration agreement with Pfizer and the hemoglobinopathies agreement with Sanofi represented </span><span style="font-family:inherit;font-size:10pt;"><span>52%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>26%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>17%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue. During the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, revenues related to the Company&#8217;s hemophilia A collaboration agreement with Pfizer, the hemoglobinopathies agreement with Sanofi and the agreement with Kite represented </span><span style="font-family:inherit;font-size:10pt;"><span>47%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>26%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>22%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue. For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, revenues related to the Company&#8217;s hemophilia A collaboration agreement with Pfizer, Kite and the hemoglobinopathies agreement with Sanofi represented </span><span style="font-family:inherit;font-size:10pt;"><span>38%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>21%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of the Company&#8217;s total revenue. Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Funds received from third parties under contract or grant arrangements are recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#8217;s development programs. Contract funds received are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Simplified Disclosure</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No.&#160;33-10532, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Update and Simplification</span><span style="font-family:inherit;font-size:10pt;">, as updated. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders&#8217; equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments are effective for all filings made on or after November&#160;5, 2018. As such, the Company adopted these SEC amendments on November&#160;5, 2018 and has presented the analysis of changes in stockholders&#8217; equity in these interim financial statements for </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> presented in this Quarterly Report on Form 10-Q. The Company&#8217;s adoption of these SEC amendments had no material effect on the Company&#8217;s reporting of financial position, results of operations, cash flows or stockholders&#8217; equity.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Accounting for Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016</span><span style="font-family:inherit;font-size:10pt;">-2</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 842&#8221;). ASC Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a ROU asset and corresponding liability, measured at the present value of the lease payments. On January&#160;1, 2019, the Company adopted ASC Topic 842 using the modified retrospective approach with a cumulative-effect adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9&#160;million</span></span><span style="font-family:inherit;font-size:10pt;"> reflected as a decrease to the opening balance of accumulated deficit as of the adoption date. Results for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are presented under ASC Topic 842. No prior period amounts were adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840 &#8212; </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 840&#8221;).</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC Topic 842 provides a number of optional practical expedients in transition. The Company elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effective date and did not elect the practical expedient pertaining to land easements as this is not applicable to the current contract portfolio.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Not yet adopted</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASC Topic 808&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance will be effective for the Company beginning January&#160;1, 2020. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Goodwill Impairment Testing</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;">&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step </span><span style="font-family:inherit;font-size:10pt;">2</span><span style="font-family:inherit;font-size:10pt;"> from the goodwill impairment test. ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;"> requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;"> requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017</span><span style="font-family:inherit;font-size:10pt;">-4</span><span style="font-family:inherit;font-size:10pt;"> will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6847141504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Impact of Adoption of ASC on Condensed Consolidated Balance Sheet</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact of the adoption of ASC Topic 842 on the accompanying Condensed Consolidated Balance Sheet as of January&#160;1, 2019 was as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments Due to</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">the Adoption of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC Topic 842</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78,723</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(62,500</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid rent</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - current</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred rent</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(271</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Build-to-suit lease obligation</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,689</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27,689</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - long-term</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(562,696</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>897</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(561,799</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">___________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Operating lease liabilities &#8211; current and deferred rent are included in accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Build-to-suit lease obligation and operating lease liabilities &#8211; long-term are included in long-term portion of lease liabilities on the Condensed Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22580-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e725-108305<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838633232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value measurements of the Company&#8217;s cash equivalents, available-for-sale marketable securities and the free share asset/liability are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2019<br/>Fair Value Measurements</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,441</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,441</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,931</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,441</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170,953</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170,953</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and marketable securities</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382,258</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>310,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Free shares asset</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018<br/>Fair Value Measurements</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and marketable securities</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>363,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Free shares liability</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Estimated Fair Value of Free Shares Valuation Assumptions</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Free Shares valuation assumptions:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo Stock Price (USD)</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TxCell Stock Price (EUR)</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8364;</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR / USD Exchange Rate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated Correlation Sangamo and TxCell Stock Prices</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72.2%</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sangamo Stock Price (USD) Volatility Estimate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.6%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79.9%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TxCell Stock Price (EUR) Volatility Estimate</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.2%</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.6%</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EUR / USD Exchange Rate Volatility Estimate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.7%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk Free Rate and Cost of Debt by Expected Exercise Date</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varies</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varies</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843706896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,418</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in Restricted cash, current portion</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in Non-current restricted cash</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,918</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,906</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,418</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in Restricted cash, current portion</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in Non-current restricted cash</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,918</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,906</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the Company&#8217;s cash equivalents and available-for-sale securities (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,441</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101,931</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,280</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71,383</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>279,851</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381,780</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382,258</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale securities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,981</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government-sponsored entity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,640</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,974</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(259</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>363,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(259</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>363,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair value of investments available-for-sale</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271,877</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturing after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6831103264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue related to Kite agreement:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,386</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research services</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,515</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,515</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee related to Pfizer SB-525 agreement</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,595</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,841</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee related to Pfizer C9ORF72 agreement</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>617</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,076</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Bioverativ Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues recognized under the agreement for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue related to Sanofi agreement:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of upfront fee</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>901</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research services</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,158</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,332</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,898</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6599263392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,763</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,120</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,061</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,879</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,329</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,867</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,514</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,564</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838620128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:89%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six months ending December&#160;31, 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,065</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,253</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,969</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Imputed interest</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,669</span></span></div></td><td style="vertical-align:top;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reported as of June&#160;30, 2019:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed    Consolidated Balance Sheet)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,485</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities - long-term</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838666864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Txcell S.A. (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary of Estimated Fair Value of Net Assets Acquired</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the estimated fair value of the net assets acquired as of the Acquisition Date (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:89%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">October 1, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consideration transferred</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,911</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of TxCell</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,857</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,761</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assumed debt liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,798</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of net identifiable assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,745</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,995</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total fair value of net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock', window );">Summary of Non-controlling Interest</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was as follows (in thousands):</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:89%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at Acquisition Date</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,829</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares acquired post acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest of acquired entity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency effect</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss attributable to non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(555</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at December&#160;31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>739</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss attributable to non-controlling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(125</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-controlling interest at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>614</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843474096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Decrease in revenues</a></td>
<td class="num">$ (17,548)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,619)<span></span>
</td>
<td class="num">$ (34,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Increase in net loss</a></td>
<td class="nump">30,356<span></span>
</td>
<td class="nump">$ 42,203<span></span>
</td>
<td class="nump">$ 16,640<span></span>
</td>
<td class="nump">$ 20,187<span></span>
</td>
<td class="nump">72,559<span></span>
</td>
<td class="nump">$ 36,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (634,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(634,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (562,696)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Topic 606 | Difference between Revenue Guidance in Effect before and after Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (561,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842 | Adjustments Due to the Adoption of ASC Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=sgmo_IntangibleAssetsMember', window );">Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Reclassification adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Decrease in revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Customer Concentration Risk | Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember', window );">Brammer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Option deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DepositAssetsNonrefundable', window );">Option deposit, nonrefundable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Decrease in revenues</a></td>
<td class="num">$ (9,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,372)<span></span>
</td>
<td class="num">$ (7,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Customer Concentration Risk | Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Bioverativ Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Decrease in revenues</a></td>
<td class="num">$ (3,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,516)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,009)<span></span>
</td>
<td class="num">$ (8,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Bioverativ Inc | Customer Concentration Risk | Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Agreement | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Decrease in revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingCapabilityEstablishmentMember', window );">Manufacturing Capability Establishment | Brammer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember', window );">Change in Collaboration Agreement Scope | Collaboration Agreement | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Decrease in revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Increase in net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Increase in basic net loss per share (Usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DepositAssetsNonrefundable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deposit Assets, Nonrefundable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DepositAssetsNonrefundable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=sgmo_IntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=sgmo_IntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingCapabilityEstablishmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingCapabilityEstablishmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6842596512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 21,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">79,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredRentNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">41,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (634,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(562,696)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BuildToSuitLeaseMember', window );">Build-to-Suit Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(561,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842 | Adjustments Due to the Adoption of ASC Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredRentNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842 | Build-to-Suit Lease | Adjustments Due to the Adoption of ASC Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredRentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred rent noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredRentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_BuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843242752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 280,327<span></span>
</td>
<td class="nump">$ 259,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">71,490<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">170,953<span></span>
</td>
<td class="nump">177,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">71,383<span></span>
</td>
<td class="nump">63,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">37,991<span></span>
</td>
<td class="nump">18,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">101,931<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">280,327<span></span>
</td>
<td class="nump">259,715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">382,258<span></span>
</td>
<td class="nump">363,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">71,490<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">170,953<span></span>
</td>
<td class="nump">177,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">71,383<span></span>
</td>
<td class="nump">63,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">37,991<span></span>
</td>
<td class="nump">18,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">71,490<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">71,490<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">71,490<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Free shares liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,441<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">280,327<span></span>
</td>
<td class="nump">259,715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">310,768<span></span>
</td>
<td class="nump">259,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">170,953<span></span>
</td>
<td class="nump">177,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Free shares liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">71,383<span></span>
</td>
<td class="nump">63,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">37,991<span></span>
</td>
<td class="nump">18,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Free shares liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6827832160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - TxCell S.A. - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liability recorded on acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Estimated fair value liability of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability', window );">Increase in fair value of free shares</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares', window );">Estimated fair value asset of free shares</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Valuation Technique, Option Pricing Model [Member] | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Estimated fair value liability of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition estimated fair value assets of free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition estimated fair value liabilities of free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in fair value of free shares asset and liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6841689104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>$ / shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Free shares measurement input | $ / shares</a></td>
<td class="nump">9.65<span></span>
</td>
<td class="nump">11.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember', window );">Exchange Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Free shares measurement input</a></td>
<td class="nump">0.89<span></span>
</td>
<td class="nump">0.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Stock Price Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Free shares measurement input</a></td>
<td class="nump">77.6<span></span>
</td>
<td class="nump">79.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">EUR / USD Exchange Rate Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Free shares measurement input</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">TxCell S.A. | Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Free shares measurement input | &#8364; / shares</a></td>
<td class="nump">2.24<span></span>
</td>
<td class="nump">2.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">TxCell S.A. | Stock Price Correlation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Free shares measurement input</a></td>
<td class="nump">72.2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">TxCell S.A. | Stock Price Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Free shares measurement input</a></td>
<td class="nump">76.2<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6829402272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 169,222<span></span>
</td>
<td class="nump">$ 140,418<span></span>
</td>
<td class="nump">$ 59,406<span></span>
</td>
<td class="nump">$ 49,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash included in Restricted cash, current portion</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included in Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">172,722<span></span>
</td>
<td class="nump">$ 143,918<span></span>
</td>
<td class="nump">$ 62,906<span></span>
</td>
<td class="nump">$ 53,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit established as a deposit</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6842564480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 169,222<span></span>
</td>
<td class="nump">$ 140,418<span></span>
</td>
<td class="nump">$ 59,406<span></span>
</td>
<td class="nump">$ 49,826<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">279,851<span></span>
</td>
<td class="nump">259,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">280,327<span></span>
</td>
<td class="nump">259,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost', window );">Total cash equivalents and available-for-sale securities, Amortized Cost</a></td>
<td class="nump">381,780<span></span>
</td>
<td class="nump">363,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">382,258<span></span>
</td>
<td class="nump">363,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">71,490<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash Equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash Equivalents, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">71,490<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">30,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash Equivalents, Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash Equivalents, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">30,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">170,598<span></span>
</td>
<td class="nump">177,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">170,953<span></span>
</td>
<td class="nump">177,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">101,929<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash Equivalents, Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash Equivalents, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">101,931<span></span>
</td>
<td class="nump">103,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">71,280<span></span>
</td>
<td class="nump">63,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">71,383<span></span>
</td>
<td class="nump">63,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">37,973<span></span>
</td>
<td class="nump">18,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">$ 37,991<span></span>
</td>
<td class="nump">$ 18,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for Sale Securities Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents Gross Unrealized Gain Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6839143792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities Summary of cost and estimated fair value of short-term investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Maturing in one year or less</a></td>
<td class="nump">$ 271,877<span></span>
</td>
<td class="nump">$ 259,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Maturing after one year through five years</a></td>
<td class="nump">8,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 280,327<span></span>
</td>
<td class="nump">$ 259,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838648208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporarily impaired investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6835560272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber', window );">Stock options and RSUs outstanding (in shares)</a></td>
<td class="nump">10,155,033<span></span>
</td>
<td class="nump">8,757,528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6860440976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1">25 Months Ended</th>
<th class="th" colspan="1">65 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>Product</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>Product</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,416,000<span></span>
</td>
<td class="nump">$ 25,619,000<span></span>
</td>
<td class="nump">$ 34,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,960,000<span></span>
</td>
<td class="nump">$ 3,288,000<span></span>
</td>
<td class="nump">$ 3,288,000<span></span>
</td>
<td class="nump">$ 3,288,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California Institute For Regenerative Medicine Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California Institute For Regenerative Medicine Agreement | Research Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,515,000<span></span>
</td>
<td class="nump">17,372,000<span></span>
</td>
<td class="nump">7,515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,953,000<span></span>
</td>
<td class="nump">12,386,000<span></span>
</td>
<td class="nump">5,953,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective', window );">Collaboration waiting period under HSR expiration date at which time agreement became effective</a></td>
<td class="text">Apr.  05,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Initial research term of agreement</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchAgreementTerm', window );">Research agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">an option to extend the research term of the agreement for up to two additional one-year periods for a separate upfront fee of $10.0 million per year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SeparateUpfrontFee', window );">Separate upfront fee</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="nump">185,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="nump">35,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,500,000<span></span>
</td>
<td class="nump">119,100,000<span></span>
</td>
<td class="nump">119,100,000<span></span>
</td>
<td class="nump">119,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">3,010,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration and License Agreement | Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="nump">1,260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration and License Agreement | Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="nump">14,300,000<span></span>
</td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="nump">14,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Revenue reduction due to decrease in measure of proportional cumulative performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617,000<span></span>
</td>
<td class="nump">$ 1,070,000<span></span>
</td>
<td class="nump">1,076,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Royalty Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Maximum | SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Maximum | Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Achievement of Specified Clinical Development Intellectual Property and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Achievement of First Commercial Sale Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones | Maximum | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Achievement of Commercial Milestones | Maximum | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,635,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,183,000<span></span>
</td>
<td class="nump">1,595,000<span></span>
</td>
<td class="nump">15,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Bioverativ Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,059,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,516,000<span></span>
</td>
<td class="nump">5,009,000<span></span>
</td>
<td class="nump">8,898,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Bioverativ Inc | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,184,000<span></span>
</td>
<td class="nump">$ 1,654,000<span></span>
</td>
<td class="nump">$ 2,338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Bioverativ Inc | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Bioverativ Inc | Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Sanofi | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Sanofi | Collaboration and License Agreement | Royalty Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Sanofi | Collaboration and License Agreement | Achievement Of Specified Clinical Development And Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Sanofi | Collaboration and License Agreement | Achievement of Specified Sales Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration waiting period expiration date at which time agreement became effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent development and sales based milestone payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GrantFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research agreement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ResearchAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SeparateUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Separate upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SeparateUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BioverativIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BioverativIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6853695216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 21,416<span></span>
</td>
<td class="nump">$ 25,619<span></span>
</td>
<td class="nump">$ 34,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9,060<span></span>
</td>
<td class="nump">7,515<span></span>
</td>
<td class="nump">17,372<span></span>
</td>
<td class="nump">7,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,227<span></span>
</td>
<td class="nump">5,953<span></span>
</td>
<td class="nump">12,386<span></span>
</td>
<td class="nump">5,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Research Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,833<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">4,986<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,635<span></span>
</td>
<td class="nump">8,183<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">15,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">455<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Bioverativ Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,059<span></span>
</td>
<td class="nump">4,516<span></span>
</td>
<td class="nump">5,009<span></span>
</td>
<td class="nump">8,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Bioverativ Inc | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">2,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Bioverativ Inc | Research Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,158<span></span>
</td>
<td class="nump">$ 3,332<span></span>
</td>
<td class="nump">$ 3,355<span></span>
</td>
<td class="nump">$ 6,560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6841260272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,867<span></span>
</td>
<td class="nump">$ 3,514<span></span>
</td>
<td class="nump">$ 9,390<span></span>
</td>
<td class="nump">$ 6,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
<td class="nump">5,061<span></span>
</td>
<td class="nump">3,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,104<span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
<td class="nump">$ 4,329<span></span>
</td>
<td class="nump">$ 2,685<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844685808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_option </div>
<div>contract</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs | $</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense | $</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities included net cash used in operating activities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted-average remaining lease term</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted-average discount rate</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondLeaseMember', window );">Richmond Lease | Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft)</a></td>
<td class="nump">37,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondLeaseMember', window );">Richmond Lease | Operating Lease One | Research and Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft)</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_ValbonneLeaseMember', window );">Valbonne Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseNumberOfContracts', window );">Additional property available under lease | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_ValbonneLeaseMember', window );">Valbonne Lease | Operating Lease One | Research and Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft)</a></td>
<td class="nump">14,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_ValbonneLeaseMember', window );">Valbonne Lease | Operating Lease Two | Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft)</a></td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondAndValbonneLeasesMember', window );">Richmond and Valbonne Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional five to ten years.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondAndValbonneLeasesMember', window );">Richmond and Valbonne Leases | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondAndValbonneLeasesMember', window );">Richmond and Valbonne Leases | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneLeaseMember', window );">Brisbane Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_RemainingCommencementLandSubjectToGroundLeases', window );">Remaining commencement, area of space leased (in sqft)</a></td>
<td class="nump">52,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ExpectedLeaseCommencementPeriod', window );">Expected lease commencement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance', window );">Tenant improvement allowance | $</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance', window );">Lease not yet commenced, tenant improvement allowance | $</a></td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OperatingLeasesNumberOfExtensionOptions', window );">Number of lease term extension options | renewal_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneLeaseMember', window );">Brisbane Lease | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneLeaseMember', window );">Brisbane Lease | Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft)</a></td>
<td class="nump">87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneLeaseMember', window );">Brisbane Lease | Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommencementLandSubjectToGroundLeases', window );">Commencement, area of space leased (in sqft)</a></td>
<td class="nump">35,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LeaseCommencementPeriod', window );">Lease commencement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommencementLandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commencement land subject to ground leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommencementLandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExpectedLeaseCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected lease commencement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ExpectedLeaseCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LeaseCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LeaseCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, lease not yet commenced, tenant improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, liability, tenant improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseNumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseNumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OperatingLeasesNumberOfExtensionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases number of extension options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OperatingLeasesNumberOfExtensionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RemainingCommencementLandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining commencement land subject to ground leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RemainingCommencementLandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_ValbonneLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_ValbonneLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondAndValbonneLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondAndValbonneLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6845528992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Nine months ending December 31, 2019</a></td>
<td class="nump">$ 2,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">6,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">6,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">6,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">6,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">31,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">58,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(14,669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">44,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheet)</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">41,550<span></span>
</td>
<td class="nump">$ 27,689<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 44,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6845457152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 07, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,566<span></span>
</td>
<td class="nump">$ 215,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock issuable and sellable under offering agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price of common stock issued (in USD per share)</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="nump">$ 16.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Net proceeds from issuance of common stock, after deducting offering expenses</a></td>
<td class="nump">$ 136,300<span></span>
</td>
<td class="nump">$ 215,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NetProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844569088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Txcell S.A. - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 23, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction', window );">Number of shares not purchased by the acquirer | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,981,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired | shares</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,528,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of share capital and voting rights acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration', window );">Loan deemed to be part of purchase consideration</a></td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to ordinary shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares', window );">Fair value of consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase consideration</a></td>
<td class="nump">45,911,000<span></span>
</td>
<td class="nump">45,900,000<span></span>
</td>
<td class="nump">$ 33,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests', window );">Fair value percentage at acquirer recognizes and consolidates assets acquired, liabilities assumed, and any non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration payable</a></td>
<td class="nump">$ 45,911,000<span></span>
</td>
<td class="nump">$ 45,900,000<span></span>
</td>
<td class="nump">33,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction', window );">Number of remaining outstanding share owned by sellers | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire', window );">Percentage of equity interests agreed to acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Purchase price per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.58<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice', window );">Exchange rate on purchase price</a></td>
<td class="nump">1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Estimated fair value liability of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares', window );">Estimated fair value asset of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement | Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Estimated fair value liability of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Purchase price per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">TxCell S.A. | SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired | shares</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of share capital and voting rights acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition estimated fair value assets of free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition estimated fair value liabilities of free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, estimated fair value of free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition exchange rate on purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition number of shares owned by sellers under block transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, percentage of equity interests agreed to acquire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition remaining number of shares owned by seller under block transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination, fair value percentage at acquirer recognizes and consolidated assets, liabilities assumed and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination, loan adjusted in purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6831294048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Txcell S.A. - Summary of Estimated Fair Value of Net Assets Acquired (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,829<span></span>
</td>
<td class="nump">$ 35,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,044<span></span>
</td>
<td class="nump">40,044<span></span>
</td>
<td class="nump">$ 39,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 45,911<span></span>
</td>
<td class="nump">$ 45,900<span></span>
</td>
<td class="nump">$ 33,900<span></span>
</td>
<td class="nump">$ 80,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of non-controlling interest</a></td>
<td class="nump">35,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Fair value of TxCell</a></td>
<td class="nump">81,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">4,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current assets</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment', window );">IPR&amp;D</a></td>
<td class="nump">55,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(9,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Assumed debt liabilities</a></td>
<td class="num">(4,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability, net</a></td>
<td class="num">(6,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Fair value of net identifiable assets acquired</a></td>
<td class="nump">42,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">38,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total fair value of net assets acquired</a></td>
<td class="nump">$ 81,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838926000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Txcell S.A. - Summary of Non-controlling Interest (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Non-controlling interest at Acquisition Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PostBusinessAcquisitionSharesAcquiredAmount', window );">Shares acquired post acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,516)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Non-controlling interest of acquired entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect', window );">Foreign currency effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to non-controlling interest</a></td>
<td class="num">$ (72)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest, ending balance</a></td>
<td class="nump">$ 614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase decrease from foreign currency effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PostBusinessAcquisitionSharesAcquiredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Post business acquisition shares acquired amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PostBusinessAcquisitionSharesAcquiredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M=/WA=Q5VP=B=_<?&%T'9P*^[D%]02P,$%     @ BX4'3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M]2 ?G0QU/#5U-_TNGEZ[OCG,I0Q6#N7W\W5_G*[OYW\<S6%Z ,X!> D \V$
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M@EW*#QO/\!='<>2P$9SF4DBLCHK[R;#1&S\0.S_@G7^"]&TH]L2#B4EBH+%
M$DLUUD=B\H$Z>O<'1:CC6)TB]B\ILF!>AERN.<Y[3;ECF4CQ?D"Y@TS@XVER
M<UZN37L8+B]=M+7GQO4'FYO>ZP7IA??G;=2_A.<5$/WK_D(UG,]_N!]O8[\7
M[:%LNNC-.G_*'\[B>VN=\=FS)Y_WT5\ KXW*[%W_JOU[.]Z"QH:SI^F&EURO
MF8M_ 5!+ P04    " "+A0=/(T9D%[P"  "_"0  &    'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;(U646^;,!#^*XCWEMB @2B)5-),F[1)U:9MSV[B)*B
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MM#?;GG/%=/:S>]V0HYZFQDW-]LHL,[T6_4S1;Q3OAG$I&F>VU1]02P,$%
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MF/$'#"=E<4*)DVWD&]S"K02S)L/3&1;%R6!X6P!O8>%6PGMBM<[X,QJL4_S
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M#D/;3"=^+VT[..\P_N+':N^JW?6F=B_#>&G]=7<Y";W<#.UI/N6-KD?-Z_\
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MS<;Y5X@.O)3-E5^AQC^PV9%0N6!^\;89UVQT'';3"V+S,\[_ %!+ P04
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M9SS;<<Q&PYMN^D%L_L;%7U!+ P04    " "+A0=/08[Q[[,!  #2 P  &0
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MX?M8' 5-B.8[M-VT)9,3;#\_ +:\PO(/4$L#!!0    ( (N%!T]*F_4PP $
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M4&C+0,UR@T=@S!*9-'[/G&B1M('K_1O[9U>[J>5*%3P*]JLM=9.A(PI*J.C
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MC"?)@6DA.UIDT7<V18:#4[*#LR%VT%J8WR=0..9T1U\=3[)I77"P(NM% ]_
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M+Z$R,-09<SVTQW@ $+[?QLQ=3!BV(8^0&SOAF\$L;P_TY$*D-<X*BL5R\QW
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M0Z*LS=@<@OF26N>M!02C/O?M$\9-=^T$$9'@D$@@W9-C9X,>(L$1D>!=1 (
M<>*4&0)1N\@0R*DP!$*.!1P1"0Z(A,)J@X@$[R$2'!$)#NU@G87LBL0W3NR3
MP!R"">D<OR!8*03VN0*"!4&([$8X(DW<E29.,,% 1(>'/0ZYB.@(8/?LK&,
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MXD80Q[\*X@,<^_QP"I&:5%4KM5)T5=O73G ".L#4=I+KMZ\-!F'O?Y;=-Y?
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MYEQP8DQ21>@YRMQ<'17[04E/4C_&ZIFWYZ5V(%G3G07=_D"Z^0=02P,$%
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MXO5K 4%X^0)-R$G@B JMK7CY6KEFXH\UD-SH4*(QJ"Q:4_'BG43Q^RSQ9.9
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M<8?9^&8XN[#FTAK7O=2K+"WQQ0M%S..$R1>8_#UB_Q&QW<X0[ S,+O*[+O+
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MN^,7I(X?ZNKI_/CMK]G+5] N_@%02P,$%     @ BX4'3_?0,#?# P  ?Q$
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M6,9\38:+;=@PW*E+VQG_.>3_ %!+ P04    " "+A0=/$'M^JD,$   <%P
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MT*Q[#;O3Q)$NV=@2>E,$C8&;"X9<K)DU7$1<G^+%UK P-&R@.@(;X; =O"O
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MWE7E[0AP?:77!5DJ']U3Y@#1HEKE29M]??Q4MXS'F]OR )+YHD5TY4LT!V4
MD"POY]V'44EYU:RS>?[/OP,MI,GK^_QW_Y)T&#:RC+MJN<CKYK_2=6@?.H@
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M1!Z/E [Z$9/WZ=-?39-K1W@1G<A-]5WCY7@7AT:ZW*S7?'2@R"%Q D*RJ>E
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M_*ZLEM7M ^H#+898X>KS$AD&T2A<?5["?<X=_<V2^3)K""7) #:O"])ODQM
MGJINDE_*Z@M@:)/\"B>!5.X6V.B;#[/1=<$2(!#!-B] (=8C_K>WGQH]PEU
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M;XM"@(H5IF\.Y"QBD38&5\0I\SYMGFU"0H%UL\WF!N. 9;- <>#(Z,$2S;.
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MH]$HZB>-A/#:.5!1F\?,CR5C1.I+.-4NV8I)@SH_\'@PW9AC,'U&*?,V*@N
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MB;K$P;O"3R^,D%3WT M/N<R3EHBX?G&>?)BZ:=UM:'LI(]LI/<5(?!%+^-?
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MXR69PF7F\BWC2T:F^YXK;BY(< VD3)(S30Q?YR^^NZJ__&P0)-.)N]Z"W &
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M,[O!6ZT@0ZC;D,\(-YZ#]"11>^0:RU?,%J^I64_?*;GCT>/*R*-)JB%:*C>
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M*'7;!=<,%("6 A;F"'0@7Z[X^B&L0)JZ52_(2D_U\>*'.+A"'^MSR2-&S_T
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M9LZ;4QJF16DKJ><@[5G&4M>/GBF:'GKX?;)O$^<;ND14VYW#-9GPN]!T5$X
M1&2FZOZNXV$ +]_,*IK,-'CH%+%,,4_S("[!(L(GTQ?;TI#!SI$@"TIDVKI
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M./[]2UNU96AT5QAJ8*].%?:&1:R>ZKH&-#_1+=N!V:S0:Y"';L(.%89Z&>
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M) @Q="YZ>942)81 I)V!)2HL* @@)I%X"3V!KN&N%L6"=01G!.W9&Z>CZNT
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MF%U=EA&7M K=<5 GPS*USA'/Y"J45;I8Y(C,)I$RDL$Y"_-?7RUNV1Q.)0+
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MU>H_.M7J%!Z,-5*>M9,R9DEYHV61%;'NCH/C2KTCLK<Z&Y'T)W\<O*$<P80
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M:+GN5.06 (>$+]?KS5__#5!+ P04    " "+A0=/>;L).F8"  !>#   #0
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M GF 0![DA;PRMUR)IUCQVC\O5EBBEV1NP/H+>0+Y!H%\DQ?R(Q>&W'#9 [D
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MM1^2$\M>RE-?=J6^:!Z_#(9[;#ZLOOL%4$L#!!0    ( (N%!T]XLDPMN@$
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M'>-:E<U?23ZU7A[FL^ZOM-DW4$L! A0#%     @ BX4'3Q\CSP/     $P(
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M4$L! A0#%     @ BX4'3^[J:6]^ P  <@X  !@              ( !.Q$
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (N%!T\C1F07
MO (  +\)   8              "  >\4  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "+A0=/K7^+:)D'  !_+0  &
M@ 'A%P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ BX4'
M3_>JK#:J!   =A8  !@              ( !L!\  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( (N%!T\>?/L4L0$  -(#   8
M      "  9 D  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "+A0=/ =)-/+4!  #2 P  &               @ %W)@  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ BX4'3Y3Z78&U 0  T@,  !@
M             ( !8B@  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( (N%!T^ONXFQM $  -(#   9              "  4TJ  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ BX4'3Q\Z89^Q 0
MT@,  !D              ( !."P  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "+A0=/#;^PD+8!  #2 P  &0              @ $@
M+@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (N%!T]!
MCO'OLP$  -(#   9              "  0TP  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ BX4'3^^!_@*T 0  T@,  !D
M     ( !]S$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (N%!T]7GN:VJ $  )$#   9              "
M 1D\  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ BX4'
M3TJ;]3#  0  -P0  !D              ( !^#T  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "+A0=/T-_5O.(!   !!0  &0
M        @ 'O/P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( (N%!T]&4%V/%@(  -4&   9              "  0A"  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ BX4'3_D9<!*W 0  T@,
M !D              ( !540  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "+A0=/^&I'OK@!  #2 P  &0              @ %#1@
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (N%!T\K9?&_
MQ0$  #<$   9              "  3)(  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ BX4'3P86#ICO!   3!H  !D
M ( !+DH  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "+
MA0=/H:\Q-U\#  "!#P  &0              @ %43P  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (N%!T]H.-9C908  +HK   9
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M970S,BYX;6Q02P$"% ,4    " "+A0=/KD@5^.(!  #M!   &0
M    @ $V9@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M (N%!T]T&4K! @(  %L%   9              "  4]H  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ BX4'3[6)!^JX 0  V0,  !D
M             ( !B&H  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " "+A0=/X0K.Y$L(  ".-@  &0              @ %W;   >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (N%!T_WT# WPP,
M '\1   9              "  ?ET  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ BX4'3R3$:TQ\ @  10@  !D              ( !
M\W@  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "+A0=/
M$'M^JD,$   <%P  &0              @ &F>P  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (N%!T_D,1-": (  $T(   9
M      "  2"   !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ BX4'3SL3R*&C @  - D  !D              ( !OX(  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "+A0=/,',7$!8$  !=%
M&0              @ &9A0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( (N%!T_&((,4 0,  #8,   9              "  >:)  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ BX4'3\3/=%&?
M @  ' D  !D              ( !'HT  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " "+A0=/ "X\/\*'  !_,@( %
M@ 'TCP  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "+A0=/>;L)
M.F8"  !>#   #0              @ 'H%P$ >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( (N%!T\NTL<WRP,  -P=   /              "  7D: 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "+A0=/>+),+;H!   I&P  &@
M        @ %Q'@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "+A0=/$Z1#MK4!  !2&P  $P              @ %C( $ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     -0 U &4.  !)(@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>284</ContextCount>
  <ElementCount>333</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0002000 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Cash and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashAndMarketableSecurities</Role>
      <ShortName>Cash and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Basic and Diluted Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BasicAndDilutedNetLossPerShare</Role>
      <ShortName>Basic and Diluted Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Major Customers, Partnerships and Strategic Alliances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Acquisition of Txcell S.A.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionOfTxcellSA</Role>
      <ShortName>Acquisition of Txcell S.A.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Cash and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashAndMarketableSecuritiesTables</Role>
      <ShortName>Cash and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CashAndMarketableSecurities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/StockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Acquisition of Txcell S.A. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionOfTxcellSATables</Role>
      <ShortName>Acquisition of Txcell S.A. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/AcquisitionOfTxcellSA</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2401404 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Cash and Marketable Securities - Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash and Marketable Securities - Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Cash and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail</Role>
      <ShortName>Cash and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Cash and Marketable Securities Summary of cost and estimated fair value of short-term investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails</Role>
      <ShortName>Cash and Marketable Securities Summary of cost and estimated fair value of short-term investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Cash and Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash and Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basic and Diluted Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BasicAndDilutedNetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Basic and Diluted Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Acquisition of Txcell S.A. - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail</Role>
      <ShortName>Acquisition of Txcell S.A. - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Acquisition of Txcell S.A. - Summary of Estimated Fair Value of Net Assets Acquired (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail</Role>
      <ShortName>Acquisition of Txcell S.A. - Summary of Estimated Fair Value of Net Assets Acquired (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sgmo-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Acquisition of Txcell S.A. - Summary of Non-controlling Interest (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail</Role>
      <ShortName>Acquisition of Txcell S.A. - Summary of Non-controlling Interest (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sgmo-20190630x10q.htm">sgmo-20190630x10q.htm</File>
    <File>sgmo-20190630.xsd</File>
    <File>sgmo-20190630_cal.xml</File>
    <File>sgmo-20190630_def.xml</File>
    <File>sgmo-20190630_lab.xml</File>
    <File>sgmo-20190630_pre.xml</File>
    <File>sgmo-20190630xex311.htm</File>
    <File>sgmo-20190630xex312.htm</File>
    <File>sgmo-20190630xex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>61
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgmo-20190630x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "contextCount": 284,
   "dts": {
    "calculationLink": {
     "local": [
      "sgmo-20190630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgmo-20190630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "sgmo-20190630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20190630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20190630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20190630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 447,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 12,
    "http://www.sangamo.com/20190630": 5,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 22
   },
   "keyCustom": 54,
   "keyStandard": 279,
   "memberCustom": 41,
   "memberStandard": 32,
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20190630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0002000 - Document - Cover",
     "role": "http://www.sangamo.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Basic and Diluted Net Loss Per Share",
     "role": "http://www.sangamo.com/role/BasicAndDilutedNetLossPerShare",
     "shortName": "Basic and Diluted Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Major Customers, Partnerships and Strategic Alliances",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances",
     "shortName": "Major Customers, Partnerships and Strategic Alliances",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Income Taxes",
     "role": "http://www.sangamo.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Stock-Based Compensation",
     "role": "http://www.sangamo.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.sangamo.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Stockholders' Equity",
     "role": "http://www.sangamo.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Acquisition of Txcell S.A.",
     "role": "http://www.sangamo.com/role/AcquisitionOfTxcellSA",
     "shortName": "Acquisition of Txcell S.A.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Subsequent Events",
     "role": "http://www.sangamo.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301302 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Cash and Marketable Securities (Tables)",
     "role": "http://www.sangamo.com/role/CashAndMarketableSecuritiesTables",
     "shortName": "Cash and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables",
     "shortName": "Major Customers, Partnerships and Strategic Alliances (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.sangamo.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Acquisition of Txcell S.A. (Tables)",
     "role": "http://www.sangamo.com/role/AcquisitionOfTxcellSATables",
     "shortName": "Acquisition of Txcell S.A. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401403 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2018Q4YTD_us-gaap_BalanceSheetLocationAxis_sgmo_IntangibleAssetsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PriorPeriodReclassificationAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401404 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Details)",
     "role": "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies - Impact of Adoption of ASC on Condensed Consolidated Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "lang": null,
      "name": "sgmo:DeferredRentNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail",
     "shortName": "Fair Value Measurements - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember_us-gaap_TypeOfArrangementAxis_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember",
      "decimals": "-5",
      "lang": null,
      "name": "sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Fair Value Measurements - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail",
     "shortName": "Fair Value Measurements - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Cash and Marketable Securities - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Cash and Marketable Securities - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Cash and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
     "shortName": "Cash and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Cash and Marketable Securities Summary of cost and estimated fair value of short-term investments (Details)",
     "role": "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails",
     "shortName": "Cash and Marketable Securities Summary of cost and estimated fair value of short-term investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403405 - Disclosure - Cash and Marketable Securities - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash and Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basic and Diluted Net Loss Per Share - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/BasicAndDilutedNetLossPerShareAdditionalInformationDetail",
     "shortName": "Basic and Diluted Net Loss Per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
     "shortName": "Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "D2014Q1Jan01-Jan31",
      "decimals": "INF",
      "lang": null,
      "name": "sgmo:NumberOfResearchProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail",
     "shortName": "Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD_srt_CounterpartyNameAxis_sgmo_KitePharmaIncMember_srt_ProductOrServiceAxis_sgmo_ResearchServicesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "role": "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail",
     "shortName": "Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409401 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_SubsidiarySaleOfStockAxis_sgmo_AtTheMarketOfferingAgreementMember",
      "decimals": "-5",
      "lang": null,
      "name": "sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "I2018Q4Oct01",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Acquisition of Txcell S.A. - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
     "shortName": "Acquisition of Txcell S.A. - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "I2018Q4Oct01",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "sgmo:ScheduleOfNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Acquisition of Txcell S.A. - Summary of Estimated Fair Value of Net Assets Acquired (Detail)",
     "role": "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail",
     "shortName": "Acquisition of Txcell S.A. - Summary of Estimated Fair Value of Net Assets Acquired (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "I2018Q4Oct01_us-gaap_BusinessAcquisitionAxis_sgmo_TxCellSAMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Acquisition of Txcell S.A. - Summary of Non-controlling Interest (Detail)",
     "role": "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail",
     "shortName": "Acquisition of Txcell S.A. - Summary of Non-controlling Interest (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "sgmo:ScheduleOfNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "sgmo:PostBusinessAcquisitionSharesAcquiredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Fair Value Measurements",
     "role": "http://www.sangamo.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Cash and Marketable Securities",
     "role": "http://www.sangamo.com/role/CashAndMarketableSecurities",
     "shortName": "Cash and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 73,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgmo_AchievementOfCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of Commercial Milestones.",
        "label": "Achievement Of Commercial Milestones [Member]",
        "verboseLabel": "Achievement of Commercial Milestones"
       }
      }
     },
     "localname": "AchievementOfCommercialMilestonesMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of first commercial sale milestones.",
        "label": "Achievement Of First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of First Commercial Sale Milestones"
       }
      }
     },
     "localname": "AchievementOfFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of Specified Clinical Development and Regulatory Milestones.",
        "label": "Achievement Of Specified Clinical Development And Regulatory Milestones [Member]",
        "terseLabel": "Achievement Of Specified Clinical Development And Regulatory Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified clinical development intellectual property and regulatory milestones.",
        "label": "Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of Specified Clinical Development Intellectual Property and Regulatory Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified preclinical development clinical development and first commercial sale milestones.",
        "label": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]",
        "verboseLabel": "Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones.",
        "label": "Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.",
        "label": "Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]",
        "terseLabel": "Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of Specified Sales Milestones.",
        "label": "Achievement Of Specified Sales Milestones [Member]",
        "terseLabel": "Achievement of Specified Sales Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesMilestonesMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate additional revenue recognition milestone method revenue eligible to receive.",
        "label": "Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive",
        "terseLabel": "Potential amount to be funded for achievement of specified commercialized and sales milestones"
       }
      }
     },
     "localname": "AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "At the market offering agreement.",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BioverativIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bioverativ Inc.",
        "label": "Bioverativ Inc [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "BioverativIncMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BrammerBioMAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Brammer Bio MA [Member]",
        "label": "Brammer Bio MA [Member]",
        "terseLabel": "Brammer"
       }
      }
     },
     "localname": "BrammerBioMAMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BrisbaneLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Brisbane lease.",
        "label": "Brisbane Lease [Member]",
        "terseLabel": "Brisbane Lease"
       }
      }
     },
     "localname": "BrisbaneLeaseMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BuildToSuitLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Build-to-suit lease.",
        "label": "Build To Suit Lease [Member]",
        "terseLabel": "Build-to-Suit Lease"
       }
      }
     },
     "localname": "BuildToSuitLeaseMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition estimated fair value assets of free shares.",
        "label": "Business Acquisition Estimated Fair Value Assets Of Free Shares",
        "terseLabel": "Estimated fair value asset of free shares",
        "verboseLabel": "Business Acquisition Estimated Fair Value Assets Of Free Shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition estimated fair value liabilities of free shares.",
        "label": "Business Acquisition Estimated Fair Value Liabilities Of Free Shares",
        "terseLabel": "Estimated fair value liability of free shares",
        "verboseLabel": "Business Acquisition Estimated Fair Value Liabilities Of Free Shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionEstimatedFairValueOfFreeShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, estimated fair value of free shares.",
        "label": "Business Acquisition Estimated Fair Value Of Free Shares",
        "terseLabel": "Fair value of consideration payable"
       }
      }
     },
     "localname": "BusinessAcquisitionEstimatedFairValueOfFreeShares",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionExchangeRateOnPurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition exchange rate on purchase price.",
        "label": "Business Acquisition Exchange Rate On Purchase Price",
        "terseLabel": "Exchange rate on purchase price"
       }
      }
     },
     "localname": "BusinessAcquisitionExchangeRateOnPurchasePrice",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, number of free shares held by the holders.",
        "label": "Business Acquisition Number Of Free Shares Held By Holders",
        "terseLabel": "Number of free shares held by the holders (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesHeldByHolders",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, number of shares acquired.",
        "label": "Business Acquisition Number Of Shares Acquired",
        "terseLabel": "Number of ordinary shares acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSharesAcquired",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition number of shares owned by sellers under block transaction.",
        "label": "Business Acquisition Number Of Shares Owned By Sellers Under Block Transaction",
        "terseLabel": "Number of shares not purchased by the acquirer"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSharesOwnedBySellersUnderBlockTransaction",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, percentage of equity interests agreed to acquire.",
        "label": "Business Acquisition Percentage Of Equity Interests Agreed To Acquire",
        "terseLabel": "Percentage of equity interests agreed to acquire"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition remaining number of shares owned by seller under block transaction.",
        "label": "Business Acquisition Remaining Number Of Shares Owned By Seller Under Block Transaction",
        "terseLabel": "Number of remaining outstanding share owned by sellers"
       }
      }
     },
     "localname": "BusinessAcquisitionRemainingNumberOfSharesOwnedBySellerUnderBlockTransaction",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business combination, fair value percentage at acquirer recognizes and consolidated assets, liabilities assumed and noncontrolling interests.",
        "label": "Business Combination Fair Value Percentage At Acquirer Recognizes And Consolidated Assets Liabilities Assumed And Noncontrolling Interests",
        "terseLabel": "Fair value percentage at acquirer recognizes and consolidates assets acquired, liabilities assumed, and any non-controlling interest"
       }
      }
     },
     "localname": "BusinessCombinationFairValuePercentageAtAcquirerRecognizesAndConsolidatedAssetsLiabilitiesAssumedAndNoncontrollingInterests",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_BusinessCombinationLoanAdjustedInPurchaseConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business combination, loan adjusted in purchase consideration.",
        "label": "Business Combination Loan Adjusted In Purchase Consideration",
        "terseLabel": "Loan deemed to be part of purchase consideration"
       }
      }
     },
     "localname": "BusinessCombinationLoanAdjustedInPurchaseConsideration",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CNineORFSevenTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "C nine ORF seven two.",
        "label": "C Nine O R F Seven Two [Member]",
        "verboseLabel": "C9ORF72"
       }
      }
     },
     "localname": "CNineORFSevenTwoMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "California institute for regenerative medicine agreement.",
        "label": "California Institute For Regenerative Medicine Agreement [Member]",
        "terseLabel": "California Institute For Regenerative Medicine Agreement"
       }
      }
     },
     "localname": "CaliforniaInstituteForRegenerativeMedicineAgreementMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities.",
        "label": "Cash Equivalents And Available For Sale Securities",
        "terseLabel": "Total cash equivalents and available-for-sale securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for Sale Securities Amortized Cost",
        "label": "Cash Equivalents And Available For Sale Securities Amortized Cost",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized gain, before tax.",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax",
        "terseLabel": "Total cash equivalents and available-for-sale securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized loss, before Tax",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Equivalents Gross Unrealized Gain Before Tax",
        "label": "Cash Equivalents Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash Equivalents, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Equivalents, Gross Unrealized Loss, Before Tax",
        "label": "Cash Equivalents, Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Cash Equivalents, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ChangeInCollaborationAgreementScopeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Collaboration Agreement Scope [Member]",
        "label": "Change In Collaboration Agreement Scope [Member]",
        "terseLabel": "Change in Collaboration Agreement Scope"
       }
      }
     },
     "localname": "ChangeInCollaborationAgreementScopeMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "verboseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and license agreements number of products approved under agreement.",
        "label": "Collaboration And License Agreements Number Of Products Approved Under Agreement",
        "terseLabel": "Number of products approved"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration waiting period expiration date at which time agreement became effective.",
        "label": "Collaboration Waiting Period Expiration Date At Which Time Agreement Became Effective",
        "terseLabel": "Collaboration waiting period under HSR expiration date at which time agreement became effective"
       }
      }
     },
     "localname": "CollaborationWaitingPeriodExpirationDateAtWhichTimeAgreementBecameEffective",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement estimated reimbursable service costs.",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCosts",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement transaction price.",
        "label": "Collaborative Arrangement Transaction Price",
        "terseLabel": "Collaborative arrangement transaction price"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPrice",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CommencementLandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commencement land subject to ground leases.",
        "label": "Commencement Land Subject To Ground Leases",
        "terseLabel": "Commencement, area of space leased (in sqft)"
       }
      }
     },
     "localname": "CommencementLandSubjectToGroundLeases",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "sgmo_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock capital shares value reserved for future issuance.",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "terseLabel": "Common stock issuable and sellable under offering agreement"
       }
      }
     },
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent development and sales based milestone payments to be received.",
        "label": "Contingent Development And Sales Based Milestone Payments To Be Received",
        "terseLabel": "Contingent development - and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer contract liability milestone payment eligible to receive.",
        "label": "Customer Contract Liability Milestone Payment Eligible To Receive",
        "terseLabel": "Development and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "CustomerContractLiabilityMilestonePaymentEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DeferredRentNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred rent noncurrent.",
        "label": "Deferred Rent Noncurrent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentNoncurrent",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DepositAssetsNonrefundable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deposit Assets, Nonrefundable",
        "label": "Deposit Assets, Nonrefundable",
        "terseLabel": "Option deposit, nonrefundable"
       }
      }
     },
     "localname": "DepositAssetsNonrefundable",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ExpectedLeaseCommencementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected lease commencement period.",
        "label": "Expected Lease Commencement Period",
        "terseLabel": "Expected lease commencement period"
       }
      }
     },
     "localname": "ExpectedLeaseCommencementPeriod",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "sgmo_FreeSharesAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Free shares asset.",
        "label": "Free Shares Asset [Member]",
        "terseLabel": "Free shares asset"
       }
      }
     },
     "localname": "FreeSharesAssetMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_FreeSharesLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Free shares liability.",
        "label": "Free Shares Liability [Member]",
        "terseLabel": "Free shares liability"
       }
      }
     },
     "localname": "FreeSharesLiabilityMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_GainOnFreeShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain on free shares.",
        "label": "Gain On Free Shares",
        "negatedLabel": "Gain on free shares"
       }
      }
     },
     "localname": "GainOnFreeShares",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_GrantFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant funding amount.",
        "label": "Grant Funding Amount",
        "terseLabel": "Funds due under the agreement"
       }
      }
     },
     "localname": "GrantFundingAmount",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (decrease) in long-term portion of lease liabilities.",
        "label": "Increase Decrease In Long Term Portion Of Lease Liabilities",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLongTermPortionOfLeaseLiabilities",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase decrease in operating lease right of use asset.",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase in fair value of free shares asset and liability.",
        "label": "Increase In Fair Value Of Free Shares Asset And Liability",
        "terseLabel": "Increase in fair value of free shares"
       }
      }
     },
     "localname": "IncreaseInFairValueOfFreeSharesAssetAndLiability",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_InitialResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial research term of agreement.",
        "label": "Initial Research Term Of Agreement",
        "terseLabel": "Initial research term of agreement"
       }
      }
     },
     "localname": "InitialResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_IntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets",
        "label": "Intangible Assets [Member]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_KitePharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kite Pharma Inc.",
        "label": "Kite Pharma Inc [Member]",
        "terseLabel": "Kite Pharma Inc"
       }
      }
     },
     "localname": "KitePharmaIncMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease commencement date.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "sgmo_LeaseCommencementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease commencement period.",
        "label": "Lease Commencement Period",
        "terseLabel": "Lease commencement period"
       }
      }
     },
     "localname": "LeaseCommencementPeriod",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "sgmo_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, operating lease, lease not yet commenced, tenant improvement allowance.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Tenant Improvement Allowance",
        "terseLabel": "Lease not yet commenced, tenant improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementAllowance",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, operating lease, liability, tenant improvement allowance.",
        "label": "Lessee Operating Lease Liability Tenant Improvement Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LesseeOperatingLeaseNumberOfContracts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Contracts",
        "label": "Lessee, Operating Lease, Number Of Contracts",
        "terseLabel": "Additional property available under lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfContracts",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_ManufacturingCapabilityEstablishmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing Capability Establishment [Member]",
        "label": "Manufacturing Capability Establishment [Member]",
        "terseLabel": "Manufacturing Capability Establishment"
       }
      }
     },
     "localname": "ManufacturingCapabilityEstablishmentMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MeasurementInputExchangeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Exchange Rate [Member]",
        "label": "Measurement Input, Exchange Rate [Member]",
        "terseLabel": "Exchange Rate"
       }
      }
     },
     "localname": "MeasurementInputExchangeRateMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MeasurementInputStockPriceCorrelationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Stock Price Correlation [Member]",
        "label": "Measurement Input, Stock Price Correlation [Member]",
        "terseLabel": "Stock Price Correlation"
       }
      }
     },
     "localname": "MeasurementInputStockPriceCorrelationMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payments received.",
        "label": "Milestone Payments Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsReceived",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneRevenueReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone\u200b revenue receivable.",
        "label": "Milestone Revenue Receivable",
        "terseLabel": "Milestone revenue receivable"
       }
      }
     },
     "localname": "MilestoneRevenueReceivable",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_NetProceedsFromIssuancePublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net proceeds from issuance public offering.",
        "label": "Net Proceeds From Issuance Public Offering",
        "verboseLabel": "Net proceeds from issuance of common stock, after deducting offering expenses"
       }
      }
     },
     "localname": "NetProceedsFromIssuancePublicOffering",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncontrolling interest, increase decrease from foreign currency effect.",
        "label": "Noncontrolling Interest Increase Decrease From Foreign Currency Effect",
        "negatedTerseLabel": "Foreign currency effect"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseDecreaseFromForeignCurrencyEffect",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of clinical or regulatory milestones included in transaction price.",
        "label": "Number Of Clinical Or Regulatory Milestones Included In Transaction Price",
        "terseLabel": "Number of milestones included in transaction price"
       }
      }
     },
     "localname": "NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfResearchProgram": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of research program.",
        "label": "Number Of Research Program",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "NumberOfResearchProgram",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office and laboratory.",
        "label": "Office And Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office space.",
        "label": "Office Space [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_OperatingLeasesNumberOfExtensionOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating leases number of extension options.",
        "label": "Operating Leases Number Of Extension Options",
        "terseLabel": "Number of lease term extension options"
       }
      }
     },
     "localname": "OperatingLeasesNumberOfExtensionOptions",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other products.",
        "label": "Other Products [Member]",
        "terseLabel": "Other Products"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer.",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerSB525Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer SB-525 [Member]",
        "label": "Pfizer SB-525 [Member]",
        "terseLabel": "Pfizer SB-525"
       }
      }
     },
     "localname": "PfizerSB525Member",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PostBusinessAcquisitionSharesAcquiredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Post business acquisition shares acquired amount.",
        "label": "Post Business Acquisition Shares Acquired Amount",
        "negatedLabel": "Shares acquired post acquisition"
       }
      }
     },
     "localname": "PostBusinessAcquisitionSharesAcquiredAmount",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_PropertySubjectToOperatingLeaseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property subject to operating lease one.",
        "label": "Property Subject To Operating Lease One [Member]",
        "terseLabel": "Operating Lease One"
       }
      }
     },
     "localname": "PropertySubjectToOperatingLeaseOneMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PropertySubjectToOperatingLeaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property subject to operating lease two.",
        "label": "Property Subject To Operating Lease Two [Member]",
        "terseLabel": "Operating Lease Two"
       }
      }
     },
     "localname": "PropertySubjectToOperatingLeaseTwoMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RemainingCommencementLandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining commencement land subject to ground leases.",
        "label": "Remaining Commencement Land Subject To Ground Leases",
        "terseLabel": "Remaining commencement, area of space leased (in sqft)"
       }
      }
     },
     "localname": "RemainingCommencementLandSubjectToGroundLeases",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "sgmo_ResearchAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research agreement term.",
        "label": "Research Agreement Term",
        "terseLabel": "Research agreement term"
       }
      }
     },
     "localname": "ResearchAgreementTerm",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_ResearchAndOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and office space",
        "label": "Research And Office Space [Member]",
        "terseLabel": "Research and Office Space"
       }
      }
     },
     "localname": "ResearchAndOfficeSpaceMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research services.",
        "label": "Research Services [Member]",
        "terseLabel": "Research Services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RichmondAndValbonneLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Richmond and Valbonne leases.",
        "label": "Richmond And Valbonne Leases [Member]",
        "terseLabel": "Richmond and Valbonne Leases"
       }
      }
     },
     "localname": "RichmondAndValbonneLeasesMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RichmondLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Richmond Lease.",
        "label": "Richmond Lease [Member]",
        "terseLabel": "Richmond Lease"
       }
      }
     },
     "localname": "RichmondLeaseMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SBFiveTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SB five two five.",
        "label": "S B Five Two Five [Member]",
        "terseLabel": "SB-525"
       }
      }
     },
     "localname": "SBFiveTwoFiveMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi.",
        "label": "Sanofi [Member]",
        "terseLabel": "Bioverativ Inc"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ScheduleOfNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of noncontrolling interest.",
        "label": "Schedule Of Noncontrolling Interest Table [Text Block]",
        "terseLabel": "Summary of Non-controlling Interest"
       }
      }
     },
     "localname": "ScheduleOfNoncontrollingInterestTableTextBlock",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSATables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_SeparateUpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Separate upfront fee.",
        "label": "Separate Upfront Fee",
        "terseLabel": "Separate upfront fee"
       }
      }
     },
     "localname": "SeparateUpfrontFee",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number",
        "terseLabel": "Stock options and RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/BasicAndDilutedNetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share purchase agreement and tender offer agreement.",
        "label": "Share Purchase Agreement And Tender Offer Agreement [Member]",
        "terseLabel": "Share Purchase Agreement and Tender Offer Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementAndTenderOfferAgreementMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "SPA"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_TxCellSAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TxCell S.A.",
        "label": "Tx Cell S A [Member]",
        "terseLabel": "TxCell S.A."
       }
      }
     },
     "localname": "TxCellSAMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ValbonneLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valbonne lease.",
        "label": "Valbonne Lease [Member]",
        "terseLabel": "Valbonne Lease"
       }
      }
     },
     "localname": "ValbonneLeaseMember",
     "nsuri": "http://www.sangamo.com/20190630",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r38",
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r113",
      "r160",
      "r162",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range",
        "verboseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range",
        "verboseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r78",
      "r82",
      "r83",
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement Adjustment [Member]",
        "terseLabel": "Adjustments Due to the Adoption of ASC Topic 842"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Restatement"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Restatement"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Topic 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Topic 842",
        "verboseLabel": "Topic 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r16",
      "r161"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discount on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r29"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r42",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r41",
      "r45",
      "r46",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r170",
      "r171",
      "r179",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r150",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Issuance costs related to public offering and TxCell Acquisition"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r171",
      "r176",
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r111",
      "r260",
      "r272"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r37"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and marketable securities and free shares asset"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale securities, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "verboseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r116",
      "r121"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total marketable securities",
        "totalLabel": "Total",
        "verboseLabel": "Available-for-sale securities, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCostAndEstimatedFairValueOfShortTermInvestmentsDetails",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r217",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r190",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of share capital and voting rights acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Purchase price per share"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "terseLabel": "Fair value of non-controlling interest",
        "verboseLabel": "Non-controlling interest at Acquisition Date"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail",
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "positiveTerseLabel": "Consideration transferred",
        "terseLabel": "Purchase consideration",
        "verboseLabel": "Consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisition of Txcell S.A."
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSA"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedLabel": "Current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent",
        "negatedLabel": "Deferred tax liability, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Assumed debt liabilities",
        "verboseLabel": "Liability recorded on acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Fair value of net identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Fair value of TxCell",
        "totalLabel": "Total fair value of net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment included in accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r24",
      "r66"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash equivalents, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents",
        "verboseLabel": "Cash equivalents, Estimated Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r67",
      "r72",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r61",
      "r66",
      "r71"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r61",
      "r232"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r76",
      "r81",
      "r94",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r76",
      "r81",
      "r94",
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Major Customers, Partnerships and Strategic Alliances"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliances"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper securities",
        "verboseLabel": "Commercial paper securities"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r147",
      "r264",
      "r278"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r146",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Sangamo Therapeutics, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r50",
      "r206",
      "r207",
      "r215"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r50",
      "r205",
      "r215"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r104",
      "r105",
      "r229",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r104",
      "r105",
      "r229",
      "r230",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r104",
      "r105",
      "r229",
      "r230",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r100",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r104",
      "r105",
      "r229",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r104",
      "r105",
      "r229",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r155",
      "r156",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "negatedTerseLabel": "Revenue reduction due to decrease in measure of proportional cumulative performance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r155",
      "r156",
      "r161"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r155",
      "r156",
      "r161"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r166",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cumulative effect on retained earnings net of related income tax effect.",
        "label": "Cumulative Effect on Retained Earnings, Net of Tax",
        "terseLabel": "Cumulative-effect adjustment of ASC"
       }
      }
     },
     "localname": "CumulativeEffectOnRetainedEarningsNetOfTax1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Realized losses of available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r186",
      "r187"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositAssets": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.",
        "label": "Deposit Assets",
        "terseLabel": "Option deposit"
       }
      }
     },
     "localname": "DepositAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r64",
      "r110"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.",
        "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]",
        "verboseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606"
       }
      }
     },
     "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r153",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r78",
      "r85",
      "r86",
      "r87",
      "r88",
      "r90",
      "r266",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "negatedTerseLabel": "Increase in basic net loss per share (Usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/BasicAndDilutedNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effects of changes in foreign exchange rates"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r226",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r226",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Free Shares Valuation Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r221",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r221",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r221",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r221",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r219",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r219",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r231",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Net loss on lease termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r136",
      "r138"
     ],
     "calculation": {
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail",
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r64",
      "r137",
      "r139",
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Research Grants"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Fair value of investments available-for-sale"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r133",
      "r258",
      "r270",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Cash and Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Area of space leased (in sqft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "verboseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lease option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "Nine months ending December 31, 2019"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease agreement, extendable lease term",
        "verboseLabel": "Lease agreement, extendable lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit established as a deposit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r262",
      "r276"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "Collaboration Agreements",
        "verboseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Stock Price Volatility Estimate"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "EUR / USD Exchange Rate Volatility Estimate"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Stock Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r34",
      "r261",
      "r275"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Non-controlling interest, ending balance",
        "periodStartLabel": "Non-controlling interest, beginning balance",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail",
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r61",
      "r62",
      "r65"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r47",
      "r49",
      "r52",
      "r65",
      "r89",
      "r265",
      "r279"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss to Sangamo Therapeutics, Inc. stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r49",
      "r209",
      "r214"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Loss attributable to non-controlling interest",
        "verboseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail",
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r77",
      "r79",
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r152",
      "r194",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "verboseLabel": "Non-controlling interest of acquired entity"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfNonControllingInterestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r243",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheet)",
        "verboseLabel": "Operating lease liabilities - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - long-term",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail",
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r240",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities included net cash used in operating activities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r248",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r247",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r75",
      "r109",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization, Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Other commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r39",
      "r233"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r39",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Change in unrealized gain on available-for-sale securities",
        "verboseLabel": "Net unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporarily impaired investments"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r59",
      "r169"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.",
        "label": "Payments Related to Tax Withholding for Share-based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r56",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid to ordinary shares acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r3",
      "r5",
      "r134",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts.",
        "label": "Prior Period Reclassification Adjustment",
        "negatedLabel": "Reclassification adjustment"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.",
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r47",
      "r49",
      "r60",
      "r111",
      "r112",
      "r205",
      "r208",
      "r210",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Increase in net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r25",
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r144",
      "r277"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "terseLabel": "Property Subject to or Available for Operating Lease"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease.",
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "terseLabel": "Property Subject to or Available for Operating Lease"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "verboseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r183",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Revenues under agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "verboseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r182",
      "r285"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r10",
      "r66",
      "r71"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash included in Restricted cash, current portion"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r7",
      "r13",
      "r66",
      "r71",
      "r284"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash included in Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r10",
      "r71"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash, current portion"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r13",
      "r71",
      "r284"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r151",
      "r274"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r157",
      "r159",
      "r160"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "negatedLabel": "Decrease in revenues",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r246",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty Revenues"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, after sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Sales Revenue, Net [Member]",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r124",
      "r127",
      "r128",
      "r129",
      "r130",
      "r132",
      "r267",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r190",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/AcquisitionOfTxcellSASummaryOfEstimatedFairValueOfNetAssetsAcquiredDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]",
        "terseLabel": "Revenues Recognized under Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r171",
      "r175",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r171",
      "r175",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r77",
      "r79",
      "r80",
      "r92",
      "r93",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]",
        "terseLabel": "Impact of Adoption of ASC on Condensed Consolidated Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Net Assets Acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSATables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r71",
      "r259",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r173",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Public offering price of common stock issued (in USD per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r33",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r14",
      "r15",
      "r150",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r150",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r150",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r14",
      "r15",
      "r150",
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r150",
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r151",
      "r172",
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r115"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Sangamo Therapeutics, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r203",
      "r204",
      "r213"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAscOnCondensedConsolidatedBalanceSheetDetails",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions",
        "verboseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r166",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored entity debt securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashAndMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleMarketableSecuritiesAndFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r98",
      "r99",
      "r101",
      "r102",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation technique calculating price of option.",
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "terseLabel": "Option Pricing Method",
        "verboseLabel": "Valuation Technique, Option Pricing Model [Member]"
       }
      }
     },
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionOfTxcellSAAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r244",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Free shares measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementsSummaryOfEstimatedFairValueOfFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "305",
   "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=SL6284422-111562"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=107668666&loc=SL79513924-113897"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888415&loc=SL77918607-209975"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "305",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r286": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r287": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r288": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r289": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r291": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21843-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e777-108305"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01(a)(5))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(a)(5))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(b)(6))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001628280-19-010300-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-19-010300-xbrl.zip
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M4ZPJ.1S<#T3FU[Y4>T]"^&I&I'FM!=W>$#;2EUP]\6@X37:/7H);$=DY#H\
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MBI>C>8GW^/?R\=+B%J%>B[?!UQG@2ISZ>]_6'>^_*>W#HF[:6%IXW<;1)/Y
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M=.]%ZQ:\H8AR'P24?J/+A&W_6$+O<91FLZ8.E_/8]L^3PO[[R;;7<*J;%U1
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MY?B3VTB8C%%)REF"!0O6%P/@3I/6P C5W"#H+0UXQ\M"3T@-Q9;W^2):J0'
MT/27-\%>+;+EZBA!#E5+A/$L3 IB"6#,V*!3J=(8!UBCYLM%Y\?U_7"B0W"&
MTQG^N;Y[2=#GQ?OL6^!U/,4)_?]0Y(OPXS9&^ICWX*1V$F:)4D 3&D;/H(6(
MRFI* $B:G^WWE!F^8V]"GV -19R8U.GB2DWSS5G.T75C5_$D+(>"*",TL=I@
M',PMPZJ1,:?&[5OH28IY;\"])FJ,TM$P8D:<326]&W]8.1?3M)@N?[N-9T.A
M/ .HCCIZO'X2-'%CI:"28,RHQ4)(5)X!>")&F'"]G0B?:Z*=@S0&@A @6Q&D
MJI\8P;73!F*A  C_< "5,PT"#X94-\9&D*8@#4608$D5FPSSV?;?;Q;/3Y(_
M!GT[K+??PL .4.7$EA(6W\! P9QW,;FD)XP*6^+A&!CAJM+A\6B_8)W![7UY
MG09;[,URN<X.D61/C<0XS#D5 $)K&=%&@+"*;L>'-&D3C-P7&7J3X'[G> O$
MAF+$<PP"3O/U-&IH>;&1S6I5S#ZO-R_=?\IW6_0'3]&[^$!BE5?$$L1,^(>&
MF,7+0'?H&=$B]4IO.]90?#L+P(,M6%N7XNQKYJZNLLGJ8O'4 _T^6UU<?4J_
M'PJ:/Z&5!&,IA:&8"J(YC+E\E2YQ4-R.*'O7X M;;R@.NMAMEV.[+N($V20Z
MV"[3FW_J=!.R=W,;#-Q-B."QE>VTUA+.!#!(80]##P$ST )SAPOV% R9\WID
M[.H?S3.S[._I?)UU1;(#C24*0X<1"Y,/<FZUEYY5J"#:XI)@;X<.9^98=V".
M8B%S-[?S_$>6;0I]6!>3ZWA#;I[NS&#0LL7$0601ML% -L'F#FN\IO .'P)Q
MB^M G=])' G9.D9T#(O:WL$T7-?VMI<8[KD$6D&&I'5<*&1XB8UFK+D3O/.[
MC"-A6Z=XCF)U>Y]]V_RI\6)6-9! +@Q@W  B!&4<8JM<.7K@6R3BZ/PFXTC8
MU [ ,2Q5+=CSN'["M>;"*:X%8F'%EIJ0:NH$JZ=YN$_G5QI'0IY6^)TA^N-3
MOB?0\<'XXC_C%;^8?:)F,,C)S29:$N8I=@1!$Z:;]@27LPQKH5KD@.D\,=W0
M5!L0UU$Q,*[#GY_:*A^S@.MRMLHNL^+K;))MI]W';))_V8I^,P/;LK3%IQ/I
M+930 ZHMX$P)R6#I8\1 BA;I:U[\J<'(L!\LD\6>2-%X0SA FLV^+,RZ*++%
MY,>G(EA'\\V0[\'ZE'X_0.@.6D\PQ$@P*T5\T8TRXQ!E%6Y$M,A=\.)/'H:'
M]]RT_&T1 )W/_IU-_R> &52;OP5YQ.%>+"ZSR5T&!%6$Z;CX\E#W*1WC#;C:
M]I.)I!X3(067&"K-!/>HG/B$"=_\G:GNTPV.A< #8SX4JS\4^=5L]3#YPNZ'
ML>\*)1(*QQQ'/G0<"FJI="6LQ''5@CDO_K2B,4K])VOY>H]/]VDM?#HK-OK$
MNX#NNL@>I;(;Z'/WVM&;Q55>W&Q?%CJ46V8 G\/D.INNYS%$[6OH1SQI#Q2[
M3.?9_8+QMDYVC5/:22 PR%-#@9><2L,T C88-!@Z9QQ0M?3I\^%Q-"='W382
MK)@S!EI,P^133!@%S1T.4FK3_,R^ZW0=_4CWJ?^E)]Q&G>0CKA*;A>!3-KE>
MS/ZUWO<&]>$*"6+(&QUP<9@1(*AQ&M]!HBRX3Y,ZNK0>W0O]6;K5#@ ;2M5Y
MWMFC^1WV54D$PMAY!X$B@"HB/&"\'*&1SHS[4DY;L1UE02N47B,?SL.#(S=Q
MQD*#L8A_FW'Q0S&;!.OM73[-CF>%J-]( A"1$%$<[S43K[U@CI4H*.Z&3 Y5
MTW!J+]"C#.D(K:$XH]?!O,^62S79^E>C( ZK%'MJ)!*[L,T"P00"WF(, 53E
M^(*YV5RGZ/MR;^\Z13>(G9,1\<<B.[Z;'*V;& RYL=Q9;P5"R 'G]=V8M>.2
MC%O-:"W)&LSH J\_!E=&J8*,CR*G4F//^U&?OIML/K]4>S6(':42+Z3#4G'/
M*'5AL?1$57TSV(XPAUB'>.==X3+P#?ZB2!=?MH^4'58%=I9/P@",MQ3:H$?%
MY.&0,E"-3;=0!$X_B1F9(M %7H-%:-SW,N89?Y\OTOO?; XZT\DFN_3QR]JG
MM90@%]!07#)(A CKI4)*E'A B?&X5826,GX:,#$(=G]R:I2JQ+BIU)%:L0GW
M*<.UU9>PS6Y&NH@O9D[C>XE765']^K#NT:"IQ -.F+7 AKT8 HK"GD[+XP<"
MV9"'*C45E-[DF \*96/"[%#0RJ<U?>C0-GK[?[+Y5/_XG^V!^#Z^G-Y2PJ1U
M06VGFDF,-/1,5)//(,A:Q/;U19=^3^.&P7%H<];D-Y]GB[NXPTV$X;^SZ9MI
MH/KL:O,8GUHNL]7RSBZ8AFGQX/V7\+?U3?;P-S6,X(Z_F,!H8#BIG<$T>C6A
M5Z6ST5AMFGOO>POG&^;4>!QX=[GVN>5J=A/3D591) _Z]7 "GK *UFXSD3BJ
M'"@81$8*98U S)7C%D@VC]KO+>KN/.MA7X@V9E(90O9F4?7H83<V]'_ ^A_[
MV'-J.XE6QB*C(8NW811PR/ 246LU0(T9TUNTW0",Z1G%?M>;[5+9V5+SO+G$
M0P)]U"(I1D@XC+ H3^>LTZAY3J[>[OJ/995I#6;?D9P[8Q^K!_>>#^CA4*K#
MU\V&O#EW/?SZ7O\:Y!/@'^L-=T.<QI0R@00QHGIKP!7E?^IT.5L^/U.N%539
M]Z<30CF7,.@Y$G,FE1,4*$H89H00'2R_\\5A]C3T8Z&;?7XV89!JI8Q@AE/'
M).50ZBW:6,58[K%$>XZ'=OEHI3/JF-+N(D"L88!KX[7BU(;M3%!F[D#10@\:
M#W32P<\XF%(S:.0TD%]'( !G$!OK 0'<A&7 .N)P.68,],@3QK>6Y,D1 <WP
M^F-P990G/>.CR%F#1AS AD,MI61(0R0]EF7?$$$O,FBD-MZ'@D9.PF6HZ?S
M<'NSN%VOXJGE$05B7Y4$,<VI1E@)0KA&S!I=CM! [II+ON<8TE%J$!VA?$X>
M'=T/]E=*@+.64"\I#'-/ D.4O5L[2;0FZ+B5AO;"J\&&5DB]5EZ,4D$8$QW&
M08-MA$(QFQQ_W?!8U41RC[!G0$LD,2%44>#+$2-&1GBJWX7XCC"B)4J-5<:G
M_7#?)]<QO.5CNMHOZIHU$R&@0X8@IACU00\+([B;+@0Y#YN[*'H[%^]0TOV
MU)F@MXD[(^%,7A39-H_.:1(_T$2B@AFEK=4:<Z2T%- "48X*6]G\X+&WH^J^
M1=\=6N?:!+:7[?Z>QZ['<]&3MX+=#23$8A@,;B:$@8R#&*Q?C9X3T#Q\IK=#
MZ@$VA$ZP.A=3-C1O092=]1.D!.,!5FF-]"#,&(9X.78-=//W@7H[F!Z )UU
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MD"C<XE!KA)%<#=C30]A6$]Q'':-5@:)_/%@EPV(7]I;%Y,>1X]8:M1,H B(
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MW%4T080!I1DPS @;'Y?GJ,*"0MI\YSS=5_62=LX.L!R %?=9#K/]^? /ED^
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MY)QZY:JH(*G=F&YDGY$,76 WW'(PRXNM#?TQF\S3Y7(#S :Q:@L]N%+4J)_
M,"F4"2AB:  P!EB(J_M.F#571KJ_$'[61:1[+ =S=V6W^7*VVMYR.^2W>E@N
M<<H 1PV$\1J$=T$-@Y62I^F@E\5'S(LVF#6^ /KHH^_S12B[7DP/O;^TOT82
MZ.H\HY0RS03'5!A2[8F<M'C,]_1[@".4<[?H#37CGR13/C#GGY1,M/<F[((2
MDIA"2"*M?>6+Q<XWWPU.OYXQ0C9T@]K9(NO#_A5_D7[)X %*'*J6Q(7(TF#\
M!W(3;+SEO,I.!+%O[FX^/3)VQ/SH$,+AO!VK@&8V+17D ,OVW":;VB"OR>S0
M*G*\<N*U!%Q!*)TT1G,6MLCJZ%$C/&3<R8B)TSF0]_09]\NC;VYNT\GJ/E(L
M_+2<7"S"1)IFBV4V#3\L0]$8[#5]F AB^_3GOH=+^Y\V!V)C+XKG;QX%,V(Q
MF=W.L[<'7@OMK.W$ NT\09! CJP(S$$.$H<L#,JIAK)6KKUQX;;OE=%.VDTD
M I:SF,&;<8H=<![2.[RT\7A(Q_S.MT;/P(S\?/BF8WYW]#P7DXS7+%B4&#$7
M+ ]KE)*B!- 1->2[;[4.^P>F3:OK2:=A^Z+NH!CD84S['H.\A(*..WPW,F.,
M4.,,%>A9BK4NHS0"[C518U21!B^ $>=APC"W3SSW7@IFF5*0.0<@M:H<NPU8
MCN<XNAL1-KI]<AI(0Q'D;193Z#YXB.1X[KA]51($PO\PA,9)P)2AA"A4CE H
M/F0"[Q>@@W0$XSF)<C3V?G^E! ;R*^1(,"F\)4I8H5DYRA@6-F[5H[WP:K"A
M%5*OE1>CU#O&1(>.CA+U>C:??LHOU[/5IC-'GG/863I!4%C/PBX8-C^IC6#"
MZ+N^6LC5H'?<ZRD&70"?=PW,^"X7.(ZHE5A##IG%DDN-2=E_+6WS2R@]O2!Z
MGJV^/7+CC$*7 "&)A'+<8Z&(=U16[+7:C_3E\%;2.!B.W@R/ERG;4>V_YQ/I
M>1;H]C<,J*,02&BEPT8+C@SSH'+O,S3Z&P:UY5+SAL%I> SFMMD$%*G/RTW0
M^B'_S*."B808:$FX=RPFNB<<6U..1B MQR/=\Q]8M8)NP,#_H-VL?GR8Q\/Q
MQ=3]:SV[C>B\SPX'^.ZOED#K*0..4QY?19+QZ;#2$>4@TT,>%=5].K>AJ)['
M^W>%RF#Q>J'#:23^QGCX./MRO;JX^FVY?9CB4/3>H7I)&!X!$$IN/,$V6*18
MV[NQ^@!#<[.LMVQ!'3&@2UB&6P*RVW0V_7@LI+\JE2BG@2-8$N95M"Z#H<K+
M<7#:XCF>SB]\=#[!FX(PF+=LEGZ>S0.N69W=?4?I!'IEO3=<NY@HBU('534N
MXUI<_>MM[IYOBV^/WWG6^;+?/\RZ*(Z$:1^LF"A#9 !.A=U-<+(98VD,>0Q:
M1&WWYX!K([.#RWU+<%I<RKC*P@<WR]+[?#'9*],#I1-MM/02*(>\Y( %<X5O
M'<D4$(1%<Z6MMVG?A2"[0^3,$_F@W&O73:@R'"(,E9$Q;-@JJL7=F*F4M/D)
M:V\[^P#3N3$^KR6"'F"'@\U"L75*.06I1K0<M9>HN=7?^47-/EC1.4 O)3*^
M_/?CWE<A[G=#&$-/-Z<GYPO%ORR]?V]KQ-8_+YPP*!ET89-QFEHK-=+&0Z@P
M)_$YZ'I967H>V;'H]\<%$TZ9P([%R".$J;9&.UR.B(-!W_@\&,[>1AA/W[9H
M@\"? >?/@B=],,<,@I!)&8^_D?6@ I "/^0+.B>= #?E0:L(\M/ >EEAPI*C
MH(5S@PTFTB+@;3DRQ84>YU%PSU*L%R_<!+C71(U1G22_ $:<Z2ARD AR0JP&
MP4;CSEO)! IC-N78&77-#=NA(\AKBK!1!/EI( U%D,O)=39=SP,8AV;+8KKU
M]"YWNGJ7GX+RI$/_?C^DPW;ZH<1802E6TE*/",2":D9+-+&S([RTT*4V?$XL
M^S:P+U>A3\%>C9?#;V[#PK^Q5OLSDW=_;_=OW??X8[:]G7XVB]C=W,[S'UEV
MF15?9_'"_#;AV>.NJOF&])L[]Q^S21X,_']GT[O4W?ER=9_5X,"D[?A+"4-4
M"*X9\A @!:ER4$6FA7G H7:U+->^U\%NQGS4I._C>PFS6%.C/"9:$44\L9[=
MX<N,,'3 5?&@9^!LO-J[D)Y/"J/V3KQ9A'4RN]^Z[H9_] VCO;420I$10C')
MN080>.VI*\%1"H@!*7J:Y^&\5'GV<D=7" ^E:.[I<8T'8 [42S#6CBF # D3
M'BM'.#;EQ&<<C=R!T8D4ZS&C%5ZOFR.C]&2,CQKG.GU=9N%;U\&:L=G7;)YO
M0C[O]/"C[HL:M1-.B>426:4PX11!+14HQQV6YA&^SMF1')^=Q':-U5 <^5NV
MR(IT'E\"FMX$.2PW&?J^9G594JM^0JDVEHM@+$OKD*,H)H8LQTY-\U.WWF)X
M^N%)'V@-Y@[=:F79=+?2=C>$0_[06@TD)M@BTB",H-,:AE4Z&"7EZ(760RJY
M-;DR%HNL%X#/X[(Z&#?1E>/J.I\'8BSC98C5CR&_I:;333/I_,WB*B]NMDO+
M>1UC>UA[?Q]<_[@O\B']L;E3]BTMIG5\8>T;3[ @%A I,9* $B:@Q  2ZH"Q
MX?>\5AAHW^ZOH\-<[AMG?9=7RV\DS&#C)3424>>=)H0 =X<CU!X,^8CBX0"8
M 2FSU[,U+-BC]F95JM!V"8MXY(L:L34'ZR76  >88,0XC9&U1%%^!Y VT QI
M0#3T: U&D7U171W@.I0*^:2K1WT3.\LG)D#$N)>*(NZXLAI16XZ-(H_'[;?J
M2&Y/W_#I$*G7Q891>JC&1(+S"#^^%'%W4GS4Q_"L;+"0G4(^# "'+1V$'QPB
MY9@P'N-+T"UE\^PQA7:(#!8AL_Z\G$UG:?'C,MULEK''QQ2&?742*Q% 82J
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M",FQR"A$BQ'()T8ON%LG_YEC9TZ*E+"Z$3E2X\MS25+($*LL/3/52V 21B
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M]]OH'#<ZSZ^,])8TQ.V,?+(A%!C[%FLUVQ[]EJ.!<?Q;."[L6]5?(!TLCH6
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MN^!0S ^W^7]EU4WLV5YO!-A^8"-D!1AZ 4R\P/>BWDALAC'[F[7\'ZU9+3M
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MN=^1P'2^H;&^XGO.T4N324E:-C"AE/6@5-=(>%<+B'/T@J;VZ?J\_GURUBP
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MZ5'@1ZFZM?&)#K%144U#6??OR<(M3!_R)CV.J[:>9]H>\GW+P<2R@ST?C[M
M+0BYWA12:%;S9(VF3?L[\I.L-FA-XK0EYW1KV>1P)N?V')7TL\G92LSSZ=L
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M6(M@,M$VHY%J:=^&+"KVJ=394#G%KRKW67:H,?'Y)FWWK?V2-M3F]^O;LSB
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M<I/0LAS3B>PP&H:FT /F[FM6?2ZY7@G@-<'3DZ9H.#H2/?61C;", \$E\#X
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MC'J;F,!AJAVJL;3L9F*CHO#>E+=O'NDSL>U8(;.!F)M7-K5:CE(^N7KY .Q
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M%'K,<^7-(-:LFRVTX86B=M/1QYM?:Z,\X31^R@NCIK[6?^:8;VZ&0)8)_V;
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M6;G>WC^D^X:^C @._6W-].L;:)"O8%D<Z+-L=!Y?U.4Q/Z1T%A6G1_JB/9G
M9[S'[I:.*Z- ;C>DG.+:.T)C.'^I IT8]^Y<NE:A[M,Y8[V[)Y7&94[CUVD
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MAH&T K]STT#%;#N<( </M74@Z\R326W&]+1(%CE3)TNFGF_\VYH!&CO P1#
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M_+GE<RO6W-OZ:6<>*>WB^7U!LCZF(XH2F[I)XD6N:U'/3KS^R$N86&(7.\<
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M#[MB@C0^L7("U7-:?W$$\0ZD%>A0@AKFR.<&19B[=@10*_/SD#3--IT>S#/
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MYH\BL8"YY.<CVH_9YM6N+J[(/X.77%2>F!KQKIA(3^U8.;%N#KLW<$&#%S2
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M[39'[Z@?&IC(2P..$%P<3.!1W5M*!PK$N1,\7F# &?,[;&#"R"M'#XQQJCV
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MFV-%<L2+$:)CH+\Q^<(H5Z-E^B&NB+L8VB'D8WSW]%1]X-7'28)H%,64.'&
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MB_H:85/D<.%'+O$H3EQ(,,20!:K$YS60[-#W*:)25R2F06@Z:+1&U;5T6[-
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MXB>D=]EZ7?]COUW557A.%RXE%-"4;P0BS@S<(A>"6H_4B$$+N2N 5(,&'6K
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M2.\H'IR',H]CZKN:LJ/Q>]#UXY[YB7WU/_Y+]QWV__A^QO_X+_\?4$L#!!0
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M;*W.T.2VN!N,IP>B[$7;3"FBL('0,@LA4P1BBDJ:,:3XC/&6#(,:L$IA]GZ
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MLVY'830!A*)]-G=EQ5Y.[12P'=A3%D]B$4"<\($!@$E+'5SS \(@BO.R4RW
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M6[.\[W3S\/E(:^\@;FR4"64,P<0; :#60DAFJQQ%[U2*)>U[YD+[^JPIMI_
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M7=C=*S!W(L#]\)Y_N2LB:"5@&"PA&S_)_CX83R^F?I;G5[>!MYN0N/&YS&B
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M:"9V@8>EH;N87<Z*K^/I<+?'L;E)AL*:FG"%=2QB:A0/I*Q74X:JM%M8TA+
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M]%."*OXXR_?;P;UM,X,A-Y8[ZZU "#G@O%[3K!U/.KK>=X\]&08U8)7"[/T
MFW^Y*Y:A6, P6((F?I)=?S/Y9'*EMAJW#4]E7DB'I>*>4>K"-/)$56,SV":=
M3'Z'0#A2<$53#.Y*N\0"@$'3SF8QCS[&;/88K(W/9X$ XRV%-EA[%"L#408J
MVG22N>IKK;7NS%43+.\*3L]&.5?3T6_%=/#TR;*"6$R]+J;SO8[W@3UER 5N
M*"X9)$($W:V0$B4_H,0II7KZKK\2 ?+ZEI16&7^T45MF4Y67#*HO03<O*9V.
MKF/@>'9Q$^13?;S;\AW15>8!)\Q:8(,"AX"B8 CHFDI#(#OGR&9K@"@ZE4E7
M*K".0?@8_(T/B_QNYY5_A_2306"0IS$/6?)XV%DC8$M>.*#.^2KT]BUPFZ(X
M6B%N\%I7I]\O;GR8)ZOLTW_DDY%^_,>JJ/HV?7AX3QF3UH5%$=5,8J2A9Z(R
M+@9!EG0N\0S@=@08BBX%TG7LPA1WG\?3]55JRTO3_IV/R@)PD8-J/L\7\_6J
M:Q34_L?P\7BRNFYG/G^XRY]_4B/BT? ;,QB7;TYJ9S"-D4WH51EP-%:;E(V#
M@P-RG=_*U"[D^R6Z)O6QFR_&=_$RN6IS^-FXGL_E S1S[3XSB:.;CX+1,U(H
M&PLDN))N@63*88X>'?8YK5IN2QI'H["\K.7#M!K1\V$LI\ZS&;,I;_>H?C*M
MC$5&0Q;O/E; (<-+CEJK04HYY7-P0!.AU[(XVE5Z*WW=F+Y[VUWF(8$^KOHH
M1D@XC+ H=QRMTR@EH;Q'%9/ZINJ2!7&RO,2KA[N[P>SQXN8M4<_)J3:DEU[%
M<B]Z?H;9BP@A"@EU6B#%)!2*A;4#89@1S+7GM3+N6Z9V[?*]</76 AU=1#?Q
M818OXUR%IV;EKWHP'\_?9A7L37AL\[49@U0K900SG#HF*8=2K[FMXK5I9[QT
M;@:%VQ*E3R^L]Y=G8@T#7!NO%:<V& E!8YV+)7U:Z&YSEDX%QI/BIF9JRF%R
M.H_4%,X@-M8# KAQ$EM''"YIQD"G7.#5=VPFP^#@U)3#F-UQ:HH#V'"HI90,
M:8BDQ[(<&R+H^TY-J2VX7:DI!S&X*^WRS&'_,+U_6-Y5N<?,;6N2(:8YU0@K
M00C7B%FC2PH-Y"ZI!E+/(=1+.]>0H$X)Q;T6;GNC##AK"?62PC!])3!$V;4>
M)U!(=[+S+!W ,5WR-:!T%)M/!:95ZL-L/,SW)D7M:YI)[A'V#&B))":$*@I\
M23%BY&3[LMUAZ5#1[T%3(H>/=I1>CZ,L=?QIL-@.DYHM,R&@0X8@IACUP6D(
M%*RG&D'.PY157X\* K: DG88W!A(EF7'EF U11# 9"F<P]"RHXM,A86'ME9K
MS)'24D +1$D5MC)EBZ>'&XIMPZ8Y3I_*<*U.9_VSB$./FTX'FZ_-'63$8AB6
MMTP( QD',6^^HIX3D))KT?>MQ XL6B-,/Q7DEO,E 7$;VV=("<8#6Z4UTH,P
M]1CB)>T:Z)220TG;A^<!N"9XWA7>6EHL?ZR1[]OVJS-".9=1<A('MBLG*%!K
MCA--6$I!OKX?TNEE#*1G C^?Q#>#A$)066&PQ$A1I<UJ)Y&I\$52-D@O#^+W
M!TB-9<L=)L+WGKYDH/&!JYA#X(&D%E)@2_XZFY1-GYA<_ .P34NO*T_F7\M#
M6DOF?AI_N5T\+T3^VD/;X94<TDWPZ;1#'E,,$;>:,F@@+3D1W+R4'=L>!@AZ
MA^(.9';ZC+V-WU[<F,'\UH5Y^W4P69Y3?)48^>M@]D>^B!\\I4@&]E2S>"G"
M*GOV#'/\,&)*<X*I=R@L\SDF)(C8(V,@80S7*M?>WR57%PE]*V??: :XIT1
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M*6DL?:^DU[N9<0*!-C,)FO*8:AE*CPW3P%J#/7?*>OFT>H.TWJF1=WK,N2^
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MD!E=THP!S6DU-U0(YLN_47+ 99SN*SF .88II8Y;Z24#$ A"RE6F6J&_8W)
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M5R"V\[C:R.9IH8O-GT6QV'L!_O$XGZ5X];O%CAQ=W"RW?;;4393OU^7#?,H
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MCD!IO25*6*%9265*"AVQ_LJ7? TH-6)SXTB1?HP4?UU^>9QOMHLYT\?\X.B
MH+">1;4;M:W41C!A]'ZM%G(UYL+V-B2X;)O#PRN_<!Q1*[&&'#*+)9<:DW+]
M6MJ<BI^A]CKO9Y/*9_XP:S D0$@BH1SW6"CB'975!V"U'V,G@RQ1GJS!N(R9
M;Z<&@SH*@816.FRTX,@P#_9T.<W0&+V;F0*N68-Q&6.[LFR;:M;W)ZHV6GMV
ML$ [3Q DD",KO);(P8IGT2;H)'OO[[#E]26RSMQ2V\R@.G&R'P8&"3'0DG#O
M6.H_3CBVIJ1&("U'J U[@,)+KU2.##HLM'@H5IOOG^Y2<'DQ<_]^G#\D[GPH
M3F<M'Y\6H/64 <<I3_>UR'3-4NEH<Y#I,4=PFLK\=75%6^SM+!4P+GB2OJ#M
M6?7S_-OMYN/-K^O=#0:G$@-/S0N1/ (@E-QX@JU"!.LR'.LC&W+<"4/W:+8$
MI3;YVYU2*AXF\]GG<Y43U:B@G :.8$F85\DK8H7F)1V<9MU',W2G0FLJIRDW
M._->SR>_S>_FFWJ90@=&!^B5]=YP[5(_-DH=5!5=QF75H Y=F_1G!N4+HI\M
MK%SW=_.X6IU);C\Y,2A#9&2<BANWX&1+8^FI\1ADY;H/O\=1EOA/[F69?,ZH
MJ-GQ.ZG*#\O%]"@\3HP.VFCI)5 .><D!DP[S79B( H*PR+&1AZZ*VD!$>ZSM
M6;F<!%#MN8$JPR'"4!F94J:MHEKL::92TAP/T]#MGPX43&-&CZ6> 6"'XUF3
M8NN4<@I2C6A)M9<HQW\T= =FF_!JG=-OJ4ZA_',T!0?.(F4HAO&8[+GEDCDI
M& ,4>4>8 +5T[G4HW8OIQ=J_[_[[-;)<Q_?^?H+J>@\('DH6-UGM5-QN!>'.
M.E-RP#L^YOR?-G#QZA[8*S"]JQWHUW7Q\<:M-_/[J,U.1=-^'!@ A\P#9RBT
MF#'(!!=@3PV5Q.14E _=#KX"A+*8VQ54_')5Q(UB=VJ+R$[-;2/147CKN)EL
M__=N*\MU?875^)E!$,J 2 4_UD!BD$. E#Q2CN;XA(9N.5\!@%W)85#=?6RQ
MGJ[FVT3VD^[JRQX5%*;IXFB/)39"" ZYJKY>P;.\E4,WNJ^ S"NSO[-^"9/U
M;?R2TA\I*/C'Y"ZY<.LKREKS V?QHX,PT@F!1TYQ*&Q).\!9B=U9O8#>)O2N
MP?.N\/;+9/5[/+7^=E=\*::/J^TY>+?R$R [/BD09F \W")"(1>42T68+JED
MRN4HM:'>[7Y%9+7&Z-[:O9@HK/DF_71*:1V?%:171C$HD53 <DJI\Z)2T^+E
M+?47 6I C82NJ9U:8VYG!XC)?/7_)W>/Q2_%9/VXVD8Q+_5PU'Y&4,IP86D\
M2A'MA064Z$HO(R-S6OX/M9O0-0\(5^)[=R5TZW51;,,#%UA=)V8%X0F)AJ41
M'AF-M4=4TSV=#'F:H\"&VBOHBOAJC]/=Q6Y.-NVN#[++'A0PB.Q 3FLE#/'0
M2YZ<1'MN:)AU>?M0K\&Y(O"NROT!E%%<NL%>^JC )2!&&ZNIH]H(R*QG)4<X
MSHHQ#O:"BROB\<K\?TN1QVTMR7CBCE9*;0 D#A(, 846,0"APIPHC'"]QEW7
MH?1+635VKG/9CP,#ITQ@QU(?#H2IMD8[7%+$ 1GCK5IMRGG9(G/'W5O,HQ1:
M@)!)F0KOD?6@X@4%/LOF&3C0FJ(BJUG89?Q^6\W")$<2*&ZPP41:!+PM*5-\
ME'>\71D"]9J%7<+U<34+(\1J *CDSEO)!(HTFY)V1EU.BN?0$9>'A4;-PB[C
M=E=(JY3X^QIUZZ\'!P8E@TYRX#2U5FJDC2^I B!+:PT]VZ:E_2^;J9U!97I;
MS![OXG=S2D,O9KO:G_7!XI]UG8-^NR\*Q@I*L9*6>D0@%E0S6G(3.SOFGH@Y
MV'H)TSZ%TH5OX,LFKDM/MOW-[Q^*Q7KR//VF\S.^G:^G=\L4T/AX\WQ!GXMM
M=K=9KC?K[55FOZ4E?YI\WPG@O!\@[\'Q#"F<(PIZ;Z2+5AC&D"3!08D=X:Z6
M4ZUGCNGGA-512)E/CH8%<T8+@JAEUDO&E,$ESXS&8^X#W!7:7EZ,U:G$^E-/
MAW_K_DH_%KO[&'YJL)>8TAA%.QQPBJ!@GI'D"MO*EC&)8)_>SFJ/=?</=\OO
M1?&E6/TQ3]=KE%!]3J^ZVRYN>T/'YV*Z_+:8_T^D=YN1N&7"6:?I-=X7F,6:
M&N4QT8HHXHGUK.2O$8;^U';9R#QJF_4GQZY.(>\642463X;MGI(S3MT3LP*A
MR BAF.1< PB\]M25="H%Q(CQVC-PEM<24L]@/-L!^^2\@+%V3 %D"%00JVCH
M8+.GE3,^RDZ3K4*@'JP:,;N[%)YU$=^5DKQM\4=QM]SVZMK;=6?=OS5F!TZ)
MY1)9I3!)^XV6"I1TQX]WC#UO6P;$JW2=MIG>%=C^42R*U>0N+ES-[N>+^7J;
MNOM'41=NM>8'2K6Q7!@KI'7(491N#BUIIR8G)#]T3_%U '<-MG<%N7;,C3HQ
MBY;?%!A*>>J:(0\!4I J%Z6VYR?4;LPP'I:UV*]@.XL$[P@H9H?IVW_KIT+!
MM1X03*1<&H01=%K#:&!%%I34"ZW'? CJ#4@OP\C7D%1_KLF><R0'ZWUT&DB
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M?GC/SN5E=M/X2K%X0P:":MN*+$(D**IJF;)J:(:$;-.R>J]7H"^K E)D>DU
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MO5)QPVL\4RDE2XP @!__^\OG>W>(1PXQ4W'B!"Z>H<A;S<U2 _I2=4&KQZ&
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M!FT'3<+2#"V806N%X\C"P9/R'"K,"',>6N(\G+Q98%-N)Z#F9QJ@C9-H+<+
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MU6U$M=F2IMJBK?&R:!N*;",+6I*E:(IN6':5;OLV<2*"<?_M#H_#**E7<]R
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MC#-IG*U??""=PBE2[[U7[DN8KIRRTDG:93 S_&[!0Y'AMZ/XM05)D2Q5LX$
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M;]S8=Q+J!9;S2*GSF7>=] $33S*-F*E;B7WR2[3TBF#B^MB)J5^=ON0FSJA
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MG'&89C;JF;RB0V1\0X_H$"*SS@_2G-#$F59 ]/,2M_4KU]J]<H5O;.6*I1J
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MJ!: 80-)XE7#-&RH"$ 185&=1SXNV=<#9H05U /"07;Y:&=!"HM'&7B7P2O
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M1U\'KC^A9/B:;;2M)4GD/4X2>N+T0TBW#9JY3GLWW33<E06VMP$+A\\>Y@B
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MK#WP#RN?]$J5@HZ1'W)95_=@\,\__[ F7>O[/_P6?]&W_+V>?Z\W#3:\E0W
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M6\-WN*,1Z[4M\V!%\R%)X%UF2=XVJA-1:%\4AI%8* TTA$T_VM @Q>^O@GI
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MRQGS*5U8U3Z=F"2?VPTK^L^VPF"$>E797TTUPV_9X]'#2S<OW7:=/@]0NF$
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M(5E&>\U]J.4^'!&(0\D)IP8I2"BPK%<IP3*,U%H@YH7<UV>..>XSL6!WN.^
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MWH"Z6:U5MQ!B=\V&7="@RXUS5-.U\H:E!3C9>,N7NFRL?$<=M3-UW'6FWHN
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MQ.603>=-)EUSQ?K.T]KV7M0;5ME5I=MDXK P+P(7M_Y299'=&FX5U*;T6DC
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MJ0=IOIK9M5N'EEH!;6HMVIB;,HJEF4NIG995'0=%4)&QL8?+4NN_GX;*76Q
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MB361L3;B \91" R=Q%!1J8%&+T$GIR0Y\&85TT/0-7BK6C45! E$%3=DHP
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MBFZJB9QK55<2,;P]'=7M<:J:.*-Z-NT"/BX'M.G*:"AP82-\7;&@C[.WI3,
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M[-0+"BF5W+D]<<VS^7?+!X,@&SM+;604HZ%U1;CKJT\#MW362C'FWL(PJ[G
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M#8@)12#F1&@822XUK5H\Q"&0?,.9*ZN.!\EL?FZ4ZO-ZE>/L8M%\.K4@8,C
M0!!\U,D#WGMQDFA!FZ,?* Q6* X$ "2$4.$(8DA)PC46(< ;;6JZ1XN^GOP<
M6:B,QQZ//7W 'MXX/VFL"1"*J!A$-&1$Q#2N\I4BKC>RSON#/4<?&^R5'P]
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M73151)BH&W];L_!=9)4Y@R.MQ?OHY,ZGR\9B_+L1'-'MWXNIK1K,I;W\:;@
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M'5*Q,H]Y8TR 87ICC\CFR^S9)R>MNU=B8<":^]1^;C]^:DERLO(""(HPDN)
M=6C8I_S5>5_L9[.!P^KSEKW_,KXV@OYC]B/X/+M.-\*&?HQ'BROSIYE7&3DP
MG$TFZ4V>O:O^>+\>(_"FSBVJ\[#$F[LSCXI7L/#/[]]LQ#"4K]_M)]#Y$Y_]
MLH<3KQY9]7//Z=_E\6\WIQ!WG3GDK;.]EME\1Y[XBP?4[6$Y[HT8?'S28L]H
M@S]U+?AVRE@57&ZEVM*KQ^2PTPIX8KB/&.XWDD^OV]6Y47[3ZUEPOC#J3F"]
M)EGPT]?S^.<GQZT>^DJ\9-!U3XMK/RE8^;&I[@=>K4FPQCTKE'7",A[#F+.(
M0JQ@Y3MB!$&R;J/\ESMN=L;)9SOH_--RX<):7!AP'1OLPHX?,'#7+[?&ZXHC
M=/V"PH2U_+S-/OTMF[L+VG8J>N0!JWA+.RU7UT]>.(@&&7OA"H^#'@>WX*#
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MG"".%134D&1L$]N%5C%2"B**-(DCNLO<7;%1Y^*VQ-DN_)*N+L?ZGG50,_>
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M:R2XEC0T*@*+)((A38C6G&.$7LF!TAD<[--_XO' X\%1X$'8X($, =$)-:A
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M"01@IYX/#P > %X- %JE>8BD<1Q'!$N=:&;[JL1%Y$02QYJ1IX8;OHBWXZ4
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MX;FZ_P"YRQ7H"YRQ5M="9323B(5<)@2%$">$E$:]0D1)^>I&?4G,>^KZ3/%
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M^B<X&/F\ZF-X'?@WOCV\VGR-\!6S!R$9\%&<P^1#KL>G/>4)'+*$I>@_^>X
MW&H"FH#[M?L)"LHIW&4]6^$[PMI-UQ,)3(S%HGBQR-8@(E/QGC '(-;?ES)Y
MAP>M<*E@^<NGKOC&5H*;$#&_YW]>7(5GFF'C"_.-#)PW.4=G?J [(]_]>G95
ME\Z',2X:T8AVCGFO>-U*.ZZ3";C047)S(\)$%,!#8_WZ[T!F5\D9?#))P!?=
MPX!^V@1Y*7,!V[ M2.,J9CG;LD++LW0CM"!X"TAD!'*?TX?P2-\ 2:NKVW_%
M*4[8%U[,";\O4_$QPK^XJ_]"/4*4CM*8>WP60C4)S7 _$-&^N\PU>L;_^[]%
MOOI?'Q83R>3B?/7P"7[-R>=P)/^+4RSL+%A902Q7LM)=/2R3SS>UV*3Z6>,%
M(#/Y39BR<I"*HJZ>2DSAA?C>X31^P$,AN.T"0TQG(ZIV![8$ 0?FA/=WB:C&
MW(N9EG6S0IHJ_.8_8&;.+B?9:G7V-0.UST8N<LSGZV(UNIB#>GP3CG3D@@:
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M]L]/^ LI9*(Q"M8:M?V:UST'MG)-&*NB;KZ%/4UYWVW=2F?7L_0VELVWG/&
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MB;X(P)U)GB[%&6Z!6C3Z&4\V$NW7JZC@_])__87;* AEX<'SAVR58^HP$6
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M1RSQ_C'CAP].3FL,(:?\ZH0R?D(9WPME?'R"&6_ C&\O.SZ",]["NZQA;F]
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MH2;%JL&QTJ[0"88_03_(XPM5RMN,-]KPEC\]'H_T$&X0LC%@_M^[7-UD"3'
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MW3.MT/ =P]9UU]8=S;5HT(*"/20._.]!VD ZUJP^&3H'J@<G&WBR@2<;6-E
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M$N=.?.@?NP;*]*KJ$>EAX'M@0_7(<'QF^&X0JKUPSS7Z2XM$U:.7*(=9;3#
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M^)0$/N2!S#*H)@_&.9Y#O>A)"QC(7;^O\-I?DGRR3\BY6 N\S<I*5T;ZC.R
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MJ^!96/XG P?*:]0[/S@=]T\'!P=G)Z/.L'NHBY)Z)\<G#XBT/TVT[JC_I]@
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M5P7"[]!8;6?W&P^WS]RZ>9>E&9*A2--/&HXI<N;('.\ZPQWO'VR_?,UU#R;
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MH<06;_Y:KNG7Q'KEL/$J'/<!HX[S,J;B>]^H4K&88:T@T<%"!J-XG*);0Q4
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M/(&<$HT9"U\D;2-#GQ@55MML"+9ECI_UIG8[E]$4>4$)1ANAL&N;H/I-'!M
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MJ4T\JP_3#5IL&.&$'I-;0[P6GN'@I0R8V+8N9Y*DDRT,G#-#V\+%76(?0A*
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M_A 0AS)WF) 6L;J?/1S=&@U'7S<DB6PDV)>[:S9]>+1J1TVY+;,-=[G5*'R
M,P2K-]$8F5UW9_652FIAMW&ZCMJ*Q5W'Z:H( [3L NQOCZ1;!G'IJ+7=,@5%
MFL@D$O5)_*LE;I-XURV\VKWACEPD<T8'PN@SX<V:%K]H(W!O,9?FMA1<"];&
M%_NN@Y,ZI@ B#>4H"A2G5)O#TMHA0<L+$?*L**H8I88A#>"?=35I@ ];*)[&
M^A,=9SYO&J^!!NTL"Y;/-Q!B8^UY.<$>9M)* @X@R96&3D 1@$W1]B98+STM
M!^@AGP4FG'5[;][F3.%O;46?UN>*<O,YJ; *4/JV_+W8+'D0WP+Z;9NI=2H
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M9 TA9&@R)V]-X&]UU-L=.H_%KPN98K8QOL9V(;;D\]+)QZG/B\CB3K.IQ<K
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MFB#<)T,?:!'"4:(S]AS4.E,/QLSX1KR:F#QS=Z^IJUU$"1W+_J:B2ZO/%D_
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M.Y&?U/30D7E;@U+#:HNI JF&;&+B,UVTCX[=#6LBYS6AZ:+_2DARIG7VJ?N
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M>U9C(:SB2+[(W?D0/,V QO;)O98XL1I6@&\$R(^MB+TI*'AA":/9=@EA.R2
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MDT3X;;]7#711(/5D]C'.>L>=)Q&*D-9J44H>/TU[)U6XF!/-!]DA\B0U+!=
M!Q]5]:W0;,E3HOXG1/LT6>3'6G!.Q#@M360*Y4)2JURJ)!<+EGYAMDOG:"3
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M/9:!+Z1]\-78TX_L.RI^&Y?*]$1S6@")Z0-2U1#!G,6>4F05%&<&F(%SIM(
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M^"9A0.ZV#IW$H39PW!^("$QB4Z;)1,^89WOMG<_3=HDE/(A[$!.$?&^>DNI
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MK:@9B;4!!>D!J;&$L2\'* F*53CL-.<;M"&YGA0"$>HJDV@@[Q\ZD+M(_#U
M:I2NB:LW)\&$QUC[(+$V>=*(G+8A2GV"2WOQ^6ZJWM(.D:XQ]*NV%5+4''PS
M__!ZG.B2BQEXSZ-DN_([N!AS[C*7:'-R(*/97X$WE"*:WI,$XHC#)/K6,U[%
M<\^<?LNW^WD.0)F[C L.+1;<RH,B JP6(J_+,H8?;OW;EOT^$\M/<ZUD!MAB
M9@E6PLJ.W/H_7GGG'@<#3ZQ JU\;6+0%R*FZ'^#*]^6;2F!N5"#&5G&3)1A1
MTZ-3$L"9W76E\?K?;45(L^>\KE"Y#MZ^KL;R6(TEGKV# 7>DWV/@G$55=4^,
MW5E!]VHLC]58<NN@0(F.&)Z04#" 5GA5 'D!STJ=1YB4"*8F54HW.@J*_FGM
MXFIEC]7*O!TLQR]LA7'J2BAWQ)==K>,Q6T?L->"=QP+KUE0B'HBLAA')&$)(
M(]?E4 ^B9WL&3 ,>!O=%F[)H3TF[$U,7Q-Y\M<?_U?883\RDV\9SV>U=N-TM
MZX&<\BI)UU\-YY$:CC8!C74Y<LL](/R);9_8,WP(E^Y%X;\_N^*_?V;X[U_\
MX3O. 1S<@[V8XY')YI46*PU+F)#8EKLOI<(IF%3\I6*C;OIN//BIS-B7MBL3
M+2NITC.2Q^9'8IM8:9QL< C-"";0_T?=$CZ6]#V+U0\O_OIEL7KY_=>O7WW_
MZY>E_]TOOGWQ9%U+I,KX98/)E#I[[NXVWN=YT,S3U6O1T],#QO=]MW7/+!=*
M@>B>BH5T<!H5E(0QXDP).-K.>HVLS(9#2@:!Z.+H$&CM1T>&N-.CDSW3M\F=
M:4)A\\W. \[H-Y@_TD:@^5I=Q*9H9ZM3S/*D*[ 6T3PH"M8R1;42G?KRIB2@
MXGP<6"PQ&M%S@QA&V$4 IXGL(%7[8U?[7J?K.LJ\E-"(> *2.";&>!;VY0R]
M(.0(:BY-N,A-:</+N).$3,6$>1@,T8@P73<>"8WW=/5-UU=4_YV#,BBJX+YZ
MC\5@."8-65-?#WB.DZSN#(\!([D%>R!O4VP49<?Q ")ETJJC2,<!BUC#VU0"
M/2F9G7NX!#21I,&(]PV00&8WQ2R"N^L=/DU8A?V:ROOVW$#'OJ+[\I80_$C7
MM]7)6(=VE6@4TQF.-J>SQ 3>A.X5H-RJ0K4OWV!>C^IE-_P.0K@6.75U*:7O
M'9=C-;9X^4O/R4:C.GB^08M5C+-D#"3M.U6F3-Z:BO>M;FIV%F78V3W0!XP9
MQ2"'7?W>N%T9LJM2??.W^%YX 52B!2]EOQ*IDCW4+7^B>8/$SNOMO20*8[(+
M(Y?Q30491!ZQHPD3'IL@0J3M&':-!R>I0[0S8;Z/JQ!*#R?7)CW/$<;;4%B&
M8&X%2H6C-GX(3G83"73WT,]RY@WQ!6%LARH1&-=3$F2;N+RPQBF438F7NZ7!
M'X+JT^SU4:>4 5)UAQX&E[PZ[!0V63-F&D1QA[X6EDO>,(B@5S_X'RJ(2J."
M9Z5@(@)FXPTX45H9BHW0]^(<+Z7P';-Z8L>,>$J'EU)B^3&.><BD2EXVAI1E
M<&BR:/'P=GUF!Q"G#RA64CEIEF[DP@QE,NM?S)QJ[)3G$/>./!)OEH QPRVS
MH'%P&Q<I[#X#@-FQPM_5#2LGL")09;XZHSG+E0.3,'8>P3_'UC:95EH:92<&
M82 MV@4;4FZ/Z:;A\V<6$N[N[J),XJ%CJA/4FYR=[I'/.7(C75U$7"[S4E&5
M4/MI0K_1IN0U(N![40L;G?)XH%";'F0M,B!,K2JAF/<]WIC$]2WXE<2SRUK,
M+/Z[5IT#[+ )JO:&(;Q6H>,U3J'"",Y3T#.F(O7,'6;PR\Z/&(398,^@:1'8
M3H*S/H<1KMLG&E)Y.-Y2AV.* =X8YFL&^3LKV,SH*?8Z!,6B&&I#U#R]*N38
M'&@6 SH536/A0#1GL6L-I/,QR8W\ ,("%!9X;4BW(N:W4(G!Y%(I3:-_X8*R
MOT.,38L5:3W/-)*>KKX,7Z<\1N]LFP67DMA2UB*?=.,!P]EE+V8&9:S^*Z-A
M>*BP#8J8% F=#,V'!9/W(U71&I)[8"63MNQ[@.&9D%?+RIF&M#Z$L;D$4[62
M=/&@=Z0.;2'NF-VUA75+JK<AT1HH=SZ=H5[VKU;ZSDP?BU"?"500[3-_($?W
MWV7TQA+GF]>M^\VXMZE:6[V3GQ1>:%_/[ZD2\]22^X%,7&8_$GY.R=0U01,*
MO@Q!H0]K#2257DM,R!M##LY0_J;V0\W7_8OHYY?PGO=<&H+T!BM!/[$^2B[Z
M,<-ZF+\> R73_M5*15AWF^SHTR,B21..M^%3X1:%9$+WBX&DQ9;W54FV2 6
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M6RKEY#7@V#SC<0G:1$)<,%M2Q'*"#X; =Z.,T"QO?><IY=GFY7R'[SK(JJK
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MJ[QJ^\\/]SI7X@]_Z'2ONHVO^K %_!4=>?M[^[L7;U.(^4V8W6VWWJTZV+^
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M_Z;]K7*F;_]ZXK'\L./9(* ?MQP]'_A?W1S]"5!+ P04    " "+A0=/[)A
M8X@&  #A)P  %P   '-G;6\M,C Q.3 V,S!X97@S,C$N:'1M[5IM4]M&$/Z<
M_(J-,\W C&U9,A"P'68<XTSH$"#8:=J/9^EDW>1\I]Z=,.ZO[ZXD&QMHAK30
M&FIFL'UO^_;LK?:TUWEU=-8;_G;>A\1-))Q_>7]RW(-*S?.^-GN>=S0\@H_#
M3R>P4V_X,#1,6>&$5DQZ7O^T I7$N;3E>=/IM#YMUK49>\,+CTCM>%)KR^N1
MBRJ'+SO4=?CR12?A+,+O%YU7M1H<Z3";<.4@-)PY'D%FA1K#UXC;;^!#K;:8
MV=/IS(AQXB!H^ ?P59MOXI+-9SCA)#_L7R5B)%S'*YK(S"NY=48ZFH%U,\G?
M56*M7"UF$R%GK:&8< NG? H7>L)4.Q^SX@_>\ANI:Y/@D;@\[#!0;()K[?O]
M8*?WMK<3[/G[N[W=9G>WV^CO^0?!01!\V#\(*H<=C^%_OFK^,><LA>*UA),:
M+3]H_-1.612APC6GT]9^>G6;?8=Z[A)<J(0;X>Y8,3+(GKKG4BS)DH_]L%2.
M7[D:DV*L6CD$_US,O#DM6(ZTC)!$"1XT@[J_*O_?%#5$O^+F463M<>-$+$)&
M.\'">69LQI"HT^#OPY?ZH-ZKPYO7_M[;MM_<;52!6>A&.D4/_WNJ[?QKJBWK
M4FAPT-@#'8-+. R8&3'%;>WL2O(9=$-'(T&C$3P(8I+'#^!;JSJ0V(;_G@G#
M\T!CN8-8&Y> 4'"120Y^D]7\G:W1]D)+'F9(5V!@Z%^%"5-C/E?5/VCNY&AB
M,% 1CZJP12O>O-X/@D9[>7;>Y;>W@:F(*)*G #D#D>DE#'W!P%Z36D.*5N0X
M)?\O2E H'#B,B!8#7\1AZRZWVJX"9V$R7Y:A0,:B'7$M&H:/9A 6?HI44-E$
M6 A9RD+A9KD*"E>B$Z,<2&& @K.)AB$N92G/G AM%8Y56%]1L:<G*5.SN795
MY,Q<=6[H$;>YF8C5-Z6GDD=CWEHKW]CRM\F"C3;)NZ2-_[9MX7/&#.(B9W#!
M4W020,P^:#,!OU'[3&Z3:YDB91U![@#P<Z9X0;")^YR>3;DUIHE 9!P98B58
M '8PYQ V7,O(P:ZCWHJA"P$67A1G$J4*45Y)<$Z%2VZZMLUA+#RMD,AO;C'T
M:G/M?[M;T<+-E[VU36ZZ7C@%2S@)A;:?% 8,<283Y.3HTS180A4S0<"EAELR
M1I6&F92 RY #DV@JFZ(=;#5?%0O%5$C]2##*4YI\J^*L3!:VU AT&>%+DY7^
M4G],2RU1FR^FF:W&?+5 OU-%>YF=(@O)%88^S4&2CHTPP(1<RG+T7:51R=N6
MPD'9_O'L:"HBE^!/U'.D#4:?6JBE9*GEK?F/6PJ3.)B$N CM3NS5NTJ>,[F(
M/LQBM)2F8+&/'.:3;HX%2V-W$+BDW1<R6<HPTL[IR5S<HM7RTRNP6HH(7C?R
MO_:*Y0.TXK)9E]LEA>6N/$7*>U;1?(1-XED/NB?]7[NG1_T+.*K#IV[OHMN_
MD?ZM6NUN@SR&PAI9Q5)/6XF(T&4?0N$B)-RAW[V1?R+(=B6_8O1 SU%EH6%\
M@^J31_4<GRZ"HG?^J.DE@L?X&,9TTXE+#F=%-K;!^<GCO'5N!"87*687M^#=
MWN#[WRI:YDM!XV'>M_RETO\G7==E S_0ZZG*X1&>&EK0S<:9=876;XO3W9H"
M_6S!W>S>-=J]S^C8-!B^>8W[N7W^L7O:A_=GQX-!_V1-_6 ML'\BV XP7 ?-
M9CM-F.+P7@MKN=S@^N1QO<ZC?\$LNE![<9RJ0D^;5!M\:,/ T==X5DS!<U;Q
MXY@J)F)2'+J*K@_S5X!%<W/\>BZ^LG3\6F"\.7YM$KAGJ^NZ;.#-\>NQP/7R
M&LZM&QWWJCOY>X]1HBN:-+TE'!(.D<8PKS&OU#M9&.9%,ZI:4@GM^R761>54
M.#!<4@&\2B53I1U$G$]X!+&0^+DH@"X5Z^F=ZJ*HV=.3">9^\[)>20/ICZB<
M&,[3A0A&,^04<\-52",X@ZD9<:&+2-\OC.<5]YM27-\4:*[>%"BKQRM7"K:F
M"<=. Q,64?D\UH;31!:[DG)$.4U9?B0[E95=--8V6L:414W*BW 223[F"@65
M2TJ2#22RS!AR72F?V@Q-7:A:ARZ4EP<T>CT^-F7!%BTW1=4<Q^ET(R&_15&6
MG7/KK92<[W59!!*TRX@CQ=3H2T%E=#3[=PQ-"$Z%E 2>X:7\Q/K[2^+,*&&3
M@OP]G06-+YPE5>,8LA1[2%=NW>VB[XWK5.MRT^M%QZ/;;H<O._DUO,,_ 5!+
M 0(4 Q0    ( (N%!T\_E0_79A(  )W%   1              "  0    !S
M9VUO+3(P,3DP-C,P+GAS9%!+ 0(4 Q0    ( (N%!T]QB6[NQAT  !!) 0 5
M              "  942  !S9VUO+3(P,3DP-C,P7V-A;"YX;6Q02P$"% ,4
M    " "+A0=/JA#"H2A-  ""M@, %0              @ &.,   <V=M;RTR
M,#$Y,#8S,%]D968N>&UL4$L! A0#%     @ BX4'3]N:8X;LO0  F-@) !4
M             ( !Z7T  '-G;6\M,C Q.3 V,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( (N%!T_^$+FDHW0  !_,!0 5              "  0@\ 0!S9VUO+3(P
M,3DP-C,P7W!R92YX;6Q02P$"% ,4    " "+A0=/D&Y!*X&V @#/XQL %0
M            @ '>L $ <V=M;RTR,#$Y,#8S,'@Q,'$N:'1M4$L! A0#%
M  @ BX4'3ZL/@F4E"   5C,  !<              ( !DF<$ '-G;6\M,C Q
M.3 V,S!X97@S,3$N:'1M4$L! A0#%     @ BX4'3^BSK)E1"   T#,  !<
M             ( ![&\$ '-G;6\M,C Q.3 V,S!X97@S,3(N:'1M4$L! A0#
M%     @ BX4'3^R80&.(!@  X2<  !<              ( !<G@$ '-G;6\M
H,C Q.3 V,S!X97@S,C$N:'1M4$L%!@     )  D 70(  "]_!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
